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Abstract 
 
Monochorionic twin pregnancies are high-risk and closely monitored antenatally. A 
systematic review revealed no existing predictive factors for twin-twin transfusion 
syndrome (TTTS), growth restriction, or intrauterine fetal death (IUFD). The Optimal 
Management of Monochorionic Twins (OMMIT) study found that first trimester inter-
twin nuchal translucency discordance, crown-rump length discordance, β-hCG, 
PAPP-A, AFP, PlGF and sFlt-1 do not predict adverse outcome.  
 
A difference was seen in novel second trimester biomarkers: in the recipient twin 
amniotic fluid metabolites pre- and post-fetoscopic laser ablation; and a relationship 
with recipient twin cardiac function was demonstrated. Discovery work on miRNA in 
second trimester maternal serum of TTTS pregnancies found no difference compared 
to uncomplicated monochorionic twin pregnancies.  
 
A systematic review provided a more personalised risk prediction for the surviving co-
twin in single IUFD, including that that the rate of abnormal brain imaging is 20% and 
the IUFDs occurring at 14-28 weeks are at higher risk. 
 
A preliminary study of parent-fetal antenatal and postnatal attachment and 
depression in TTTS pregnancies found maternal attachment increased postnatally 
and depressive symptoms decreased, whereas paternal scores did not change. This 
  
 
 
thesis has reported exciting findings which have clinical implications, and advance 
knowledge of complicated monochorionic twin pregnancies. 
 
  
 
 
Executive Summary 
Background 
Monochorionic (MC) twin pregnancies are high risk and thus are closely monitored 
antenatally with ultrasound scans every 2 weeks from 16 weeks gestation. The aim of 
this intensive monitoring is to detect complications including twin-twin transfusion 
syndrome (TTTS) which affects 10-15% MC twin pregnancies and is thought to be 
related to abnormal inter-twin placental vascular anastomoses and without detection 
and treatment has a high mortality rate (>90%). Other serious complications include 
selective intrauterine growth restriction (sIUGR) and single intrauterine fetal demise 
(sIUFD) which can have serious sequelae for the surviving co-twin because of the 
placental anastomoses. At present it is not possible to predict which MC twins will 
develop these complications, thus all MC twins are closely monitored which has an 
impact on resources and patients. It is also not known how having a pregnancy 
affected by TTTS affects parents psychologically. 
 
Aims 
The aims of this thesis are to a) identify and evaluate first trimester potential 
prognostic factors of adverse outcome in MCDA twin pregnancies; b) perform 
discovery work to identify second trimester novel potential prognostic factors of TTTS 
(metabolomics in amniotic fluid, microRNA in maternal serum); c) examine the 
prognosis of surviving co-twins following spontaneous sIUFD to aid a personalised 
risk prediction; d) assess antenatal and postnatal parento-fetal/infant attachment and 
  
 
 
depression in pregnancies complicated by TTTS, to help health care professionals 
identify which couples may need additional support. 
 
Methods 
The Optimal Management of Monochorionic Twins (OMMIT) study consisted of 
different groups of retrospectively and prospectively recruited participants with MC 
twin pregnancies. Different study designs were employed to assess first and second 
trimester potential prognostic factors, and the psychological impact of TTTS on 
recruited parents. To examine the prognosis of surviving co-twins following 
spontaneous sIUFD a systematic review and meta-analysis was performed.  
 
To identify first trimester potential prognostic factors a systematic review and meta-
analysis was performed. Inclusion criteria were studies that reported ultrasound 
measurements, maternal characteristics, or potential biomarkers, measured in the 
first trimester (i.e. up to 14 weeks gestation), in MCDA twin pregnancies that provided 
sufficient information to assess the association between the variable and outcome.  
 
The results of the meta-analysis and previous second trimester work were used to 
inform a retrospectively recruited cohort study to assess the prognostic ability of first 
trimester potential prognostic factors. Stored first trimester maternal serum samples 
and ultrasound measurements from women who had undergone first trimester 
aneuploidy screening in the UK and Australia were used to investigate the 
association between nuchal translucency (NT) % discordance, crown-rump length 
  
 
 
(CRL) % discordance, β-human chorionic gonadotropin (β-hCG), pregnancy-
associated plasma protein-A (PAPP-A), alpha-fetoprotein (AFP), soluble fms-like 
tyrosine kinase-1 (sFlt-1), (placental growth factor) PlGF and adverse outcomes in 
MC twin pregnancies. Potential prognostic factors were analysed as continuous data, 
and adjusted odds ratios calculated. 
 
As normal levels of AFP, sFlt-1 and PlGF in the first and second trimester in MC twin 
pregnancies were not known, a prospectively recruited case series was performed to 
determine maternal serum levels in uncomplicated MCDA twin pregnancies by 
performing repeated maternal blood sampling at 12, 16 and 20 weeks on MC twin 
pregnancies. 
 
Discovery work was undertaken to explore novel potential prognostic factors in the 
second trimester using two different types of –omics technology. Untargeted 
metabolomic analysis on amniotic fluid samples taken during FLA from the recipient 
twin amniotic fluid sac was performed in a retrospectively recruited case series. The 
metabolite findings were correlated to the degree of cardiac dysfunction in the 
recipient twin.  
 
Transcriptomics was conducted to explore the role of microRNAs as potential 
prognostic factors in a prospectively recruited case-control study. Microarrays were 
performed on second trimester maternal serum samples taken at diagnosis of TTTS 
and comparing the microRNA profiles to gestationally-matched serum samples taken 
  
 
 
from women with uncomplicated MCDA twin pregnancies. The initial array findings 
were validated in a different cohort. 
 
To examine the prognosis of surviving co-twins following spontaneous sIUFD a 
systematic review and meta-analysis was performed. The inclusion criteria were 
studies including twin pregnancies, irrespective of chorionicity, that reported the 
outcome of the surviving co-twin following spontaneous sIUFD after 14 weeks 
gestation. Outcomes evaluated were: co-twin death, preterm birth, abnormal 
antenatal and postnatal brain imaging, neurodevelopmental comorbidity and neonatal 
death. Sub-group analyses were performed based on pregnancy characteristics. 
 
The final aspect of the OMMIT study was a prospectively recruited case series to 
explore antenatal and postnatal parento-fetal/infant attachment and depression in 
pregnancies complicated by TTTS. This was assessed quantitatively using 
questionnaires that mothers and fathers were asked to complete separately prior to 
fetoscopic laser ablation (FLA), 1 month after FLA, and postnatally. 
 
Results 
Main findings of first trimester prognostic factors meta-analysis: 
48 studies were able to be included in the review. The commonest potential 
prognostic factors which were evaluated were ultrasound markers. Although first 
trimester NT >95th centile in ≥1 twin, and CRL discordance >10% demonstrated 
statistically significant associations with TTTS, their actual predictive abilities were 
  
 
 
poor. Only one small study (n=51 pregnancies) looked at first trimester maternal 
serum biomarkers, they demonstrated a trend in association between β-hCG and 
PAPP-A and TTTS. One of the main issues was the variable way potential prognostic 
factors and outcomes were defined by different studies.  
 
Main findings of first trimester prognostic factors retrospective cohort study: 
First trimester maternal serum samples were analysed from 177 pregnancies. A 
significant association was found between NT % discordance and the fetal composite 
adverse outcome and TTTS; CRL % discordance and fetal composite, antenatal 
growth restriction, sIUFD; AFP and TTTS; PlGF and TTTS, sIUFD and double IUFD. 
When the aORs were converted into absolute risks based on extreme values for 
each potential prognostic factor, their prognostic abilities were too low to justify 
combining the factors in a prognostic model. 
 
Main findings of first and second trimester prospective case series study: 
There were 19 women with blood samples taken at all 3 time points. The longitudinal 
patterns of AFP, PlGF and sFlt-1 at 12, 16 and 20 weeks were demonstrated. 
 
Main findings of amniotic fluid metabolomics retrospective case series: 
A statistically significant difference was seen in 200 metabolites in amniotic fluid 
samples taken from the recipient twin pre-FLA compared to post-FLA in the 19 
women who were included in the study. A correlation was also seen with the 
  
 
 
metabolomic profile of the amniotic fluid samples taken pre-FLA and the 
cardiovascular function of the recipient twin prior to FLA. 
 
Main findings of maternal serum microRNA prospective case-control study: 
In the initial investigation cohort, 17 microRNAs were upregulated, and 14 
microRNAS were downregulated in maternal serum samples taken from pregnancies 
complicated by TTTS compared to uncomplicated MC twin pregnancies. These 
differences did not remain significant after correction for multiple testing. Eight 
microRNAs were tested in the validation cohort, 6/8 were not significantly different 
between the 2 groups, and 2/8 microRNAs could not be assessed. 
 
Main findings of co-twin prognosis systematic review: 
The review confirmed that MC twins are at higher risk of co-twin IUFD and abnormal 
postnatal brain imaging than dichorionic twins. No difference was seen between the 
chorionicities regarding preterm birth, neurodevelopmental comorbidity or neonatal 
death. The risk of preterm birth was high in both chorionicities (dichorionic OR 53.7% 
[95%CI 40.8, 70.6] and MC OR 58.5% [95%CI 48.2, 70.9]). The risk of abnormal 
antenatal brain imaging could only be examined in MC twins, and a rate of 20% was 
calculated. MC twin pregnancies were at higher risk if the first twin IUFD occurred at 
14-28 weeks compared to after 28 weeks. 
 
Main findings of parental attachment depressive symptoms prospective case series: 
  
 
 
Twenty-five couples were recruited and completed questionnaires at the first time 
point. Five couples completed questionnaires at all 3 time points. Maternal parento-
fetal attachment increased pre-FLA to postnatally, and maternal depressive 
symptoms decreased, although no difference was seen 4 weeks after FLA. No 
difference was seen in the fathers, although mothers and fathers with a history of or 
current mental health problems did report significantly more depressive symptoms.  
 
Conclusions 
This thesis has progressed knowledge in the field of MC twin pregnancies. Although 
it is still not possible to predict which MC twin pregnancies will develop an adverse 
outcome based on factors measured in the first trimester, novel potential biomarkers 
have been explored in the second trimester and interesting findings have been 
reported which may improve understanding of the pathophysiology of TTTS.  
New knowledge has been synthesised to produce a more personalised risk prediction 
for parents with a sIUFD, which has the clinical implications of improving patient 
counselling and decision making. The high risk of preterm birth, and the importance 
of offering antenatal brain imaging has been highlighted. Additional knowledge has 
been obtained to help referring centres identify mothers and fathers who may need 
additional psychological support following FLA. 
  
The limitations of researching conditions which are relatively rare in the general 
obstetric population have been discussed: obtaining adequate sample sizes was 
difficult, including the recruitment of appropriate controls, and of obtaining different 
  
 
 
tissue samples. The lack of an appropriate animal model impedes research in this 
area. The importance of having a defined set of core outcomes for future twin 
pregnancy research was highlighted.  
 
A multitude of research ideas have been generated. Further work is required in larger 
cohorts looking at new prognostic factors, but this will require collaboration between 
centres. Women with complicated MC twin pregnancies should be recruited to the 
longitudinal prospective study of AFP, PlGF and sFlt-1 to compare levels at 12, 16 
and 20 weeks with uncomplicated MC twin pregnancies. The metabolomics work 
should be continued by investigating the biological function of the significantly 
different metabolites by performing targeted assays to assess the phenotype. The 
microRNA work should be continued by performing the validation work in a different 
cohort, and trying to get the placenta-specific assays to work, particularly as TTTS 
may be considered a placental disease. It would be very interesting to explore 
microRNA in other tissue types, particularly placental tissue, but the logistics of 
sample collection makes this particularly challenging. The systematic review on 
sIUFD revealed a dearth of research regarding antenatal brain imaging in dichorionic 
twins, and very little research linking antenatal brain imaging with postnatal brain 
imaging. The psychological work should be continued in a larger cohort with 
additional strategies to improve questionnaire return rates. It would be fascinating to 
perform interviews to delineate the reasons behind the answers on the 
questionnaires.  
  
 
 
MC twin pregnancies will remain at risk of complications unique to monochorionicity, 
but it is hoped that with continued research in this specialist area, adverse outcomes 
from these complications can be reduced. 
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Figure 1.1 Multiple maternity rate, 1940-2016, England and Wales 
(taken from Office for National Statistics (ONS 2017)) 
 
 
CHAPTER 1 INTRODUCTION AND METHODS 
 
1.1 Overview of multiple pregnancy 
 
1.1.1 Epidemiology 
Multiple pregnancies, meaning twins, triplets and higher order births, have been 
increasing in incidence due to advancing maternal age, increased use of assisted 
reproductive technologies (ART), and immigration. The Office for National Statistics 
(ONS) reported in 2016 that 10,786 women in England and Wales gave birth to twins, 
160 to triplets, and 5 to quadruplets or greater, equating to 1.59% of all women who 
gave birth, including live births and stillbirths, although rates have varied over time 
(Figure 1.1). 
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This rate is likely to be an underestimate due to the high rate of unrecognised first 
trimester miscarriages of multiple pregnancies, and “vanishing twins” whereby the 
pregnancy may start as a multiple pregnancy, but the second fetus is not viable and 
is absorbed into the mother’s body prior to 14 weeks gestation, usually with little 
adverse effect on the surviving fetus. 
 
1.1.2 Aetiology of multiple pregnancy 
Multiple pregnancy rates vary depending on setting. The lowest rates are reported in 
Asian countries such as Japan, Hong Kong and Singapore, with rates as low as 
0.09% (Imaizumi 2005). The highest rates reported are in African countries such as 
Nigeria and Benin with rates as high as 6.65% (Nylander 1971). These discrepancies 
may be related to the levels of follicle-stimulating hormone (FSH) and luteinising 
hormone (LH) which are lower in Japanese women compared to American women, 
and Nigerian women (Soma 1975), and are involved in ovulation – a process 
implicated in the development of twin pregnancy (see section 1.1.3). Although recent 
accurate data from lower income countries is sparse, the rates in these countries are 
thought to be stable (Smits 2011). The increase in the multiple pregnancy rates in 
higher income countries is related to women child-bearing later in life, which in itself 
is a risk factor for multiple pregnancy (Hoekstra 2008), as well as the increased use 
of ART (Pison 2015). The Human Fertilisation and Embryology Association (HFEA) 
has successfully decreased the rate of multiple pregnancies created by ART as a 
result of the ‘single embryo transfer’ policy (HFEA 2018), but this guidance does not 
apply to countries outside the UK and women undergoing ART abroad still have a 
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higher risk of a multiple pregnancy, particularly higher order multiples. This thesis 
predominantly focuses on twin pregnancy. 
 
1.1.3 Zygosity 
Twin pregnancies arise from either two zygotes (dizygous, DZ), or one zygote 
(monozygous, MZ). DZ twins are formed when two oocytes are fertilised in the same 
menstrual cycle and are always genetically non-identical. This is related to altered 
endocrine milieu, including raised FSH levels (Lambalk 1998). MZ twins are formed 
when one single embryonic mass divides and are considered genetically identical, 
although there are reported cases of discordant anomalies in MZ twins, thought to be 
due to trisomy rescue, post-zygotic chromosomal non-disjunction, unequal 
blastomere allocation, anaphase lagging, point mutations in a single gene and 
epigenetic changes (Machin 2009, Saffery 2012). The reason for MZ splitting is not 
known.  
 
1.1.4 Chorionicity and amnionicity 
In addition to classifying twins based on zygosity, twins can also be classified by 
chorionicity and amnionicity. The majority of twins (80%) are dichorionic diamniotic 
(DCDA) meaning that each twin has its own separate placenta and separate amniotic 
fluid sac and thus is the lowest risk type of twin pregnancy (Figure 1.2). DCDA twins 
are DZ, or MZ if cleavage occurs before day 4. The second commonest type of twins 
are monochorionic diamniotic (MCDA) meaning that the twins share a placenta, but 
have separate amniotic fluid sacs; the shared placenta makes them higher risk than 
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DCDA twins. MCDA twins are always MZ and form when cleavage occurs later at 4-8 
days. If cleavage occurs later than 8 days, monochorionic monoamniotic (MCMA) 
twins form, and if cleavage occurs after 13 days conjoined twins will form.  
 
As MC twins share a placenta, this can result in various complications unique to MC 
twin pregnancies either secondary to inter-twin placental vascular anastomoses or 
unequal placental territories (Sebire 1997, Denbow 2000, Acosta-Rojas 2007). 
Placental vascular anastomoses allow blood to flow freely between the twins and 
Figure 1.2 Chorionicity and amnionicity of twin pregnancy according to 
zygosity  
(taken from Greaves et al. (Greaves 2003)) 
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occur in the majority of MC twins (Denbow 2000). There are three different types of 
anastomoses: arteriovenous anastomoses (AVA), arterioarterial anastomoses (AAA) 
and venovenous anastomoses (VVA), which have different flow directions (see 
Figure 1.3(a) and Figure 1.3(b)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 Placenta injection study of (a) uncomplicated monochorionic 
twin pregnancy (b) monochorionic twin complicated by twin-twin 
transfusion syndrome 
(pictures courtesy of Professor Dr Lopriore) 
 
(a) Uncomplicated monochorionic twin pregnancy, delivered at 36 weeks 
gestation. Red and blue injected vessels are from one twin, and yellow and 
green injected vessels from the other twin. White star demonstrates an arterio-
arterial anastomosis (AAAs) 
 
(b) Quintero stage I, treated at 24 weeks with amnioreduction, delivered at 24+5 
weeks. The recipient twin’s placental share is on the left (red and blue injected 
vessels) and the donor twin’s placental share is on the right with a smaller 
share (yellow and green injected vessels). White stars demonstrate arterio-
venous anastomoses (AVAs) from donor to recipient twin. Black star 
demonstrates a cluster of AVAs from recipient to donor twin. There are no 
arterio-arterial anastomoses. 
(a) (b) 
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AVAs occur ‘deep’ at capillary level and are unidirectional: the anastomosis receives 
arterial blood from one twin and sends venous blood to the other twin (Denbow 
2000). AAAs and VVAs are considered ‘superficial’ and are bidirectional: flow is 
allowed in either direction dependent on the gradient of inter-twin vascular pressure 
(Lewi 2013). As VVAs and AAAs form direct communications between the two fetal 
circulations, rather than at a capillary level as in AVAs, VVAs and AAAs have a much 
lower resistance. Anastomoses may be pathological or compensatory and different 
combinations of type, number and size of anastomoses are implicated in different 
complications unique to monochorionicity, including twin-twin transfusion syndrome 
(TTTS), growth restriction, and intrauterine fetal death (IUFD). This is why 
chorionicity determination dictates antenatal care (NICE 2011, Kilby 2016), and why 
MCDA twins are the focus of this thesis. These MC complications are investigated in 
this thesis and will now be outlined. 
 
1.2 Twin-twin transfusion syndrome (TTTS) 
 
1.2.1 Epidemiology and pathophysiology 
Twin-twin transfusion syndrome (TTTS) can occur acutely in the intrapartum period 
(Lopriore 2014) although this is rare. The focus of this thesis is the more common 
“chronic TTTS” which occurs in the second, and less commonly the third, trimester. 
Where TTTS is referred to in the remainder of the thesis it is referring to chronic 
TTTS unless otherwise stated. TTTS affects approximately 10-15% of MC twin 
pregnancies (Berghella 2001, Lewi 2008) and without treatment has a perinatal 
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mortality rate of up to 90% (Haverkamp 2001). TTTS disease is due to abnormal 
placental vascular anastomoses creating a ‘recipient’ twin and a ‘donor’ twin which 
have different pathophysiology and sequelae, with serious adverse effects on the 
fetal cardiovascular and renal systems being demonstrated. There is a dearth of 
knowledge regarding the pathophysiology of TTTS because ethically-acceptable 
invasive in-utero sampling is limited as invasive sampling increases risks such as 
intrauterine infection and preterm birth (PTB). There are few occasions invasive 
sampling would be performed as part of clinical care in MC twin pregnancies, 
particularly uncomplicated MC twin pregnancies which also means that finding an 
appropriate control group is difficult. There are no adequate animal models of TTTS 
either (Shaw 2016, Wohlmuth 2016, Caloone 2017). The current knowledge will now 
be outlined. 
 
1.2.1.1 Placental pathophysiology 
No unique anastomotic pattern solely attributable to TTTS has been identified (Lewi 
2013).  
The general consensus is that AVAs allow the ‘donor’ twin to drain deoxygenated 
arterial blood into the shared chorionic villus tree, gaseous exchange occurs, but the 
‘recipient’ twin then receives the oxygenated venous blood, not the donor twin. AVAs 
can exist in the opposite direction: arterial blood from the ‘recipient’ twin flows to 
venous blood in the ‘donor’ twin. However, when there is a net unbalanced inter-twin 
blood flow, for example if there are an odd number of AVAs, TTTS occur. Another 
contributing factor to the unbalanced inter-twin blood flow seen in TTTS is the lower 
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number of AAAs in TTTS placentas compared to unaffected MC placentas (Denbow 
2000). AAAs are believed to be better at compensating for unbalanced blood flow 
than AVAs (De Villiers 2015, Zhao 2015) as AAAs have a much lower resistance 
than AVAs, according to a computer mode (Lewi 2013). VVAs are present in 
approximately 20-25% of MC placentas (Denbow 2000, De Villiers 2015) and are 
associated with TTTS although the reason for this is not clear (De Villiers 2015, Zhao 
2015). There is debate as to whether TTTS is associated with angiogenesis whereby 
existing blood vessels are transformed, or vasculogenesis whereby new blood 
vessels are created. 
The unbalanced inter-twin blood flow results in one twin, the ‘recipient’ twin, 
becoming hypervolaemic, which is associated with polyuria and polyhydramnios in all 
recipient twins, and cardiac dysfunction in 70% (Van Mieghem 2009c). The other 
twin, the ‘donor’ twin, becomes hypovolaemic and develops renal failure and 
oligohydramnios. There is no change in the inter-twin haemoglobin levels in TTTS 
(Saunders 1991), therefore the pathophysiology is linked to abnormal circulating 
volume and vascular resistance.  
 
1.2.1.2 Fetal cardiac pathophysiology 
As TTTS is fundamentally a difference in inter-twin circulating volumes, the cardiac 
anomalies associated with TTTS are thought to reflect the physiological response to 
chronic unbalanced circulating volumes (Manning 2016). These anomalies can be 
both acquired structural anomalies and functional anomalies, and are mainly seen in 
the recipient twin (Michelfelder 2007). The recipient twin has an increased total 
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circulating volume, with increased preload and afterload, the latter demonstrated by 
an increased tricuspid regurgitation velocity, and associated with increased 
resistance and fetal hypertension (Mahieu-Caputo 2003). This can cause progressive 
biventricular hypertrophy in the recipient twin with associated atrioventricular valvular 
regurgitation, pulmonary valve atresia or stenosis, reduced myocardial compliance, 
and abnormal ductus venous Doppler velocimetry (Zosmer 1994, Stirnemann 2010b). 
Systolic and diastolic dysfunction may be present, with diastolic dysfunction being 
more common (Barrea 2005). Approximately 70% of recipient fetuses will have 
abnormal echocardiographic structural or functional findings at diagnosis of TTTS 
(Habli 2008a). The methods of assessing fetal cardiac function in TTTS pregnancies 
are outlined in section 1.2.4. There is debate whether the left or right side of the 
heart, and systolic or diastolic function is affected first. Previously it was thought that 
the right side of the heart was affected before the left, and ventricular hypertrophy 
and diastolic dysfunction occurred before subsequent systolic dysfunction (Barrea 
2005). However, a more recent study has found that the left ventricle demonstrates 
abnormal filling pressure and greater systolic dysfunction before abnormalities in the 
right side of the heart (Wohlmuth 2017). See Figure 1.4 for proposed 
pathophysiology in the recipient twin (Wohlmuth 2017). 
The donor twin on the other hand usually has a functional normal heart (Barrea 
2005), with any right ventricular diastolic dysfunction due to increased placental 
resistance, possibly related to concurrent IUGR (Bajoria 2003, Van Mieghem 2010, 
Rychik 2012). 
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1.2.1.3 Fetal renal pathophysiology 
The hypervolaemia of the recipient twin causes the myocardial tissue to stretch, 
stimulating the release of atrial natriuretic protein (ANP) and brain natriuretic protein 
(BNP). ANP and BNP act on the kidneys and result in diuresis, polyuria and the 
polyhydramnios characteristic of TTTS (Bajoria 2001, Bajoria 2003). The fetal 
Figure 1.4 Proposed pathophysiology of recipient twin in twin–twin 
transfusion syndrome 
(adapted from Wohlmuth et al. (Wohlmuth 2017)) (1) Neuroendocrine factors such 
as brain natriuretic peptide (BNP) and endothelin-1 are transferred via anastomoses 
from the donor twin to the recipient twin causing increased recipient blood pressure. 
(2) Decreased right-to-left shunting and altered ductus venosus (DV) filling times are 
observed. (3) Altered left ventricular (LV) function and, ultimately, (4) bilateral 
atrioventricular valve regurgitation and ventricular hypertrophy are seen.  
Ao: aorta, DA: ductus arteriosus, FO: foramen ovale, LA: left atrium, PA: pulmonary 
arteries, PV: pulmonary veins, RA: right atrium, RV: right ventricle, SVC: superior 
vena cava, UA: umbilical artery, UV: umbilical vein. 
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hypertension of the recipient twin is secondary to vasoactive mediators produced by 
the donor twin to compensate the hypovolaemia that are transferred to the recipient 
twin via the anastomoses. The renin-angiotensin system (RAS) is upregulated in the 
donor twin in response to the chronic hypovolaemia and subsequent hypoperfusion, 
resulting in increased vascular resistance to compensate (Kilby 2001, Mahieu-Caputo 
2005). Although the RAS is downregulated in the recipient’s kidneys, the 
anastomoses allow the transfer of potent vasoconstrictors such as endothelin-1 that 
is involved in TTTS (Bajoria 1999a, Bajoria 2003). Consequently both the donor and 
recipient have hyperdynamic circulations.  
 
1.2.1.4 Maternal pathophysiology 
There is no substantive evidence to suggest that TTTS affects the mother’s 
physiology. One observational study with no control group suggested that maternal 
hypoproteinaemia may play a role in TTTS by affecting amniotic fluid volumes (De 
Lia 2000). This led to a retrospective cohort study comparing 51 women with MCDA 
twin pregnancies who took nutritional supplement drinks three times a day, to 52 
women with MCDA twins who did not take nutritional supplement drinks (Chiossi 
2008). The gestational age at which supplementation was commenced is not clear, 
but a significantly lower incidence of TTTS in the supplemented group compared to 
the non-supplemented (15.5% and 38% respectively) was reported. The rate of TTTS 
in the non-supplemented is higher than would be expected, which is not commented 
on in the study. The maternal serum albumin and protein levels were measured in 16 
and 15 of the supplemented and non-supplemented women and were significantly 
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different, with higher rates reported in the supplemented group. The authors state 
that the maternal nutritional status may affect the materno-fetal colloid osmotic 
pressure, although this hypothesis has not been investigated further.   
 
1.2.2 Prediction of TTTS 
First trimester 
At present it is not possible to predict which pregnancies will develop TTTS, based on 
factors measured in the first trimester. CHAPTER 2 will systematically review and 
meta-analyse existing literature on first trimester potential prognostic factors. 
CHAPTER 3 will assess existing factors identified by the systematic review in a 
retrospective cohort, and CHAPTER 4 will look at the biomarkers in normal first and 
second trimester MC twins. CHAPTER 5 and CHAPTER 6 will take the work further 
by investigating novel potential biomarkers in the form of metabolites and microRNA 
(miRNA).  
 
Second trimester and third trimester 
Descriptive differences in maternal serum biomarkers have been demonstrated at 
diagnosis of TTTS in the second trimester. Maternal serum alpha-fetoprotein (AFP) 
and beta-human chorionic gonadotropin (β-hCG) in MC twins complicated by severe 
TTTS were significantly higher compared to gestationally-matched uncomplicated 
MC twin pregnancies (Figure 1.5(a) and (b)) (Fox 2009). Additionally, the ratio of 
soluble fms-like tyrosine kinase-1 (sFlt-1) to placental growth factor (PlGF) levels was 
significantly increased in TTTS (Figure 1.6) (Fox 2013), although no difference was 
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demonstrated when these biomarkers were examined individually. These biomarkers 
and their potential effects on the pathophysiology of TTTS and other MC twin 
complications will be explored in CHAPTER 3. 
 
 
 
 
 
 
 
 
Figure 1.5 Concentration of (a) maternal serum alpha-fetoprotein (AFP) and 
(b) beta-human chorionic gonadotropin (β-hCG) in uncomplicated dichorionic 
twin pregnancies (DC), uncomplicated monochorionic twin pregnancies (MC) 
and twin-twin transfusion syndrome (TTTS) pregnancies 
taken from Fox et al. (Fox 2009)) 
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Placental umbilical cord site insertion has been investigated by several studies but a 
systematic review and meta-analysis reported no association between velamentous 
cord insertion and TTTS (Kalafat 2017). Since the systematic review was performed, 
the first study to report cord insertion site based on antenatal assessment has been 
published (Couck 2017). This study demonstrated an association between 
velamentous cord insertion identified at 16 weeks gestation in one or both twins, and 
TTTS, but reported low positive and negative predictive values. 
 
Figure 1.6 Ratio of soluble fms-like tyrosine kinase-1 (sFlt-1) to placental 
growth factor (PlGF) in uncomplicated dichorionic twin pregnancies (DC), 
uncomplicated monochorionic twin pregnancies (MC) and twin-twin 
transfusion syndrome (TTTS) pregnancies 
(taken from Fox 2013) 
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1.2.3 Signs and symptoms 
The main clinical signs and symptoms of TTTS are a sudden increase in abdominal 
girth due to the polyhydramnios that can be associated with breathlessness and 
abdominal discomfort/pain. These signs may be difficult to recognise as a woman’s 
abdominal girth will increase as part of a normal twin pregnancy, and this may be 
different to the rate of increase seen in singleton pregnancies. Women who develop 
TTTS later in pregnancy may also notice decreased fetal movements.  
 
1.2.4 Diagnostic criteria and staging 
The majority of TTTS cases are picked up on routine antenatal ultrasonography as 
the discordant amniotic fluid volumes are apparent on ultrasonography from 16 
weeks gestation, see section 1.7. In Europe, TTTS is diagnosed when one twin has 
polyhydramnios defined as a maximum pool depth (MPD) >8cm at <20 weeks 
gestation, or MPD >10cm at >20 weeks gestation, and the other twin has 
oligohydramnios with a MPD <2cm irrespective of gestation (Quintero 1999). In North 
America, the gestation does not make a difference and the definition is MPD >8cm in 
one twin and <2cm in the other twin, irrespective of gestation of either twin. As TTTS 
can only occur in MC twins, the twins must be the same sex, and ideally 
monochorionicity should have been diagnosed in the first trimester (NICE 2011, Kilby 
2016), based on a single placental mass, thin inter-twin membrane, and the presence 
of the ‘T’ sign (Sepulveda 1996).  
TTTS is staged according to the Quintero staging to monitor disease progression and 
guide treatment (Table 1.1) (Quintero 1999). However, Quintero staging is not able to 
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predict outcome, including not being able to determine those at Stage I that will 
spontaneously resolve and those that will progress, and is criticised for not including 
cardiac function (Ville 2007, Stirnemann 2013, Djaafri 2017).  
 
Table 1.1 Staging of twin-twin transfusion syndrome 
(taken from Quintero et al. (Quintero 1999) 
 *Polyhydramnios: deepest vertical pocket (DVP) >8 cm; oligohydramnios: DVP <2 
cm 
†At least one of the following: a) Absent or reverse end diastolic flow velocity in the 
umbilical artery; b) Reverse flow in the ductus venosus; c) Pulsatile umbilical venous 
flow 
 
There are other scores that exist including the Children’s Hospital of Philadelphia 
(CHOP) cardiovascular score (Rychik 2007), myocardial performance index (MPI)  
(Figure 1.7), also known as the ‘Tei-index’, and speckle tracking, that consider the 
cardiovascular dysfunction associated with TTTS, however there are conflicting 
results regarding the clinical utility of these scores (Rychik 2007, Stirnemann 2010a, 
Gapp-Born 2014, Zanardini 2014, Henry 2018). The measurement of the CHOP 
score is more time-consuming than the other two methods, thus MPI is more practical 
for clinical use. MPI and speckle tracking can both be performed on an ultrasound 
Stage 
Poly- and 
oligo-
hydramnios* 
Absent 
bladder 
 in 
donor 
Critically 
abnormal 
Dopplers† 
Hydrops: ascites, 
pericardial or pleural 
effusion, scalp oedema, 
or overt hydrops 
Demise of 
one or 
both twins 
I + - - - - 
II + + - - - 
III + + + - - 
IV + + + + - 
V + + + + + 
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machine used for standard fetal assessment, and no additional skills are needed 
other than the ability to acquire a four-chamber view of the heart. Van Mieghem et al. 
evaluated MPI and speckle tracking and stated MPI is preferred as it is highly 
feasible and reproducible in MC twins, whereas speckle tracking was only feasible in 
80% of singleton pregnancies and would thus be even lower in twin pregnancies, and 
the inter- and intra-observer variation was higher in speckle tracking (Van Mieghem 
2009a, Van Mieghem 2009b, Van Mieghem 2011a). Another group also stated MPI is 
the preferred assessment score (Villa 2014).  
 
Figure 1.7 Measuring Myocardial Performance Index (MPI): Doppler trace 
and sample volume positioning 
(taken from Van Mieghem et al. (Van Mieghem 2009b)) 
The isovolumetric contraction time (ICT), ejection time (ET) and isovolumetric 
relaxation time (IRT) are indicated. Ao: aorta, FO: foramen ovale, LA: left 
atrium, LV: left ventricle, RA: right atrium, RV: right ventricle. 
Speckle tracking assesses ventricular function by tracking the velocity vectors 
generated from myocardial displacement (Van Mieghem 2011a). The MPI reflects 
global ventricular function and includes measures of systolic (isovolumetric 
contraction and ventricular ejection time) and diastolic (isovolumetric relaxation time) 
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function (Tei 1995). The MPI is calculated for each ventricle, with a higher score 
indicating greater dysfunction. It is calculated by the sum of the isovolumetric 
contraction time and the isovolumetric relaxation time, divided by ventricular ejection 
time.  
 
In TTTS, the MPI is raised in at least 50% of stage I cases (Van Mieghem 2009c) and 
the proportion of TTTS pregnancies with a raised MPI increases as the Quintero 
stage worsens (Habli 2012, Gapp-Born 2014). Pre-fetoscopic laser ablation (FLA) the 
recipient twin’s left MPI score is higher than the donor twin’s left MPI, indicating the 
recipient has worse cardiac function (Ortiz 2018). When compared to MC twins with 
no TTTS, the recipient twin has a higher left MPI pre-FLA than control MC twins (Van 
Mieghem 2009c, Zanardini 2014, Wohlmuth 2017, Ortiz 2018).  
 
1.2.5 Treatment 
There are different treatment modalities that mainly depend on: severity of TTTS, 
gestation, and fetoscopic access.  
 
1.2.5.1 Septostomy 
Prior to the invention of FLA, amniotic septostomy was performed whereby a hole 
was created in the inter-twin membrane, converting the twins from MCDA to MCMA. 
Septostomy attempted to rebalance the differing amniotic fluid levels. However it 
makes diagnosis of TTTS recurrence more difficult, does not treat the underlying 
cause of TTTS, and may create the additional problems of preterm prelabour rupture 
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of membranes (PPROM), amniotic band syndrome and cord entanglement. As a 
result of the risk of the latter, earlier delivery at 32-34 weeks is required. Septostomy 
is no longer routinely practised, but does occur inadvertently in approximately 20% of 
pregnancies treated with FLA (Peeters 2014a). 
 
1.2.5.2 Termination 
Selective termination of the recipient twin was the main treatment for TTTS prior to 
the invention of FLA, particularly in severe TTTS (Taylor 2002), but is less common 
now due to the success of FLA. More recently, selective termination is usually only 
performed if there is evidence of a severe brain injury or concurrent severe growth 
discordance (see section 1.3.5 for more details) (Fisk 2009). 
 
1.2.5.3 Fetoscopic laser ablation (FLA) and amnioreduction 
For women diagnosed as stage II or worse, the gold standard of treatment prior to 26 
weeks gestation is FLA (Roberts 2014). FLA involves the percutaneous insertion of a 
2mm fetoscope through a 3.3mm port into the recipient twin’s amniotic fluid sac 
under ultrasound guidance. A laser fibre of 500μm is inserted under direct fetoscopic 
guidance and used to coagulate all inter-twin AVAs, using the inter-twin membrane 
for guidance. A trial examining FLA technique reported that the Solomon Technique, 
whereby the ablated AVAs are “joined up” by ablating along the vascular equator, left 
fewer residual unablated anastomoses than the selective technique of only ablating 
the AVAs (Slaghekke 2014a), thus reducing the rate of twin anaemia polycythaemia 
sequence (TAPS) and recurrent TTTS (Slaghekke 2014b). No difference was seen in 
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perinatal mortality, and a subsequent study revealed no difference in 
neurodevelopmental comorbidity at 2 years of age (van Klink 2016) with the two 
techniques, but the Solomon technique is preferred. FLA is performed under local 
anaesthetic and sedation, or spinal anaesthetic. Following completion of FLA, 
amnioreduction is then performed in which the amniotic fluid is drained from the 
recipient twin’s sac to a MPD of 5-6cm. Before the invention of FLA, amnioreduction 
was performed alone, and repeated as necessary. It is thought that amnioreduction 
reduces the intra-amniotic pressure thus reducing the risk of preterm labour, and 
allowing placental vessels to open further and improve placental blood flow (Garry 
1998). However, as with any procedure involving the insertion of a needle into the 
uterus, it is associated with a risk of infection, preterm birth, and the polyhydramnios 
may recur. 
 
The Eurofetus Trial, an international multicentre trial performed in 1999-2002, 
randomised 172 women to FLA or amnioreduction) and reported higher survival 
rates, and lower neurological comorbidity, in those who underwent FLA (Senat 2004). 
Amnioreduction is currently performed if the patient is unable to travel to a Centre 
that performs FLA, or is a therapeutic option if TTTS is diagnosed after 26 weeks 
gestation. In the latter, the risks of continuing the pregnancy and performing serial 
amnioreductions need to be weighed against the risks of preterm iatrogenic delivery, 
and the administration of antenatal corticosteroids for fetal lung maturation should be 
considered.  
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Effect of FLA on cardiac function 
The recipient twin cardiac function slightly worsens during FLA, but improves 
following FLA (Gratacós 2002a, Barrea 2006, Habli 2008b, Papanna 2011, Gapp-
Born 2014, Finneran 2017, Wohlmuth 2017, Henry 2018, Ortiz 2018), with 
improvement in function demonstrable within 48 hours of FLA (Van Mieghem 2009c, 
Wohlmuth 2017). The donor twin may exhibit temporary signs of cardiac overload 
with tricuspid insufficiency and abnormal ductus venosus (DV) flow (Van Mieghem 
2009c), likely due to the sudden hypervolaemia on a background of vasoconstriction 
that can cause transitory hydrops (Gratacós 2002b) and increased umbilical artery 
pulsatility index following FLA (Wohlmuth 2017). By 4 weeks post-FLA many recipient 
and donor twins display a normal cardiac function (Van Mieghem 2009c). This is 
thought to be due to the interruption of transfer of fluid and vasoactive mediators 
between the twins through the ablated anastomoses (Wohlmuth 2017). This 
remodelling is quicker in-utero than after birth which may be a consequence of fetal 
cardiomyocytes having plasticity and being able to replicate in-utero, whereas this 
ability is lost after birth (Ahuja 2007, Drenckhahn 2008). Cardiac dysfunction is not 
resolved in all twins and acquired structural anomalies can develop, most commonly 
in the form of right ventricular outflow tract (RVOT) anomalies in recipient twins 
(Michelfelder 2015), and coarctation of the aorta in donor twins (van den Boom 
2010), although the latter is less well substantiated (Manning 2016). RVOT 
anomalies include valvular dysplasia, stenosis and regurgitation and may require 
postnatal intervention (Bajoria 2002, Moon-Grady 2011, Michelfelder 2015). MC twins 
have a higher background risk of congenital heart disease compared to singletons, 
  
22 
 
with estimates around 4-11% for at least one twin. Often these defects are discordant 
between the twins. In TTTS pregnancies, the rate of postnatal RVOT anomalies is 
above 20%. 
In the long term, although the systolic and diastolic blood pressure of both the 
recipients and donors is still raised at 2 years of age (Pruetz 2015), by 10 years no 
significant cardiac dysfunction is evident (Gardiner 2014, Herberg 2014). 
 
Effect of FLA on renal function 
Measuring fetal levels of biomarkers related to renal function, such as ANP, BNP or 
endothelin-1, post-FLA is difficult for ethical reasons as it would require an invasive 
procedure for which there is rarely a concurrent clinical indication. Samples post-
delivery have been collected but this is a logistical challenge as often deliveries are 
preterm and vaginal, and women deliver at their referring hospital which is usually not 
the hospital they attended for FLA. One group that did collect amniotic fluid samples 
at caesarean section to assess ANP, BNP and endothelin-1 also collected amniotic 
fluid samples at time of fetal blood sampling and combined the groups, thus the 
range of time at which samples were collected was 20-36 weeks gestation and it is 
difficult to interpret these results (Bajoria 2003). Consequently the best measure of 
renal function in-utero is the MPD, which does increase in the donor twin following 
successful FLA. 
 
A study from the Netherlands found that in the neonatal period, twins with TTTS who 
underwent FLA had a better renal function than twins with TTTS who underwent 
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expectant management or serial amnioreduction (Verbeek 2017). The definition of 
renal function used was based on: urine output on days 1-3, creatinine and urea 
levels at days 3-7 of life, although the bodily fluid measured was not clear. Only 7.1% 
of survivors treated with FLA had a creatinine level >100μmol/L, compared to 37.9% 
of survivors who did not undergo FLA (p<0.01). As the study highlights, large, long-
term studies are required, with a clear explanation as to how renal function was 
assessed. 
 
When to perform FLA 
For women with Quintero stage I TTTS there is debate as to whether conservative or 
active management is best. Quintero stage I TTTS progresses in 27% [95%CI 16-
39%) according to a meta-analysis of 7 studies (172 pregnancies) (Khalil 2016a) thus 
three quarters will regress or remain stable, but it is not currently possible to identify 
those pregnancies that will regress and those that will progress. Consequently it is 
not clear whether stage I should be managed conservatively with continued 
surveillance, or with intervention (FLA). An international multicentre cluster 
randomised controlled trial (RCT) (NCT01220011) is being performed to answer this 
question and is due to report in Spring 2019 (Ville 2010).  
 
1.2.6 Outcome 
Without FLA, the perinatal mortality rate is up to 90% (Haverkamp 2001). With FLA 
the rates of adverse outcomes have decreased over time (Akkermans 2015), and are 
thought to be related to operator experience (Morris 2011, Peeters 2014b). A 
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systematic review of 37 studies which described 3868 women who underwent FLA 
between 1990 and 2015 reported a rate of perinatal survival of at least one twin in 
81% (SD 8.3), both twins in 52% (SD 14.8) and only one twin in 20% (SD 10.5) 
(Akkermans 2015). A sub-group analysis was performed to compare the rate of 
perinatal survival pre-2011 to post-2011 and revealed a significant increase in the 
perinatal survival rate of both twins (31% to 62%) and at least one twin (70% to 88%) 
over time. This does still mean that even with treatment at least 12% of pregnancies 
will result in a double fetal loss.  
 
A major contributor to perinatal mortality and long-term outcome in TTTS 
pregnancies is PTB, with PTB occurring in up to 17% <28 weeks gestation, 30% <32 
weeks gestation, and 50% <34 weeks gestation after FLA for TTTS (Robyr 2005, 
Yamamoto 2005). A review of 1092 pregnancies treated with FLA for TTTS found 
that fetal survival and PPROM rates had risen significantly over the 16 year study 
period (Stirnemann 2018). The authors argue that the focus should move from IUFD 
prevention, to strategies to prevent PTB and treat PPROM as these are now the 
current main postoperative complications. There are no effective prediction or 
prevention methods at present and research in this area is ongoing, but beyond the 
scope of this thesis.  
 
Neurodevelopmental comorbidity is decreased by FLA (Salomon 2010), but even 
with FLA still affects approximately 10% of pregnancies (Rossi 2011). A core 
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outcome set to stipulate which outcomes should be reported in TTTS research is 
being developed (Perry 2018). 
 
TTTS is viewed as one disease on a spectrum of feto-fetal transfusional disorders. 
TAPS is a gradual process that may occur following treatment for TTTS (2-13% 
TTTS pregnancies) or spontaneously (3-5% MC twins) (Slaghekke 2010, Tollenaar 
2016). It is defined as a large difference in the inter-twin haemoglobin levels, without 
twin oligo-polyhydramnios sequence (TOPS) and is due to tiny (<1mm) AVAs. Post-
FLA pregnancies should be monitored for TAPS (Kilby 2016) and the anaemic fetus 
may require cordocentesis and in-utero transfusion. 
 
1.2.7 Psychological impact of TTTS on parents 
Given the high-risk nature of TTTS pregnancies, and the wide range of possible 
outcomes, there has been little research on the psychological and emotional effects 
TTTS has on parents. Only one study was identified which has explored antenatal 
materno-fetal attachment in TTTS pregnancies, and they found that whilst attachment 
increased in mothers of uncomplicated MC and DC twins, it did not increase in 
mothers whose pregnancies were complicated by TTTS (Beauquier-Maccotta 2016). 
The same study also reported greater antenatal and postnatal depressive symptoms 
in mothers with pregnancies affected by TTTS. The effect on fathers does not appear 
to have been examined. CHAPTER 8 will look at the impact of TTTS on attachment 
and depressive symptoms in mothers and fathers as these factors are known to 
affect future child development. 
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As FLA is a relatively new treatment, long-term follow up studies looking at effects on 
subsequent pregnancies are only just able to be published. FLA appears to have no 
adverse effect on future obstetric and gynaecological health (Le Lous 2018, Vergote 
2018). However, adverse psychological and emotional effects on mothers at a 
median of 7 years post-FLA are still apparent (Vergote 2018). 
 
1.2.8 Prediction of adverse outcome following diagnosis of TTTS 
Some studies have attempted to create a model to predict the outcome following 
diagnosis and treatment of TTTS, although none are suitable for clinical application at 
present (Stirnemann 2013). As TTTS can be viewed as a predominantly 
cardiovascular disorder, the ability to include measures of cardiac disease may aid 
prediction of outcome of TTTS. This is particularly important given that severe 
cardiac dysfunction can result in poor end-organ perfusion and long-term 
neurological comorbidity. Current studies are conflicting whether the severity of 
cardiac impairment can predict survival (Stirnemann 2010b, Van Mieghem 2013, 
Delabaere 2016). As there are other factors that influence the outcome of TTTS, 
including technical surgical factors, and placental territory proportions, it is likely that 
cardiac function assessment alone is unable to predict outcome. There is a line of 
thought that duration rather than severity of cardiac disease is more influential on 
recovery (Van Mieghem 2013). Functional cardiovascular changes are present early 
in the disease process (Baschat 2011), prior to the diagnosis of TTTS (Barrea 2005, 
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Van Mieghem 2011b, Zanardini 2014), therefore the ability to predict which 
pregnancies will develop TTTS with severe cardiac sequelae may be possible.  
 
A potential way to improve the prognostic ability of these scores is to add biomarkers 
to the ultrasound measures. As well as possibly improving prognostic ability, the use 
of biomarkers is not as time-consuming for clinicians compared to detailed 
echocardiography, and inter- and intra-observation variation is reduced. Furthermore, 
additional training is not required, or scanning resources. ANP and BNP are used as 
serum biomarkers of cardiac failure in adults and are present in the amniotic fluid of 
TTTS recipient twins (Bajoria 2001, Habli 2010), with BNP levels higher in TTTS 
recipient twins than in normal singleton pregnancies (Bajoria 2003, Van Mieghem 
2010). Individually, although increasing levels of amniotic fluid N-terminal 
prohormone BNP (NT-proBNP) is associated with worsening cardiomyopathy in the 
recipient twin, the sensitivities and specificities are sub-optimal (Bajoria 2002, Habli 
2010). Plasma BNP in women with pregnancies complicated by TTTS and MC twins 
without TTTS are not different (Bajoria 2002), therefore the use of BNP as a 
prognostic marker would require an invasive procedure. Endothelin-1 is used as a 
biomarker of adult cardiac failure with higher levels associated with higher mortality 
(Zhang 2017), and is present in the amniotic fluid of TTTS pregnancies. As with BNP, 
endothelin-1 is higher in the amniotic fluid of recipient twins than singletons and 
differences are also seen in fetal plasma (Bajoria 2002, Bajoria 2003). Cardiac 
troponin, another serum biomarker used in adults to denote myocardial damage, is 
also present in the amniotic fluid of recipient twins (Van Mieghem 2010), but again 
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the clinical utility is yet to be determined. New biomarkers need to be identified and 
CHAPTER 5 investigates the potential use of metabolomics in predicting cardiac 
dysfunction. 
 
1.3 Growth restriction 
 
1.3.1 Epidemiology and pathophysiology 
Although not unique to MC twins, growth restriction, particularly selective intrauterine 
growth restriction (sIUGR), is more common in MC twins than DC twins affecting 10-
25% of MC twins (Lewi 2008a). As MC twins are MZ, differences in growth cannot be 
explained by genetic factors (Gao 2012). The factor believed to be most important in 
growth discordance is placental territory (Lewi 2013), which correlates strongly with 
birthweight discordance (BWD) (Denbow 2000). Unequal placental sharing equates 
to a decreased area for nutrient transfer, gaseous exchange and removal of waste 
products and thus affecting fetal growth. Velamentous cord insertion is often 
associated with abnormal placental sharing, and growth discordance (Konno 2018) 
(see section 1.3.2 for more details). Placental anastomoses also play a role. Unlike 
TTTS which is associated with unbalanced unidirectional AVAs and a lack of AAAs, 
growth discordance and unequal placental sharing is associated with large 
bidirectional AAAs, AVAs with a large net flow, and a large total diameter of 
anastomoses that appear to equalise inter-twin blood flow (Lewi 2013, De Villiers 
2015). Thus it is believed that twins with greater inter-twin blood flow will be 
associated with milder growth restriction and a better outcome, than growth restricted 
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fetuses with less inter-twin blood flow (Bennasar 2017). It is thought that blood is 
‘transfused’ from the larger twin to the growth restricted twin, ameliorating the 
placental insufficiency and ‘rescuing’ the growth restricted twin (Denbow 2000). This 
may explain why 20% of the larger twins with Gratacós Type III growth restriction 
develop hypertrophic cardiomyopathy, compared to 2.5% of Type I and II, because 
they are acting as a “pump” to rescue the smaller twin (Munoz-Abellana 2007). The 
large AAAs produce an umbilical artery Doppler waveform unique to MC twins with 
‘cyclical’ intermittent absent/reversed end diastolic flow (AREDF) and positive EDF, 
this is discussed further in section 1.3.4. Differences in placental characteristics have 
been noted between those with early-onset growth restriction, defined as prior to 20 
weeks gestation, and late-onset growth discordance (Lewi 2008a). Placentas from 
early-onset growth discordance MCDA twin pregnancies demonstrate more unequal 
placental territories, larger AAAs and a larger total diameter of anastomoses 
compared to those with late-onset discordant growth. The latter group was not 
significantly different to placentas taken from concordant MCDA twin pregnancies, 
suggesting that different pathophysiological mechanisms may be involved in growth 
restriction.  
 
Growth restriction in MC twins can also be non-selective (non-sIUGR) in which both 
fetuses are IUGR. This is less commonly reported than sIUGR (2.7% vs 34.5% 
respectively in a Chinese cohort) (Gao 2012), and is more difficult to diagnose as 
outlined in section 1.4.4. The pathophysiology of non-sIUGR is likely to be different to 
that of sIUGR, however there has been little research on non-sIUGR as the majority 
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has focused on sIUGR (Gao 2012). In theory, the pathophysiological process should 
affect the whole placenta, so the cause may be genetic or viral, and environmental 
factors known to affect fetal growth in singleton pregnancies such as maternal diet, 
smoking status and drug taking could also play a part (Denbow 2000), although 
evidence in twin pregnancies is conflicting (Schwendemann 2005, Fox 2011). The 
sparse literature that does exist either makes no distinction between non-sIUGR and 
sIUGR (Chang 2009, Fox 2011), or the number of non-sIUGR twin pregnancies 
included have been too small (Gao 2012). 
 
1.3.2 Prediction of growth restriction 
First trimester 
At present it is not possible to predict which pregnancies will develop growth 
restriction, based on factors measured in the first trimester. CHAPTER 2 will 
systematically review and meta-analyse existing literature on first trimester potential 
prognostic factors. CHAPTER 3 will assess existing factors identified by the 
systematic review in a retrospective cohort. 
 
Second and third trimester 
The same systematic review that reported no association between velamentous cord 
insertion and TTTS did report a significant association between velamentous cord 
insertion and selective fetal growth restriction, and BWD >20%. The authors suggest 
this is due to velamentous cord insertions being more likely to be compressed, thus 
reducing the blood flow (Kalafat 2017). When this relationship was examined in the 
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study that used antenatal assessment of umbilical cord insertion site, selective 
growth restriction was associated with velamentous cord insertion in one twin but 
poor positive and negative predictive values were reported (Couck 2017). The 
Gratacós classification divides twins into three types of sIUGR based on umbilical 
artery Doppler findings and is associated with clinical outcome, this is outlined in 
Table 1.2 in section 1.3.4.  
 
1.3.3 Signs and symptoms 
The measurement of symphysis-fundus height in multiple pregnancy is not 
recommended. Women who develop growth restriction later in pregnancy may notice 
decreased fetal movements but the majority of growth restriction is diagnosed on 
routine ultrasonography, see section 1.7. 
 
1.3.4 Diagnostic criteria and staging 
As alluded to, growth restriction in twin pregnancies is difficult to diagnose for various 
reasons. As in singletons, it is important to delineate between small for gestational 
age (SGA) fetuses which are constitutionally small, and those that are pathologically 
growth restricted. Another problem common to both singleton and twin pregnancies is 
that ultrasound measurement of fetal growth is not always correct. The accuracy of 
ultrasound assessment of fetal growth in twin pregnancies is even lower than in 
singleton pregnancies however it is the best imaging modality most widely available 
(Leombroni 2017, Neves 2017, Kadji 2018). 
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A particular issue specific to growth restriction in twin pregnancy is the myriad of 
definitions used to define pathological growth. The results of a Delphi procedure to 
formulate a consensus definition of sIUGR were published in January 2018 (Khalil 
2018). The definition for MC twins was: (i) estimated fetal weight (EFW) <3rd centile 
in one twin; or (ii) two out of the following four parameters: EFW <10th centile in one 
twin, abdominal circumference (AC) <10th centile in one twin, estimated fetal weight 
discordance (EFWD) ≥25%, umbilical artery pulsatility index >95th centile in the 
smaller twin. This differed to the definition in DC twins which did not include AC as an 
acceptable measure. These definitions require validation prior to clinical use. 
Although a consensus definition has been decided, the issue remains that there are 
no published validated twin-specific growth charts available at present. The expert 
panel in the Delphi procedure did not state twin-specific or customised growth charts 
as essential parameters, despite studies demonstrating a significant difference in 
singleton and twin growth, particularly later in pregnancy (Ong 2002, Liao 2012, 
Odibo 2013, Stirrup 2014). The use of twin-specific growth charts may change in the 
future as groups in the UK (Kalafat 2018), Spain (Torres 2017), Italy (Ghi 2017), and 
Slovenia (Bricelj 2017) have recently developed twin-specific growth charts. These 
charts require vigorous validation before they can be used in a routine clinical 
context.  
 
Prior to the publication of the Delphi procedure, the most widely accepted definition of 
sIUGR was EFWD ≥25% with one twin concurrently below the 10th centile. MC 
pregnancies fitting this definition can be sub-divided based on umbilical artery 
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Doppler findings in the smaller twin as described by Gratacós et al. (Gratacós 2007) 
(Table 1.2). The different types reflect different placental angioarchitecture and unlike 
the Quintero staging of TTTS, pregnancies do not progress through Gratacós 
classification types (Lopriore 2012). 
 
Table 1.2 Gratacós classification of selective intrauterine growth restriction 
EDF: end diastolic flow, GA: gestational age. *taken from Bennasar et al. (Bennasar 
2017). †taken from a systematic review of 610 MC twin pregnancies by Buca et al. 
(Buca 2017) 
 
Type Umbilical artery Doppler 
Typical placental 
features* 
Proportion of 
Type (%) 
(95%CI)† 
GA at 
diagnosis 
(weeks) mean 
(95%CI)† 
I positive EDF 
Milder discordance in 
placental territories and/or 
large number of inter-twin 
anastomoses 
39.0 
(35.1, 43.0) 
26.5 
(22.2, 30.9) 
II 
persistently 
absent/ reversed 
EDF 
Substantial discordance in 
placental territories and 
number and diameter of 
placental anastomoses 
smaller than type I 
38.2 
(34.3, 43.0) 
21.1 
(19.4, 22.8) 
III 
intermittent 
absent/reversed 
EDF 
Large discordance in 
placental territories, large 
placental AAAs, short 
distance between placental 
cord insertion sites 
22.8 
(19.5, 26.3) 
20.2 
(15.2, 25.3) 
 
 
1.3.5 Treatment 
There is no specific guidance on how to treat, and when to deliver growth restricted 
twin pregnancies (Buca 2017). Management may vary depending on gestational age, 
Gratacós classification and if there is evidence of fetal deterioration as assessed by 
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DV Doppler. Expectant management is often employed for sIUGR Type I, with 
weekly umbilical artery Doppler assessment, and bi-weekly ultrasonography fetal 
growth measurement. The management of Type II and III is less clear.  
 
FLA of anastomoses may be an option before viability, but is not routinely offered for 
growth restriction at present, and choosing candidates is difficult (Bennasar 2017). 
Survival rates are not as good as in TTTS, a study published in 2015 reported that at 
least one twin survived in 71.8% (102/142), and both twins survived in 34.5% 
(49/142) (Peeva 2015). FLA for IUGR is technically more difficult than in TTTS as 
there is no polyhydramnios (Quintero 2001). There is a train of thought that as some 
anastomoses may be beneficial to the growth restricted twin, ablating them may in 
fact worsen the growth restricted twins prognosis which is an additional complexity of 
the procedure (Lewi 2013). The National Institute for Health Research has issued a 
commissioned call for a Health Technology Assessment Programme grant to perform 
a feasibility study of an RCT of intervention or expectant management for early-onset 
fetal growth restriction which will determine whether an RCT in this complex area is 
feasible (NIHR 2017).  
 
If the prognosis is extremely poor, termination of the whole pregnancy may be 
discussed. This is performed by injecting potassium chloride. Selective feticide of the 
growth restricted fetus is also an option and is used in an attempt to save the 
normally grown twin. This is performed by ultrasound guided bipolar cord occlusion 
(BCO), or intrafetal radiofrequency ablation (RFA). The overall survival rate of the co-
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twin following BCO is 79.1% (95%CI 71.3-87.5) (459 procedures), and 76.8% (95%CI 
67.6, 87.2) (310 procedures) following RFA although the systematic review reporting 
these rates was unable to perform sub-group analysis according to those performed 
for sIUGR (Gaerty 2015). A study that performed BCO for Type II and III sIUGR 
reported a survival rate of 93.4% (84/90), and 92.9% (78/84) delivered after 32 weeks 
gestation (Parra-Cordero 2016).  
 
1.3.6 Outcome 
The outcomes of sIUGR pregnancies can vary and may be linked to Gratacós 
classification/placental anastomoses (Table 1.3). 
 
Table 1.3 Outcome of selective intrauterine growth restricted pregnancies 
according to Gratacós classification 
(taken from a systematic review of 610 monochorionic twin pregnancies by Buca et 
al. (Buca 2017), does not include pregnancies with concurrent TTTS that underwent 
fetal therapy) GA: gestational age, IUFD: intrauterine fetal death 
  
Type IUFD (%) (95%CI) 
Overall perinatal 
mortality (%)  
(95%CI) 
Abnormal brain 
imaging (%)  
(95%CI) 
GA at delivery 
(weeks) mean  
(95%CI) 
I 3.1 (1.6, 5.0) 
4.1 
(1.2, 8.7) 
3.82 
(0.5, 10.0) 
33.7 
(33.0, 34.3) 
II 11.0 (4.1, 20.6) 
16.1 
(4.6, 32.7) 
14.15 
(6.7, 23.8) 
30.9 
(30.0, 31.8) 
III 9.6 (6.2, 13.6) 
11.5 
(7.7, 16.0) 
11.88 
(4.6, 22.0) 
32.0 
(31.3, 32.8) 
 
Pregnancies classified as sIUGR Type II have a significantly worse perinatal mortality 
rate (OR 4.1 [95%CI 1.6, 10.3]) and higher rate of abnormal postnatal brain imaging 
(OR 4.9 [95%CI 1.9, 12.9]) than Type I (Buca 2017). No significant difference is seen 
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between Type II and III in these outcomes. When smaller twins were compared to 
larger twins, in Type II the smaller twins had a significantly higher perinatal mortality 
rate than the larger twin (OR 2.4 [95%CI 1.3-4.4]), but no difference was seen 
between the larger and smaller twins in Type I and Type III. This fits with Type II 
being associated with smaller anastomoses, and thus “rescue” transfusion is unable 
to occur. The large AAAs associated with Type III mean that any change in blood 
pressure, for example during a bradycardia, has a substantial effect on the other twin 
and thus sIUGR Type III has an unpredictable clinical course (Buca 2017). This may 
explain why neurological comorbidity is seen in the normally grown twin from a 
sIUGR twin pregnancy with 2 survivors. The mean gestational age at delivery 
demonstrates that prematurity is a major problem for sIUGR pregnancies. 
 
The outcome of non-sIUGR pregnancies are worse than sIUGR pregnancies which is 
perhaps not surprising considering both twins are pathologically growth restricted 
(Gao 2012, Ananicz 2016).  
 
1.4 Intrauterine fetal death (IUFD) 
 
1.4.1 Epidemiology and pathophysiology 
Single IUFD (sIUFD) after 14 weeks gestation is thought to affect 4% of MC twins, 
whereas double (dIUFD) occurs in 6%, however these rates are from a study over 20 
years old, during which time antenatal care of twin pregnancies has changed, and all 
IUFDs were included irrespective of cause (Sebire 1997). An ongoing study by the 
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UK Obstetric Surveillance System (UKOSS) aims to report the rate of spontaneous 
single MC twin demise in the UK, and subsequent adverse outcomes (UKOSS 2016). 
sIUFD and dIUFD may be secondary to underlying aforementioned pathology: TTTS, 
TAPS, growth restriction, but the pathophysiology surrounding spontaneous IUFD is 
less clear. What is known is that shared circulation means sIUFD may lead to brain 
injury and/or dIUFD due to the acute exsanguination of the surviving co-twin and 
consequent hypoperfusion, secondary to the extreme hypotension that occurs at the 
death of the first twin resulting in hypoxic-ischaemic injury to the surviving co-twin’s 
central nervous system and potentially IUFD. The presence of large bidirectional 
anastomoses, particularly VVAs, appears related to a worse prognosis (Denbow 
2000, De Villiers 2015), although there are no specific placental characteristics 
unique to IUFD.  
 
1.4.2 Prediction of IUFD 
First trimester 
Currently, it is not possible to predict which pregnancies will develop IUFD based on 
factors measured in the first trimester. CHAPTER 2 will systematically review and 
meta-analyse existing literature on first trimester potential prognostic markers. 
CHAPTER 3 will assess existing factors identified by the systematic review in a 
retrospective cohort. 
 
  
38 
 
Second and third trimester 
One study has attempted to create a score to predict IUFD and neonatal death 
(NND) from 26 weeks gestation onwards, but did not demonstrate acceptable 
predictive ability to aid clinical care (Oohashi 2014).  
 
1.4.3 Signs and symptoms 
As with singleton pregnancies, IUFD may occur with no warning and be detected at 
the woman’s next ultrasound scan. Some women report decreased fetal movements, 
but this can be difficult to delineate if the other twin is still alive and moving. 
 
1.4.4 Diagnostic criteria 
This is confirmed by the absence of a fetal heartbeat on ultrasound scan. 
 
1.4.5 Management 
There is no specific guidance for the management of the surviving co-twin. 
Immediate preterm delivery of the surviving co-twin at diagnosis of the sIUFD is not 
advised unless the surviving co-twin is in fetal distress. Middle cerebral artery peak 
systolic velocity (MCA-PSV) measurement can be performed to assess for the 
presence of fetal anaemia, indicating major exsanguination and a worse prognosis 
for the surviving co-twin (Senat 2003). There is no evidence at present that in-utero 
transfusion improves outcome. Detailed brain imaging is advised for all co-twin 
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survivors, ideally by fetal MRI 4 weeks after the IUFD, to assess for brain injury (Kilby 
2016, Mackie 2016). 
 
1.4.6 Outcome for surviving co-twin 
If the sIUFD occurs prior to 14 weeks there is no effect on the health of the surviving 
co-twin and the dead fetus is reabsorbed into the mother’s body. If the sIUFD occurs 
after 14 weeks gestation the outcome for the surviving co-twin may be worse, 
depending on the type and direction of blood flow in the inter-twin anastomoses. A 
systematic review published in 2011 reported that subsequent co-twin death occurred 
in 15% of MC twins, PTB in 68%, and neurodevelopmental problems in 25% (Hillman 
2011). This systematic review and meta-analysis has been updated in CHAPTER 7 
with a focus on spontaneous IUFD, and additional outcomes have been explored to 
enable more tailored patient counselling.  
 
1.5 Preterm birth (PTB) 
 
PTB is a major cause of perinatal morbidity and mortality in twin pregnancies, with 
the majority of MC twins delivering before 37 weeks, according to international 
guidance (Khalil 2016b, Kilby 2016). The causes of PTB are multi-factorial and 
beyond the scope of this thesis.  
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1.6 Maternal complications 
 
Women with twin pregnancies are at higher-risk of various pregnancy complications 
compared to women with singleton pregnancies, including: gestational diabetes 
mellitus (GDM), gestational hypertension, pre-eclampsia, eclampsia, post-partum 
haemorrhage, and caesarean section (Roach 1998, Conde-Agudelo 2000, Campbell 
2004, Rao 2004, Rauh-Hain 2009). When these complications are examined in the 
context of chorionicity, no difference has been demonstrated between MC and DC 
twins in incidence of GDM and caesarean section, and although studies are 
conflicting regarding pre-eclampsia, the general consensus is that there is no 
difference in chorionicities (Carter 2015). This supports that these complications are 
related to the presence of greater placental mass, rather than characteristics inherent 
to MC or DC twins specifically. 
 
1.7 Monochorionic twins antenatal care surveillance 
 
1.7.1 Uncomplicated monochorionic twins 
In the first trimester, all twin pregnancies should undergo ultrasound examination to 
assess: gestation of pregnancy based on crown-rump length (CRL), chorionicity, the 
position and labelling of the twins, and major congenital malformations (NICE 2011, 
Kilby 2016). Screening for aneuploidy should be offered (see CHAPTER 3 for more 
detail). Risks of MC twins should be outlined to parents. As it is currently not possible 
to predict which pregnancies will develop TTTS, growth restriction or IUFD, all MC 
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twins are closely monitored. According to national and international guidance, all MC 
twin pregnancies should undergo ultrasonographic assessment of fetal growth, liquor 
volume, and umbilical artery Doppler assessment every 2 weeks, from 16 weeks 
gestation to assess for signs of TTTS and/or sIUGR (Figure 1.8) (ACOG 2016, Khalil 
2016b, Kilby 2016, RANZCOG 2017). It is not known if this is the best model of care, 
but it is not ethically acceptable to decrease the level of antenatal surveillance, 
despite the fact that the majority of MC twins will not develop TTTS or growth 
restriction, and the resources and patient and health care professional time involved 
in this monitoring is intensive (McDonald 2017). A Cochrane review (Woolcock 2017) 
attempted to look at ultrasound surveillance regimes in twin pregnancies, but was 
only able to include one study (Giles 2003) which compared performing umbilical 
artery Doppler assessment at 25, 30 and 35 weeks gestation to not performing 
umbilical artery Doppler assessment, but was inadequately powered to demonstrate 
a statistically significant difference in outcome.  
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1.7.2 Complicated monochorionic twins 
If TTTS or EFWD >20% is suspected, referral to a tertiary fetal medicine centre is 
advised (Kilby 2016). If a woman has undergone FLA for TTTS, she should be 
monitored for TAPS by MCA PSV measurement. Women with a sIUFD after 14 
weeks gestation should also be referred to a fetal medicine centre for further 
assessment, particularly of potential brain injury.  
 
Figure 1.8 Antenatal surveillance in uncomplicated monochorionic twins 
(taken from RCOG Green-top guidance (Kilby 2016) and ISUOG (Khalil 2016b)) 
AREDV: absent or reversed end-diastolic velocities, DVP: deepest vertical pocket, 
EFW: estimated fetal weight, FASP: Fetal Anomaly Screening Programme, UA: 
umbilical artery, UAPI: umbilical artery pulsatility index 
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1.7.3 Mode of delivery 
In uncomplicated MC twins, to lower the risk of IUFD, delivery is recommended at 
36+0-37+0 weeks gestation, with antenatal corticosteroid cover (Kilby 2016). Mode of 
delivery is dependent on the presentation of the 1st twin and maternal choice. If the 
1st twin is breech presentation, caesarean section is recommended. If the 1st twin is 
cephalic, vaginal delivery or caesarean section may be chosen. Women should be 
counselled regarding the higher risk of post-partum haemorrhage associated with all 
multiple pregnancies and thus active management of the third stage of delivery. The 
possibility of acute intrapartum TTTS should be discussed and continuous electronic 
fetal monitoring used to aid detection. If vaginal delivery is chosen, the possibility of 
requiring an emergency caesarean section for the 2nd twin should also be conferred. 
MC twins with a history of treated TTTS should be delivered between 34+0-36+6 
weeks gestation (Kilby 2016). The guidance for timing of delivery of pregnancies 
affected by sIUGR is less clear, and should be decided on an individual case basis, 
based on fetal growth velocity, umbilical artery and DV Doppler velocity waveforms. 
   
1.8 Prediction and prognosis of complications 
 
1.8.1 Prediction, prognosis and risk factors 
Prediction is a general term that encompasses diagnosis (the presence of a disease 
at that time) and prognosis (the future outcome risk). As this thesis is investigating 
the risk of developing a complication in the future, not the presence or absence of a 
complication at that present moment in time, this is prognostic research, not 
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diagnostic research. According to the international Prognosis Research Strategy 
(PROGRESS) Group, in clinical medicine “prognosis refers to the risk of future health 
outcomes in people with a given disease or health condition” (Hemingway 2013). It is 
thus the examination of the relationship between a baseline health state (startpoint) 
and a future outcome (endpoint). This may be from a startpoint of a clinical context 
such as pregnancy and examining the natural course of pregnancy and future 
development of complications, or it may be from the startpoint of the diagnosis of a 
pregnancy complication and the future outcome as a result of different treatments. 
This thesis will focus on the former as it does not investigate the effectiveness of 
treatment. In CHAPTER 2 and CHAPTER 3 the startpoint is MC twin pregnancy, and 
the endpoint is diagnosis of an adverse complication e.g. TTTS, growth restriction or 
IUFD. In CHAPTER 7 the startpoint is spontaneous sIUFD and the endpoint is the 
outcome for the surviving co-twin e.g. co-twin death, PTB, abnormal brain imaging. 
The first step in prognostic research is investigating potential prognostic factors. 
 
1.8.2 Prognostic factors 
A prognostic factor is any measure present in the startpoint population that is 
associated with a future outcome (Riley 2013). The term ‘risk factor’ is often used 
interchangeably with ‘prognostic factor’, but the former term is more appropriately 
reserved to indicate causal factors of disease onset. Whilst some prognostic factors 
are causal, the majority are not. The term ‘predictive factor’ may also be used, but as 
described previously, this is a more generic term and is not specific to prognosis, 
therefore the term ‘prognostic factor’ will be used in this thesis. Prognostic factors 
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may be: maternal characteristics such as body mass index (BMI); biomarkers such 
as metabolites or ultrasound measures; or symptoms or behavioural characteristics 
such as concurrent depression. These factors may already be known to be 
prognostic in clinical situations, or studies may be performed to discover novel 
potential prognostic factors based on biological feasibility and hypotheses of 
pathophysiology. To assess a potential prognostic factor, the association between 
the factor and outcome should be calculated, and its prognostic ability above existing 
prognostic factors ascertained (see section 3.4.8 for more details).  
 
Establishing individual prognostic factors may inform diagnosis, highlight new 
disease sub-types, indicate disease progression, identify modifiable targets for 
intervention, and aid prediction of treatment response (see section 1.8.4). Prognostic 
factors can also be used in further research to inform sample size, randomisation 
procedure, and analysis strategy in randomised trials. However, a combination of 
multiple prognostic factors in a prognostic model often has a better prognostic ability 
than individual prognostic factors (Riley 2013).  
 
1.8.3 Prognostic models 
The aim of a prognostic model is to accurately calculate the risk an individual has of 
reaching a specific endpoint. Prognostic models are usually developed using data 
from cohort studies, and performing multivariable logistic regression. A prognostic 
model should be developed according to a robust statistical methodology, be easy to 
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use in a clinical setting, acceptable by patients, externally validated in a different 
cohort, and its implementation should have a positive impact on patient care.  
 
To develop a prognostic model, several steps should be taken and various aspects 
should be reported, as outlined by the Transparent Reporting of a multivariable 
prediction model for Individual Prognosis Or Diagnosis (TRIPOD) statement (Moons 
2015). The performance of the model is indicated by the discrimination that describes 
the ability of the model to discriminate between patients with TTTS and those without 
TTTS for example. The calibration of the model is another indicator of performance 
and reports the agreement between the predictive outcome and the observed 
outcome. Once the initial model has been developed, this requires internal validation 
to demonstrate the reproducibility of the model in the setting where the model was 
originally developed. Internal validation may be performed by boot-strapping whereby 
random samples are taken from the original dataset to create an additional dataset. 
Following internal validation, external validation should be performed to demonstrate 
the applicability of the model to different patient populations, ideally this should be 
performed by independent investigators in a different geographical area. This step is 
important as most models perform well when they are internally validated, however 
their prognostic ability is often optimistic, thus external validation is required (Smith 
2014).  
 
To produce a clinically useful prognostic model, several criteria need to be fulfilled as 
highlighted by Cheong-See et al. (Cheong-See 2016). There should be a suitable 
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sample size, which is particularly hard for conditions considered relatively rare in the 
general obstetric population such as TTTS. The choice of prognostic factors is 
important and should be based on a systematic review of existing factors, and 
evaluation of individual prognostic factors, prior to being combined in a prognostic 
model (Kleinrouweler 2016). The measurement of the prognostic factors and 
outcome(s) must be reliable so that the model can be replicated in various clinical 
settings.  
 
As Cheong-See et al. highlight, many models, particularly in obstetrics, are not able 
to be used in clinical practice due to insufficient/non-existent external validation in a 
different cohort (Cheong-See 2016) and even fewer have been evaluated with 
regards to their impact on health outcome (Steyerberg 2013). This has been echoed 
by Kleinrouweler et al. who stated that there is “a rise in the number of prognostic 
models being published, including for obstetric outcomes, without the corresponding 
increase in the number of models being applied in practice”(Kleinrouweler 2016). 
Models should ultimately improve patient outcome by allowing timely prediction of 
adverse outcome and enabling subsequent prevention or treatment. A systematic 
review of obstetric prognostic models by Kleinrouweler et al. demonstrated that the 
majority of obstetric models do not meet these criteria and more work is required 
(Kleinrouweler 2016).  
If a validated prognostic model is created, they produce more accurate risk 
predictions than clinical intuition (Grove 2000), and ideally allow the implementation 
of stratified medicine. 
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1.8.4 Stratified medicine 
Stratified medicine is targeting care or treatment based on the risk shared by a sub-
group of patients with similar characteristics (Hingorani 2013). For patients this 
means they receive more tailored care based on their individual risk prediction 
determined by either the presence of prognostic factors or the output of a prognostic 
model, with the aim of achieving an improved outcome. This may be receiving the 
best treatment option for them, or preventing the use of a treatment that will not be 
beneficial to them. As well as improving individual patient care, stratified medicine 
also has financial implications by allowing treatments to be used more appropriately.  
 
In the setting of MC twin pregnancies, being able to stratify pregnancies as high-risk 
or low-risk in the first trimester could have several important effects. For those 
considered low-risk, patients could be reassured, and it may allow decreased 
antenatal surveillance. As previously highlighted, the majority of MC twin pregnancies 
will not develop TTTS or growth restriction for which additional ultrasonography is 
performed to detect. Decreased surveillance may improve patient satisfaction as they 
would not be required to attend antenatal clinic as frequently and have to arrange 
childcare or work cover. It would also decrease the impact MC twin pregnancies have 
on health care professionals’ time and clinic resources. However, the prognostic 
factor/model would have to be highly accurate, as the consequence of classifying a 
patient incorrectly as low-risk and decreasing surveillance may mean that TTTS is 
not detected until too late, and fetal death has occurred. Alternatively, low-risk 
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patients could continue with the current antenatal surveillance, and high-risk patients 
could receive additional surveillance such as more frequent ultrasonography, or 
earlier/additional assessment by a fetal medicine centre. This does have financial 
implications, but may prevent fetal death as TTTS is a highly morbid and rapidly 
progressive condition, and even with current surveillance every 2 weeks, fetuses still 
die before FLA. Identifying high-risk pregnancies may enable the development of 
new therapies, and prophylactic treatments that at present are not possible. 
 
The ability to predict which twins will develop a poor cardiac outcome following FLA 
may allow the targeted use of drugs such as nifedipine that has been associated with 
improved survival in recipient twins (Crombleholme 2010), and is currently being 
evaluated in an ongoing study (Gardiner 2018). It may also allow the opportunity to 
explore the use of other drugs such as digoxin (De Lia 1985, Arabin 1998) or 
sildenafil (Zaretsky 2014) either as adjuvants to FLA, novel pharmacological agents, 
or even first trimester prophylaxis. 
 
1.9 First trimester potential prognostic factors 
 
The first trimester potential prognostic factors examined in CHAPTER 3 are outlined 
in the chapter. 
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1.10 Potential prognostic factors from novel technologies 
 
Potential prognostic factors may be found using novel technologies. ‘-omics’ 
technologies are an evolving area of research that study the molecules of the whole 
biology of a system whether it is an organism, tissue, or cell. This is referred to as a 
holistic view, or high-dimensional biology (Horgan 2011). The molecular mechanisms 
of normal biological processes or disease processes can be studied. Another benefit 
of –omics technologies is that they are an ideal method to discover potential 
biomarkers. A large number of molecules can be explored simultaneously, various 
biofluids can be used, and experiments are hypothesis-generating i.e. no hypothesis 
is required before the study so the data are analysed and hypotheses are formed 
based on the results. 
 
1.10.1 Genomics 
Genomics covers the study of all DNA in an organism or cell. This can be in the form 
of the whole genome down to individual genes, or fragments of DNA such as cell-free 
fetal DNA. Although there are no published whole-genome arrays in TTTS 
pregnancies, there has been targeted gene work, for example examining renin gene 
expression in the fetal kidneys that is useful for understanding more regarding the 
pathophysiology (Kilby 1994).  
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1.10.2 Transcriptomics 
Transcriptomics investigate the transcriptome, which are factors involved in 
translation of genes for protein synthesis. Most commonly this is messenger RNA 
(mRNA), but miRNA is also included in this category. No published studies have 
looked at changes in miRNA in TTTS and this will be explored in CHAPTER 6. The 
data derived from transcriptomics can then be related to which genes they are 
associated with, and which biological functions they affect. 
 
A pilot study in 2005 demonstrated that cell-free fetal mRNA is present in the cell-free 
supernatant of amniotic fluid of TTTS pregnancies, and allows the investigation of 
fetal gene expression (Larrabee 2005). In 2013 the same group performed whole 
transcriptome analysis of cell-free RNA from amniotic fluid and reported a significant 
difference in the expression of 801 genes in samples from TTTS pregnancies prior to 
FLA compared to gestationally-matched singleton controls (Hui 2013). The group 
validated their findings in 4/6 genes they chose to validate: FLT1, NTRK3, NRXN3 
and AVPR1A. These genes are involved in cardiac and neurological development, 
and angiogenesis thus supporting that transcriptomics may be a useful tool to 
improve knowledge of TTTS pathophysiology, and provide potential candidates for 
fetal therapies in the future. Targeted work has also been performed based on initial 
transcriptomic studies. Miura et al. targeted 9 placenta predominant mRNAs in 
maternal plasma they had identified in singleton pregnancy transcriptomics. They 
found a significant difference in 6/9 mRNAs: hPL, PSG2, PSG3 syncytin, syncytin2, 
ADAM12, and suggested they may act as potential biomarkers for the development 
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of TTTS (Miura 2014). Fox et al. reported a significant difference in cell-free fetal 
mRNA in maternal plasma of: VEGF-A, Endoglin, and Ang-2 between women with 
TTTS and uncomplicated twin pregnancies (Fox 2012). Another study reported a 
higher fold count of mitochondrial RNA in placental tissue from pregnancies with 
TTTS and concurrent sIUGR compared to those with sIUGR but no TTTS (Chang 
2018). All these studies demonstrate that the transcriptome appears altered in TTTS 
and further research in this area is warranted.  
 
1.10.3 Proteomics 
Proteomics explore all the proteins expressed in the organism, tissue or cell and 
reflect the interaction between genes and the environment. Although many individual 
proteins have been examined in TTTS (Bajoria 1999a, Bajoria 2003, Adama van 
Scheltema 2005, Fox 2010, Van Mieghem 2010, Fox 2014a), see section 1.2.1.3, no 
hypothesis-generating studies were found where non-targeted proteomics were 
performed in the setting of TTTS.  
 
1.10.4 Metabolomics 
Metabolomics investigate metabolites, the phenotypes of metabolism, which 
represent the dynamic interaction between the genotype and its environment, and 
are the final downstream product. Consequently metabolomics may produce 
prognostic factors able to be used for prediction of diagnosis or prognosis, to stratify 
care, and improve knowledge of underlying molecular mechanisms (Beger 2016).  
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In singleton pregnancies, research using metabolomics is becoming increasingly 
popular with studies using the technique on various biofluids, including amniotic fluid, 
to examine IUGR (Horgan 2010, Diaz 2013, Stevens 2014), pre-eclampsia (Dunn 
2009, Kenny 2010, Bahado-Singh 2015, Bahado-Singh 2017, Chen 2017) PTB 
(Thomas 2015, Baraldi 2016, Cecatti 2016, Virgiliou 2017), GDM (Dani 2014, 
Lehmann 2015, Chorell 2017), maternal smoking (Fischer 2017), also specifically in 
the first-trimester for prediction of aneuploidy (Bahado-Singh 2013a) and pre-
eclampsia (Bahado-Singh 2012, Bahado-Singh 2013b, Austdal 2015, Koster 2015). 
In non-pregnant adults, relevant to this work it has been used to profile functional and 
metabolic changes associated with heart failure (Deidda 2015, Wang 2015). 
Metabolomics have also been investigated in first trimester maternal serum samples 
to predict congenital heart disease (Bahado-Singh 2014) and abnormal lipid 
metabolism appears to play a role. 
 
In twin pregnancies there are fewer metabolomics studies with only one untargeted 
metabolomics study published in humans (Cosmi 2013). This study used liquid 
chromatography-high resolution mass spectrometry to examine the metabolome in 
cord blood from 4 sIUGR MC pregnancies and compare it to the metabolome in 4 
appropriately grown MC twins (Cosmi 2013). They reported a trend of increased 
phenylalanine, and decreased isoleucine, proline, tryptophan and valine in sIUGR 
twins and theorise that the results did not reach statistical significance due to the 
small sample size. No hypothesis-generating metabolomics studies in TTTS could be 
found, but this is explored further in CHAPTER 5. 
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1.11 Conclusion 
 
MC twins share a placenta which can result in various complications including highly 
morbid TTTS, growth restriction and IUFD. Currently it is not possible to predict which 
MC twin pregnancies will develop these complications. One way to improve care in 
these pregnancies is by identifying first trimester prognostic factors capable of 
determining which MC twin pregnancies will develop an adverse outcome. A further 
way to potentially improve care is to examine the relationship between FLA and 
parento-fetal/infant attachment and depression in pregnancies complicated by TTTS. 
 
1.12 Hypothesis 
 
I hypothesise that prognostic factors to predict the development of complications in 
MC twin pregnancies do exist, and that mothers and fathers cope with having a 
pregnancy affected by TTTS in different ways. 
 
1.13 Thesis rationale and aims 
 
This thesis aims to evaluate first trimester maternal serum and ultrasound measures 
as potential prognostic factors of complications in MC twins; investigate metabolite 
and miRNA changes in pregnancies with TTTS as novel second trimester potential 
prognostic factors; examine the prognosis of surviving co-twins following sIUFD to aid 
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counselling of parents regarding the risk of potential outcomes; and assess antenatal 
and postnatal parento-fetal/infant attachment and depression in pregnancies 
complicated by TTTS to help health care professionals identify couples needing 
additional support. 
 
1.13.1 Aims 
The aims of this thesis are to: 
1) Identify first trimester potential prognostic factors of adverse outcome in MCDA 
twin pregnancies by systematically reviewing existing literature. (CHAPTER 2) 
(Systematic review and meta-analysis) 
2) Evaluate first trimester potential prognostic factors (NT % discordance, CRL % 
discordance, β-hCG, Pregnancy-associated plasma protein-A (PAPP-A), AFP, 
sFlt-1, PlGF) of adverse outcome in MCDA twin pregnancies. (CHAPTER 3) 
(Retrospectively recruited cohort study) 
3) Determine maternal serum levels of first trimester potential prognostic factors 
(AFP, sFlt-1, PlGF) in uncomplicated MCDA twin pregnancies. (CHAPTER 4) 
(Prospectively recruited case series) 
4) Perform discovery work to identify second trimester novel potential prognostic 
factors (metabolomics in amniotic fluid, miRNA in maternal serum) of TTTS. 
(CHAPTER 5 and CHAPTER 6) (Retrospectively recruited case series, and 
prospectively recruited case-control study respectively) 
5) Examine the prognosis of surviving co-twins following sIUFD by systemically 
reviewing existing literature. (CHAPTER 7) (Systematic review and meta-analysis) 
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6) Assess antenatal and postnatal parento-fetal/infant attachment and depression in 
pregnancies complicated by TTTS. (CHAPTER 8) (Prospectively recruited case 
series) 
 
1.14  Methods 
 
To identify first trimester potential prognostic factors a systematic review and meta-
analysis was performed. The OMMIT (Optimal Management of Monochorionic Twins) 
study was designed to assess the prognostic ability of first trimester potential 
prognostic factors identified by the systematic review and meta-analysis, and by 
previous work performed in the second trimester that demonstrated a significant 
difference in various serum biomarkers in TTTS pregnancies (Figure 1.9). The 
prognostic ability was investigated in a retrospectively recruited cohort of women with 
MCDA twin pregnancies for whom there were stored first trimester maternal serum 
samples and ultrasound measures. Discovery work was undertaken to explore novel 
potential prognostic factors in the second trimester using two different types of –
omics technology. Untargeted metabolomics on amniotic fluid samples taken during 
FLA from the recipient twin amniotic fluid sac was performed. The metabolite findings 
were correlated to the degree of cardiac dysfunction in the recipient twin. 
Transcriptomics was conducted to explore the role of miRNAs as potential prognostic 
factors by performing microarrays on second trimester maternal serum samples 
taken at diagnosis of TTTS and comparing the miRNA profiles to gestationally-
matched serum samples taken from women with uncomplicated MCDA twin 
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pregnancies who were also recruited as part of the OMMIT study. The prognosis of 
surviving co-twins following spontaneous sIUFD was examined by systematic review 
and meta-analysis with sub-group analyses based on pregnancy characteristics to 
aid a personalised risk prediction. Antenatal and postnatal parento-fetal/infant 
attachment and depression in pregnancies complicated by TTTS was examined 
quantitatively using questionnaires that mothers and fathers were asked to complete 
separately prior to FLA, 1 month after FLA, and postnatally, to help health care 
professionals identify which couples may need additional support. See each chapter 
for more detailed methods.  
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Figure 1.9 The ‘Optimal Management of Monochorionic Twins’ (OMMIT) study 
Dates refer to sample collection, or search date for systematic reviews  
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CHAPTER 2 EARLY PROGNOSTIC FACTORS OF 
OUTCOMES IN MONOCHORIONIC TWIN 
PREGNANCY: SYSTEMATIC REVIEW AND META-
ANALYSIS 
 
• These findings have been published in full article form [Mackie FL, Hall MJ, Morris 
RK and Kilby MD (2018). “Early prognostic factors of outcomes in monochorionic 
twin pregnancy: systematic review and meta-analysis.” Am J Obstet Gynecol; 
219:436-46.] 
 
2.1 Introduction 
 
Monochorionic (MC) twin pregnancies are considered high-risk because of the 
potential to develop the morbid conditions of TTTS, TAPS, or TOPS (Sebire 1997, 
Moldenhauer 2015). Additionally, MC twins have a greater likelihood of developing 
sIUGR, and sIUFD and dIUFD compared to DC twins (Hillman 2011). Consequently, 
international professional guidelines advise that all MC twin pregnancies undergo 
ultrasound assessment of fetal growth, amniotic fluid volume, and umbilical artery 
Doppler velocimetry every 2 weeks from 16 weeks gestation (ACOG 2016, Khalil 
2016b, Kilby 2016). However, the majority of MC twins will not develop any of these 
complications (Lewi 2008). At present, no screening test is available to predict which 
MC twin pregnancy will develop complications and therefore all MC twins undergo 
this intensive antenatal surveillance that has an impact on patients and healthcare 
resources. 
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2.1.1 Objectives 
To assess the ability of first trimester pregnancy related factors (ultrasound 
measurements, maternal characteristics, and biomarkers) to predict complications in 
MC twin pregnancies.  
 
2.2 Materials and methods 
 
The systematic review was performed according to an a priori protocol and complied 
with recommended guidance including the ‘Meta-analyses and systematic reviews Of 
Observational Studies’ (MOOSE) and ‘Preferred Reporting Items for Systematic 
reviews and Meta-Analyses’ (PRISMA) guidelines (Stroup 2000, Moher 2009). 
Previous work by our group has shown a correlation between comparing 
methodological and reporting quality in diagnostic test accuracy, and prognostic 
factor accuracy (Selman 2011). Ethical approval was not required. 
 
2.2.1 Eligibility criteria 
Studies that reported ultrasound measurements, maternal characteristics, or potential 
biomarkers, measured in the first trimester (i.e. up to 14 weeks gestation), in MCDA 
twin pregnancies that provided sufficient information to assess the association 
between the variable and outcome were eligible for inclusion. Monochorionicity had 
to have been confirmed either by the presence of the ‘T’ sign or absence of the 
‘lambda [λ]’ or ‘twin peak’ sign on first trimester ultrasound (Sepulveda 1996), or 
postnatally by placental examination. If DC twin pregnancies were included, these 
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were removed prior to analysis; if it was not possible to identify and remove the DC 
twin pregnancies, the study was not considered eligible for inclusion. Pregnancies 
affected by the following were excluded: major structural or chromosomal anomalies, 
twin-reversed arterial perfusion (TRAP), miscarriage, sIUFD <14 weeks gestation, 
higher order multiple or monoamniotic pregnancies. All study designs were included, 
although case series needed to include at least 5 MCDA twin pregnancies. 
  
2.2.2 Potential prognostic factors 
All first trimester potential prognostic factors were included. Data were extracted 
using the same cut-offs as reported by the authors. For the meta-analysis thresholds 
were not combined (i.e. CRL discordance >10% was not combined with CRL 
discordance >20%). Maternal age and BMI were analysed as continuous variables. 
Maternal ethnicity was dichotomised to ‘Caucasian’ and ‘non-Caucasian’ to enable 
meta-analysis, parity was dichotomised to ‘multiparous’ and ‘nulliparous’, maternal 
smoking was dichotomised to current ‘smoker’ and ‘non-smoker’ with ex-smokers 
included in the ‘non-smoker’ group, and mode of conception was dichotomised to 
‘spontaneous’ or ‘ART’.  
 
2.2.3 Outcomes 
The outcomes evaluated were:  
• TTTS, irrespective of whether treatment was required/performed, and 
according to definitions used by authors of individual studies (see Table 2.1 in 
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section 2.3.3) including significant discrepancy in inter-twin amniotic fluid 
volumes as per Quintero (Quintero 1999). 
• Antenatally-detected growth restriction only (AGR), based on EFW 
(irrespective of the presence of umbilical artery Doppler abnormalities), as 
defined by each study. Regardless of definition used within individual studies, 
the consensus definition of ≥20% inter-twin EFW discordance as per the 
American College of Obstetricians and Gynecologists, the International 
Society of Ultrasound in Obstetrics & Gynecology (ISUOG) and the Royal 
College of Obstetricians and Gynaecologists in the UK (RCOG) (ACOG 2016, 
Khalil 2016b, Kilby 2016) was adopted. 
• Postnatally-detected growth restriction only (PGR), based on birthweight (BW) 
as defined by each study, but if reported as inter-twin discordance, must be 
≥20% 
• Antenatal and postnatal growth restriction within the same pregnancy i.e. 
antenatal growth restriction was diagnosed and confirmed postnatally. 
• Antenatal or postnatal growth restriction (AoPGR) which includes all the 
growth restricted pregnancies in the other three growth restriction groups 
(AGR, PGR, antenatal and growth restriction within the same pregnancy) 
• sIUFD after 14 weeks gestation 
• dIUFD after 14 weeks gestation 
The definitions of the outcomes were not pre-specified to allow for variation of 
definitions. Where a definition exists e.g. Quintero for TTTS, ≥20% for antenatal 
growth discordance, this was adopted for decisions regarding inclusion of studies for 
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meta-analysis. For those analyses where there was variation in definitions, sensitivity 
analysis was employed where possible to determine the effects of the definition on 
the results.  
 
2.2.4 Information sources 
Electronic databases were searched: MEDLINE, EMBASE, ISI Web of Science, 
CINAHL, the Cochrane Central Registration of Controlled Trials and Research 
Registers, and Google Scholar, from inception to 12 May 2017. Grey literature was 
hand searched and bibliographies of articles checked. 
 
2.2.5 Search strategy 
Keywords and MeSH terms relating to the following were used: TTTS, TAPS, TOPS, 
fetal death, IUGR, diseases in twins, amniotic fluid, placenta, biomarkers, 
ultrasonographic markers and prediction; and combined with “monochorionic” and 
“twins” (Appendix 10.1). 
 
2.2.6 Study selection and data extraction 
Manuscripts to be included in the review were selected by two reviewers (FLM, MJH) 
independently in a two stage process; the first being review of titles and abstracts for 
selection for the second stage of full manuscript review. Where there was 
disagreement consensus was reached by a third reviewer (RKM). There was no 
restriction on language or study design. Abstracts were included if there was 
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sufficient information to assess the study quality and association between the 
variable and the outcome. Data were extracted independently by FLM and MJH using 
a purposely-designed data collection form (Appendix 10.2). Any discrepancies were 
resolved by RKM and MDK. Authors were contacted to clarify information as 
required. 
 
2.2.7 Quality assessment of included studies 
The quality of the studies was assessed by FLM and MJH using the Strengthening 
the Reporting of Observational Studies in Epidemiology (STROBE) tool (von Elm 
2007) as this was considered most appropriate as the majority of studies were 
observational. It was not possible to use the recommended quality checklists for 
prognostic factor research (Riley 2013) e.g. Quality in Prognosis Studies (QUIPS) 
(Hayden 2013), REporting recommendations for tumour MARKer prognostic studies 
(REMARK) (McShane 2005), nor diagnostic studies Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS) (Whiting 2011) due to the large number of 
included studies that were not focused on the prognostic value of factors. 
 
2.2.8 Assessment of heterogeneity 
Forest plots were created to visually assess outliers and any unusual results were 
investigated with sensitivity analysis. The I2 value was calculated for each meta-
analysis. A measurement ≥50% indicated a substantial risk of heterogeneity. Where 
there was significant heterogeneity (visually or statistically), a sensitivity analysis was 
performed to assess the effect.  
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2.2.9 Assessment of reporting bias 
In meta-analyses with >10 studies, a funnel plot was generated using the metafunnel 
command (Sterne 2003) in Stata (Stata, 2015 Release 13.1 StataCorp, Texas, USA), 
and Egger’s test was performed using the metabias command (Harbord 2000), with a 
significance level of 10%.  
 
2.2.10 Data synthesis 
Meta-analyses were reported per pregnancy, not per fetus for two reasons. Firstly, 
reporting at the fetus level would require an adjustment for clustering, but more 
importantly when considering prognostic factors for pregnancy related diseases in 
multiple pregnancy, any change in antenatal management due to a prognostic 
test/model would be effected at the pregnancy level.  
 
2.2.11 Data synthesis for factors reported as means and medians 
For continuous data with a normal distribution, medians were converted to means to 
enable meta-analysis. When the interquartile range (IQR) was reported, the standard 
deviation (SD) was calculated as IQR/1.35 (Cochrane 2011). When medians were 
not reported with IQRs, the mean and SD was estimated (Hozo 2005). For non-
normally distributed data (NT discordance, CRL discordance and parity) where only 
the median was reported, it was not possible to convert the median to means, 
therefore these results could not be included in meta-analysis. 
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2.2.12 Data synthesis for association 
Data were extracted to create 2x2 contingency tables to compare: a) disease vs. no 
disease but where other complications may be present, and b) disease vs. normal 
pregnancy where no complications were present at all. For outcomes with more than 
three included studies, odds ratios (OR) were calculated using the metan command 
(Harris 2009) in Stata, and pooled using the DerSimonian-Laird random effects 
model to account for expected clinical heterogeneity. ORs >2 were considered to 
demonstrate a moderate association (Morris 2014), thus the prognostic ability of the 
factor was subsequently investigated. For continuous variables reported as, or 
converted into, means and SDs, the standardised mean difference (SMD) was 
calculated using the metan command in Stata. SMDs ≥0.5 were considered to 
demonstrate a moderate effect (Cohen 1977) and the prognostic ability of the factor 
was investigated.  
 
2.2.13 Data synthesis for prognostic ability 
Bivariate meta-analysis using a random effects model was performed in analyses of 
more than three studies to calculate the summary sensitivity, specificity, positive 
likelihood ratio and negative likelihood ratio using the metandi command (Harbord 
2008) in Stata. Hierarchical Summary Receiver Operating Characteristic (HSROC) 
curves were generated using the metandiplot command (Harbord 2008) to represent 
the level of uncertainty of sensitivity and specificity for bivariate analyses. Univariate 
analysis was carried out for analyses with less than four studies using MetaDiSc 
(v1.4116, Madrid, Spain)(Zamora 2006), with symmetrical Summary Receiver 
  
67 
 
Operating Characteristic (SROC) curves generated. 0.5 was added to cells of 0 to 
perform univariate meta-analysis, but not bivariate meta-analysis, due to the 
necessary use of different computer programs. When a prognostic factor was found 
to have a moderate association with the outcome, the predictive ability was 
investigated and the post-test probability using Fagan’s nomogram (Fagan 1975), 
which accounts for pre-test probability, was calculated. 
 
2.3 Results 
 
2.3.1 Study selection 
Electronic searches identified 2439 citations of which 1312 titles were excluded after 
review of titles and 743 after abstract review. The full papers of the remaining 384 full 
articles were assessed (Figure 2.1) of which 48 studies (Sebire 2000, Sooranna 
2001, Matias 2005, Bajoria 2006, Sueters 2006, Bajoria 2007, El Kateb 2007, Kagan 
2007, Tai 2007, Kusanovic 2008, Lewi 2008a, Lewi 2008b, Chang 2009, Linskens 
2009a, Maiz 2009, Linskens 2010, Matias 2010, Torres-Torres 2010, Carver 2011, 
Fratelli 2011, Matias 2011, Murakami 2011, Memmo 2012, Velayo 2012, Ashoor 
2013, Chai 2013, Cosmi 2013, Flock 2013, Ghalili 2013, Moriichi 2013, Schrey 2013, 
Taylor-Clarke 2013, Zhao 2013a, Baraa Allaf 2014, Fujioka 2014, Johansen 2014, 
Miura 2014, Yinon 2014, Zanardini 2014, Zoppi 2014, Sarais 2015, Zhang 2015, 
Ben-Ami 2016, Chang 2016, Stagnati 2016, Chang 2017, McDonald 2017, Sun 
2017) met the inclusion criteria equating to the evaluation of 5365 MC twin 
pregnancies. See Table 2.1 for the study characteristics of all included studies.  
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Figure 2.1 Flow diagram of study inclusion 
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2.3.2 Studies and potential prognostic factors not included in meta-analyses 
Studies that met the inclusion criteria but were unable to be included in meta-analysis 
are described below, as are individual prognostic factors that were unable to be 
included in meta-analysis. 
 
Studies 
In calculating discordance between ultrasound measures, all studies used the larger 
measure as the denominator, apart from Memmo et al. (Memmo 2012) who used the 
smaller NT as the denominator, however as they only reported the median NT 
discordance, there were too few studies to include this variable in meta-analysis. 
Chang et al. (Chang 2009) could not be included in the analysis because they 
divided their AGR group into those with and without umbilical artery Doppler 
abnormalities and as the variable of maternal age was reported as a mean, the 
groups could not be combined. Cosmi et al. (Cosmi 2013) was not included in the 
maternal age analysis for the same reason as Chang et al. Sun et al. (Sun 2017) 
divided their control group into two sub-groups that could not be combined and thus 
could not be included in the maternal age analysis. Velayo et al. (Velayo 2012) could 
not be included in this analysis because they did not report the standard deviations. 
 
Flöck et al. (Flock 2013) was not included in the TTTS outcome as the participants 
were also included in the larger cohort reported by Ben-Ami et al. (Ben-Ami 2016). 
Zhao et al. (Zhao 2013a) was not included in the TTTS analysis because they 
excluded those with TTTS who had undergone FLA and the group would have been 
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heterogeneous. El Kateb et al. (El Kateb 2007) could not be included in the PGR 
group because the variables and outcomes were only reported per fetus. The ‘early 
onset’ growth discordance group in the study by Lewi et al. (Lewi 2008a) was not 
included as their definition of the outcome and variable both included difference in 
CRL. Kagan et al. (Kagan 2007) could not be included in the IUFD outcome because 
they only reported sufficient information for a 2x2 contingency table on their sub-
group of IUFD at 13-18 weeks. Nine studies were unable to be included in any meta-
analysis due to an insufficient number of studies reporting the same variable and 
outcome (Tai 2007, Lewi 2008a, Lewi 2008b, Maiz 2009, Linskens 2010, Matias 
2010, Matias 2011, Johansen 2014, Zoppi 2014). 
 
Potential prognostic factors 
The following factors were reported for the outcomes under examination, but were 
unable to be included in meta-analysis: 
 
Ultrasound measurements 
The following factors were reported by less than 3 studies thus could not be included 
in meta-analysis: abnormal DV Doppler in one/both fetuses (Maiz 2009, Matias 
2010); umbilical venous volume flow in fetus 1 ≥ fetus 2 (Zoppi 2014). NT 
discordance ≥10%, ≥30%, ≥40%, ≥50% (Kagan 2007); NT discordance >3.5 mm 
(Linskens 2009a); NT difference (Matias 2010, Flock 2013); NT ratio (Matias 2010); 
NT larger twin (Memmo 2012, Zoppi 2014); NT smaller twin (Memmo 2012, Zoppi 
2014); NT any twin (Matias 2010). CRL discordance >4%, ≥5%, ≥5.5%, ≥7%, ≥10%, 
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≥15%, ≥20% (Kagan 2007, Fratelli 2011, Johansen 2014); CRL discordance >11% 
(Tai 2007); CRL discordance ≥6 mm, ≥12 mm (Lewi 2008b); CRL difference (Matias 
2010); CRL ratio (Matias 2010); CRL larger twin (Memmo 2012, Zoppi 2014); CRL 
smaller twin (Memmo 2012, Zoppi 2014); CRL any twin (Matias 2010).  
 
Maternal characteristics 
Gravida (Kusanovic 2008, Yinon 2014), height, and weight (Kusanovic 2008). 
 
First trimester serum markers 
Four first trimester maternal serum markers were investigated: β-hCG, PAPP-A, 
thyroid stimulating hormone (TSH) and free thyroxine (FT4), but meta-analysis was 
not possible. Linskens et al. (Linskens 2010) reported a trend in difference in β-hCG 
multiples of the median (MoM) in pregnancies with TTTS, and uncomplicated MC 
twins (median 1.99 vs 1.53 respectively, p=0.32, 51 pregnancies) and PAPP-A 
(median 1.94 vs 1.69 respectively, p=0.51, 51 pregnancies). Ashoor et al. (Ashoor 
2013) reported no difference in TSH, FT4 or free β-hCG MoM in 17 pregnancies with 
TTTS and ‘normal outcome twins’, although the authors do not state if the control 
group included DC twins thus the number of MC twin pregnancies in the analysis is 
not clear. The following levels are reported in the TTTS and ‘normal outcome twins’ 
respectively: TSH (median 1.38 [IQR 0.52–2.05] vs 1.00 [IQR 0.26–1.36] 
respectively, p=0.424, number of pregnancies not clear), FT4 MoM (median 0.94 
[IQR 0.90–1.16] vs 0.98 [IQR 0.91–1.08], p=0.773, number of pregnancies not clear), 
free β-hCG MoM (median 0.95 [IQR 0.51–2.22] vs 1.00 [IQR 0.69–1.36], p=0.997, 
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number of pregnancies not clear). These serum markers were only reported in the 
context of TTTS, and not the other outcomes. 
 
2.3.3 Study characteristics 
Table 2.1 displays the study characteristics of the included articles and details 
regarding individual measurements such as definitions of growth restriction. 26/48 
studies were published in the 5 years prior to May 2017 when the search was 
performed. The oldest study was from 2000. 37 studies were cohort studies, 4 
studies were case-controls, 2 were case series, and 5 were unclear in their study 
design. Data collection was a retrospective search of a prospectively recorded 
database in 15 studies, 20 performed prospective data collection, 6 were 
retrospective data collection, and it was not clear in 7 studies. Enrolment was 
consecutive in 16 studies, and not stated in 32 studies. 32 groups of patients were 
from 9 different European countries, the UK being the commonest (n=10), 6 from the 
USA and Canada, 4 from China, 4 from Japan, 3 from Taiwan, 2 from Australia, 2 
from Israel, 1 from Mexico. The longest study ran for 16 years, with the modal time 
period being 2 years and shortest being 1 year. The smallest study analysed 12 
women, and the largest analysed 470 women.  
The ultrasound measurements reported were: NT, CRL, the presence of reversed ‘a’ 
wave in the DV, and umbilical venous flow velocity. The maternal characteristics 
reported in eligible studies were: maternal age, ethnicity, BMI, parity and smoking. 
Mode of conception and fetal gender were also reported. The first trimester 
biomarkers reported were all from maternal serum, and included TSH, FT4, β-hCG 
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and PAPP-A. The most frequently investigated outcomes were TTTS (n=31 studies), 
AGR (n=14 studies), and PGR (n=12 studies). 
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Table 2.1 Characteristics of studies eligible for inclusion 
Abbreviation: 1st T: 1st trimester, AC: abdominal circumference, AFI: amniotic fluid index, ART: assisted reproduction technology, 
AUC: area under (receiver operating characteristic) curve, β-hCG: beta-human chorionic gonadotropin, BMI: body mass index, 
BWD: birthweight discordance, C-section: Caesarean section, CRL: crown-rump length, DA: diamniotic, DC: dichorionic, DV: ductus 
venosus (Doppler), DVP: deepest vertical pocket, EFWD: estimated fetal weight discordance, EXC: exclusion criteria, FLA: 
fetoscopic laser ablation, GD: growth discordance, INC: inclusion criteria, IUFD: intrauterine fetal demise, IUGR: intrauterine growth 
restriction, IVF: in vitro fertilisation, LBW: low birthweight, MA: monoamniotic, MC: monochorionic, MoM: multiple of median, NT: 
nuchal translucency, PAPP-A: pregnancy-associated plasma protein A, proBNP: prohormone of brain natriuretic peptide, sIUGR: 
selective intrauterine growth restriction, TAPS: twin anaemia-polycythaemia sequence, TOP: termination of pregnancy, TRAP: twin 
reversed arterial perfusion syndrome, TTTS: twin-twin transfusion syndrome, UAD: umbilical artery Doppler, USS: ultrasound scan, 
UVVF: umbilical venous volume flow A 
*additional information/clarification obtained by contacting the authors 
 
Author  
year 
Study 
design, data 
collection, 
enrolment 
Study population 
(Location, years, 
inclusion and exclusion 
criteria) 
Total 
pregnancies 
eligible for 
study 
Total MC 
pregnancies 
analysed in 
study 
Outcomes 
used in 
review 
Outcome 
definition used 
by study 
Control group(s) 
definitions used by 
study 
Potential 
prognostic 
factors 
Ashoor 
2013 
(Ashoor 
2013) 
Case series, 
prospective, 
not stated 
Location: ?1 centre in UK  
Years: 2006-2011 
INC: twin pregnancies 
with live fetuses at 11-13 
weeks 2 livebirths at ≥33 
weeks, or severe TTTS 
necessitating FLA 
EXC: Maternal history of 
hypo/ 
hyperparathyroidism or 
diabetes, fetal 
abnormalities, pre-
eclampsia, BW<5th 
centile 
Not stated 77 TTTS ‘polyhydramnios 
surrounding the 
recipient fetus 
whose bladder 
was enlarged, 
oligo-
/anhydramnios 
around the 
smaller donor 
fetus whose 
bladder was 
collapsed.’ 
Normal pregnancies 
with 2 livebirths at >33 
weeks 
Thyroid 
hormones, 
mode of 
conception 
(spontaneous 
or use of 
ovulation 
inducing 
drugs), 
maternal age 
(median), BMI 
(median), 
ethnicity 
Bajoria 
2006 
(Bajoria 
Unclear, not 
stated, not 
stated 
Location: 1 centre in UK  
Years: not stated 
INC: MC pregnancies 
Not stated 32 BWD and 
sIUGR in 
same 
BWD ≥20% with 
no 
polyhydramnios in 
BWD ≤10% and normal 
liquor volume in both 
twins 
Maternal age 
(median), 
ethnicity 
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2006) with/without discordant 
growth 
EXC: chronic TTTS, 
single/double IUFD, 
intrapartum stillbirth, 
aneuploidy, structural 
abnormalities, 
pregnancies with: 
diabetes, hypertension, 
renal disease, cardiac 
disease 
pregnancy the larger twin, 
and smaller twin 
must have AC 
≤5th centile with 
abnormal UAD, in 
same pregnancy 
Bajoria 
2007 
(Bajoria 
2007) 
Unclear, not 
stated, not 
stated 
Location: ? centres in UK  
Years: not stated 
INC: MC pregnancies 
with/without TTTS 
EXC: single/double IUFD, 
intrapartum stillbirth, 
aneuploidy, structural 
abnormalities, 
pregnancies with: 
diabetes, hypertension, 
renal/cardiac disease 
Not stated 30 TTTS AFI ≥40cm in 
larger twin and 
≤4cm in smaller 
twin. The smaller 
twin must also 
have IUGR, and 
the EFWD ≥15%, 
all in same 
pregnancy. 
Concordant growth and 
AFI ≤24cm 
Maternal age 
(median) 
Baraa Allaf 
2014 
(Baraa 
Allaf 2014) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
consecutive 
enrolment to 
database and 
study 
Location: 9 centres in 
USA  
Years: 2007-2011 
INC: 2 live fetuses at 11-
13+6 weeks 
EXC: chromosomal 
abnormalities, major 
congenital malformations, 
single/double IUFD in 1st 
T 
 
Not stated 177 TTTS Polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS NT >95th 
centile in 
one/both 
fetuses, NT 
discordance 
≥20% (AUC), 
CRL 
discordance 
(AUC), 
combined NT 
and CRL 
discordance 
(AUC) 
IUGR EFW<10th centile 
in either fetus 
No IUGR NT >95th 
centile in 
one/both 
fetuses 
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Ben-Ami 
2016 
(Ben-Ami 
2016) 
Cohort, not 
stated, not 
stated 
Location: 7 centres in 
Israel, Spain, Germany 
and Canada 
Years: 1997-2013 
INC: MCDA twin 
pregnancies undergoing 
NT scan at 11-14 weeks 
with 2 live fetuses 
EXC: fetal 
congenital/structural 
abnormalities, 
single/double IUFD, 
higher order multiple 
reductions, non-IVF 
fertility treatments 
337 327 TTTS Polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS Mode of 
conception 
(spontaneous 
or IVF/ICSI), 
maternal age 
(mean) 
Carver 
2011 
(Carver 
2011) 
Cohort, 
retrospective 
collection of 
prospectively 
recorded 
data, 
consecutive 
Location: 1 centre in USA  
Years: 2000-2009 
INC: MCDA twins 
delivered at hospital and 
who underwent antenatal 
care at that hospital 
EXC: No sonographic 
examinations in 2nd T, no 
antenatal records 
151 145 TTTS Polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS Maternal age 
(mean), 
ethnicity 
Chai 2013 
(Chai 2013) 
Cohort, 
retrospective, 
not stated 
Location: 1 centre in 
China 
Years: 2005-2012 
INC: MCDA pregnancies 
EXC: Aneuploidy/fetal 
anomalies, TTTS, TRAP, 
TAPS, LBW in both twins 
Not stated 113 LBW BW <10th centile 
in 1 twin, BW>10th 
centile in the 
other twin 
No LBW Maternal age 
(mean) 
Chang 
2009 
(Chang 
2009) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in 
Taiwan  
Years: 2006-2008 
INC: live-born MCDA 
twins with a placenta able 
to be studied postnatally  
EXC: fetal anomalies, 
single IUFD, TTTS 
53 51 sIUGR  EFW <10th 
percentile in 1 
twin, with and 
without UAD 
abnormalities 
No TTTS or sIUGR Maternal age 
(mean) 
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Chang 
2016 
(Chang 
2016) 
Cohort, 
unclear, 
consecutive 
Location: 1 centre in 
Taiwan 
Years: 2013-2015 
INC: MC twins delivered 
by C-section with cord 
blood samples 
EXC: women who went 
into labour, TTTS, TAPS, 
congenital/structural or 
genetic malformations 
 
Not stated 32 sIUGR  The definitions 
are not clear. The 
terms sIUGR, 
fetal weight and 
BWD are used 
inter-changeably. 
Authors state: 
BWD >20% and 
BW <10th centile 
in 1 twin 
according to 
pregnancy 
birthweight chart, 
which is 
subdivided to 
those with and 
without UAD 
abnormalities 
“Normal” MC twins, 
definition not stated 
Fetal gender 
Chang 
2017 
(Chang 
2017) 
 
Cohort, 
unclear, 
unclear 
Location: 1 centre in 
Taiwan 
Years: 2013-2014 
INC: MC twins delivered 
at centre with cord blood 
samples 
EXC: TTTS, 
congenital/structural or 
genetic malformations 
Not stated 24 BWD and 
sIUGR in 
same 
pregnancy 
EFW <10th centile 
and BWD >20% 
in same 
pregnancy 
No sIUGR Maternal age 
(mean), parity 
(mean) 
Cosmi 
2013 
(Cosmi 
2013) 
Unclear, 
prospective, 
selected but 
unclear how 
Location: 1 centre in Italy 
Years: 2009-2011 
INC: MCDA pregnancies 
selected from previously 
published cohort but 
inclusion criteria not 
stated 
EXC: unknown last 
menstrual period, 
unknown chorionicity, 
triplets, TTTS or related 
conditions, MCMA, 1st T 
Not stated 12 sIUGR EFW<10th centile 
in smaller twin, 
>10th centile 
larger twin, with 
and without UAD 
abnormalities 
EFW >10th centile in 
both twins and 
confirmed after birth, 
and normal UAD 
Maternal age 
(median), 
parity 
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discrepancy in CRL>5 
days, structural/ 
chromosomal 
abnormalities, single 
IUFD, selective feticide, 
maternal history of 
cardiovascular disease, 
endocrine disorders, 
clinical chorioamnionitis, 
maternal consumption of: 
alcohol, drugs of abuse 
El Kateb 
2007 
(El Kateb 
2007) 
Cohort, 
prospective, 
consecutive 
Location: 1 centre in 
France 
Years: 2002-2006 
INC: MCDA pregnancies 
with 1st T NT and CRL 
measurements 
EXC: chromosomal 
abnormalities or 
congenital malformations 
Not stated  103 TTTS Polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS NT >95th 
centile (per 
fetus), CRL 
discordance 
≥10% (per 
pregnancy) 
LBW BW <5th 
percentile (per 
twin analysis) 
No LBW NT >95th 
centile (per 
fetus), CRL 
discordance 
≥10% (per 
fetus)  
Flöck 2013 
(Flock 
2013) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
enrolment to 
database and 
study not 
stated 
Location: ? centre in 
Germany  
Years: 2004-2010 
INC: ‘unaffected’ twins on 
perinatal database 
EXC: structural fetal 
malformations, 
aneuploidy, vanishing 
twin, embryo reduction 
849 fetuses 
(does not 
state how 
many 
pregnancies) 
706 fetuses, 
equating to 353 
pregnancies in 
total, 73/353 
MCDA, 280 
DCDA 
sIUGR Not stated No sIUGR Mode of 
conception 
(spontaneous 
or IVF/ICSI) 
Fratelli 
2011 
Cohort, 
retrospective, 
Location: 1 centre in Italy 
Years: 2001-2009 
136 135 TTTS Polyhydramnios 
(DVP ≥8cm 
No TTTS NT 
discordance 
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(Fratelli 
2011) 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
consecutive 
enrolment to 
database but 
unclear to 
study 
INC: 1st T viable MC twin 
at 11-13+6 weeks and 
follow-up at that centre 
EXC: pregnancies 
referred at later gestation, 
aneuploidy 
 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
≥20%, NT 
>95th centile in 
one, NT >95th 
centile in both, 
NT >95th 
centile in 
one/both 
fetuses, NT 
discordance 
(median), NT 
discordance 
(AUC), CRL 
discordance 
≥10%, CRL 
discordance 
(median), CRL 
discordance 
(AUC) 
sIUGR EFW<10th 
percentile and 
abnormal UAD in 
same pregnancy 
No sIUGR As for TTTS 
outcome 
IUFD Miscarriage <24 
weeks or 
spontaneous 
death of at least 1 
fetus 
No IUFD As for TTTS 
outcome 
Fujioka 
2014 
(Fujioka 
2014) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in 
Japan  
Years: 2007-2010 
INC: MCDA twins with N-
terminal proBNP levels 
measured at delivery 
EXC: congenital/ 
chromosomal 
abnormalities, TTTS, 
referred to centre >26 
weeks 
124 73 sIUGR EFW <10th 
percentile at 18-
26 weeks 
No sIUGR Mode of 
conception 
(spontaneous 
or ART), fetal 
gender, 
maternal age 
(median) 
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Ghalili 
2013 
(Ghalili 
2013) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
consecutive 
enrolment to 
database and 
study 
Location: 2 centres in 
Australia 
Years: 2006-2010 
INC: MCDA twins 
undergoing 1st T scan,  
EXC: higher order 
multiples, non-viable or 
lethal structural anomalies 
at 12 week scan, unable 
to determine mode of 
conception or pregnancy 
outcome 
312 294 LBW in 
one/ both 
twins 
BW <10th centile 
in one/both twins 
BW >10th centile in both 
twins 
Mode of 
conception 
(spontaneous 
or IVF) 
TTTS Polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS Mode of 
conception 
(spontaneous 
or IVF) 
Johansen 
2014 
(Johansen 
2014) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
enrolment to 
database and 
study unclear 
Location: 14 centres in 
Denmark 
Years: 2004-2006 
INC: 2 live DA fetuses 
and chorionicity 
determined in 1st T 
EXC: unknown 
chorionicity, MCMA, 
reduction from higher 
order multiple, selective 
feticide or termination due 
to severe malformation/ 
chromosomal anomaly 
 
281 260 BWD BWD ≥20% BWD <20% CRL 
discordance 
≥10%, CRL 
discordance 
≥10% (AUC), 
CRL 
discordance 
≥4% (OR), 
CRL 
discordance 
≥5.5% (OR), 
CRL 
discordance 
≥7% (OR), 
CRL 
discordance 
≥10% (OR) 
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Fetal loss 
of at least 1 
fetus 
Miscarriage 
≤23+6 weeks, 
IUFD >23+6 
weeks 
2 livebirths As for BWD 
outcome 
Kagan 
2007 
(Kagan 
2007) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
enrolment to 
database and 
study unclear 
Location: 1 centre in UK 
Years: 2001-2006 
INC: MCDA pregnancies 
undergoing combined 1st 
T aneuploidy screening 
EXC: chromosomal or 
structural defects, 
pregnancies with missing 
outcome data 
 
560 470 TTTS 
 
Severe TTTS 
requiring FLA. 
TTTS defined as: 
polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS NT 
discordance 
≥20%, NT 
discordance 
(median), NT 
discordance 
(AUC), CRL 
discordance 
≥10%, CRL 
discordance 
(median), CRL 
and NT 
discordance 
(AUC) 
IUFD 
(‘early’) 
Single/double 
IUFD at 13-18 
weeks with no 
intervention 
Not clear NT 
discordance 
(AUC), CRL 
and NT 
discordance 
(AUC) 
Kusanovic 
2008 
(Kusanovic 
2008) 
Case-control, 
database with 
prospectively 
recorded 
data, 
enrolment to 
database and 
study unclear 
Location: ? centres in 
USA and China  
Years: not stated 
INC: MCDA twin 
pregnancies 16-26 weeks 
EXC: pre-eclampsia at 
time of venepuncture, 
fetal congenital anomalies 
Not stated 69 TTTS Polyhydramnios 
(DVP ≥8cm) in 
the recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS Maternal age 
(median), 
gravida, height 
(median), 
weight 
(median), BMI 
(median), 
smoking 
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Lewi 2008a 
(Lewi 
2008a) 
Cohort, 
prospective, 
not stated 
Location: 2 centres in 
Belgium and Germany 
Years: 2004-2007 
INC: MCDA twin 
pregnancies 
EXC: TTTS, spontaneous 
miscarriage, IUFD <16 
weeks, structural 
anomalies that influence 
biometry 
208 163 GD (‘late’ 
onset) 
BWD ≥25% but 
EFWD<20% at 20 
weeks 
BWD <25% CRL difference 
(mean) 
Lewi 2008b 
(Lewi 
2008b) 
Cohort, 
prospective, 
not stated 
Location: 2 centre in 
Belgium and Germany  
Years: 2002-2007 
INC: MCDA twin 
pregnancies with 2 live 
fetuses at 11-14 weeks 
EXC: single/double IUFD, 
TRAP, structural 
anomalies 
202 200 TTTS polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS CRL 
discordance 
≥6mm 
Linskens 
2009 
(Linskens 
2009a) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
consecutive 
enrolment to 
database and 
study 
Location: 1 centre in 
Netherlands  
Years: 2004-2008 
INC: MCDA twins 
undergoing combined 1st 
T aneuploidy screening 
and followed up 
EXC: single/ double IUFD, 
PTB 
 
 
 
61 55 TTTS polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS and birth >26 
weeks 
NT 
discordance 
≥20%, NT 
discordance 
≥3.5mm, NT 
discordance 
(median), NT 
discordance 
(AUC), CRL 
discordance 
(median), 
maternal age 
(median), 
ethnicity, 
smoking, 
parity, mode of 
conception 
(spontaneous 
or ART) 
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Linskens 
2010 
(Linskens 
2010) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
consecutive 
enrolment to 
database and 
study 
Location: 1 centre in 
Netherlands  
Years: 2004-2009 
INC: MCDA twins 
undergoing combined 1st 
T aneuploidy screening 
and followed up 
EXC: not stated 
 
56 51 TTTS polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS or single or 
double IUFD 
PAPP-A 
(median MoM), 
β-hCG 
(median MoM) 
Maiz 2009 
(Maiz 2009) 
Cohort, 
prospective, 
unclear 
enrolment 
Location: 1 centre in UK 
Years: 2006-2008 
INC: MCDA and DCDA 
twin pregnancies with 2 
live fetuses at 11-13+6 
weeks 
EXC: unable to measure 
DV in both fetuses, 
outcome data missing 
 
733 MCDA 
and DCDA 
(does not 
state number 
of MCDA) 
179 (MCDA but 
we exclude 4 
from analysis 
with 
aneuploidy/major 
defects, therefore 
175) 
Severe 
TTTS 
Severe TTTS 
requiring FLA or 
in which the 
fetus(es) died 
prior to FLA: 
‘ultrasound 
diagnosis of 
hydramnios in 
one twin and 
anhydramnios in 
the other, and 
absent or 
reversed end 
diastolic flow in 
either the 
umbilical artery or 
ductus venosus in 
one or both 
fetuses’ 
No TTTS or 
aneuploidy/major fetal 
defects 
DV abnormal 
in one, DV 
abnormal in 
both, DV 
abnormal in 
one/both 
fetuses 
sIUGR Severe sIUGR 
requiring FLA, 
definition of 
sIUGR not stated 
No sIUGR or 
aneuploidy/major fetal 
defects 
DV abnormal 
in one, DV 
abnormal in 
both, DV 
abnormal in 
one/both 
fetuses 
Single 
IUFD or 
Gestation at IUFD 
not stated but 
No single IUFD or 
aneuploidy/major fetal 
DV abnormal 
in one, DV 
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miscarriage must be >14 
weeks 
defects abnormal in 
both, DV 
abnormal in 
one/both 
fetuses 
Matias 
2005 
(Matias 
2005) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in 
Portugal 
Years: not stated 
INC: MCDA pregnancies 
referred to unit for ‘routine 
1st T ultrasonographic 
assessment’ 
EXC: not stated 
 
Not stated 50 TTTS Anhydramnios 
and nonvisible 
bladder in the 
donor in 
combination with 
polyhydramnios 
and dilated 
bladder in the 
recipient. 
No TTTS, 2 livebirths Raw NT 
values, NT 
discordance 
≥20%, DV 
abnormal in 
one, DV 
abnormal in 
both, DV 
abnormal in 
one/both 
fetuses, 
maternal age 
(median) 
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Matias 
2010 
(Matias 
2010) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in 
Portugal 
Years: 1997-2008 
INC: MCDA pregnancies 
undergoing 1st T 
assessment 
EXC: malformations (e.g. 
megacystis), single IUFD 
 
 
 
 
 
 
 
 
 
 
Not stated 99 TTTS Oligohydramnios 
and non-visible 
bladder in the 
donor in 
combination with 
polyhydramnios 
and dilated 
bladder in the 
recipient  
No TTTS NT per fetus 
(mean), NT 
difference 
(mean), NT 
ratio (mean), 
NT difference 
(AUC), NT 
ratio (AUC), 
CRL per fetus 
(mean), CRL 
difference 
(mean), CRL 
ratio (mean), 
CRL difference 
(AUC), CRL 
ratio (mean), 
DV abnormal 
in one, DV 
abnormal in 
both, DV 
abnormal in 
one/both 
fetuses, DV 
abnormal 
(AUC) 
Matias 
2011 
(Matias 
2011) 
Cohort, 
prospective, 
not stated 
Location: 2 centres in 
Portugal and UK 
Years: 2006-2009 (UK), 
1998-2009 (Portugal) 
INC: MC pregnancies that 
did not require antenatal 
interventions, and 
resulted in 2 healthy 
livebirths 
EXC: major fetal 
abnormalities, 
single/double IUFD, FLA 
for TTTS or sIUGR 
326 237 BWD BWD ≥20% BWD <20% DV abnormal 
in one/both 
fetuses 
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*McDonald 
2017 
(McDonald 
2017) 
Case series, 
prospective, 
consecutive 
Location:1 centre in 
Australia 
Years: 2011-2014 
INC: All MCDA twins 
attending for antenatal 
care at centre  
EXC: patients referred to 
centre for FLA, but 
remainder of care 
elsewhere 
162 156 TTTS Polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS or 
chromosomal/ structural 
anomalies (parity, 
ethnicity). 
No TTTS, sIUGR, 
IUFD, TAPS, 
chromosomal/structural 
anomalies (maternal 
age, BMI) 
Maternal age 
(mean), BMI 
(mean), 
ethnicity, parity 
sIUGR EFW ≤10th centile 
in one or both 
twins, and/or 
EFWD >20% 
No sIUGR or 
chromosomal/ structural 
anomalies (parity, 
ethnicity). 
No TTTS, sIUGR, 
IUFD, TAPS, 
chromosomal/structural 
anomalies (maternal 
age, BMI) 
Maternal age 
(mean), BMI 
(mean), 
ethnicity, parity 
Single or 
double 
IUFD 
Gestation at IUFD 
not stated, but 
median 22.0 (IQR 
20.1-30.0 weeks) 
thus presumed 
2nd trimester 
No IUFD or 
chromosomal/ structural 
anomalies 
Maternal age 
(mean), BMI 
(mean), 
ethnicity, parity 
Memmo 
2012 
(Memmo 
2012) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
consecutive 
enrolment to 
database and 
study 
Location: 1 centre in UK  
Years: 2000-2010 
INC: MC pregnancies with 
1st T CRL and NT 
measurements 
EXC: TTTS Stage I 
managed conservatively 
who did not undergo FLA, 
MCMA, aneuploidy, fetal 
structural anomalies, 
spontaneous pregnancy 
loss <16 weeks 
 
279 242 TTTS Polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
2 healthy livebirths at 
>34 weeks with no 
TTTS or sIUGR for all 
outcomes except parity 
which was compared to 
no TTTS. 
NT 
discordance 
(median), NT 
larger twin 
(median), NT 
smaller twin 
(median), CRL 
discordance 
(median), CRL 
larger twin 
(median), CRL 
smaller twin 
(median), CRL 
discordance 
(AUC), 
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maternal age 
(median), 
parity 
sIUGR 
‘early’ 
1 twin EFW <10th 
centile, before 26 
weeks gestation 
and no signs of 
TTTS 
2 healthy livebirths at 
>34 weeks with no 
TTTS or sIUGR except 
parity which was 
compared to no sIUGR. 
As for TTTS 
outcome 
*Miura  
2014 
(Miura 
2014) 
Cohort, not 
stated, not 
stated 
Location: 1 centre in 
Japan 
Years: not stated 
INC: MC pregnancies who 
visited centre at 12-21 
weeks 
EXC: not stated 
Not stated 28 TTTS Polyhydramnios 
(DVP ≥8cm) in 
the recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS or 
chromosomal/ structural 
anomalies 
Maternal age 
(mean), parity 
Moriichi 
2013 
(Moriichi 
2013) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in 
Japan 
Years: 2007-2011 
INC: MC pregnancies with 
2 livebirths 
EXC: chromosomal 
aberrations, congenital 
anomalies, IUFD, TTTS 
Not stated 36 BWD BWD ≥20% BWD <20% Maternal age 
(mean), parity 
Murakami 
2011 
(Murakami 
2011) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
consecutive 
enrolment to 
database and 
study 
Location: 1 centre in 
Japan 
Years: 2006-2010 
INC: Twins pregnancies 
attending for antenatal 
care at centre 
EXC: congenital 
anomalies associated 
with IUGR, multifetal 
pregnancy reduction 
 
125 (51 
MCDA, 74 
DCDA) 
42 TTTS Polyhydramnios 
(DVP ≥8cm) in 
the recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS Mode of 
conception 
(spontaneous 
or IVF/ 
ovulation 
induction) 
IUFD Single/double 
IUFD >16 weeks 
No IUFD Mode of 
conception 
(spontaneous 
or IVF/ 
ovulation 
induction) 
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*Sarais  
2015 
(Sarais 
2015) 
 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
enrolment to 
database and 
study unclear 
Location: 1 centre in Italy 
Years: 2007-2011 
INC: MC pregnancies 
undergoing antenatal care 
at centre, which 
progressed >16 weeks 
EXC: higher order 
multiples, those 
presenting >16 weeks 
Not stated 145 TTTS Not stated No TTTS or 
chromosomal/ structural 
anomalies 
Mode of 
conception 
(spontaneous 
or IVF) 
IUFD Single and double 
IUFD, >16 weeks  
No IUFD or 
chromosomal/ structural 
anomalies 
Mode of 
conception 
(spontaneous 
or IVF) 
Schrey 
2013 
(Schrey 
2013) 
Cohort, not 
stated, not 
stated 
Location: ? centres in 
Canada  
Years: not stated 
INC: ‘potential discordant 
MC twin pregnancies as 
candidates for placental 
sampling were identified 
in the antenatal period’ 
EXC: fetal abnormalities, 
syndromes or infections, 
pre-eclampsia, diabetes, 
placental tumours 
Not stated 15 BWD BWD ≥20%  
(all smaller twins 
also below the 
10th centile) 
BWD <20% Fetal gender 
Sebire 
2000 
(Sebire 
2000) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
consecutive 
enrolment to 
database 
unclear, but 
consecutive 
to study 
Location: ? centre in UK 
Years: unclear start date 
but delivered prior to June 
1999 
INC: MCDA pregnancies 
with 2 live fetuses at 10-
14 weeks gestation, with 
outcome information 
available 
EXC: 
structural/chromosomal 
anomalies, TOP 
 
303 287 Severe 
TTTS 
Anhydramnios 
and no-visible 
bladder in the 
donor fetus and 
polyhydramnios 
and a dilated 
bladder in the 
recipient fetus, 
which resulted in 
either miscarriage 
or fetal death or 
required 
intrauterine 
treatment or post-
mortem evidence 
that the cause of 
death was TTTS. 
No TTTS NT >95th 
centile per 
fetus, NT >95th 
centile in 
one/both 
fetuses 
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Sooranna 
2001 
(Sooranna 
2001) 
Unclear, 
prospective, 
not stated 
Location: ? centres in UK 
Years: not stated 
INC: MC and DCDA 
pregnancies 
EXC: chronic TTTS, 
single IUFD, 
structural/chromosomal 
abnormalities, selective 
feticide, embryo 
reduction, maternal 
complications: 
hypertension, pre-
eclampsia, renal/cardiac 
disease 
Not stated 29 sIUGR EFWD ≥20% with 
smaller twin’s AC 
≤5th centile and 
abnormal UAD in 
same pregnancy, 
with absence of 
polyhydramnios in 
the larger twin’s 
sac 
EFWD ≤10% and 
normal AFI throughout 
pregnancy 
Fetal gender 
Stagnati 
2016 
(Stagnati 
2016) 
Cohort, 
retrospective 
search of 
database with 
prospectively 
recorded 
data, 
consecutive 
enrolment to 
database and 
study 
Location: 1 centre in Italy  
Years: 2008-2013 
INC: MCDA pregnancies 
of with 1st T scan and 
antenatal care at centre 
EXC: referral after 1st T 
and/or incomplete follow-
up, fetal structural 
abnormalities or abnormal 
karyotype, TTTS, TAPS, 
sIUGR or EFWD ≥25% at 
<28 weeks 
172 136 sIUGR EFW <5th centile No sIUGR Maternal age 
(median), BMI 
(median), 
mode of 
conception 
(spontaneous 
or ART), parity 
BWD BWD >25% BWD ≤25% As for sIUGR 
outcome 
Sueters 
2006 
(Sueters 
2006) 
Cohort, 
prospective, 
consecutive 
Location: 1 centre in 
Netherlands  
Years: 2002-2004 
INC: MCDA pregnancies, 
<16 weeks at referral, no 
signs of TTTS at initial 
USS 
EXC: fetal abnormalities 
25 23 TTTS Polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS NT >95th 
centile in 
one/both 
fetuses, 
maternal age 
(median), 
parity (median) 
Sun 2017 
(Sun 2017) 
 
Case-control, 
retrospective, 
not stated 
Location: 1 centre in 
China 
Years: not stated 
INC: MCDA twins 
Not stated 14 BWD BWD >20% BWD <10% and normal 
UAD 
Maternal age 
(mean), fetal 
gender 
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EXC: pre-eclampsia, 
TTTS, TAPS, fetal 
structural/chromosomal 
anomalies, maternal or 
pregnancy complications 
Tai 2007 
(Tai 2007) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in USA 
Years: 2000-2006 
INC: twin pregnancies 
undergoing 1st T 
aneuploidy screening with 
2 fetal heartbeats 
detected 
EXC: chromosomal/major 
congenital anomalies, 
1st/2nd T TOP, MCMA 
Not stated 43 TTTS Not stated No TTTS CRL 
discordance 
≥11% 
Taylor-
Clarke 
2013 
(Taylor-
Clarke 
2013) 
Case-control, 
prospective, 
consecutive 
Location: 1 centre in UK 
Years: not stated 
INC: MCDA pregnancies 
referred for ultrasound 
assessment from local 
maternity units  
EXC: not stated 
 
Not stated 55 TTTS Polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS Maternal age 
(median) 
Torres-
Torres 
2010 
(Torres-
Torres 
2010) 
Cohort, 
retrospective, 
consecutive 
Location: 1 centre in 
Mexico 
Years: 2008-2009 
INC: MCDA twins 
undergoing antenatal care 
at centre 
EXC: not stated 
 
Not stated 34 (but we 
excluded 4 from 
analysis with 
aneuploidy/major 
defects, therefore 
30) 
TTTS Polyhydramnios 
(DVP ≥8cm) in 
the recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
‘Normal’ with no 
complications, structural 
abnormalities, TTTS or 
sIUGR 
Maternal age 
(median) 
sIUGR EFW >10th centile 
in one fetus 
‘Normal’ with no 
complications, structural 
abnormalities, TTTS or 
sIUGR 
Maternal age 
(median) 
*Velayo 
2012 
(Velayo 
2012) 
Case-control, 
retrospective, 
not stated  
Location: ? centre in ? 
country 
Years: 2008-2009 
INC: MCDA twins 
EXC: not stated 
Not stated 35 TTTS Polyhydramnios 
in 1 twin, 
oligohydramnios 
in the other twin. 
FLA performed for 
No TTTS or 
chromosomal/ structural 
anomalies. EFWD 
<15%, no 
polyhydramnios or 
Maternal age 
(mean), BMI 
(mean), 
ethnicity, 
parity, mode of 
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 all TTTS patients oligohydramnios, UAD, 
MCA and DV Dopplers 
normal. 
conception 
(spontaneous 
or not stated) 
Yinon 2014 
(Yinon 
2014) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in 
Israel 
Years: 2010-2012 
INC: MCDA twins 
EXC: chronic 
hypertension, pre-
gestational diabetes, 
congenital/chromosomal 
abnormalities, single 
IUFD at presentation 
 
 
60 45 TTTS Polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
Normal: appropriately 
grown, EFWD <25%, 
normal amniotic fluid 
volumes, normal UADs, 
similar MCA-PSV in 
both twins for all 
outcomes, except 
smoking which is no 
TTTS. 
Maternal age 
(median), 
gravida, BMI 
(median), 
smoking 
37 sIUGR EFW <10th centile 
in one fetus and 
EFWD ≥25% in 
same pregnancy 
Normal: appropriately 
grown, EFWD <25%, 
normal amniotic fluid 
volumes, normal UADs, 
similar MCA-PSV in 
both twins for all 
outcomes, except 
smoking which is no 
sIUGR 
Maternal age 
(median), 
gravida, BMI 
(median), 
smoking 
Zanardini 
2014 
(Zanardini 
2014) 
Cohort, 
prospective, 
not stated 
Location: 1 centre in Italy  
Years: 2009-2012 
INC: MCDA pregnancy 
attending centre for 
antenatal care 
EXC: MCMA, congenital 
cardiac 
anomaly/arrhythmia, fetal 
anomaly, TRAP, IUFD at 
presentation, maternal 
age <18 years, higher 
order multiples, patients 
lost to follow-up, TTTS 
diagnosed at <17 weeks 
139 100 TTTS Polyhydramnios 
(DVP ≥8cm 
before 20 weeks, 
or ≥10cm after 20 
weeks) in the 
recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
‘Uncomplicated’ 
throughout pregnancy, 
plus 4 with sIUGR (not 
defined) 
Mode of 
conception 
(spontaneous 
or not stated), 
maternal age 
(median), 
parity 
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Zhang 
2015 
(Zhang 
2015) 
Not stated, 
retrospective, 
not stated 
Location: ? centres in 
China 
Years: 2009-2013 
INC: MCDA twins 
EXC: severe maternal 
complications, TTTS, 
IUFD 
Not stated 24 LBW BW <10th centile 
in one twin 
No LBW Maternal age 
(mean), BMI 
(mean), fetal 
gender 
*Zhao 
2013 
(Zhao 
2013a) 
Cohort, 
retrospective, 
consecutive 
Location: 1 centre in The 
Netherlands 
Years: 2002-2012 
INC: MCDA twins with 
stored placentas 
EXC: TRAP, IUFD, higher 
order multiples, if 
underwent FLA or 
selective feticide  
 
Not stated 235 TTTS Polyhydramnios 
(DVP ≥8cm) in 
the recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS or 
chromosomal/ structural 
anomalies  
Fetal gender 
    BWD BWD ≥25% No BWD or 
chromosomal/ structural 
anomalies 
Fetal gender 
TAPS Antenatally MCA-
PSV 
>1.5 MoM in the 
donor and MCA-
PSV <1.0 MoM in 
the recipient, 
and/or 
postnatally inter-
twin haemoglobin 
difference >8.0 
g/dl, and at 
least one of the 
following: 
reticulocyte count 
ratio >1.7 and 
placenta with only 
small (diameter < 
1mm) vascular 
anastomoses 
No TAPS or 
chromosomal/ structural 
anomalies 
Fetal gender 
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Zoppi 2014 
(Zoppi 
2014) 
Cohort, 
prospective, 
not stated 
Location: ? centre in Italy  
Years: 2010-2012 
INC: MCDA pregnancies 
11-14 weeks gestation 
EXC: malformations, 
single or double IUFD <16 
weeks, TOP <16 weeks 
 
87 71 TTTS Diagnosed <26 
weeks. 
Polyhydramnios 
(DVP ≥8cm) in 
the recipient twin, 
oligohydramnios 
(DVP ≤2cm) in 
the donor twin 
No TTTS, sIUGR, 
amniotic fluid 
discordance 
UVVF larger 
twin (median), 
UVVF smaller 
twin (median), 
NT larger twin 
(median), NT 
smaller twin 
(median), CRL 
larger twin 
(median) CRL 
smaller twin 
(median) 
70 sIUGR AC <5th centile in 
one fetus, and 
EFWD >25% in 
same pregnancy 
?No TTTS, sIUGR, 
amniotic fluid 
discordance 
As for TTTS 
outcome 
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2.3.4 Risk of bias of included studies 
Most studies were not designed for the recruitment of participants to examine first 
trimester potential prognostic factors, consequently, the quality assessment should 
be interpreted with caution. The quality assessment results are likely to be reflective 
of the ability of the studies to demonstrate a difference in potential prognostic factors 
between groups, however the quality assessment of the ability of the individual 
studies to demonstrate prognostic ability for each factor is likely to be sub-optimal, as 
the QUIPS checklist could not be used as previously mentioned. The different 
aspects of the ‘STROBE’ classification are demonstrated in Figure 2.2.  
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Figure 2.2 Quality assessment of included studies according to ‘Strengthening 
The Reporting of Observational studies in Epidemiology’ (STROBE) checklist 
Of note is that the studies were poor at stating how they addressed missing data, and 
which data were missing meaning that attrition bias may have affected the results of 
the meta-analysis. Another notable finding is that the method of enrolment was not 
stated in the majority of studies, thus the level of selection bias is not clear. One 
aspect of the study design that may increase the risk of heterogeneity was that 
different control groups were used: (i) MC twin pregnancies with no maternal or fetal 
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complications, (ii) MC twins with no fetal complications, (iii) other MC twin 
pregnancies in the study who did not have the condition being examined but did have 
other MC complications. For the growth restriction outcomes, studies were classified 
according to the time that the growth measurement was performed, meaning that 5 
studies (El Kateb 2007, Chai 2013, Ghalili 2013, Zhao 2013a, Zhang 2015) despite 
calling their outcome IUGR, were included in the PGR group as their definition was 
based on birthweights, not antenatal ultrasound measurements. In calculating 
discordance between EFWs, or BWs, all studies used the larger measure as the 
denominator. Four studies included in the PGR meta-analyses only measured 
abnormal growth by BWD, Moriichi et al. (Moriichi 2013), Stagnati et al. (Stagnati 
2016), Sun et al. (Sun 2017), Zhao et al. (Zhao 2013a), meaning that both babies 
may have weighed >10th centile. All other studies that reported abnormal growth as 
an outcome had to have at least one fetus/baby <10th centile, except for three studies 
that were not able to be included in meta-analyses due to being the only studies 
which measured their potential prognostic factor (Lewi 2008a, Matias 2011, 
Johansen 2014). Not all the participants in the study by Murakami et al. (Murakami 
2011) had delivered at the time the study was published, therefore only those who 
had delivered were included in the meta-analysis. Only one funnel plot and Egger’s 
test was required, that did not suggest significant publication bias in the maternal age 
and TTTS analysis (Figure 2.7(b)). 
 
2.3.5 Synthesis of results 
Meta-analysis could be performed for the following prognostic factors:  
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a) Ultrasound measurements: NT >95th centile in one/both fetuses, NT discordance 
≥20%, CRL discordance ≥10%. 
b) Maternal characteristics: age, ethnicity, BMI, parity, smoking, mode of conception, 
fetal gender. 
In total, 20 separate meta-analyses were performed; of these, 3 demonstrated a 
moderate association (OR >2) (Table 2.2, section 2.3.6, 2.3.7 and 2.3.8), but none 
demonstrated a prognostic ability for any outcome under investigation. The other 17 
analyses that did not demonstrate an association are reported in section 2.3.9. Meta-
analysis was unable to be performed on first trimester biomarkers because of the 
way the data were presented. An insufficient number of studies reported antenatal 
and postnatal growth restriction within the same pregnancy (Bajoria 2006, Chang 
2017), and IUFD as outcomes to include in meta-analysis. Only 4 studies (Memmo 
2012, Ashoor 2013, Yinon 2014, Chang 2016) used a control group of ‘normal’ 
pregnancies, the other 44 studies used a control group of ‘no disease under 
investigation’ e.g. TTTS vs no TTTS, therefore the results should be considered as 
comparing to ‘no disease’. 
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Table 2.2 Summary of accuracy of prognostic factors with a significant 
association with twin-twin transfusion syndrome 
*Analysed by bivariate analysis. †Analysed by univariate analysis. CRL: crown-rump 
length, NT: nuchal translucency 
 
Prognostic 
factor 
Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
Positive 
likelihood 
ratio (95%CI) 
Negative 
likelihood 
ratio (95%CI) 
NT>95th 
centile in 
one/both 
fetuses* 
0.118 
(0.035, 0.330) 
0.926 
(0.882, 
0.954) 
1.589 
(0.589, 4.290) 
0.953 
(0.830, 1.094) 
CRL 
discordance 
≥10%† 
0.203 
(0.120, 0.308) 
0.908 
(0.882, 
0.929) 
2.180 
(1.147, 4.142) 
0.904 
(0.794, 1.030) 
Maternal 
ethnicity* 
0.826 
(0.672, 0.917) 
0.278 
(0.135, 
0.917) 
1.145 
(0.941, 1.394) 
0.624 
(0.349, 1.117) 
 
2.3.6 NT>95th centile in one/both fetuses and TTTS 
A significant association between NT>95th centile in one/both fetuses and TTTS was 
found (OR 2.29 [95%CI 1.05, 4.96] I2=6.6%, 4 studies, 615 pregnancies) (Figure 
2.3(a)). Bivariate meta-analysis results are in Table 2.2. The post-test probability of a 
positive result was 0.22 (95%CI 0.13, 0.35), and a negative result was 0.14 (95%CI 
0.13, 0.15), assuming pre-test probability of 0.176 based on a prevalence of 15%. 
See Figure 2.3(b) for the HSROC that shows reasonable specificity but poor 
sensitivity. 
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Figure 2.3 (a) Forest plot of association between NT>95th centile (NT>95th) in 
one/both fetuses and twin-twin transfusion syndrome (TTTS) and (b) 
Hierarchical summary receiver operating characteristic curves (HSROC) 
This visually represents the global summary of prognostic factor performance by 
plotting the mean sensitivity against the reversed mean specificity produced by the 
bivariate analysis. The ellipses represent the 95% confidence intervals of the mean 
sensitivities and specificities and 95% prediction region. The closer the values are to 
the top left corner, the greater the accuracy of the prognostic factor. 
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2.3.7 CRL discordance ≥10% and TTTS 
A significant association between CRL discordance ≥10% and TTTS was found (OR 
2.43 [95%CI 1.13, 5.21] I2=14.1%, 3 studies, 708 pregnancies) (Figure 2.4(a)). 
Univariate meta-analysis results are in Table 2.2. The post-test probability of a 
positive result was 0.28 (95%CI 0.20, 0.38), and a negative result was 0.13 (95%CI 
0.12, 0.15), assuming pre-test probability of 0.176 based on a prevalence of 15%. 
See Figure 2.4(b) for the SROC. 
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Figure 2.4 (a) Forest plot of association between crown-rump length 
discordance ≥10% (CRLD>10%) and twin-twin transfusion syndrome (TTTS) 
and (b) Summary receiver operating characteristic curves 
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2.3.8 Maternal ethnicity and TTTS 
An OR >1 indicated a higher-risk of TTTS if the woman was Caucasian, and an OR 
<1 indicated a higher-risk of TTTS if the woman was non-Caucasian. A significant 
association between maternal ethnicity and TTTS was found (OR 2.12 [95%CI 1.17, 
3.83] I2=0.0%, 5 studies, 467 pregnancies) (Figure 2.5(a)). Bivariate meta-analysis 
results are in Table 2.2. The post-test probability of a positive result was 0.17 (95%CI 
0.15, 0.19), and a negative result was 0.10 (95%CI 0.06, 0.16), assuming pre-test 
probability of 0.176 based on a prevalence of 15%. See Figure 2.5(b) for HSROC 
that shows moderate sensitivity but poor specificity. 
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Figure 2.5 (a) Forest plot of association between maternal ethnicity and twin-
twin transfusion syndrome (TTTS) (b) Hierarchical summary receiver operating 
characteristic curves 
This visually represents the global summary of prognostic factor performance by 
plotting the mean sensitivity against the reversed mean specificity produced by the 
bivariate analysis. The ellipses represent the 95% confidence intervals of the mean 
sensitivities and specificities and 95% prediction region. The closer the values are to 
the top left corner, the greater the accuracy of the prognostic factor. 
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2.3.9 Meta-analyses with no moderate/strong prognostic association 
NT discordance ≥20% and TTTS 
There was a trend towards a significant association between NT discordance ≥20% 
and TTTS, however there was a high-risk of heterogeneity (OR 2.48 [95%CI 0.90, 
6.84] I2=67.6%, 4 studies, 710 pregnancies) (Figure 2.6). To investigate the 
heterogeneity a sensitivity analysis was performed removing Kagan et al. (Kagan 
2007) as it only included those with severe TTTS requiring FLA in their group, 
whereas others included those with a diagnosis of TTTS irrespective of intervention. 
Removing Kagan et al. made no difference to the results or level of heterogeneity 
(results not shown) therefore this study was included. On visual inspection of the 
forest plot, Matias et al. was noted to be an outlier, however there was no reason to 
remove the study based on study design or characteristics, therefore this study was 
included. 
 
Figure 2.6 Forest plot of association between NT discordance ≥20% and TTTS 
 
NOTE: Weights are from random effects analysis
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Maternal age and TTTS 
No significant association between maternal age and TTTS was found (SMD 0.02 
[95%CI -0.19, 0.24] I2=54.9%, 15 studies, 1336 pregnancies) (Figure 2.7(a)). 
Although the I2 suggests a high-risk of heterogeneity, there were no obvious outliers 
from visual inspection of the forest plot or in study design. The funnel plot (Figure 
2.7(b)) does appear asymmetrical, although Egger’s test does not suggest small-
study effects with p=0.576.  
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Figure 2.7(a) Forest plot of association between maternal age and TTTS and (b) 
Funnel plot of maternal age and TTTS studies 
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Maternal age and AGR 
No significant association between maternal age and AGR was found (SMD -0.02 
[95%CI -0.62, 0.57] I2=87.5%, 6 studies, 529 pregnancies) (Figure 2.8). To 
investigate the high-risk of heterogeneity, a sensitivity analysis was performed 
removing Memmo et al. (Memmo 2012), Fujioka et al. (Fujioka 2014) and Stagnati et 
al. (Stagnati 2016) as these studies restricted their definitions of AGR based on 
gestation. Removing these studies made no difference to the results or level of 
heterogeneity (results not shown) therefore the studies were included. An additional 
sensitivity analysis was performed by removing Yinon et al. (Yinon 2014) and 
McDonald et al. (McDonald 2017) following visual assessment of the forest plot. This 
decreased the I2 to 0.0% and produced a significant association between maternal 
age and AGR (SMD 0.32 [95%CI 0.08, 0.56], 4 studies, 359 pregnancies) (forest plot 
not shown), however as the effect of maternal age was small, the prognostic ability 
was not further investigated. When the studies were examined in more detail, these 
were the only 2 studies in the meta-analysis that included twins with EFWD in their 
abnormal growth group, whereas the definition used in the other 4 studies required 
the EFW of 1 twin to be <10th centile (Torres-Torres 2010, Memmo 2012, Fujioka 
2014) or 5th centile (Stagnati 2016).   
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Figure 2.8 Forest plot of association between maternal age and antenatal 
growth restriction (AGR) 
 
Maternal age and PGR 
No significant association between maternal age and PGR was found (SMD 0.05 
[95%CI -0.75, 0.85] I2=78.3%, 3 studies, 173 pregnancies) (Figure 2.9). It was not 
possible to investigate the high-risk of heterogeneity as there were too few studies.  
 
Figure 2.9 Forest plot of association between maternal age and postnatal 
growth restriction (PGR) 
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Maternal age and AoPGR 
No significant association between maternal age and AoPGR was found (SMD -0.07 
[95%CI -0.51, 0.37] I2=82.1%, 10 studies, 622 pregnancies) (Figure 2.10). To 
investigate the high-risk of heterogeneity, a sensitivity analysis was performed 
removing Memmo et al. (Memmo 2012) and Fujioka et al. (Fujioka 2014) as these 
studies restricted their definitions of AGR based on gestation. However, removing 
these studies made no difference to the results or level of heterogeneity (results not 
shown) therefore these studies were included. 
 
Figure 2.10 Forest plot of association between maternal age and antenatal or 
postnatal growth restriction (AoPGR) 
 
 
 
 
 
NOTE: Weights are from random effects analysis
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Maternal BMI and TTTS 
No significant association between maternal BMI and TTTS was found (SMD -0.03 
[95%CI -0.30, 0.25] I2=0.0%, 4 studies, 291 pregnancies) (Figure 2.11). 
 
Figure 2.11 Forest plot of association between maternal BMI and TTTS 
 
Maternal BMI and AGR 
No significant association between maternal BMI and AGR was found (SMD 0.40 
[95%CI -0.37, 1.16] I2=87.9%, 3 studies, 281 pregnancies) (Figure 2.12). Following 
visual assessment of the forest plot, Stagnati et al. (Stagnati 2016) was noted to be 
an outlier, which was the only study in the meta-analysis that did not include EFWD 
in their definition of abnormal growth. It was not possible to investigate this further as 
there were too few studies. 
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Figure 2.12 Forest plot of association between maternal BMI and antenatal 
growth restriction (AGR) 
 
Maternal BMI and AoPGR 
No significant association between maternal BMI and AoPGR was found (SMD 0.03 
[95%CI -0.49, 0.55] I2=55.4%, 3 studies, 194 pregnancies) (Figure 2.13). It was not 
possible to investigate the high-risk of heterogeneity as there were too few studies. 
 
Figure 2.13 Forest plot of association between maternal BMI and antenatal or 
postnatal growth restriction (AoPGR) 
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Parity and TTTS 
An OR >1 indicated a higher-risk of TTTS if the woman was nulliparous, and an OR 
<1 indicated a higher-risk of TTTS if the woman was multiparous. No significant 
association between parity and TTTS was found (OR 1.08 [95%CI 0.58, 2.02] 
I2=46.4%, 6 studies, 615 pregnancies) (Figure 2.14). 
 
Figure 2.14 Forest plot of association between parity and TTTS 
 
Parity and AGR  
An OR >1 indicated a higher-risk of AGR if the woman was nulliparous, and an OR 
<1 indicated a higher-risk of AGR if the woman was multiparous. There appears to be 
an association between parity and AGR (OR 1.73 [95%CI 1.11, 2.70] I2=6.8%, 4 
studies, 545 pregnancies) (Figure 2.15) although as it was a weak association with 
an OR <2 this was not further investigated. 
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Figure 2.15 Forest plot of association between parity and antenatal growth 
restriction (AGR) 
 
Parity and AoPGR 
An OR >1 indicated a higher-risk of AoPGR if the woman was nulliparous, and an OR 
<1 indicated a higher-risk of AoPGR if the woman was multiparous. A trend towards 
an association between parity and AoPGR was found (OR 1.56 [95%CI 0.97, 2.50], 
I2=0.0%, 4 studies, 445 pregnancies) (Figure 2.16). 
 
Figure 2.16 Forest plot of association between parity and antenatal or postnatal 
growth restriction (AoPGR) 
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Maternal smoking and TTTS 
An OR >1 indicated a higher-risk of TTTS if the woman was a smoker, and an OR <1 
indicated a higher-risk of TTTS if the woman was a non-smoker. No significant 
association between maternal smoking and TTTS was found (OR 1.64 [95%CI 0.50, 
5.40] I2=0.0%, 3 studies, 184 pregnancies) (Figure 2.17). 
 
Figure 2.17 Forest plot of association between maternal smoking and TTTS 
 
Mode of conception and TTTS 
An OR >1 indicated a higher-risk of TTTS if the pregnancy was conceived by ART, 
and an OR <1 indicated a higher-risk of TTTS if the pregnancy was conceived 
spontaneously. No significant association between mode of conception and TTTS 
was found (OR 1.06 [95%CI 0.57, 1.99] I2=22.0%, 7 studies, 1040 pregnancies) 
(Figure 2.18). 
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Figure 2.18 Forest plot of association between mode of conception and TTTS 
 
Mode of conception and AGR 
An OR >1 indicated a higher-risk of AGR if the pregnancy was conceived by ART, 
and an OR <1 indicated a higher-risk of AGR if the pregnancy was conceived 
spontaneously. No significant association between mode of conception and AGR 
was found (OR 1.79 [95%CI 0.68, 4.70] I2=0.0%, 3 studies, 282 pregnancies) (Figure 
2.19).  
 
Figure 2.19 Forest plot of association between mode of conception and 
antenatal growth restriction (AGR) 
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Mode of conception and AoPGR 
An OR >1 indicated a higher-risk of AoPGR if the pregnancy was conceived by ART, 
and an OR <1 indicated a higher-risk of AoPGR if the pregnancy was conceived 
spontaneously. As Ghalili et al. (Ghalili 2013) presented both BWD and LBW in one 
baby, and in two babies, the latter two measures were combined to reflect LBW in at 
least one twin. No association between mode of conception and AoPGR was found 
(OR 1.02 [95%CI 0.64, 1.65], I2=0.0%, 3 studies, 440 pregnancies) (Figure 2.20). 
 
 
Fetal gender and PGR 
An OR >1 indicated a higher-risk of PGR if the fetuses were male, and an OR <1 
indicated a higher-risk of PGR if the fetuses were female. No significant association 
between fetal gender and PGR was found (OR 0.73 [95%CI 0.42, 1.29] I2=0.0%, 4 
studies, 288 pregnancies) (Figure 2.21). 
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Figure 2.21 Forest plot of association between fetal gender and postnatal 
growth restriction (PGR) 
 
 
 
Fetal gender and AoPGR 
An OR >1 indicated a higher-risk of AoPGR if the fetuses were male, and an OR <1 
indicated a higher-risk of AoPGR if the fetuses were female. No significant 
association between fetal gender and AoPGR was found (OR 0.68 [95%CI 0.43, 
1.08], I2=0.0%, 7 studies, 422 pregnancies) (Figure 2.22).  
 
Figure 2.22 Forest plot of association between fetal gender and antenatal or 
postnatal growth restriction (AoPGR) 
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2.4 Comment 
 
2.4.1 Main findings 
This is the first systematic review to look at first trimester potential prognostic factors 
for growth restriction in MC twins, and explore maternal characteristics and first 
trimester maternal serum biomarkers as prognostic factors for TTTS. Although a 
significant association was found between NT>95th centile in one/both fetuses and 
TTTS, and CRL discordance ≥10% and TTTS, both demonstrated poor individual 
prognostic ability. A moderate significant association between maternal ethnicity and 
TTTS was found, with Caucasian women more likely to develop TTTS, but as there is 
no plausible biological mechanism for this association this may reflect the lack of 
diversity within the study populations and publication bias. The other first trimester 
ultrasound measurements and maternal characteristics demonstrated no association 
with adverse outcomes. 
 
Only 2 studies examined first trimester maternal serum biomarkers, with Ashoor et al. 
(Ashoor 2013) finding no significant difference in TSH, FT4 or β-hCG in those 
pregnancies that developed TTTS, and Linskens et al. (Linskens 2010) noting a trend 
towards increased β-hCG and PAPP-A levels in those pregnancies that developed 
TTTS. As Linskens only reported the median and not the IQR these studies could not 
be combined in meta-analysis, but this warrants further investigation due to the small 
study sizes and biological plausibility of β-hCG and PAPP-A being implicated in 
TTTS as markers of placental function. 
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2.4.2 Strengths and limitations 
A major strength of this study was to include all possible prognostic factors and 
perform a robust statistical analysis to look at the association and prognostic ability of 
the factors. The search strategy was as inclusive as possible, and there was no limit 
on language. It was particularly important to look at modifiable factors such as 
smoking and maternal BMI where lifestyle changes may be associated with a lower 
risk for adverse outcome. 
 
One limitation of this review was the different definitions that studies used for their 
control groups, variables and outcomes, which is why individual definitions were not 
rigidly stipulated prior to commencing the search. This was an issue for growth 
restriction as there is currently no validated standard definition of abnormal growth in 
MC twins. Consequently, the included studies defined growth restriction in a myriad 
of ways: AC ≤5th centile, EFW <10th centile, EFW <5th centile, EFWD >20%, LBW 
<10th centile, LBW <5th centile, BWD ≥20%, BWD ≥25%, and in different 
combinations of in one twin, or both twins when not measuring discordance, all of 
which can be associated with adverse outcome. This issue has attempted to be 
investigated by a recent Delphi consensus looking at selective fetal growth restriction 
in twin pregnancy (Khalil 2018), and will be addressed by the creation of a ‘Core 
Outcome Set’ for ‘selective fetal growth restriction in twin pregnancies’(Gordijn 2017) 
which is due to be completed by August 2019. In this systematic review, the problem 
was attempted to be addressed by creating different growth restriction groups so as 
to be as inclusive as possible. The AGR group reflects real life and is what 
obstetricians base their management on. However, ultrasound scanning and 
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calculation of EFWD only has a moderate ability to detect BWD with a recent 
systematic review reporting a sensitivity of 65.4% (95%CI 57.9, 72.3) and specificity 
of 90.8% (95%CI 87.1, 93.5%) for EFWD ≥20% predicting BWD ≥20%, although the 
analysis did include DC and MC twins (Leombroni 2017). Therefore, the PGR group 
was included as an absolute measure, which avoids scan error. However, there is 
controversy whether BWD is reflective of pathological growth, and indeed what the 
cut-off should be. A recent meta-analysis, that also highlighted the problem of 
different definitions of abnormal growth in twins, demonstrated that MC twins with 
BWD ≥20% (which also included EFWD ≥20%) had a higher risk of IUFD than 
concordant MC twins (OR 2.8 [95%CI 1.3,5.8] 6 studies, 1286 pregnancies, I2 not 
reported) (D'Antonio 2017a). Currently, MC twins with isolated BWD are not 
managed differently neonatally as this is guided by the actual birthweight. 
Additionally, BWD is not always reflective of IUGR with 21.1% of pregnancies with 
BWD ≥20% not including at least one fetus with an EFW <10th centile, and 21% of 
pregnancies with at least one fetus with an EFW <10th centile not demonstrating 
concurrent BWD (Neves 2017). However, most studies in the search that reported 
growth based on postnatal measures used BWD as opposed to LBW, therefore it 
was decided to include BWD in the systematic review. The use of inter-twin growth 
discordance in isolation, whether EFWD or BWD, also presents the problem of 
missing pregnancies where both twins are growth restricted, but irrespective of 
choice of definition and cut-offs, all growth outcomes have the common problem of 
not being based on specific twin growth charts, which until July 2017 did not exist. 
Since performing this review, twin growth charts have been launched in the UK to 
enable more accurate assessment of twin fetal growth (TAMBA 2017). Another issue 
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was that of cut-offs for the variables as the cut-offs have not been adequately 
validated and may not be appropriate for the study’s patient population, or the 
conditions being explored. The initial aim was to compare a) disease vs. no disease 
but where other complications may be present, and b) disease vs. normal pregnancy 
where no complications were present at all. However as most studies used the 
former control group, it was not possible to perform a separate analysis for the latter 
comparison. This has only allowed the evaluation of the ability of each potential 
prognostic factor to predict a specific condition, and not any condition (and thus 
cannot predict the chance of the pregnancy being completely ‘normal’). 
 
2.4.3 Comparison with existing literature 
A systematic review evaluating prognostic factors up to 16 weeks for TTTS has 
recently been published, however they only looked at ultrasound prognostic markers, 
and their search was up to April 2014 (Stagnati 2017). They stated that an increased 
risk of TTTS was associated with inter-twin NT discrepancy, NT>95th centile, and 
CRL discrepancy, but similar to the results in this chapter, the prognostic ability of 
these factors was low. In addition to the inclusion of other MC twin complications, 
there are other differences between this review and the review by Stagnati et al., 
including that Stagnati et al. did not exclude pregnancies with chromosomal/structural 
anomalies that affect first trimester ultrasound measurements. D’Antonio et al. 
performed a systematic review examining the ability of first trimester CRL 
discordance ≥10% to predict BWD ≥20%, PTB, fetal anomalies, IUFD and NND, and 
found it also had a low prognostic ability for all outcomes (D'Antonio 2014). 
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2.4.4 Implications 
The main clinical implication of the results of this systematic review is that they 
support the guidance from the Royal College of Obstetricians and Gynaecologists 
(RCOG) that ‘screening for TTTS by first trimester NT measurements should not be 
offered’(Kilby 2016). Although significant associations between first trimester 
variables and subsequent pregnancy outcome have been shown, the prognostic 
ability of each individual variable is poor, thus the results do not suggest their use to 
screen MC pregnancies in clinical practice. 
 
A gap in knowledge has been identified which has implications for research as most 
studies able to be included in the systematic review were not designed with the 
intention of assessing first trimester prognostic factors for subsequent outcomes in 
MC twins. Consequently, the OMMIT study (ISRCTN13114861) was designed: a 
large cohort study, purposefully-designed to investigate potential prognostic factors 
and explore novel prognostic markers that have not previously been evaluated: 
including AFP, PAPP-A, and sFlt-1 (Mackie 2017). To avoid the problem of using 
non-validated cut-offs, variables should be kept continuous and not dichotomised.  
 
2.5 Conclusion 
 
The association and prognostic ability of first trimester factors, including maternal 
characteristics, associated with TTTS, growth restriction and IUFD were investigated. 
It is not currently possible to predict adverse outcomes in MC twin pregnancies, and 
a lack of research investigating first trimester biomarkers in MC twin pregnancies has 
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been revealed. Different assessment methods and definitions of each variable and 
outcome were an issue and this highlights the need for a large cohort study to 
evaluate these factors. 
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CHAPTER 3 IDENTIFYING FIRST TRIMESTER 
PROGNOSTIC FACTORS OF COMPLICATIONS IN 
MONOCHORIONIC TWIN PREGNANCIES 
 
• These findings were presented as an oral presentation at the British Maternal and 
Fetal Medicine Society 18th Annual Conference, March 2017, Amsterdam, The 
Netherlands, and as a platform poster presentation at the Royal College of 
Obstetricians and Gynaecologists Annual Academic Meeting, February 2018, 
London, both presented by F Mackie. 
• The protocol for this study has been published [Mackie FL, Morris RK and Kilby 
MD (2017). “The prediction, diagnosis and management of complications in 
monochorionic twin pregnancies: the OMMIT (Optimal Management of 
Monochorionic Twins) study.” BMC Pregnancy Childbirth 17(1):153].  
• These findings have been published in abstract form [Mackie FL, Hall MJ, Hyett J, 
Mills I, Riley R, Morris RK and Kilby MD (2017). “First trimester prediction of 
adverse events in monochorionic diamniotic twins: The OMMIT study.” BJOG 
124(S2):6]. 
• These findings have been accepted for publication in full article form [Mackie FL, 
Whittle R, Morris RK, Hyett J, Riley RD and Kilby MD (2019). “First trimester 
ultrasound measurements and maternal serum biomarkers as prognostic factors 
in monochorionic twins.” J Diagn Progn Res] 
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3.1 Overview 
 
Monochorionic (MC) twins are high-risk pregnancies. At present it is not possible to 
delineate which MC twins will develop complications. The systematic review in 
CHAPTER 2 demonstrated that first trimester ultrasound measurements are 
associated with adverse outcome, and that there is a dearth of research into 
biomarkers in MC twin pregnancies with the only validated biomarkers in MCDA twins 
being those used in the combined and quadruple aneuploidy screening tests. After a 
systematic review of current research, the next step in prognostic research is to 
assess the predictive ability of individual prognostic factors. This chapter will outline 
potential first trimester ultrasound measurements and maternal serum biomarkers, 
and will evaluate their ability to predict adverse outcomes in MCDA twin pregnancies 
in an international retrospectively recruited cohort of MCDA twin pregnancies 
undergoing first trimester aneuploidy screening.  
 
3.2 Potential prognostic factors  
 
In this section, unless stated otherwise, the ultrasound measurements and 
biomarkers referred to were measured in the first trimester, and the biomarkers were 
evaluated in maternal serum or plasma samples. Studies in twin pregnancies were 
used where possible, but if no evidence was found in twin pregnancies, research in 
singleton pregnancies was presented. Every attempt was made to report results 
according to chorionicity, but if this was not possible using the information provided in 
the published article, MC and/or DC twins were referred to as ‘twin pregnancies’. 
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3.2.1 Nuchal translucency (NT) 
NT is an ultrasound measurement of subcutaneous fluid in the nuchal fold at the 
back of the fetal neck. It is performed in a mid-sagittal view, with the fetus at 90° to 
the angle of insonation and in a neutral position with the neck neither hyperextended 
nor flexed (FMF 2004). There should be adequate magnification, the callipers should 
be placed on the outer borders at the widest part of the nuchal fold, and the mean of 
2 measurements should be used. The commonest association with a raised NT, 
defined as ≥3.5mm, is chromosomal anomalies (Montenegro 1997, Snijders 1998, 
Souka 1998, Souka 2001). Consequently NT is one component of first trimester 
combined aneuploidy screening test that consists of: NT, maternal age, free β-hCG 
and PAPP-A which are detailed elsewhere in this section. There is a strict time frame 
in which combined screening can be performed, 11+0 to 14+1 weeks, which is 
calculated based on the CRL (see below) (FASP 2015). The time frame and process 
is the same when combined aneuploidy screening is performed in twin pregnancies 
as in singleton pregnancies, but the NT measurement of each twin in included in the 
algorithm, and an individual risk of each DC twin may be calculated. However, the 
accuracy of the combined aneuploidy screening test in twin pregnancies is lower than 
in singletons (Wald 2003). One study compared the screening accuracy of combined 
screening in singleton pregnancies, MC twins, and DC twins (Wald 2003). They 
found a detection rate of 85%, 84% and 70% respectively based on a 5% false 
positive rate. Accuracy is lower in twins because of inter-twin differences in the 
biochemical levels of β-hCG and PAPP-A. The substantial decrease in accuracy in 
DC twins reflects aneuploidy often being discordant in DC twins, thus the alteration in 
the affected twin’s biochemical levels is compensated by the other twin’s normal 
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levels and the detection rate is lower (Garchet-Beaudron 2008). Additionally, MC 
twins have a higher prevalence of an increased NT in euploid fetuses than DC twins, 
and singleton fetuses (8.4% vs 5.4% vs 5.2% respectively) which also increases the 
false positive rate (Sebire 1996). A recent Cochrane review reported that at a cut-off 
point of 1:250 risk of trisomy 21, the sensitivity and specificity of combined 
aneuploidy screening in all pregnancies is 85% (95%CI 81, 87) and 95% (95%CI 95, 
96) (25 studies, 174,712 fetuses including 1032 fetuses affected by Down’s 
syndrome) (Alldred 2017). Two of the 25 studies were performed in multiple 
pregnancies, but when the authors removed these 2 studies as part of a sensitivity 
analysis, it made no difference to the results. Prats et al. performed a meta-analysis 
of first trimester combined screening in twin pregnancies only (5 studies, 12,974 
fetuses, 69 cases of trisomy 21) and reported a higher sensitivity (89.3% [95%CI 
79.7, 94.7]) and similar specificity (94.6% [95%CI 93.3, 95.7]) compared to Alldred et 
al. (Prats 2014). The reason for the discrepancy in included studies in the two meta-
analyses is not clear, but despite Alldred et al. being published in 2017, the search 
was run up to 2011, whereas Prats et al. performed their search up to 2013. Prats et 
al. also performed an analysis comparing MC with DC twins, but found no difference 
in test accuracy.  
 
In addition to aneuploidy, a raised NT measurement is also associated with fetal 
structural abnormalities particularly cardiac defects (Souka 1998, Hyett 1999). The 
pathogenesis of how an increased NT measurement is linked to cardiac defects is 
not clear, but one hypothesis is that the raised fluid in the nuchal fold is a result of 
cardiac failure (Montenegro 1997). Other hypotheses include compressed umbilical 
  
128 
 
veins due to a nuchal cord (Maymon 1999), increased type VI collagen in the skin of 
the nuchal fold (von Kaisenberg 1998), or delayed endothelial remodelling causing 
jugular lymphatic sac distension (Haak 2002), which also links to cardiovascular 
function.  
 
The relationship between NT and growth restriction in twin pregnancies, was not able 
to be explored in CHAPTER 2 due to too few studies being able to be grouped 
together for meta-analysis. Individual studies report conflicting findings. One study 
suggested NT discordance has excellent test accuracy to predict sIUGR in MC twin 
pregnancies with an AUC of 0.93 (95%CI 0.87, 1.00) although this is based on 4 
(2.96%) MC sIUGR pregnancies out of a total cohort of 136 MC twin pregnancies 
(Fratelli 2011). Other studies have found no relationship between growth restriction 
and NT measurements in twin pregnancies in the first trimester (El Kateb 2007, 
Memmo 2012, Zoppi 2014). 
 
The systematic review in CHAPTER 2 did find an association between a first 
trimester NT measurement >95th centile in one/both fetuses and TTTS (OR 2.29 
[95%CI 1.05, 4.96] I2=6.6%, 4 studies, 615 pregnancies), but it had a low predictive 
ability. A trend towards a significant association between NT discordance ≥20% and 
TTTS was also reported, although there was a high-risk of heterogeneity (OR 2.48 
[95%CI 0.90, 6.84] I2=67.6%, 4 studies, 710 pregnancies). No studies could be meta-
analysed that had not dichotomised the NT data which is important to note as by 
dichotomising the data important data is lost, and it may be that by examining the 
data as continuous variables the predictive ability may be improved. The connection 
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between a raised NT and TTTS is interesting given the association between a raised 
NT and cardiac defects, and the high rate of cardiac dysfunction seen in TTTS, 
especially in the recipient twin. A substantial proportion of the initial work on cardiac 
defects and raised NT measurements was performed in fetuses with aneuploidy 
(Haak 2003). However euploid fetuses with a raised NT and abnormal DV Doppler 
are often found to have cardiac defects as well (Matias 1999). In TTTS, Sebire et al. 
hypothesise that the raised NT is because of hypervolaemic congestion which the 
developing fetal heart is less able to cope with in the first trimester compared to later 
in pregnancy (Sebire 2000). No other meta-analyses of NT measurement and its 
association with adverse outcome in MC twins could be performed in CHAPTER 2. 
The study that reported a high AUC for predicting sIUGR by NT discordance (Fratelli 
2011) suggests a relationship may exist. In view of the lack of research, and the 
possible link between NT and TTTS, this warrants further investigation as a potential 
prognostic factor of adverse outcome in MC twin pregnancies. 
 
3.2.2 Crown-rump length (CRL) 
CRL is the ultrasound measurement that assesses the length of the fetus from the 
top of the fetal head to the bottom of the buttocks. It is performed in a mid-sagittal 
view, with the fetus at 90° to the angle of insonation and in a neutral position 
(Intergrowth-21st 2010). The image should fill ≥30% of the monitor screen and the 
callipers to perform the measurement should be placed on the outer borders. The 
CRL is routinely used to date the pregnancy so that antenatal care can be planned 
accordingly. The correct dating of twin pregnancies is vital to ensure management 
plans are performed in a timely manner, such as delivery at 36 weeks gestation for 
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normal MCDA twins to avoid perinatal death. The use of the last menstrual period is 
not as reliable as ultrasound due to the natural biological variation in menstrual cycle 
length and frequency, and the reliance on self-reporting by women (Mongelli 1996, 
Taipale 2001, Savitz 2002). There are various formulae to convert the CRL into 
gestational age (Sladkevicius 2005), but the differences between the formulae are 
not considered clinically significant. The formulae used for singleton charts are able 
to be used for twin pregnancies (Dias 2010) because the rate of growth in singletons 
and twins is similar in the first trimester (Martins 2009, Morin 2011). In twin 
pregnancies there is the additional complexity of which twin’s CRL measurement to 
use. The most accurate method of dating twin pregnancies by ultrasound has been 
debated with some studies supporting the use of the smallest twin CRL (Salomon 
2005, Dias 2010, Chaudhuri 2013), others the largest twin CRL (Simpson 2013), and 
others the mean inter-twin CRL (Dias 2010), although the majority of these studies 
have been performed on DC twins. As advised by various national bodies (Morin 
2011, NICE 2011, Khalil 2016b, Kilby 2016), the consensus is to use the largest twin 
CRL (Simpson 2013) as it is rare for a twin to be pathologically large, and this means 
that the pregnancy is not dated based on a potentially pathologically small fetus 
affected by aneuploidy (Nakamura 2015), or a fetus which may already be 
demonstrating signs of IUGR (Memmo 2012, Zoppi 2014). CRL measurements 
including both twins, such as the use of the mean inter-twin CRL in MC twins is 
controversial due to the reported association between inter-twin CRL discordance, 
and subsequent adverse outcomes such as TTTS.  
The CRL is important if the woman opts to undergo aneuploidy screening as the 
normal values of the NT measurement and serum biomarkers depend on gestation at 
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measurement. A CRL of 45-84mm is equivalent to 11+0 to 14+1 weeks (Robinson 
1975) which is considered the optimum time for combined first trimester aneuploidy 
screening (FASP 2015). If the woman presents after the first trimester as indicated by 
a CRL >84mm, the head circumference should be used to date the pregnancy as the 
CRL after this time is less accurate (NICE 2011). Combined aneuploidy screening is 
not an option at this stage due to decreased accuracy; if the woman would like to 
undergo aneuploidy screening she will need to have the quadruple test. The 
quadruple test may be performed up to 20+0 weeks gestation and consists of serum 
inhibin-A, unconjugated oestriol, β-hCG and AFP, the latter two biomarkers are 
described below.  
 
The association between TTTS and CRL was explored by the meta-analysis in 
CHAPTER 2 that found that CRL discordance ≥10% was significantly associated with 
TTTS (OR 2.43 [95%CI 1.13, 5.21] I2=14.1%, 3 studies, 708 pregnancies) but had a 
low prognostic ability. However, studies dichotomised the data using a non-validated 
cut-off, and it may be that when examined as continuous data, the prognostic ability 
is improved. Other cut-offs and calculations involving CRL were investigated, but 
there were insufficient studies to group together to perform meta-analyses.  
 
With regards the relationship between CRL and growth restriction in twin 
pregnancies, two studies have suggested fair to good test accuracy with AUCs of 
0.77 (95%CI 0.37,1.00) (Fratelli 2011) and 0.89 (95%CI 0.83, 0.95) (Memmo 2012) 
when using CRL to predict sIUGR in MC twin pregnancies. Another study reported a 
possible link between CRL discordance ≥10% and SGA fetuses in MC and DC twins 
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as a higher proportion of twins in the CRL discordance group had a SGA fetus 
compared to the proportion of SGA fetuses in the CRL concordant group (Grande 
2016). This study also found a possible link between CRL discordance and BWD, but 
only in MC twins. Another study found no relationship between growth restriction and 
CRL discordance in twin pregnancies (El Kateb 2007). 
 
3.2.3 β-human chorionic gonadotropin (β-hCG) 
hCG is fundamental for a healthy pregnancy. It is a non-covalent heterodimer 
comprised of α- and β- subunits common to the 3 isoforms of hCG. hCG is a member 
of the glycoprotein hormone family and is structurally similar to LH, TSH and FSH. 
This means that hCG can bind to LH receptors and there is an overlap in function at 
the start of pregnancy. The β-subunit is 80% homologous to LH, whereas the α-
subunit is almost completely homologous to LH, TSH and FSH; therefore it is difficult 
to distinguish the α-subunit in most commonly used assays, thus β-hCG is most 
frequently measured (Stenman 2006). There are three dimeric isoforms of hCG that 
are a result of post-translational modifications, and the three isoforms have different 
sites of production and distinct functions: “regular” hCG, sulphated hCG and 
hyperglycosylated hCG (Nwabuobi 2017). Sulphated hCG is only produced by the 
anterior pituitary gland and mainly acts during the menstrual cycle. Hyperglycosylated 
hCG is produced by cytotrophoblasts and is an autocrine/paracrine factor, as 
opposed to a hormone, and promotes cell growth and differentiation. 
Hyperglycosylated hCG levels are also high in germ cell tumours such as testicular 
cancer (Milose 2011), but this thesis will focus on pregnancy. In the first 11 weeks of 
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gestation, invasive extravillous trophoblasts secrete hCG, is mainly in the 
hyperglycosylated form (Guibourdenche 2010). 
 
Since its discovery in the early 1900s, hCG has been found to be involved in a 
plethora of processes crucial for pregnancy development, as summarised by Cole et 
al. (Cole 2010), including promoting blastocyst signalling to the endometrium prior to 
implantation, progesterone secretion from the corpus luteum, uterine vasculature 
angiogenesis, immunosuppression and blockage of phagocytosis of invading 
trophoblast cells, and myometrial quiescence. hCG is mainly produced by 
syncytiotrophoblast during pregnancy (Handschuh 2007, Fournier 2015) and has a 
half-life of 37 hours, thus making it a useful pregnancy-specific biomarker (Faiman 
1968). Prior to conception, hCG injections are used in ART to stimulate oocyte 
maturation and ovulation before oocyte retrieval (Filicori 2005). In pregnancy, 
maternal serum β-hCG levels increase in the first trimester and decrease for the 
remainder of pregnancy (Figure 3.1), with levels related to the rate of cytotrophoblast 
differentiation into syncytiotrophoblast, as opposed to placental mass (Hay 1988). 
The same pattern is seen in twin pregnancies, although maternal serum levels are 
higher in twin than singleton pregnancies in the first trimester (Spencer 2000, 
Spencer 2008, Madsen 2011) and second trimester (Nebiolo 1991, Neveux 1996, 
O'Brien 1997, Räty 2000, Xie 2008, Ren 2016, Svirsky 2016). When chorionicities 
were compared MC twins had higher maternal serum β-hCG levels than DC twins in 
the second trimester (Muller 2003), although findings in the first trimester are 
conflicting with the majority of studies reporting no difference (Spencer 2001, 
Niemimaa 2002, Gonce 2005, Spencer 2008, Koster 2010, Madsen 2011, Svirsky 
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2016), and two studies reporting higher levels in DC than MC twin pregnancies in the 
first trimester (Linskens 2009b, Prats 2012).  
Due to the sharp increase in the first trimester, maternal serum β-hCG levels are 
used to diagnose pregnancy itself, and to monitor early pregnancy complications 
including miscarriage (Stenman 2006) and ectopic pregnancy (Silva 2006), in 
conjunction with ultrasound assessment (Seeber 2006). Low maternal serum levels, 
or those with a sub-optimal rise are more likely to result in miscarriage in singleton 
pregnancies (Stenman 2006), although no studies were found supporting this in twin 
pregnancies (Rosner 2015). Maternal serum levels are part of the first trimester  
combined, and second trimester quadruple test as part of the aneuploidy screening 
programme (FASP 2015) as increased first and second trimester β-hCG is 
associated with aneuploidy (Bogart 1987, Wapner 2003). This increase is also seen 
 
Figure 3.1 Maternal serum levels of human chorionic gonadotropin (hCG) in 
singleton pregnancy  
(n=443 pregnancies) (Braunstein 1976). Mean and Standard error of the mean 
displayed. 
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in twin pregnancies affected by aneuploidy (Noble 1997, Madsen 2011). Another 
focus of research on first trimester hCG is on pre-eclampsia prediction. The biological 
basis behind this hypothesised link is that low first trimester hyperglycosylated hCG 
levels are associated with non-invasive, and thus dysfunctional, syncytiotrophoblasts 
(Keikkala 2013). Although initial studies showed promise in singletons, a combination 
of first trimester biomarkers, including decreased first trimester β-hCG, and 
ultrasound measures with sufficient predictive ability for clinical practice has not yet 
been discovered (Zhong 2015). Results are more encouraging from second trimester 
work (Spencer 2006) with a combination of β-hCG and PAPP-A improving the current 
predictive ability of maternal characteristics which the current National Institute for 
Health and Care Excellence (NICE) guidance uses to indicate which women should 
receive low dose aspirin to reduce their risk of pre-eclampsia (Wright 2016).  
 
In singletons, increased second trimester β-hCG is associated with the following 
complications as summarised by Gagnon et al. (Gagnon 2008): IUGR, PTB, 
miscarriage, stillbirth and pregnancy-induced hypertension. In twins, one study that 
only included DCDA twins reported an association between increased second 
trimester β-hCG and PTB, and neonatal unit (NNU) admission, but these 
associations were not present with first trimester β-hCG (Rosner 2015). Another 
study that did not perform sub-group analysis according to chorionicity reported 
increased first trimester β-hCG was associated with pregnancy-induced 
hypertension, IUGR and SGA in twin pregnancies, but there was no association with 
β-hCG levels and miscarriage, PTB <34 weeks, GDM and sIUGR (Iskender 2013). 
Another study did find an association between first trimester β-hCG and PTB <32 
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weeks gestation, although chorionicity and predictive ability were not reported 
(Laughon 2009). The evidence in singleton pregnancies shows poor predictive ability 
of first trimester hCG to predict PTB, and SGA fetuses (Zhong 2015).  
 
Two studies have investigated β-hCG levels in second trimester maternal serum at 
diagnosis of TTTS and both studies found significantly higher β-hCG levels in women 
with pregnancies affected by TTTS than matched MC and DC controls (Fox 2009, 
Sermondade 2009). Following FLA, there was no difference in maternal serum β-
hCG 1 week post-FLA (Fox 2009), but another study reported a decrease at 2 and 4 
weeks post-FLA (Hanaoka 2011) although this study did not perform blood sampling 
1 week post-FLA. A difference between Quintero stages I and II, compared to III and 
IV was also reported, with the worse Quintero stages associated with higher β-hCG 
levels (Hanaoka 2011). Linskens et al. (Linskens 2010) examined first trimester β-
hCG in the context of TTTS and although they reported a trend in increasing β-hCG 
in 12 TTTS pregnancies compared to 39 uncomplicated MC twin pregnancies, the p 
value was 0.32 suggesting there was actually no difference between the groups. 
Ashoor et al. also looked at first trimester β-hCG in 19 TTTS pregnancies and found 
no difference compared to 58 uncomplicated MC twin pregnancies (Ashoor 2013). 
Given the relationship between β-hCG and TTTS in the second trimester, and the 
lack of first trimester research, β-hCG merits further investigation in the first trimester 
in MC twin pregnancy complications. 
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3.2.4 Pregnancy-associated plasma protein A (PAPP-A) 
PAPP-A is a metalloprotease that cleaves insulin-like growth factor binding protein 
(IGFBP) -4 and -5 (Byun 2001). It is produced by the syncytiotrophoblast and decidua 
(Schindler 1984, Barnea 1986) and has a half-life of 53±26 hours (Bischof 1981). 
When PAPP-A releases insulin-like growth factors (IGFs) from their IGFBPs by its 
protease activity, the IGFs are able to aid trophoblast invasion and thus placental 
development (Jones 1995). Consequently low PAPP-A is associated with the 
adverse outcomes detailed below. Maternal serum PAPP-A levels increase 
throughout gestation (Figure 3.2). 
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In twin pregnancies, PAPP-A levels are higher in the first trimester (Spencer 2000, 
Niemimaa 2002, Spencer 2008, Madsen 2011, Sung 2017) and second trimester 
(Svirsky 2016) compared to singleton pregnancies, no studies were found comparing 
third trimester levels. When chorionicities are compared results are conflicting; some 
studies report no difference in first trimester PAPP-A (Niemimaa 2002, Koster 2010, 
Svirsky 2016), and other studies report lower levels in MC compared to DC twins in 
the first trimester (Spencer 2008, Linskens 2009b, Madsen 2011, Prats 2012). 
First trimester PAPP-A levels are used clinically as part of the combined aneuploidy 
screening programme for twin and singleton pregnancies (FASP 2015) as low  
Figure 3.2 Maternal serum levels of pregnancy-associated plasma protein A 
(PAPP-A) in singleton and twin pregnancy 
n=204 singleton pregnancies, represented by circles and n=2 twin pregnancies, 
represented by triangles. (Lin 1974). Individual values and mean line displayed. 
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PAPP-A is associated with aneuploidy in singleton and twin pregnancies (Madsen 
2011). Low first trimester PAPP-A is considered a “major risk factor for delivery of a 
SGA neonate” in singletons according to RCOG guidance (Robson 2013). Maternity 
units have their own local guidance for low PAPP-A results. There is little evidence to 
support a significant association between low first trimester PAPP-A and growth 
restriction in twin pregnancies. Other associations between low first trimester PAPP-
A and adverse outcome in singleton pregnancies, as reviewed by Gagnon et al. 
(Gagnon 2008) include: IUGR, PTB, pregnancy-induced hypertension, miscarriage 
and stillbirth, although the predictive ability for low birthweight (LBW), pre-eclampsia 
and stillbirth is poor (Morris 2017). In twin pregnancies research is sparse and 
conflicting. Rosner et al. only included DCDA twins and reported an association with 
low first trimester PAPP-A and PTB <37 weeks (relative risk 5.56 [95%CI 1.53-
20.22]), but no association with PTB <34 weeks, LBW, hypertensive disorders of 
pregnancy or IUFD (Rosner 2015). Iskender et al. did not divide results according to 
chorionicity and did not find any difference in first trimester PAPP-A and miscarriage, 
PTB <34 weeks, pregnancy-induced hypertension, GDM, discordant growth, IUGR, 
SGA, or sIUGR in twin pregnancies (Iskender 2013). Another study also found no 
association between first trimester low PAPP-A and PTB at <37 or <32 weeks 
gestation (Laughon 2009). The relationship between pre-eclampsia and low PAPP-A 
in twin pregnancies is also inconsistent with one study reporting no difference in 
PAPP-A levels in twin pregnancies with pre-eclampsia and twin pregnancies without 
pre-eclampsia (Francisco 2017), and another study reporting increased PAPP-A in 
12 twin pregnancies with pre-eclampsia whereas the singleton pre-eclampsia 
pregnancies were associated with decreased PAPP-A (Svirsky 2016). This appears 
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to be the only study in which increased PAPP-A is associated with an adverse 
outcome as Gagnon et al. reported that no studies have found any relation between 
high PAPP-A in the first trimester and adverse outcome (Gagnon 2008). 
Nevertheless, in singletons, when first trimester PAPP-A is combined with first 
trimester PlGF, mean arterial pressure, and uterine artery pulsatility index, a recent 
study demonstrated that the combination has better predictive ability than the 
maternal factors currently used in the NICE guidance to determine which women 
should be prescribed prophylactic low dose aspirin (Tan 2018).  
 
Linskens et al. (Linskens 2010) was the only study to examine first trimester PAPP-A 
in TTTS and reported no difference in maternal serum PAPP-A in 12 TTTS 
pregnancies compared to 39 uncomplicated MC twin pregnancies. Considering the 
inconsistent associations between low PAPP-A and adverse outcomes in twin 
pregnancies, further research is required, including in TTTS.  
 
3.2.5 Alpha-fetoprotein (AFP) 
AFP is a large plasma protein produced by the yolk sac, and hepatocytes in the fetal 
liver (Gitlin 1975). The exact action of AFP is not known but it is considered a marker 
of placental function (Mizejewski 2001). Altered serum levels are linked to various 
conditions outside pregnancy, including nonseminomatous germ cell tumours and 
hepatocellular carcinomas, but this thesis will focus on pregnancy. AFP is found in 
the amniotic fluid as the fetus urinates it out (Gitlin 1975). It is transferred from the 
fetus to the mother by different methods: paracellular diffusion across the fibrinoid 
deposits which act as breaks in the normally continuous syncytiotrophoblast 
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(Mizejewski 2001, Sharony 2016); or by entering the maternal blood vessels in the 
basal plate of the decidua basalis. Some attribute high maternal serum AFP levels to 
increased fibrin deposition which is associated with adverse outcome (Katzman 
2002), and thought to create a “leaky” and dysfunctional placenta. AFP has a half-life 
of 2.5-5.5 days (Bredow 1985), and increases throughout gestation (Figure 3.3).  
Wald et al. first highlighted that second trimester AFP levels in 11 euploid multiple 
pregnancies were significantly higher than in 22 matched singleton pregnancies 
(Wald 1975). These findings have been replicated by other studies (Barnabei 1995, 
Neveux 1996, O'Brien 1997, Perenc 1998, Räty 2000, Xie 2008, Ren 2016, Svirsky 
2016) and demonstrate that singleton levels cannot be used for twin pregnancies, 
 
Figure 3.3 Maternal serum levels of alpha-fetoprotein (AFP) in singleton 
pregnancy  
(n=17071 at 11+0 to 13+6 weeks, n=8583 at 19+0 to 24+6 weeks, n=8607 at 
30+0 to 34+6 weeks) (Bredaki 2015). Median and 95%CI displayed. 
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although no distinction was made by the studies of MC or DC twins. There is less 
research on first trimester AFP levels, particularly in twin pregnancies, as only one 
study could be found comparing first trimester AFP levels in twins and singletons 
(Berry 1995). They found “a less marked rise” in the first trimester than second 
trimester but highlight that they were not able to capture all the twin pregnancies in 
the first trimester, with half the “true rate” being identified as twin pregnancies in the 
first trimester, and again no distinction between chorionicities was made. When 
chorionicities are compared results are conflicting; one study reported no difference 
in second trimester maternal serum AFP (Muller 2003), but another study reported 
higher AFP levels in DC than MC twin pregnancies (Svirsky 2016), although it is not 
clear what gestation the blood samples were taken in the latter study.  
 
The lack of focus on first trimester AFP in twin pregnancies may be because of its 
clinical ineptness in first trimester singleton pregnancies (Alldred 2015) with no 
studies found exploring first trimester AFP in twins in view of future growth restriction. 
In singleton pregnancies in the first trimester, one study has shown raised AFP is 
associated with spontaneous PTB but the predictive ability is poor (Beta 2011). 
Second trimester maternal serum AFP levels are widely used as part of the national 
aneuploidy screening programme (FASP 2015) as decreased second trimester AFP 
is associated with trisomy 21 (Merkatz 1984). Elevated second trimester AFP also 
has additional associations with a host of complications in singleton pregnancies, as 
summarised by Gagnon et al. (Gagnon 2008), including: IUGR, placental abruption, 
PTB, miscarriage, and pregnancy-induced hypertension, but AFP levels are not used 
clinically to predict or diagnose any of them. Decreased AFP is also associated with 
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adverse outcomes such as triploidy, PTB, miscarriage and stillbirth (Thomas 1990, 
Zarzour 1998, Krause 2001). The enigma of high and low levels of AFP resulting in 
the same adverse outcomes suggests that its function is integral to the development 
of a healthy pregnancy. In twin pregnancies, abnormal second trimester AFP is linked 
to PTB, LBW, miscarriage and NNU admission (Wald 1978, Ghosh 1982, Hong 1996, 
Rosner 2015).  
 
Both amniotic fluid and maternal serum AFP levels have been examined in TTTS, but 
only in samples taken at diagnosis of TTTS in the second trimester. Fox et al. (Fox 
2009) reported higher AFP levels in TTTS pregnancies (n=21) compared to matched 
uncomplicated MC (n=6) and DC (n=12) twin pregnancies. AFP levels increased 
even further following FLA (Fox 2009). Sermondade et al. (Sermondade 2009) found 
no significant difference in maternal serum AFP levels in pregnancies affected by 
TTTS (n=60) compared to MC twins without TTTS (n=380). Huber et al. (Huber 2004) 
was the only study to explore amniotic fluid AFP, which was taken from the recipient 
twin’s sac; when compared to singleton pregnancies with normal karyotypes, no 
difference was seen. A positive correlation was demonstrated between AFP and the 
DV pulsatility index in the recipient twin which the authors state reveals an 
association between AFP and severity of congestive heart failure. Considering the 
lack of information on AFP in twin pregnancies, particularly in the first trimester, this 
warrants further investigation. 
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3.2.6 Placental growth factor (PlGF) 
PlGF is a dimeric glycoprotein and a member of the vascular endothelial growth 
factor family (Carmeliet 2001, Sung 2017), promoting angiogenesis and 
vasculogenesis. It is produced mainly by trophoblasts, placental villi and human 
umbilical vein endothelial cells. Levels are higher in twin pregnancies than singleton 
pregnancies (Maynard 2008, Sánchez 2012, Cowans 2013, Faupel-Badger 2015, 
Sung 2017), and increase in pregnancy up to the third trimester, then decrease in 
both singleton and twin pregnancies (Maynard 2008, Romero 2008, Wataganara 
2012, Faupel-Badger 2015, Tsiakkas 2015a) (Figure 3.4). The difference between 
twin and singleton pregnancy levels in the first trimester is much smaller, but remains 
significant (Cowans 2013, Faupel-Badger 2015). A recent study reported that first 
trimester maternal serum PlGF levels were higher in DC twin pregnancies compared 
to singleton pregnancies, but that there was no difference in MC twin pregnancies 
compared to singletons; they did not directly compare MC with DC twin pregnancies 
(Francisco 2017). This is supported by another study that found that first trimester 
maternal serum PlGF levels were significantly higher in DC twin pregnancies 
compared to singletons (41% higher AFP level), and although MC twin levels were 
significantly higher than singletons (16%), the difference was not as big (Cowans 
2013). This study also did not directly compare MC with DC twin pregnancies. Other 
studies found no difference in first trimester (Sánchez 2012) or third trimester PlGF 
(Faupel-Badger 2015) when MC twins were compared to DC twins, although there 
were only 5 MC twin pregnancies in the latter study. Another study combined first and 
second trimester samples and reported no difference between chorionicities (n=126 
DC, 18 MC twin pregnancies) (Svirsky 2016). 
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The relationship of PlGF with placental mass is controversial (Shibata 2005, Maynard 
2008, Wataganara 2012) and serum levels are likely to be affected by additional 
factors. For example in trophoblast-like BeWo cells and cultured cytotrophoblasts, 
hypoxia downregulates PlGF mRNA and decreases PlGF production, thus 
decreasing angiogenesis (Lash 2002, Nagamatsu 2004). This has created a 
biological conundrum as it is unclear whether low PlGF occurs first, or hypoxia. It is 
thought that hypoxia secondary to the failure of extravillous trophoblast invasion 
might decrease placental output of PlGF thus contributing to decreased circulating 
free PlGF (Shibata 2005). This is one hypothesis regarding the link between PlGF 
and pre-eclampsia. Since its initial identification in 1991, there has been increasing 
interest in the use of PlGF for the prediction of pre-eclampsia. Studies in singletons 
 
* 
* 
* 
*p<0.05 
Figure 3.4 Maternal serum levels of placental growth factor (PlGF) in twin 
pregnancy (n=91) compared to singleton pregnancy (n=2193)  
(Faupel-Badger 2015). Information on chorionicity not available. 
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have shown that PlGF is decreased in pregnancies affected by pre-eclampsia 
(Maynard 2003, Levine 2004b, Shibata 2005, Staff 2005, Romero 2008, Wikström 
2008, Nanjo 2017). This decrease is present in the first trimester, prior to the 
appearance of the clinical signs of pre-eclampsia, although the predictive ability of 
first trimester PlGF as a single marker is insufficient for clinical use. However, second 
trimester PlGF levels can be used as a single marker for pre-eclampsia. NICE 
evaluated the use of the ‘Triage PlGF test’ for the diagnosis of pre-eclampsia, and 
the recommendations made in May 2016 were that it could be used as a “rule out” 
test for pregnancies 20-34+6 weeks gestation, in addition to clinical information, but 
stated that there was insufficient evidence to use it as a “rule-in” test (NICE 2016). 
The guidance does not state whether this evaluation includes use in multiple 
pregnancies. Research on PlGF levels and pre-eclampsia in twin pregnancies 
indicate that different levels need to be used in twin pregnancies as PlGF levels in 
pre-eclamptic twin pregnancies are significantly higher than those in pre-eclamptic 
singleton pregnancies, irrespective of gestation (Boucoiran 2013, Faupel-Badger 
2015, Sung 2017). PlGF levels in twin pregnancies affected by pre-eclampsia follow 
the same pattern as singletons and are lower than twin pregnancies not affected by 
pre-eclampsia (Boucoiran 2013, Dröge 2015, Svirsky 2016) including in the first 
trimester, prior to the appearance of clinical signs and symptoms (Francisco 2017).  
 
The association between PlGF and pathologically abnormal twin fetal growth has 
been explored superficially, although the results are conflicting as Boucoiran and 
Yinon (Boucoiran 2013, Yinon 2014) found combined first and second trimester PlGF 
to be lower in twin pregnancies affected by SGA and sIUGR, whereas Kusanovic 
  
147 
 
found no difference in second trimester PlGF levels between twins pregnancies in 
which at least one twin had a birthweight below the 10th centile (Kusanovic 2008). 
This conflict may be due to the different definitions of abnormal growth, and a 
reflection of the small numbers of twin pregnancies in the study (69, 60, 69 
pregnancies respectively) although the gestation at testing was similar in all 3 
studies. Studies of abnormal growth in singleton pregnancies have demonstrated 
decreased second and third trimester PlGF is associated with SGA fetuses in 
normotensive pregnancies i.e. with no concurrent pre-eclampsia (Bersinger 2004, 
Shibata 2005, Romero 2008) thus supporting that PlGF is related to fetal growth, and 
the conflicting results in twin pregnancies may reflect different growth restriction 
phenotypes and pathogenesis, as discussed in section 1.3. Unlike in pre-eclampsia, 
the decrease in PlGF in normotensive SGA pregnancies is not accompanied by an 
increase in sFlt-1 (see section 3.2.7), suggesting that decreased PlGF is not a result 
of increased sFlt-1 “mopping up” PlGF, and that there is an unrelated mechanism. 
 
Very little research has looked at the relationship between PlGF and TTTS. Fox et al. 
demonstrated no difference in second trimester maternal serum PlGF in twin 
pregnancies affected by TTTS, and uncomplicated MCDA and DCDA pregnancies 
(Fox 2010). However other studies have found significantly lower PlGF levels in 
maternal serum on the day prior to FLA in TTTS pregnancies compared to 
uncomplicated MCDA twins (Kusanovic 2008, Chon 2017). Interestingly Chon et al. 
demonstrated that this difference was no longer apparent at 1 day post-FLA, and 3 
weeks post-FLA (Chon 2017). Yinon et al. also found lower PlGF in TTTS 
pregnancies compared to uncomplicated MCDA twins at 15-20, and 21-28 weeks 
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gestation (Yinon 2014). No studies have looked at first trimester PlGF and future 
TTTS risk with the earliest sample being taken at 15 weeks gestation when the 
clinical signs of TTTS have appeared (Yinon 2014). Given the role that PlGF plays in 
angiogenesis and that changes in twin pregnancies that will go on to develop pre-
eclampsia are present in the first trimester, one could hypothesise that PlGF is 
altered in the first trimester in pregnancies that will go on to develop TTTS and other 
adverse outcomes. 
 
3.2.7 Soluble fms-like tyrosine kinase-1 (sFlt-1) 
Soluble feline McDonough sarcoma (fms)-like tyrosine kinase is also known as 
soluble vascular endothelial growth factor receptor 1 (sVEGFR1). When circulating it 
binds to vascular endothelial growth factor (VEGF) and PlGF in target tissues with 
high affinity, thus antagonising the two angiogenic molecules and producing an anti-
angiogenic state (Kendall 1996, Clark 1998). It is produced by human villous and 
extravillous trophoblast (Clark 1998). sFlt-1 increases throughout pregnancy 
(Wataganara 2012, Faupel-Badger 2015) (Figure 3.5), and levels fall within 24-48 
hours of delivery, supporting that it is produced predominantly by the placenta 
(Maynard 2003, Reddy 2009). Maternal serum levels are higher in twin pregnancies 
than singleton pregnancies (Maynard 2008, Sánchez 2012, Dröge 2015, Faupel-
Badger 2015), and also increase throughout gestation (Figure 3.5). When MC twins 
were compared to DC twins, levels were higher in MC twins in the third trimester 
(Faupel-Badger 2015), although no difference was present in the first trimester 
between chorionicities in another study (Sánchez 2012). 
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As with PlGF, the relationship between sFlt-1 and placental mass is debated (Shibata 
2005, Nevo 2008, Wataganara 2012, Ruiz-Sacedón 2014, Dröge 2015, Faupel-
Badger 2015, Manthati 2017) and serum levels are likely to be affected by other 
factors. Hypoxia plays an important role but has the opposite effect on sFlt-1 
compared to PlGF as hypoxia upregulates sFlt-1 mRNA expression in 
cytotrophoblasts and increases sFlt-1 production (Nagamatsu 2004, Nevo 2006, 
Padavala 2006). Increased sFlt-1 creates the same ultimate state as decreased PlGF 
in hypoxic conditions: decreased angiogenesis. Interestingly, this effect on sFlt-1 
mRNA expression and production appears cell specific as human umbilical vein 
endothelial cells and villous fibroblasts do not demonstrate increased sFlt-1 mRNA 
expression and production in hypoxic conditions. The same conundrum exists as with 
Figure 3.5 Maternal serum levels of soluble fms-like tyrosine kinase-1 (sFlt-1) 
in twin pregnancy (n=91) compared to singleton pregnancy (n=2193)  
(Faupel-Badger 2015). Information on chorionicity not available. 
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PlGF and hypoxia: does hypoxia lead to high sFlt-1, or vice versa (Karumanchi 
2004). Irrespective of whether high levels of sFlt-1 are the cause or consequence, the 
association between increased levels of sFlt-1 and pre-eclampsia is widely reported 
(Maynard 2003, Park 2005, Staff 2005, Romero 2008, Wikström 2008, Nanjo 2017). 
This is supported by the vasoconstrictive effect that exogenous sFlt-1 has on rats that 
leads to hypertension and glomerular endotheliosis (Maynard 2003), the latter of 
which is specific to pre-eclampsia and supports that sFlt-1 has a direct action on the 
maternal endothelium. 
 
The increase in sFlt-1 is present 5 weeks before the clinical symptoms of pre-
eclampsia appear (Levine 2004b). NICE evaluated the use of the ‘Elecsys 
immunoassay sFlt-1/PlGF’ test for the diagnosis of pre-eclampsia, and the 
recommendations made in May 2016 were that it could be used as a “rule out” test 
for pregnancies 20-34+6 weeks gestation, in addition to clinical information, but 
stated that there was insufficient evidence to use it as a “rule-in” test (NICE 2016). 
The guidance does not state whether this evaluation includes use in multiple 
pregnancies. As sFlt-1 levels in twin pregnancies with pre-eclampsia are significantly 
higher than in singleton pregnancies with pre-eclampsia, different cut-offs need to be 
used (Boucoiran 2013, Dröge 2015, Faupel-Badger 2015). sFlt-1 levels in twin 
pregnancies affected by pre-eclampsia are still higher than twin pregnancies not 
affected by pre-eclampsia (Dröge 2015). Fascinatingly, when placental sFlt-1 mRNA 
expression was examined in DCDA twins with pre-eclampsia but concordant growth, 
there was a significant difference when one twin’s placenta was compared to the 
other twin’s placenta within the same pregnancy (Nevo 2008). There was no 
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difference in the control twin pairs, implying that pre-eclampsia in twin pregnancy 
may be mediated by one twin, and partially explaining why serum levels are not just 
doubled in twin pregnancies compared to singletons.  
 
The relationship between sFlt-1 and pathologically abnormal twin fetal growth is less 
clear. Boucoiran et al. reported no difference in sFlt-1 levels at 12-18 weeks or 24-26 
weeks in SGA pregnancies, defined as at least one twin with a birthweight <10th 
centile based on Canadian growth charts (Boucoiran 2013). Ruiz-Sacedon et al. also 
reported no difference in sFlt-1 in the first, second or third trimester in DCDA twins 
with BWD >20% (Ruiz-Sacedón 2014). Yinon et al. found that gestation affected sFlt-
1 significance as in MCDA twin pregnancies with sIUGR there was no difference in 
samples taken at 13-20 weeks, but at 21-28 weeks the sIUGR pregnancies had a 
significantly higher sFlt-1 level compared to uncomplicated MCDA twins (Yinon 
2014). They also found that in cord blood samples taken at delivery, sFlt-1 was 
significantly higher in the growth restricted twin, compared to the normally grown twin 
in the same pregnancy. Nevo et al. compared sFlt-1 mRNA expression in placentas 
from sIUGR MC and DC twins, and found that in both the MC and DC growth-
restricted twins placental territory, there was increased sFlt-1 mRNA expression, 
compared to the internal control of the normally grown twin in the same pregnancy 
(Nevo 2008). The group also compared sFlt-1 placental mRNA expression in 
singleton pregnancies with (i) severe IUGR defined as birthweight <5th centile and 
abnormal umbilical artery Dopplers (ii) SGA pregnancies defined as birthweight ≤10th 
centile with normal Dopplers, (iii) age-matched healthy with normal fetal growth and 
no signs of placental dysfunction. They found that the IUGR group had significantly 
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higher sFlt-1 mRNA expression than the SGA group, and the control group, but there 
was no difference between the SGA and control groups. As highlighted by the 
studies above, definition of abnormal growth may impact on findings. Concurrent pre-
eclampsia may also play a role, but this has been explored in more detail in singleton 
pregnancies. In singletons there is no difference in sFlt-1 levels in normotensive 
pregnancies with SGA babies (Shibata 2005, Romero 2008, Nanjo 2017, Yoshida 
2018), although SGA babies in pre-eclamptic pregnancies did have higher sFlt-1 
levels than controls (Nanjo 2017).  
 
There has been little research investigating sFlt-1 in TTTS, although all 4 studies that 
have explored it reported significantly higher sFlt-1 levels at diagnosis of TTTS 
compared to uncomplicated MC twins (Kusanovic 2008, Fox 2010, Yinon 2014, Chon 
2017). Chon et al. found that the sFlt-1 levels decreased 3 weeks after FLA. No 
studies have looked at first trimester sFlt-1 and future TTTS with the earliest sample 
being taken at 15 weeks gestation when the clinical signs of TTTS had begun to 
appear (Yinon 2014). Given the role that sFlt-1 plays in angiogenesis and the 
antagonistic effect it has on PlGF, one could hypothesise that sFlt-1 is altered in the 
first trimester in pregnancies that will go on to develop TTTS or other MC twin 
pregnancy complications. 
 
3.3 Existing prognostic factors 
 
Existing prognostic factors are confounding factors that affect both the dependent 
and independent variables. It is important to identify these factors so that the results 
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can be adjusted accordingly, and the additional prognostic ability of the first trimester 
ultrasound measurements and biomarkers can be calculated on top of the prognostic 
ability of these existing prognostic factors. In this study, the existing prognostic 
factors are maternal age, BMI, smoking status, ethnicity, parity and mode of 
conception.  
It is difficult to know if NT is associated with the existing prognostic factors as any 
associations are likely to be due to the link between the existing prognostic factor and 
the adverse outcome, such as maternal age and aneuploidy of which an increased 
NT is indicative, rather than there being a direct association between increasing 
maternal age and increasing NT. It is also not possible to know if CRL is affected by 
existing prognostic factors as all fetuses will have an increasing CRL throughout 
pregnancy: it will be assumed that they are a different gestational age rather than 
that anything abnormal is occurring.  
 
3.3.1 Maternal age 
The systematic review in CHAPTER 2 did not find any association between maternal 
age and TTTS, growth restriction or IUFD.  
In singleton pregnancies, first trimester β-hCG is not associated with maternal age, 
however in the second and third trimester increased β-hCG is associated with 
increased maternal age (Wright 2015a). PAPP-A and AFP are not associated with 
maternal age in singleton pregnancy at any gestation (Bredaki 2015, Wright 2015b). 
Maternal age did not appear to affect PlGF in 61 twin pregnancies (Sánchez 2012), 
although a study in 7066 first trimester serum samples, and 8078 second trimester 
serum samples from singleton pregnancies reported that PlGF increased with 
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maternal age, but this association was not seen with the 10,464 third trimester 
samples (Tsiakkas 2015a). Another study found a difference in the first trimester, but 
not second trimester PlGF levels in singletons (Faupel-Badger 2011). sFlt-1 in 
uncomplicated singletons is not associated with maternal age in first or second 
trimester (Faupel-Badger 2011, Tsiakkas 2015b). 
 
3.3.2 Maternal BMI 
Raised maternal BMI is implicated in many obstetric complications in twin 
pregnancies including GDM, pregnancy-induced hypertension and pre-eclampsia 
(Fox 2014b). The systematic review in CHAPTER 2 did not find any association 
between maternal BMI and TTTS, growth restriction or IUFD.  
In singleton pregnancies, decreased β-hCG was associated with increased maternal 
weight (Wright 2015a), as was PAPP-A throughout gestation (Wright 2015b).  
AFP should be adjusted for maternal weight (Thomas 1990) as it decreases with 
increasing maternal weight in singleton pregnancies (Bredaki 2015). Maternal BMI 
may affect PlGF with a higher BMI associated with lower PlGF throughout singleton 
gestation (Zera 2014) although other studies found no difference in first trimester 
PlGF in normal singleton pregnancies (Faupel-Badger 2011, Kosiński 2014), and 
another study found that increasing maternal weight is associated with decreasing 
PlGF throughout gestation in singleton pregnancies (Tsiakkas 2015a). In singleton 
pregnancies BMI has an inverse relationship with sFlt-1 throughout gestation (Zera 
2014, Tsiakkas 2015b, Manthati 2017), although another study in first and second 
trimester singleton pregnancies demonstrated a positive correlation (Faupel-Badger 
2011) and another study demonstrated no relationship (Staff 2005), although the 
  
155 
 
latter study dichotomised BMI to <30 or >30kg/m2 which may explain why no 
difference was seen. 
 
3.3.3 Maternal smoking status 
The systematic review in CHAPTER 2 did not find any association between maternal 
smoking and TTTS, and there were insufficient studies to investigate growth 
restriction or IUFD although maternal smoking is a well-known risk factor for growth 
restriction and IUFD in singleton pregnancies.  
In singleton pregnancies, smokers had lower β-hCG and PAPP-A compared to non-
smokers in the first and second trimester (Wright 2015a). AFP is higher in smokers 
compared to non-smokers throughout gestation (Bredaki 2015). Smoking appears to 
be associated with higher first trimester PlGF in twin pregnancies (Boucoiran 2013, 
Kosiński 2014) and singleton pregnancies (Tsiakkas 2015a). Smokers have lower 
sFlt-1 levels than non-smokers in singleton pregnancies (Tsiakkas 2015b).  
 
3.3.4 Maternal ethnicity 
The systematic review in CHAPTER 2 found that Caucasian women were at higher 
risk of TTTS than non-Caucasian women. It was not possible to investigate growth 
restriction and IUFD and the association with ethnicity in the systematic review due to 
too few studies being eligible for inclusion. However, ethnicity is associated with a 
woman’s risk of developing complications, with “black” women more likely to deliver a 
twin with a smaller birthweight compared to “white” women (Cuff 2017).  
In twin pregnancies, second trimester β-hCG is affected by ethnicity (O'Brien 1997). 
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In singleton pregnancies, Afro-Caribbean and East Asian women had higher β-hCG 
in the first trimester compared to Caucasian women, whereas South Asian women 
had lower levels (Wright 2015a). AFP is affected by maternal ethnicity in singleton 
pregnancies (Thomas 1990) with lower levels reported in South Asian and East Asian 
women, and higher levels in Afro-Caribbean women compared to Caucasian women 
throughout gestation (Wald 1997, Bredaki 2015). Second trimester AFP is also 
affected by ethnicity in twin pregnancies (O'Brien 1997). PAPP-A and PlGF was 
higher in Afro-Caribbean, South Asian and East Asian women compared to 
Caucasian throughout gestation in singleton pregnancies (Tsiakkas 2015a, Wright 
2015b). sFlt-1 was also higher in Afro-Caribbean women than Caucasian women 
throughout gestation in singleton pregnancies, although was not different in South 
Asian and East Asian women (Tsiakkas 2015b). 
 
3.3.5 Parity 
The systematic review in CHAPTER 2 did not find any association between parity 
and TTTS. There was a weak association between AGR and nulliparity. It was not 
possible to investigate parity in the context of IUFD. 
First trimester β-hCG and PAPP-A in singleton pregnancies were not affected by 
parity (Wright 2015a, Wright 2015b). First trimester AFP in singletons is higher in 
nulliparous woman than multiparous women (Bredaki 2015), whereas the relationship 
may be the opposite in PlGF: nulliparous women have lower PlGF than multiparous 
women (Tsiakkas 2015a). Other studies dispute this as no difference was found in 
first or second trimester PlGF in singleton pregnancies (Faupel-Badger 2011) or in 
first trimester twin pregnancies (Sánchez 2012). sFlt-1 in first trimester normal 
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singletons had no association with parity, however in the second trimester sFlt-1 
levels were higher in nulliparous women compared to multiparous women (Faupel-
Badger 2011), although another study reported that sFlt-1 levels were higher in 
nulliparous throughout gestation (Tsiakkas 2015b). 
 
3.3.6 Mode of conception 
The systematic review in CHAPTER 2 did not find any association between mode of 
conception and TTTS or growth restriction. There were insufficient studies to 
investigate IUFD.  
In euploid uncomplicated MC twins, the first trimester NT measurement was higher in 
ART conceived twins compared to spontaneously conceived twins, although no 
difference was seen according to mode of conception in DC twins (Flock 2013). In 
singleton pregnancies, there was increased β-hCG in ART pregnancies compared to 
spontaneously conceived singletons throughout gestation (Wright 2015a). In 
singletons conceived by (in-vitro fertilisation) IVF, maternal serum PAPP-A was lower 
in the first trimester compared to those conceived spontaneously, and was higher in 
the second and third trimester compared to spontaneously conceived singleton 
pregnancies (Wright 2015b). When first and second trimester women were combined 
PAPP-A was higher in ART conceived twins than spontaneously conceived twins, but 
β-hCG, AFP and PlGF did not demonstrate a difference (Sánchez 2012, Svirsky 
2016). Second trimester β-hCG and AFP in twin pregnancies were not affected by 
mode of conception (Räty 2000). The lack of difference in AFP and PlGF is echoed in 
other studies in singletons (Bredaki 2015, Tsiakkas 2015a). First trimester sFlt-1 is 
higher in ART conceived DCDA twin pregnancies compared to spontaneously 
  
158 
 
conceived DCDA twin pregnancies, MCDA twins were not included in the analysis 
(Sánchez 2012). In singleton pregnancies, no difference was reported in sFlt-1 levels 
and mode of conception (Tsiakkas 2015b). 
 
3.3.7 Gestational age at delivery 
This existing prognostic factor was only used to adjust the neonatal composite 
outcome as it is known to affect outcome. 
 
3.3.8 Steroids administration 
This existing prognostic factor was only used to adjust the neonatal composite 
outcome as it is known to affect outcome. 
 
3.3.9 Magnesium sulphate administration 
This existing prognostic factor was only used to adjust the spontaneous PTB and 
neonatal composite outcomes as it is known to affect these outcomes. 
 
Although the majority of outcomes were not affected by the existing prognostic 
factors according to my systematic review, previous studies have reported conflicting 
findings and most maternal serum potential prognostic factors were affected by 
existing prognostic factors, therefore the results were adjusted accordingly. 
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3.3.10 Aims 
The aims of this study are to investigate if in MC twin pregnancies, the following first 
trimester ultrasound measurements and maternal serum biomarkers individually are 
(i) associated with adverse outcome, (ii) act as prognostic factors of adverse 
outcome: 
1) NT 
2) CRL 
3) β-hCG 
4) PAPP-A 
5) AFP 
6) PlGF 
7) sFlt-1 
 
Hypotheses 
In first trimester MC twin pregnancies: 
1) Increased NT discordance is associated with adverse outcome and has 
improved predictive ability above existing prognostic factors. 
2) Increased CRL discordance is associated with adverse outcome and has 
improved predictive ability above existing prognostic factors. 
3) Increased β-hCG is associated with adverse outcome and has improved 
predictive ability above existing prognostic factors. 
4) Decreased PAPP-A is associated with adverse outcome and has improved 
predictive ability above existing prognostic factors. 
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5) Increased AFP associated with adverse outcome and has improved predictive 
ability above existing prognostic factors. 
6) Decreased PlGF is associated with adverse outcome and has improved 
predictive ability above existing prognostic factors. 
7) Increased sFlt-1 is associated with adverse outcome and has improved 
predictive ability above existing prognostic factors. 
 
3.4 Methods 
 
3.4.1 Participants 
An existing multicentre, international cohort of MC twin pregnancies was used. All 
women with a MCDA twin pregnancy in the West Midlands and North Thames 
regions who had undergone first trimester aneuploidy screening between October 
2014 and September 2015, or women with a MCDA twin pregnancy who booked at 
the Royal Prince Alfred Hospital, Sydney between June 2011 and April 2016, and for 
whom there was a stored first trimester maternal serum sample, were eligible for 
inclusion. Therefore there was retrospective consecutive enrolment. The data used 
had been prospectively recorded as part of routine clinical care. Chronicity had to 
have been determined in the first trimester based on: a single placental mass, a thin 
inter-twin membrane, the presence of the ‘T’ sign and absence of Lambda sign 
(Sepulveda 1996). If the twins were a different sex, or postnatally the pregnancy was 
diagnosed as DC based on placental assessment, these pregnancies were excluded, 
but placental histology was not routinely checked for all pregnancies. As participants 
in the study had MCDA pregnancies, the majority were spontaneous conceptions 
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therefore dates relating to ART could not be used. Consequently, the gestational age 
was calculated based on the largest twin CRL, as this is the measurement advised by 
various national bodies (Morin 2011, NICE 2011, Khalil 2016b, Kilby 2016, 
RANZCOG 2017), and is the gestational age upon which clinicians will have based 
management decisions.  
Women were booked at 29 different secondary and tertiary care maternity units, 
depending on geographical area, and were under consultant-led care due to the 
high-risk nature of multiple pregnancies. Women were not eligible for inclusion if they 
had a: miscarriage prior to 14 weeks gestation, MCMA pregnancy, higher order 
multiple pregnancy, or the pregnancy was affected by serious structural or congenital 
anomalies, whether concordant or discordant, as the aetiology of their adverse 
outcomes, such as growth restriction, PTB or IUFD would be different to pregnancies 
not affected by structural or congenital anomalies, and would therefore increase 
heterogeneity within the cohort. Where outcome data were missing, due to the time 
period and setting diversity women were not contacted for further details and these 
pregnancies were excluded. Pregnancies were cared for according to local and 
national guidelines. Postnatal outcome data were collected until discharge from 
hospital. No further follow-up data were collected. Anonymised data were collated 
using a purpose-designed data collection form (Appendix 10.3), input and coded in 
an Excel spreadsheet. Any discrepancies were clarified with the data collector and 
the original data source checked. 
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3.4.2 Sample collection and storage 
Maternal serum samples had to have been taken when the largest twin CRL was 
between 45-84mm, thus corresponding to the first trimester, as directed by the Fetal 
Anomaly Screening Programme (FASP) (FASP 2015). Venepuncture was performed 
by trained professionals at each hospital site and samples were taken in bottles 
containing sodium heparin, with or without a gel separator. The manufacturer of the 
bottle depended on hospital site.  
The UK samples were couriered to Birmingham Women’s Hospital (BWH) 
biochemistry laboratory at room temperature, the same day. At least one hour was 
allowed for clotting. Within 4 hours of arrival in the laboratory, the whole blood 
samples were centrifuged at 3000 g for 10 minutes at room temperature and the 
serum was removed and loaded onto the automated platform to measure β-hCG and 
PAPP-A (see section 3.4.4). After completion of the β-hCG and PAPP-A assays the 
samples were stored at -80°C until the AFP, sFlt-1 and PlGF analyses were 
performed, between 12 months and 1 year 11 months after initial blood sampling. 
The samples from Sydney were collected from one hospital and were centrifuged and 
transferred to the automated assay platform within 4 hours of sample collection in the 
same hospital to measure β-hCG and PAPP-A for first trimester aneuploidy 
screening. These values were not included in the results as they were converted in 
MoM and it was not possible to access the raw values. The residual serum from the 
samples was frozen at -80°C within 4 hours of completion of β-hCG and PAPP-A 
assays. The samples remained at -80°C before being transferred to BWH on dry ice, 
where they were immediately transferred to -80°C freezers.  
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Prior to the AFP, sFlt-1 and PlGF analyses, the samples had been stored for 
between 4 months and 5 years 3 months.  
 
3.4.3 Prognostic factors: ultrasound measurements (NT, CRL) 
NT and CRL measurements were performed using standard practice (FASP or Fetal 
Medicine Foundation [FMF] protocols with UK National External Quality Service 
[NEQAS] quality assessment) in women who consented to first trimester aneuploidy 
screening (FMF 2004, FASP 2015). These were performed by sonographers and 
fetal medicine doctors in the local units who were approved by the FMF to perform 
these scans. 
NT discordance (%) was calculated as the smallest NT subtracted from the largest 
NT, divided by the largest NT multiplied by 100. CRL discordance (%) was calculated 
as per NT discordance. These measurements were treated as continuous data within 
analyses, no cut-offs were applied (Royston 2006). 
 
3.4.4 Prognostic factors: biomarkers (β-hCG, PAPP-A, AFP, PlGF, sFlt-1) 
The 5 biomarkers were measured on one serum sample per woman. β-hCG and 
PAPP-A had been prospectively measured in these samples as part of the UK and 
Australian aneuploidy screening programmes according to the manufacturers’ 
instructions (see Table 3.1 and below for more details). The laboratories performing 
these analyses were CPA (UK) Ltd. accredited and are externally quality assessed 
by UK National External Quality Service (NEQAS) and Down’s syndrome Quality 
Assurance Support Service (DQASS). Consequently the people performing the 
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assays were blinded to the subsequent future outcomes of the pregnancies. The β-
hCG and PAPP-A measures were not repeated, therefore the measurements used in 
the analysis were the same as those used to guide clinical care. Due to the 
Australian laboratory reporting the β-hCG and PAPP-A results as MoM instead of the 
raw values, it was not possible to include the 64 Australian samples in the analysis 
for these two markers; however the measurements of the other factors (NT, CRL, 
AFP, PlGF and sFlt-1) were included from the Australian samples. 
 
The PlGF and sFlt-1 assays were performed in one batch using an assay approved 
by the UK’s NICE for ruling-out pre-eclampsia (Roche Diagnostics Limited, Sussex, 
UK) (20, 21). These assays were performed at the Biochemistry Department at 
University Hospital Birmingham by people blinded to the outcome and the samples 
were loaded on to the automated platform at random. The AFP assays were 
commenced immediately following the sFlt-1 and PlGF assays, thus the samples only 
went through one freeze-thaw cycle. These assays were performed at the 
Biochemistry Department at BWH by people blinded to the outcome and the samples 
were loaded on to the automated platform at random.  
The machines were successfully calibrated and the quality control procedures were 
met. The biomarker measurements were not repeated as the assays and laboratory 
have been validated for clinical use therefore the levels were believed to be accurate, 
albeit that the results have not been used for this purpose previously. The inter-assay 
coefficient of variation for β-hCG, PAPP-A, AFP, PlGF and sFlt-1 were all <5%. 
In order to measure the AFP, PlGF and sFlt-1, the samples were gradually defrosted 
from -80°C to room temperature, inverted twice and vortexed at 2700 g for 3 
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seconds, three times at room temperature. All reagents were brought up to room 
temperature and the assays were performed as detailed below. 
 
β-hCG 
Free β-hCG was measured using time-resolved fluoroimmunoassay manufactured by 
PerkinElmer (PerkinElmer Wallac Oy, Turku, Finland) on the AutoDELFIA® 
immunoanalyser, according to the manufacturer’s instructions. The assay is based on 
the sandwich principal: a two-site, non-competitive immunoassay, in which free β-
hCG is “sandwiched” between two monoclonal antibodies directed against two 
separate antigens, on the β-hCG molecule. One antibody is also bound to samarium 
which remains following the incubation with the antibodies and the washes. 
Enhancement solution is added which liberates the samarium from the antibody 
sandwich, and is detected fluorimetrically in proportion to the β-hCG concentration. 
 
PAPP-A  
PAPP-A was measured using time-resolved fluoroimmunoassay manufactured by 
PerkinElmer (PerkinElmer Wallac Oy, Turku, Finland) on the AutoDELFIA® 
immunoanalyser, according to the manufacturer’s instructions. The assay is based on 
the sandwich principal: a two-site, non-competitive immunoassay, in which PAPP-A 
is “sandwiched” between two monoclonal antibodies directed against two separate 
antigens, on the PAPP-A molecule. Initially, biotin-labelled PAPP-A-specific 
antibodies are incubated with streptavidin-coated microparticles. There is then a 
wash step and the samples are added with another PAPP-A specific antibody 
labelled with europium and there is another wash step. Enhancement solution is 
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added to liberate the europium from the complex and the fluorescence from each well 
is measured using time resolved fluorimetry which is proportional to the concentration 
of PAPP-A. 
 
AFP 
Total AFP was measured using time-resolved fluoroimmunoassay manufactured by 
PerkinElmer (PerkinElmer Wallac Oy, Turku, Finland) on the AutoDELFIA® 
automatic immunoassay system, according to the manufacturer’s instructions. The 
assay is based on the sandwich principal: a two-site, non-competitive immunoassay, 
in which AFP is “sandwiched” between two monoclonal antibodies directed against 
two separate antigens on the AFP molecule. 25μl of each sample was incubated with 
200μl buffer and incubated for 1 hour. 200μl monoclonal AFP-specific antibody 
labelled with europium (diluted 1:75) was added and incubated for one hour. The 
plate was washed 6 times and incubated with 200μl Enhancement Solution for 5 
minutes. The liberated europium was measured fluorimetrically in proportion to the 
AFP concentration. 
 
PlGF  
Free PlGF was measured using an electrochemiluminescence immunoassay (ECLIA) 
manufactured by Roche (Roche Diagnostics Limited, Sussex, UK) on the ‘Elecsys 
2010, Modular E170’ immunoassay analyser, according to the manufacturer’s 
instructions. The assay is based on the sandwich principal: a two-site, non-
competitive immunoassay, in which PlGF is “sandwiched” between two antibodies via 
two separate antigens. 500μl aliquots of the samples were loaded into the analyser, 
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50μl of each sample was incubated with biotinylated monoclonal PlGF-specific 
antibody and a monoclonal PlGF-specific antibody labelled with a ruthenium complex 
(Tris(2,2’bipyridyl)ruthenium(II)-complex) to form the sandwich complex. A second 
incubation was performed with streptavidin-coated microparticles that bind the 
complex to the plate via the interaction of biotin and streptavidin. The mixture was 
aspirated into the measuring cell and the microparticles were magnetically captured 
onto the surface of the electrode. The unbound substances were washed away by 
the ProCell wash (Roche). A voltage was applied to the electrode causing a 
chemiluminescent emission that was measured by a photomultiplier. The results 
were determined using a calibration curve generated by a 2-point calibration and 
master curve provided by the reagent barcode. 
 
sFlt-1 
Total sFlt-1 was measured in combination with the PlGF assay. The only differences 
were that 20μl of each sample was used, and the antibodies were sFlt-1 specific. 
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Table 3.1 Potential prognostic factors of primary interest 
Factor How measured When measured Biological role and clinical use Lower 
limit of 
detection 
Upper limit 
of 
detection 
Manufacturer 
Nuchal 
translucency 
(NT) 
By accredited 
sonographers 
as part of the 
National 
Aneuploidy 
screening 
programme 
11+0 – 14+1 
weeks, calculated 
based on the 
CRL which must 
be 45-84mm 
Measurement of lymphatic fluid 
at the back of the fetus’s neck. 
High measurement indicates 
high risk of chromosomal or 
cardiac problems. Discrepancy 
between twins may indicate 
adverse outcome. 
0.1cm Infinite NA 
Crown-rump 
length  
(CRL) 
By accredited 
sonographers 
as part of the 
National 
Aneuploidy 
screening 
programme 
11+0 – 14+1 
weeks, calculated 
based on the 
CRL which must 
be 45-84mm 
Measurement of the length of 
the baby used to date the 
pregnancy. Discrepancy 
between twins may indicate 
adverse outcome. 
1mm Infinite NA 
β-human 
Chorionic 
Gonadotropin 
(β-hCG) 
Clinical 
laboratory 
accredited to 
perform testing 
as part of 
National 
Aneuploidy 
screening 
programme 
Sample taken at 
11+0 -14+1 
weeks gestation, 
analysed within 
24 hours of the 
sample being 
taken 
Produced by the 
syncytiotrophoblast and 
maintains the corpus luteum 
during early pregnancy. High 
level indicates increased risk of 
aneuploidy, low levels 
associated with miscarriage. 
1.5ng/mL 200ng/mL PerkinElmer 
Wallac Oy, 
Turku, 
Finland 
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Factor How measured When measured Biological role and clinical use Lower 
limit of 
detection 
Upper limit 
of 
detection 
Manufacturer 
Pregnancy 
associated 
plasma protein 
A (PAPP-A) 
Clinical 
laboratory 
accredited to 
perform testing 
as part of 
National 
Aneuploidy 
screening 
programme 
Sample taken at 
11+0 -14+1 
weeks gestation, 
analysed within 
24 hours of the 
sample being 
taken 
Produced by the 
syncytiotrophoblast and encodes 
a gene which cleaves insulin-like 
growth factor binding proteins. 
Low level indicates increased 
risk of aneuploidy, and intra-
uterine growth restriction. 
5mU/L 10000mU/L PerkinElmer 
Wallac Oy, 
Turku, 
Finland 
Alpha-
fetoprotein 
(AFP) 
Clinical 
laboratory 
accredited to 
perform testing 
as part of 
National 
Aneuploidy 
screening 
programme 
Sample taken at 
11+0 -14+1 
weeks gestation, 
stored at -80°C 
and analysed 4 
months to 5 
years 3 months 
later 
Human function is unknown, but 
abundant in fetuses. Low level 
indicates increased aneuploidy 
risk in twin pregnancies in the 
2nd trimester as part of the Quad 
test. High level indicates 
increased risk of neural tube 
defects in 1st and 2nd trimester. 
Marker of placental function. 
1U/mL 1000U/mL PerkinElmer 
Wallac Oy, 
Turku, 
Finland 
Placental 
growth factor 
(PlGF) 
Clinical 
laboratory with 
experience of 
performing 
these assays for 
pre-eclampsia 
prediction 
Sample taken at 
11+0 -14+1 
weeks gestation, 
stored at -80°C 
and analysed 4 
months to 5 
years 3 months 
later 
Produced by the 
syncytiotrophoblast and 
promotes angiogenesis. Low 
level indicates pre-eclampsia in 
singleton pregnancies prior to 
the appearance of signs and 
symptoms. 
3pg/mL 10000pg/mL Roche 
Diagnostics 
Limited, 
Sussex, UK 
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Factor How measured When measured Biological role and clinical use Lower 
limit of 
detection 
Upper limit 
of 
detection 
Manufacturer 
Soluble fms-
like tyrosine 
kinase-1  
(sFlt-1) 
Clinical 
laboratory with 
experience of 
performing 
these assays for 
pre-eclampsia 
prediction 
Sample taken at 
11+0 -14+1 
weeks gestation, 
stored at -80°C 
and analysed 4 
months to 5 
years 3 months 
later 
Produced by the 
syncytiotrophoblast and prevents 
angiogenesis. High level 
indicates pre-eclampsia in 
singleton pregnancies prior to 
the appearance of signs and 
symptoms. 
10pg/mL 85000pg/mL Roche 
Diagnostics 
Limited, 
Sussex, UK 
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3.4.5 Adjustment factors 
The existing prognostic factors used as adjusted factors for the individual potential 
prognostic factors are detailed in Table 3.2. It was not possible to adjust for 
gestational age at blood sampling as gestational age was calculated based on CRL 
which is one of the potential prognostic factors under evaluation. 
 
Table 3.2 Standard clinical information used as adjustment factors (i.e. existing 
prognostic factors) 
Prognostic 
factor 
How measured When 
measured 
Categorical or 
continuous data 
Outcomes it 
may affect 
Maternal age From date of 
birth 
Booking Continuous All 
Maternal 
body mass 
index (BMI) 
Height and 
weight measured 
and calculated 
(kg/m2) 
Booking Continuous All 
Maternal 
smoking 
status 
Maternal 
reporting as 
documented in 
the medical notes 
Booking Categorical: 
-Never smoked 
(reference) 
-Current smoker 
-Ex-smoker 
All 
Maternal 
ethnicity 
Maternal 
reporting as 
documented in 
notes 
Booking Categorical: 
-White (reference) 
-Non-white: 
other/mixed, 
Oriental, South 
Asian, African-
Caribbean 
All 
Parity Maternal 
reporting as 
documented in 
notes 
Booking Categorical: 
-Nulliparous 
(reference) 
-1 previous delivery 
after 24 weeks 
gestation 
-2 or more previous 
deliveries after 24 
weeks gestation  
All 
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Prognostic 
factor 
How measured When 
measured 
Categorical or 
continuous data 
Outcomes it 
may affect 
Mode of 
conception 
As documented 
in the notes 
Booking Categorical: 
-Natural conception 
(reference) 
-Assisted 
conception 
All 
Gestational 
age at 
delivery 
As documented 
in the notes 
Delivery Continuous Neonatal 
composite 
Steroid 
administration 
As documented 
in the notes 
Throughout 
pregnancy 
Categorical: 
-Yes steroids 
-No steroids 
(reference) 
Neonatal 
composite 
Magnesium 
sulphate 
(MgSO4) 
administration 
As documented 
in the notes 
Throughout 
pregnancy 
Categorical: 
-Yes MgSO4 
-No MgSO4 
(reference) 
Neonatal 
composite 
Spontaneous 
PTB 
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3.4.6 Outcomes 
The primary outcome was a composite of adverse fetal events defined as the 
presence of at least one of the following: TTTS, AGR, PGR, TAPS, or IUFD. PGR 
was included in the fetal adverse outcome composite as the definition of PGR used 
does result in a change in neonatal clinical care.  
Secondary outcomes and their definitions are listed below.  
a) TTTS: polyhydramnios (>8cm MPD in the recipient at <20 weeks of gestation or 
>10cm from >20 weeks of gestation) in combination with oligohydramnios in the 
donor (<2 cm MPD irrespective of gestation) in same sex twins diagnosed as 
MCDA twins in the first trimester. It was staged as per Quintero staging criteria 
(Quintero 1999). Pregnancies affected by TTTS with concurrent growth restriction 
were not included in the AGR or PGR groups as the aetiology of the growth 
restriction is different and would make the growth restriction group 
heterogeneous. 
b) AGR: AC or EFW <10th centile in either/both fetus(es), and/or growth 
discordance >20% recorded at least twice over ≥2 week period. As a result of 
different measures and definitions of twin growth, for which there is at present no 
validated international consensus, the term ‘growth restriction’ was used to 
denote a twin which demonstrated pathologically abnormal growth. It was 
believed to be important to use the different measures, as even within UK units, 
despite the RCOG Green-top guidelines for the Management of Monochorionic 
Twin Pregnancy (Neilson 2008, Kilby 2016), the measurements and definitions 
used to make clinical decisions were different. Pregnancies were not considered 
to have a growth problem if there was only one abnormal ultrasound scan, and 
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the subsequent scans were normal. When growth was examined as an individual 
outcome, it was divided into antenatally- and postnatally-detected growth 
problems. From both growth restriction sub-groups pregnancies with TTTS and 
TAPS were excluded as the abnormal growth seen is these conditions is thought 
to be linked to the pathology of TTTS or TAPS and thus has a different aetiology 
to those with solely growth problems. Twins with an IUFD were also excluded if 
the IUFD was not preceded by evidence of growth restriction in the pregnancy. 
By including these patients it would make the growth group heterogeneous. 
Included in the ‘AGR’ group are pregnancies with: 
• SGA fetus. The definition of SGA was an EFW <10th centile in English cohort, 
and an AC <10th centile in the Australian cohort. This was based on the 
growth chart each unit used as when these pregnancies were being cared 
for, and clinical decisions were being made, this was not on a specific and 
validated growth chart for twin pregnancies. Different definitions were 
required because of differing guidance in the two countries for clinical 
decisions. 
• IUGR. As per SGA but with abnormal umbilical artery Dopplers. This may 
occur in one (see selective IUGR below) or both of the twins. 
• sIUGR. One twin EFW <10th centile or AC <10th centile and with abnormal 
umbilical artery Doppler as classified by Gratacós et al. (Gratacós 2007) as 
below: 
o Type I positive end-diastolic flow (EDF) in the umbilical artery 
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o Type II persistently absent or reversed end-diastolic flow (AREDF) 
o Type III intermittent absent or reversed end-diastolic flow (iAREDF) in the 
absence of fetal breathing. 
• Inter-twin growth discordance. Antenatal growth discordance was defined as 
>20% difference in the EFW using Hadlock’s formula. This was calculated by 
subtracting the weight of the smallest twin from the biggest twin, then dividing 
by the weight of the biggest twin, and multiplying by 100.  
c) Postnatally-detected growth restriction: birthweight <9th centile World Health 
Organization (WHO) charts. In the ‘postnatally-detected growth restriction’ group 
are fetuses with a birthweight <9th centile on the WHO growth chart (0-2 years or 
PTB charts depending on gestation at delivery) (RCPCH 2016). Although these 
charts were designed for singletons, no specific validated charts for twin 
pregnancies exist at present. It was not possible to use a specific weight cut-off 
for NNU admission as this varies between NNUs. Unlike isolated antenatal EFW 
discordance which was considered a sign of growth restriction as it changes the 
clinical management of the pregnancy, isolated postnatal actual BWD was not 
included as it is not used clinically postnatally, and it was felt too far to 
extrapolate postnatal BWD to equate to antenatal EFW discordance. For 
pregnancies in which only one twin had a birthweight <9th centile and abnormal 
growth was not detected antenatally, the naming of twin 1 and twin 2 antenatally 
and postnatally had to be assumed to be consistent. 
d) IUFD: fetal death after 14 weeks gestation. This may be a single IUFD (sIUFD) 
whereby one twin died or a double IUFD (dIUFD) whereby both twins died. The 
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pregnancy was considered a miscarriage if the pregnancy loss occurred at 14-
23+6 weeks, and a stillbirth if the loss occurred at ≥24 weeks. Pregnancies with a 
loss <14 weeks gestation were not eligible for inclusion in the study as the first 
trimester ultrasound scan and biomarkers are measured at this time, and the 
pathology and consequences of a loss at <14 weeks gestation is different to that 
of a loss >14 weeks gestation. 
e) Spontaneous PTB: if it occurred between 24-33+6 weeks gestation. Any births 
less than 34 weeks were sub-classified as spontaneous or iatrogenic as it would 
be clinically most useful if there were factors to predict spontaneous PTB, 
whereas iatrogenic PTB is more reflective of disease severity as it is a treatment 
rather than a pathological process. Only spontaneous PTBs were included in this 
outcome. 
f) Neonatal composite outcome: NND, respiratory distress syndrome, assisted 
ventilation (continuous positive airway pressure [CPAP] or endotracheal tube) for 
>24 hours, intraventricular haemorrhage or other brain injury, necrotising 
enterocolitis, neonatal encephalopathy, chronic lung disease, severe jaundice 
requiring phototherapy, severe infection e.g. septicaemia, meningitis, exchange 
transfusion, cardiac impairment, neurological impairment. 
g) Maternal morbidity composite outcome: GDM, severe infection, hypertensive 
disorders (pregnancy induced hypertension requiring medication, pre-eclampsia, 
eclampsia or HELLP [haemolysis, elevated liver enzymes, low platelets]  
syndrome), placental abruption, venous thromboembolism, disseminated 
intravascular coagulopathy, High-Dependency or Intensive Care Unit admission, 
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cerebrovascular event, renal or liver failure, pulmonary oedema, massive 
obstetric haemorrhage (>2L estimated blood loss), acute fatty liver. 
 
3.4.7 Missing data 
As the proportion of patients with missing data was greater than 5% for maternal BMI 
and smoking status, to replace the missing values for these two factors, multiple 
imputation was performed by using a chained equation approach with predictive 
mean matching for continuous variables based on maternal age, BMI, log(β-hCG), 
log(PAPP-A), log(AFP), log(sFlt-1), log(PIGF), ethnicity, assisted conception, steroid 
use, magnesium sulphate (MgSO4), smoking status, country of antenatal care, parity, 
gestation at delivery, NT discordance (%), CRL discordance (%) and fetal adverse 
outcome composite. Ten imputed datasets were created for missing maternal BMI 
and smoking status that were then combined across all datasets using Rubin’s rule to 
obtain final model estimates. The neonatal outcome was missing for 14 babies, but 
this was not imputed due to the large number of imputations needed for missing 
outcome data so these pregnancies were not included in the neonatal composite 
outcome, but were included in the other outcomes. 
 
3.4.8 Statistical analysis 
All analyses were performed using Stata/MP 14.0 (Stata Corporation, TX, USA).  
The inter-twin discordance as a percentage, calculated as the largest NT or CRL, 
minus smallest NT or CRL, divided by the largest NT or CRL multiplied by 100 were 
used as prognostic factors for outcomes reported per pregnancy (fetal adverse 
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outcome composite, maternal antenatal and postnatal composite, AGR, PGR, TTTS, 
sIUFD, dIUFD, spontaneous PTB). Each individual twin’s NT measurement was used 
for outcomes reported per fetus/baby (AGR, PGR, IUFD, neonatal composite). The 
individual twin’s CRL was not investigated as a potential prognostic factor as it was 
used as a proxy for gestational age. The inter-twin discordance in NT or CRL, and 
the five biomarkers were not investigated with regards the neonatal composite due to 
the potential prognostic factors being measured per pregnancy and the neonatal 
composite outcome being per baby. 
The five serum biomarkers (β-hCG, PAPP-A, AFP, PlGF and sFlt-1) were log 
transformed as they were highly skewed. All potential prognostic factor 
measurements remained as continuous variables during analysis, and no cut-offs 
were applied as there are no established and validated cut-offs for twin pregnancies, 
and data is lost by dichotomising variables (Altman 2006). The association between 
continuous prognostic factors and the outcome was included in the regression 
models as a linear term. The use of fractional polynomials were considered as part of 
a sensitivity analysis but the best fitting models were those with the linear term only 
included. 
 
The association between each of the seven prognostic factors of interest (NT, CRL, 
β-hCG, PAPP-A, AFP, sFlt-1, PIGF) and the primary and secondary outcomes was 
assessed by univariable logistic regression models fitted individually to each 
prognostic factor and each outcome. The unadjusted association was reported as the 
OR with 95% confidence intervals (95%CI). A random intercept term at the level of 
the mother was included in the logistic regression models, to account for clustering of 
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multiple babies per woman, where it was sensibly estimable, for outcomes relating to 
individual babies. The clustering of babies within mothers for the outcome of IUFD 
was not able to be accounted for using a random effects model due to small numbers 
and minimal variation within the clusters which created convergence issues, hence a 
fixed effect model was used. 
A multivariable logistic regression model was fitted, with random effects as necessary 
as described previously, to produce adjusted odds ratios (aOR). The potential 
prognostic factors were adjusting for standard characteristics defined a priori to be 
likely to be prognostic of adverse outcome: maternal age, BMI, smoking status, 
ethnicity, parity, mode of conception. The spontaneous PTB outcome was 
additionally adjusted for administration of MgSO4. The neonatal composite outcome 
was adjusted for the gestation at delivery, administration of steroids, and MgSO4. It 
was not possible to adjust for all these factors for the sIUFD and dIUFD per 
pregnancy outcome due to convergence issues, therefore this outcome was adjusted 
for maternal age, BMI, ethnicity and mode of conception. 
The aOR represents the prognostic ability of each individual potential prognostic 
factor above the prognostic ability of the existing prognostic factors. The p-valve 
presented is for the aOR, <0.05 was considered statistically significant.  
The c-statistic was calculated when a significant association was found between the 
prognostic factor and adverse outcome. When developing a prognostic model, the 
discrimination represents the ability of the model to separate cases from controls. 
The discrimination can be represented by the c-statistic. More specifically, the c-
statistic is the probability that for any randomly selected pair of individuals, the model 
assigns a higher probability to the individual who experiences the outcome. As the 
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aim was to evaluate individual prognostic factors, not the combination of prognostic 
factors in a prognostic model, how each individual potential prognostic factor of 
interest improved the discrimination of the existing prognostic factors was assessed, 
by reporting the change in c-statistic (the area under the curve [AUC]). 
The data are a convenience cohort of women and therefore no power calculation was 
used to determine a sample size. A typical rule of thumb is at least ten events are 
required for every candidate prognostic factor of interest (Peduzzi 1996) thus as 7 
potential prognostic factors were examined, a sample size of ≥70 women was 
required.  
 
3.4.9 Translating the prognostic effect into clinical utility 
To demonstrate how the odds of developing the fetal adverse outcome would change 
across the distribution of each potential prognostic factor, two values for each 
potential prognostic factor were chosen a priori. The values for the ultrasound 
measurements were based on cut-offs used in existing literature for NT % 
discordance (0% and 20%) and CRL % discordance (0% and 10%). The values used 
for the maternal serum biomarkers were based on centiles in the study cohort: for 
AFP and sFlt-1 the 50th centile and 95th centile were used, for PlGF the 50th and 5th 
centiles were used. The results were adjusted for using the mean values of the 
adjustment factors in the study cohort. The patient characteristics remained the same 
and were based on the mean and most common options in the patient cohort: 30 
years old, BMI 25, non-smoker, Caucasian, nulliparous and natural conception. 
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3.4.10 Ethical approval 
Ethical approval was granted from East Midlands – Derby REC (15/EM/0240) on 09 
June 2015 and the 1st amendment to include the Australian samples was approved 
on 21 April 2016, and the 2nd amendment to extend the time period of the project was 
approved on 22 February 2016. Confidential Advisory Group (CAG) approval was 
granted (15/CAG/0142) on 24 June 2015. Ethical approval was granted by the Royal 
Prince Alfred Hospital Research and Ethics Governance Office 
(HREC/11/RPAH/472) in January 2016. As the study is being conducted following the 
completion of the participants’ pregnancies, the results of the study will not affect 
patient care and patients whose blood samples were used were not informed of the 
results. This work is part of a larger study, which was registered on 22nd April 2016: 
ISRCTN 13114861 (www.isrctn.com/ISRCTN13114861). The protocol was published 
prior to analysis (Mackie 2017). Since submitting the protocol for publication, it should 
be noted that a collaboration with the Royal Prince Alfred Hospital, Sydney, Australia 
was formed to generate an international cohort. 
 
3.5 Results  
 
There were 213 women identified as MC twin pregnancies on the BWH and Royal 
Prince Alfred Hospital, Sydney first trimester aneuploidy screening databases. Of 
these women 177 pregnancies (354 fetuses/babies) (83.1%) were included in the 
study (Figure 3.6). No woman was included twice. The commonest reason for being 
unable to include a woman in the study was being unable to collect the outcome 
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data. One DCDA pregnancy was incorrectly identified as a MCDA pregnancy in the 
first trimester and was not included.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BWH aneuploidy 
screening database 
“monochorionic” 
n=143 
BWH MCDA included 
n=113 
Sydney MCDA included 
n=64 
Unable to collect outcome data n=14 
MCMA n=4 
Lost to follow-up n=4 
Structural anomaly n=3 
Left the UK n=2 
DCDA n=1 
Miscarriage <14weeks n=1 
Insufficient antenatal data n=1 
Total included in cohort 
n=177 
Unable to collect outcome data n=5 
Insufficient antenatal data n=1 
Sydney aneuploidy 
screening database 
“monochorionic” n=70 
Figure 3.6 Flow diagram of patient inclusion 
BWH: Birmingham Women’s Hospital 
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3.5.1 Existing prognostic factors  
The maternal characteristics that were considered existing prognostic factors and 
were used to calculate aORs are summarised in Table 3.3. There was no or minimal 
missing data in the majority of the factors, with the exception of BMI which had 19% 
missing and maternal smoking status which was missing in 7.34%. 
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Table 3.3 Maternal characteristics used as adjustment factors 
BMI: body mass index kg/m2, * fetal complications: twin-twin transfusion syndrome, 
twin anaemia polycythaemia sequence, growth restriction, intrauterine fetal death.  
 
 Total cohort 
(n=177) 
≥1 fetal 
complication* 
present (n=94) 
No fetal 
complication 
(n=83) 
Maternal age; mean (SD) 30.38 (5.43) 30.73 (5.30) 29.99 (5.53) 
Maternal BMI; mean (SD) 24.87 (5.41) 24.71 (5.08) 25.05 (5.77) 
Maternal smoking status; n (%) 
Never 127 (77.44) 64 (75.29) 63 (79.75) 
Current smoker 12 (7.32) 8 (9.41) 4 (5.06) 
Ex-smoker 25 (15.24) 13 (15.29) 12 (15.19) 
Maternal ethnicity; n (%) 
White 112 (64.74) 60 (64.52) 52 (65.00) 
Mixed 10 (5.78) 3 (3.23) 7 (8.75) 
Oriental 22 (12.72) 11 (11.83) 11 (13.75) 
South Asian 19 (10.98) 12 (12.90) 7 (8.75) 
African-Caribbean 10 (5.78) 7 (7.53) 3 (3.75) 
Parity; n (%) 
0 107 (60.45) 61 (64.89) 46 (55.42) 
1 48 (27.12) 23 (24.47) 25 (30.12) 
2 18 (10.17) 8 (8.51) 10 (12.05) 
3 2 (1.13) 1 (1.06) 1 (1.20) 
4 2 (1.13) 1 (1.06) 1 (1.20) 
Assisted conception; n (%) 24 (13.95) 14 (15.22) 10 (12.50) 
Gestational age at delivery; 
median (IQR) 
35.43 (33.00, 
36.57) 
34.36 (30.00, 
36.43) 
36.00 (35.00, 
36.57) 
Steroids administration 125 (71.02) 67 (71.28) 58 (70.73) 
Magnesium sulphate 
administration 
12 (6.82) 10 (10.64) 2 (2.44) 
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3.5.2 Adverse outcomes 
There were 55/177 (31.07%) participants who did not experience an adverse 
outcome and delivered 2 healthy twins after 34 weeks gestation. The fetal adverse 
outcome composite affected 94/177 (53.11%) pregnancies (Table 3.4). The rate of 
AGR, TTTS and IUFD is in-keeping with the incidence reported in the literature, 
therefore the cohort is representative of the UK and Australian general MC twin 
population. Of the 23 pregnancies with TTTS, 10 had concurrent AGR, but were only 
included in the TTTS and fetal adverse outcome composite, not the AGR outcome. 
The causes of the 11 sIUFDs were: 7 TTTS, 2 sIUGR, 1 unexplained IUFD at 20 
weeks, 1 intrapartum stillbirth at 23+6 weeks following spontaneous PTB. The causes 
of the 12 dIUFDs were: 7 TTTS, 2 sIUGR, 2 unexplained dIUFDs at 16 weeks, 1 
unexplained dIUFD at 21 weeks. 19/41 (46.3%) pregnancies diagnosed as AGR 
were also diagnosed as PGR, with 3 pregnancies not included in the PGR outcome 
due to dIUFDs. 24/43 (55.8%) pregnancies diagnosed as PGR were not diagnosed 
antenatally. Only 2 pregnancies had isolated BWD (i.e. no other sign of abnormal 
growth) and were not considered growth restricted. The other pregnancies with BWD 
had additional signs of growth restriction. The majority of pregnancies with AGR had 
an inter-twin EFWD >20% (27/41, 65.85%), of which 23 pregnancies had 1 fetus 
<10th centile, and 1 pregnancy had both fetuses below the 10th centile. 
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Table 3.4 Number of events  
(per pregnancy unless otherwise stated) 
 
Outcome N (%) 
Uncomplicated monochorionic diamniotic twin 
pregnancy, delivered >34 weeks gestation 
55 (31.07) 
Fetal adverse outcome composite 94/177 (53.11) 
Twin-twin transfusion syndrome 23/177 (12.99) 
Antenatal growth restriction 41/177 (23.16) 
Antenatal growth restriction (per fetus) 73/354 (20.6) 
Postnatal growth restriction 43/177 (24.29) 
Postnatal growth restriction (per baby) 54/354 (15.25) 
Intrauterine fetal death (single) 11/177 (6.21) 
Intrauterine fetal death (double) 12/177 (6.78) 
Maternal antenatal and postnatal composite 46/177 (25.99) 
Spontaneous preterm birth 12/177 (6.78) 
Neonatal composite 91/340 (26.76) 
 
3.5.3 Potential prognostic factors  
The median gestational age at blood sampling was 12+6 weeks (IQR: 12+3, 13+2). 
The average values of the prognostic factors for the total cohort are displayed in 
Table 3.5 and scatterplots of individual data points are in Appendix 10.4. There was 
no or minimal missing data in the majority of the factors, with the exception of β-hCG 
and PAPP-A which had 36.2% missing due to not being able to be included from the 
64 Australian women; sFlt-1, PlGF and AFP had 0.56% missing data which equated 
to one blood sample that was not transferred from Australia to the UK, but for which 
the woman was included in the NT and CRL assessment. The potential prognostic 
factor values in the UK cohort were compared to the Australian cohort, and the NT 
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measurement per fetus and sFlt-1 levels were significantly higher in the Australian 
samples than the UK sample (Table 3.5). 
There was no difference in the CRL measurement per fetus which demonstrates that 
there was no difference in the gestation at blood sampling.
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Table 3.5 Average values of potential prognostic factors in cohort  
(per pregnancy unless otherwise stated) CRLD: crown-rump length discordance, NA: 
not applicable as Australian measures not used, NTD: nuchal translucency 
discordance. 
 
Potential 
prognostic 
factor 
Measures 
in total 
cohort (n) 
Average 
value 
in total 
cohort 
Average 
value 
in UK cohort 
Average 
value 
in Australian 
cohort 
NTD %; median 
(IQR) 
177 11.76  
(5.55, 21.15) 
11.11  
(5.48, 20.00) 
13.81  
(5.66, 24.38) 
CRLD %; median 
(IQR) 
177 4.22  
(1.75, 7.02) 
3.71  
(1.77, 6.95) 
5.08  
(1.86, 7.04) 
NT (mm); median 
(IQR) (per fetus) 
354 1.6  
(1.4, 1.9) 
1.6  
(1.3, 1.8) 
1.8  
(1.5, 2.1) 
CRL (mm); mean 
(SD) (per fetus) 
354 64.02  
(8.49) 
64.11  
(9.60) 
63.86  
(9.99) 
β-hCG (ng/mL); 
median (IQR) 
113 64.15  
(45.90, 83.91) 
64.15  
(45.90, 83.91) 
NA 
PAPP-A (U/L); 
median (IQR) 
113 5354.06  
(3515.85, 
7629.06) 
5354.06  
(3515.85, 
7629.06) 
NA 
AFP (U/mL); 
median (IQR) 
176 29.29  
(23.40, 41.50) 
29.26  
(24.04, 41.06) 
29.32  
(22.26, 41.81) 
sFlt-1 (pg/mL); 
median (IQR) 
176 2163  
(1645, 2945.5) 
2109  
(1600, 2761) 
2455  
(1830, 3115) 
PlGF (pg/mL); 
median (IQR) 
176 60.45  
(40.89, 89.02) 
56.75  
(38.84, 86.85) 
62.66  
(45.785, 
90.19) 
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3.5.4 Nuchal translucency 
Table 3.6 demonstrates the unadjusted OR, aOR and 95%CIs for the association 
between inter-twin NT % discordance and each adverse outcome. The change in c-
statistic shows the added value of NT % discordance over standard previously 
identified prognostic factors (maternal age, BMI, smoking status, ethnicity, parity and 
mode of conception). There was an unadjusted significant association between 
increased NT % discordance and the fetal adverse outcome composite, and TTTS. 
These associations remained after adjustment demonstrating that increased NT % 
discordance is prognostic of the fetal adverse outcome composite, with an estimated 
3% (aOR 1.03 95%CI 1.01, 1.06) increase in the odds of experiencing an outcome in 
the fetal adverse outcome composite, for each 1% increase in NT % discordance, 
and an estimated 6% (aOR 1.06 95% CI 1.03, 1.10) increase in the odds of 
developing TTTS, for each 1% increase in NT % discordance. The change in the c-
statistic for fetal adverse outcome composite was quite high (0.05, baseline c-statistic 
0.594) as it was for TTTS (0.14, baseline c-statistic 0.617). NT % discordance was 
not able to predict any other adverse outcome. 
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Table 3.6 Association between NT % discordance and adverse outcome  
(n=177 pregnancies) Outcome per pregnancy. *Adjusted for maternal age, BMI, 
smoking status, ethnicity, parity and mode of conception. sIUFD and dIUFD was only 
able to be adjusted for maternal age, BMI, ethnicity and mode of conception. †p value 
of the adjusted OR. Bold denotes significant associations. Change in c-statistic 
represents the additional prognostic value of each individual potential prognostic 
factor above the existing standard prognostic factors (maternal age, BMI, smoking 
status, ethnicity, parity and mode of conception). 
 
Adverse outcome Unadjusted OR (95% CI) 
Adjusted* 
OR (95% CI) 
p-
value† 
change in 
c-statistic 
Fetal composite 1.03  
(1.01, 1.05) 
1.03  
(1.01, 1.06) 0.011 0.05 
TTTS 1.05  
(1.02, 1.08) 
1.06  
(1.03, 1.10) <0.001 0.14 
Antenatal growth restriction 1.01  
(0.99, 1.03) 
1.01  
(0.99, 1.04) 
NS - 
Postnatal growth restriction 1.01  
(0.98, 1.03) 
1.01  
(0.98, 1.03) 
NS - 
sIUFD 1.01  
(0.98, 1.05) 
1.02  
(0.98, 1.06) 
NS - 
dIUFD 1.02  
(0.98, 1.06) 
1.02  
(0.98, 1.06) 
NS - 
Maternal composite 1.01  
(0.99, 1.03) 
1.01  
(0.98, 1.03) 
NS - 
Spontaneous preterm birth 1.00  
(0.64, 1.04) 
0.99  
(0.95, 1.04) 
NS - 
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Table 3.7 Association between individual twin NT measurement (mm) and 
adverse outcome  
(n=354 fetuses/babies) Outcome per fetus/baby. *Adjusted for maternal age, BMI, 
smoking status, ethnicity, parity, mode of conception. Neonatal composite outcome 
additionally adjusted for gestation at delivery, administration of steroids, and 
magnesium sulphate. †p value of the adjusted OR. 
 
Adverse outcome Unadjusted OR (95% CI) 
Adjusted* 
OR (95% CI) 
p-
value† 
change in 
c-statistic 
Antenatal growth restriction 0.62 
(0.15, 2.56) 
0.67 
(0.13, 3.35) 
NS - 
Postnatal growth restriction 0.81 
(0.39, 1.68) 
0.75 
(0.36, 1.55) 
NS - 
IUFD 1.46 
(0.35, 6.08) 
1.20 
(0.62, 2.30) 
NS - 
Neonatal composite 0.93 
(0.30, 2.89) 
1.07 
(0.33, 3.50) 
NS - 
 
An individual twin’s first trimester NT measurement was not predictive of any adverse 
outcome (Table 3.7). 
 
3.5.5 Crown-rump length 
There was an unadjusted significant association between increased CRL % 
discordance and the fetal adverse outcome composite, AGR, and sIUFD (Table 3.8). 
These associations remained after adjustment demonstrating that increased CRL % 
discordance is a prognostic factor of adverse outcome in MC twin pregnancies. The 
change in the c-statistic was quite high (0.10, 0.12 and 0.09 for TTTS, AGR and 
sIUFD respectively. The baseline c-statistics for TTTS, AGR and sIUFD 0.617, 0.616 
and 0.625 respectively. CRL % discordance was not able to predict any of the other 
adverse outcomes. 
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Table 3.8 Association between CRL % discordance and adverse outcome  
(n=177 pregnancies) Outcome per pregnancy. *Adjusted for maternal age, BMI, 
smoking status, ethnicity, parity and mode of conception. sIUFD and dIUFD was only 
able to be adjusted for maternal age, BMI, ethnicity and mode of conception. †p value 
of the adjusted OR. Bold denotes significant associations. Change in c-statistic 
represents the additional prognostic value of each individual potential prognostic 
factor above the existing standard prognostic factors (maternal age, BMI, smoking 
status, ethnicity, parity and mode of conception). 
 
Adverse outcome Unadjusted OR (95% CI) 
Adjusted* 
OR (95% CI) 
p-
value† 
change in 
c-statistic 
Fetal composite 1.16  
(1.06, 1.27) 
1.17  
(1.07, 1.29) 0.001 0.10 
TTTS 1.07  
(0.96, 1.20) 
1.09  
(0.97, 1.23) 
NS - 
Antenatal growth restriction 1.17  
(1.06, 1.30) 
1.20  
(1.08, 1.34) 0.001 0.12 
Postnatal growth restriction 1.05  
(0.95, 1.15) 
1.04  
(0.94, 1.15) 
NS - 
sIUFD 1.17  
(1.00, 1.36) 
1.19  
(1.01, 1.40) 0.035 0.09 
dIUFD 1.06  
(0.91, 1.24) 
1.12  
(0.94, 1.33) 
NS - 
Maternal composite 0.96  
(0.87, 1.06) 
0.97  
(0.87, 1.07) 
NS - 
Spontaneous preterm birth 0.93  
(0.77, 1.11) 
0.92  
(0.76, 1.11) 
NS - 
 
3.5.6 β-human chorionic gonadotropin 
First trimester maternal serum β-hCG was not prognostic for any adverse outcome 
(Table 3.9). 
 
  
193 
 
Table 3.9 Association between first trimester maternal serum β-hCG and 
adverse outcome  
(n=113 pregnancies) Outcome per pregnancy. *Adjusted for maternal age, BMI, 
smoking status, ethnicity, parity and mode of conception. sIUFD and dIUFD was only 
able to be adjusted for maternal age, BMI, ethnicity and mode of conception. †p value 
of the adjusted OR. Bold denotes significant associations. Change in c-statistic 
represents the additional prognostic value of each individual potential prognostic 
factor above the existing standard prognostic factors (maternal age, BMI, smoking 
status, ethnicity, parity and mode of conception). 
 
 
Adverse outcome Unadjusted OR (95% CI) 
Adjusted* 
OR (95% CI) 
p-
value† 
change in 
c-statistic 
Fetal composite 1.41 
(0.77, 2.57) 
1.35 
(0.68, 2.68) 
NS - 
TTTS 1.11 
(0.47, 2.63) 
1.04 
(0.41, 2.65) 
NS - 
Antenatal growth restriction 1.21 
(0.61, 2.41) 
1.25 
(0.56, 2.79) 
NS - 
Postnatal growth restriction 1.04 
(0.56, 1.93) 
0.95 
(0.47, 1.94) 
NS - 
sIUFD 1.40 
(0.45, 4.36) 
1.52 
(0.44, 5.25) 
NS - 
dIUFD 1.66 
(0.50, 5.55) 
1.91 
(0.48, 7.61) 
NS - 
Maternal composite 1.30 
(0.69, 2.45) 
1.23 
(0.58, 2.62) 
NS - 
Spontaneous preterm birth 0.87 
(0.30, 2.59) 
0.81 
(0.24, 2.72) 
NS - 
 
3.5.7 Pregnancy-associated plasma protein A 
First trimester maternal serum PAPP-A was not prognostic for any adverse outcome 
(Table 3.10). 
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Table 3.10 Association between first trimester maternal serum PAPP-A and 
adverse outcome  
(n=113 pregnancies) Outcome per pregnancy. *Adjusted for maternal age, BMI, 
smoking status, ethnicity, parity and mode of conception. sIUFD and dIUFD was only 
able to be adjusted for maternal age, BMI, ethnicity and mode of conception. †p value 
of the adjusted OR. Bold denotes significant associations. Change in c-statistic 
represents the additional prognostic value of each individual potential prognostic 
factor above the existing standard prognostic factors (maternal age, BMI, smoking 
status, ethnicity, parity and mode of conception). 
 
Adverse outcome Unadjusted OR (95% CI) 
Adjusted* 
OR (95% CI) 
p-
value† 
change in 
c-statistic 
Fetal composite 1.06 
(0.63, 1.81) 
1.10 
(0.55, 2.18) 
NS - 
TTTS 1.50 
(0.61, 3.65) 
1.26 
(0.40, 3.91) 
NS - 
Antenatal growth restriction 1.09 
(0.56, 2.12) 
1.21 
(0.53, 2.78) 
NS - 
Postnatal growth restriction 0.82 
(0.43, 1.58) 
1.03 
(0.44, 2.42) 
NS - 
sIUFD 0.94 
(0.33, 2.69) 
1.09 
(0.30, 3.93) 
NS - 
dIUFD 1.36 
(0.38, 4.91) 
0.63 
(0.11, 3.65) 
NS - 
Maternal composite 0.82 
(0.45, 1.49) 
0.68 
(0.32, 1.47) 
NS - 
Spontaneous preterm birth 0.75 
(0.26, 2.17) 
0.68 
(0.20, 2.37) 
NS - 
 
3.5.8 Alpha-fetoprotein 
There was an unadjusted significant association between increased AFP and TTTS 
(Table 3.11). This association became borderline after adjustment for existing 
prognostic factors. AFP was not associated with any other adverse outcome. 
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Table 3.11 Association between first trimester maternal serum AFP and 
adverse outcome 
(n=176 pregnancies) Outcome per pregnancy. *Adjusted for maternal age, BMI, 
smoking status, ethnicity, parity and mode of conception. sIUFD and dIUFD was only 
able to be adjusted for maternal age, BMI, ethnicity and mode of conception. †p value 
of the adjusted OR. Bold denotes significant associations. Change in c-statistic 
represents the additional prognostic value of each individual potential prognostic 
factor above the existing standard prognostic factors (maternal age, BMI, smoking 
status, ethnicity, parity and mode of conception). 
 
Adverse outcome Unadjusted OR (95% CI) 
Adjusted* 
OR (95% CI) 
p-
value† 
change in 
c-statistic 
Fetal composite 1.91  
(0.93, 3.94) 
2.08  
(0.94, 4.59) 
NS - 
TTTS 3.04  
(1.05, 8.78) 
3.24  
(1.00, 10.48) 0.057 0.07 
Antenatal growth restriction 1.55  
(0.67, 3.55) 
2.10  
(0.82, 5.40) 
NS - 
Postnatal growth restriction 0.88  
(0.39, 1.98) 
0.88  
(0.35, 2.20) 
NS - 
sIUFD 0.68  
(0.16, 2.87) 
0.80  
(0.17, 3.90) 
NS - 
dIUFD 1.33  
(0.34, 5.21) 
0.97  
(0.18, 5.33) 
NS - 
Maternal composite 0.56  
(0.25, 1.26) 
0.55  
(0.21, 1.42) 
NS - 
Spontaneous preterm birth 0.96  
(0.24, 3.81) 
0.76  
(0.15, 3.80) 
NS - 
 
3.5.9 Placental growth factor 
There was an unadjusted significant association between decreased PlGF and TTTS, 
sIUFD and dIUFD (Table 3.12). These associations remained after adjustment 
demonstrating that decreased PlGF is a prognostic factor of adverse outcome in MC 
twin pregnancies. The change in the c-statistic was quite high for all the significantly 
associated adverse outcomes (the baseline c-statistics for TTTS, sIUFD and dIUFD 
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were 0.617, 0.625 and 0.783 respectively). PlGF was not able to predict any of the 
other adverse outcomes. 
 
Table 3.12 Association between first trimester maternal serum PlGF and 
adverse outcome  
(n=176 pregnancies) Outcome per pregnancy. *Adjusted for maternal age, BMI, 
smoking status, ethnicity, parity and mode of conception. sIUFD and dIUFD was only 
able to be adjusted for maternal age, BMI, ethnicity and mode of conception. †p value 
of the adjusted OR. Bold denotes significant associations. Change in c-statistic 
represents the additional prognostic value of each individual potential prognostic 
factor above the existing standard prognostic factors (maternal age, BMI, smoking 
status, ethnicity, parity and mode of conception). 
 
Adverse outcome Unadjusted OR (95% CI) 
Adjusted* 
OR (95% CI) 
p-
value† 
change in 
c-statistic 
Fetal composite 0.73  
(0.44, 1.22) 
0.65  
(0.37, 1.13) 
NS - 
TTTS 0.43 
 (0.20, 0.91) 
0.42  
(0.19, 0.93) 0.033 0.07 
Antenatal growth restriction 0.91  
(0.50, 1.66) 
0.88  
(0.44, 1.76) 
NS - 
Postnatal growth restriction 1.55  
(0.84, 2.85) 
1.62  
(0.80, 3.29) 
NS - 
sIUFD 0.35  
(0.13, 0.97) 
0.34  
(0.12, 0.98) 0.045 0.06 
dIUFD 0.23  
(0.08, 0.63) 
0.18  
(0.05, 0.58) 0.003 0.07 
Maternal composite 0.78  
(0.44, 1.39) 
0.70  
(0.34, 1.42) 
NS - 
Spontaneous preterm birth 0.69  
(0.26, 1.82) 
0.70  
(0.25, 1.98) 
NS - 
 
3.5.10 Soluble fms-like tyrosine kinase-1  
First trimester maternal serum sFlt-1 was not prognostic for any adverse outcome 
(Table 3.13). 
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Table 3.13 Association between first trimester maternal serum sFlt-1 and 
adverse outcome  
(n=176 pregnancies) Outcome per pregnancy. *Adjusted for maternal age, BMI, 
smoking status, ethnicity, parity and mode of conception. sIUFD and dIUFD was only 
able to be adjusted for maternal age, BMI, ethnicity and mode of conception. †p value 
of the adjusted OR. Bold denotes significant associations. Change in c-statistic 
represents the additional prognostic value of each individual potential prognostic 
factor above the existing standard prognostic factors (maternal age, BMI, smoking 
status, ethnicity, parity and mode of conception). 
 
Adverse outcome Unadjusted OR (95% CI) 
Adjusted* 
OR (95% CI) 
p-
value† 
change in 
c-statistic 
Fetal composite 1.12  
(0.52, 2.40) 
1.03  
(0.42, 2.50) 
NS - 
TTTS 1.91  
(0.62, 5.88) 
1.64  
(0.44, 6.03) 
NS - 
Antenatal growth restriction 1.25  
(0.50, 3.13) 
1.47  
(0.49, 4.35) 
NS - 
Postnatal growth restriction 0.63  
(0.25, 1.59) 
0.65  
(0.22, 1.88) 
NS - 
sIUFD 1.27  
(0.27, 6.04) 
1.79  
(0.30, 10.64) 
NS - 
dIUFD 4.13  
(0.92, 18.58) 
8.21  
(1.02, 66.24) 
NS - 
Maternal composite 1.36  
(0.57, 3.27) 
1.26  
(0.44, 3.58) 
NS - 
Spontaneous preterm birth 0.38  
(0.08, 1.84) 
0.30  
(0.05, 1.90) 
NS - 
 
3.5.11 Translating the prognostic effect into clinical utility 
The odds of developing the fetal adverse outcome based on 2 values for each 
potential prognostic factor were translated to demonstrate the prognostic effect for 
each individual potential prognostic factor (Table 3.14). 
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Table 3.14 Probability of developing a fetal adverse outcome according to 
potential prognostic factor measurements determined a priori 
*Adjusted for using the mean values of the adjustment factors in the study cohort. 
The patient characteristics remained the same and were based on the mean and 
most common options in the patient cohort: 30 years old, BMI 25, non-smoker, 
Caucasian, nulliparous and natural conception. 
 
Potential prognostic factor 
measurement 
Adjusted 
probability* 
NT (% discordance) 0% 0.446 
NT (% discordance) 20% 0.604 
CRL (% discordance) 0% 0.379 
CRL (% discordance) 10% 0.750 
AFP 50th centile (29.3 U/mL) 0.549 
AFP 95th centile (54.7 U/mL) 0.658 
PlGF 50th centile (60.4 pg/mL) 0.535 
PlGF 5th centile (23.6 U/mL) 0.634 
sFlt-1 50th centile (2169pg/mL) 0.545 
sFlt-1 95th centile (4089pg/mL) 0.549 
 
3.6 Discussion 
 
3.6.1 Nuchal translucency 
This study has demonstrated that increased first trimester inter-twin NT % 
discordance is a prognostic factor for the fetal adverse outcome composite, and 
TTTS. The ability of NT % discordance to predict TTTS is supported in part by a 
meta-analysis by Stagnati et al. (Stagnati 2017) of 7 studies, 128/1087 TTTS 
pregnancies, which found that NT discrepancy, defined as a combination of NT 
discordance >10%, >20%, >0.5mm, ≥0.6mm depending on the definition each study 
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used, had low sensitivity (52.8 [95% CI 43.8, 61.7] I2=48.7%) but better specificity 
(72.5 [95%CI 61.7, 82.0] I2=84.3%) although perhaps unsurprisingly these results 
were at high-risk of heterogeneity. The systematic review and meta-analyses in 
CHAPTER 2 found a trend towards a significant association between NT discordance 
≥20% and TTTS, and that NT>95th centile in one/both fetuses significantly increased 
the risk of developing TTTS. When individual NT measurements were examined in 
this cohort, no significant association was found, however the group was intentionally 
not dichotomised as in the studies in the meta-analysis as there are no validated cut-
offs for twin pregnancies. These findings suggest that there may be a link between an 
abnormal NT measurement and TTTS, although it may be more specific, for example 
in a sub-set of TTTS who will go on to develop cardiac dysfunction as demonstrated 
by the connection between a raised NT and cardiac defects outside TTTS (Souka 
1998, Hyett 1999).  
 
3.6.2 Crown-rump length 
This work has found that increased first trimester inter-twin CRL % discordance is a 
prognostic factor of the adverse fetal composite outcome, AGR and sIUFD. The 
ability of CRL % discordance to predict the fetal adverse outcome may reflect its 
ability to predict AGR as 41/94 (43.6%) pregnancies in the fetal adverse outcome 
composite were complicated by AGR, and 27/41 (65.85%) had an EFWD >20%. 
Individual twin CRL measurements were not assessed as potential prognostic factors 
as they were used to indicate gestational age. It was not possible to examine the 
association between CRL and growth restriction in the meta-analysis in CHAPTER 2, 
but two studies did demonstrate CRL discordance to have good test accuracy for 
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predicting sIUGR (Fratelli 2011, Memmo 2012). This suggests that the pathological 
mechanisms contributing to abnormal antenatal fetal growth are present in the first 
trimester. No association was seen with TTTS in the cohort study, despite the 
significant association in the meta-analysis in CHAPTER 2, but the predictive ability 
was weak. As >60% TTTS pregnancies also have an element of growth restriction 
(Lewi 2014), it may be that the association is more reflective of concurrent growth 
restriction, rather than TTTS, however this was not examined in this cohort as 
including TTTS pregnancies in the growth restriction growth would make the group 
too heterogeneous, and the sub-group of TTTS with concurrent growth restriction 
(n=10 pregnancies) would be too small. Given the different causes of sIUFD it is 
difficult to ascertain why CRL discordance is associated with sIUFD. One could 
hypothesise that if the pathological process has begun in the first trimester and is 
sufficient to cause a difference in CRL, then either protective/compensatory 
mechanisms are not in place, or the disease severity is severe – thus more likely to 
lead to sIUFD. 
 
3.6.3 β-human chorionic gonadotropin 
First trimester β-hCG was not associated with any adverse outcome. This is in line 
with the results of the systematic review as neither of the two studies included 
reported a difference in first trimester β-hCG levels in pregnancies affected by TTTS 
and uncomplicated MC twin pregnancies (Linskens 2010, Ashoor 2013). Given the 
differences seen in the second trimester in TTTS pregnancies (Fox 2009, 
Sermondade 2009), it may be that it is too early to see a significant difference in 
maternal serum levels in the first trimester, or that the β-hCG levels fail to decrease 
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in the second trimester in TTTS and it is this inability to decrease that is involved in 
the pathogenesis of TTTS. Given the myriad of biological roles that β-hCG plays in 
pregnancy, this would require further investigation. With regards growth restriction, 
there is little existing literature to compare the finding of no association with first 
trimester β-hCG. The only study on first trimester β-hCG in twin pregnancies did not 
perform sub-group analysis according to chorionicity as only 4/104 included 
pregnancies were MCDA (Iskender 2013). The authors divided their cohort into those 
with a first trimester β-hCG result >90th centile, and those <90th centile. They found 
that a higher proportion of women with “IUGR & SGA” had a first trimester β-hCG 
result >90th centile, compared to the proportion of women with “IUGR & SGA” in the 
<90th centile group. There was no difference in the first trimester β-hCG result 
centiles in women with sIUGR, or “disconcordant fetal growth”.  
 
3.6.4 Pregnancy-associated plasma protein A 
First trimester PAPP-A was not associated with any adverse outcome. This finding is 
supported by Linskens et al. who found no difference in first trimester PAPP-A levels 
in MC twin pregnancies with and without TTTS (Linskens 2010). The lack of 
significant association between first trimester PAPP-A and growth restriction is 
slightly surprising given that low PAPP-A is used clinically in singleton pregnancies to 
indicate those at high risk of delivery of a SGA neonate. However, Iskender et al. 
(Iskender 2013) reported no difference in the proportion of twin pregnancies with a 
first trimester PAPP-A >90th centile or <90th centile for any of their growth outcomes: 
growth discordance, IUGR, SGA or sIUGR. 
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3.6.5 Alpha-fetoprotein 
This study has found that increased first trimester maternal serum AFP is a 
prognostic factor for TTTS, although this became borderline significant when 
adjusted for existing prognostic factors. The wide 95%CIs should also be taken into 
consideration when interpreting this finding. As second trimester work has previously 
shown a difference in AFP levels in MC twins with and without TTTS (Fox 2009), it is 
credible that there is an association between first trimester AFP and TTTS. However 
other second trimester work did not find a difference in TTTS pregnancies 
(Sermondade 2009). The lack of associations between first trimester AFP and 
adverse outcome in twin pregnancies may reflect the pattern seen in singletons that 
most associations have been demonstrated in second trimester AFP levels, and first 
trimester AFP is not used clinically. 
 
3.6.6 Placental growth factor 
Decreased first trimester PlGF is a prognostic factor for TTTS, sIUFD and dIUFD. As 
PlGF is involved in angiogenesis, the association with decreased PlGF and TTTS 
may be biologically plausible. Studies have shown that decreased PlGF levels are 
also present in the second trimester in TTTS pregnancies (Yinon 2014, Chon 2017). 
Although another study disputes there is any difference between MC twin 
pregnancies with and without TTTS in the second trimester (Fox 2010). As with pre-
eclampsia, which is also associated with decreased first trimester PlGF, these 
findings suggest that the pathological process of TTTS may be occurring before 
clinical signs are visible on ultrasound scan. The association between PlGF and 
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sIUFD and dIUFD may be related to the high proportion of IUFDs that were affected 
by TTTS (at least 7/11 and 7/12 respectively) but it was not possible to perform a 
sub-group analysis as the numbers would be too small. Consequently, PlGF could be 
viewed as a biomarker of severity of TTTS, particularly as the aOR worsens in 
accordance with the outcome: 0.42 (95%CI 0.19, 0.93) for TTTS, 0.34 (95%CI 0.12, 
0.98) for sIUFD, and 0.18 (95%CI 0.05, 0.58) for dIUFD. First trimester PlGF was not 
a prognostic factor for antenatal or postnatal growth restriction. Results from twin 
pregnancy studies in the second trimester have been conflicting, thus further 
research is needed. 
 
3.6.7 Soluble fms-like tyrosine kinase-1 
First trimester sFlt-1 was not associated with any adverse outcome. This is slightly 
unexpected given its relationship with PlGF and the fact that this study has found that 
PlGF is a prognostic factor for certain adverse outcomes in twin pregnancies. 
However, this does echo the findings that normotensive SGA singleton pregnancies 
only demonstrate decreased PlGF and are not accompanied by increased sFlt-1, 
thus sFlt-1 and PlGF findings do not necessarily go hand in hand, and there may be 
an unrelated mechanism. Existing research does demonstrate that changes in sFlt-1 
may be present in the second trimester in the context of abnormal growth, and it may 
be that it is too early to see these changes in the first trimester. This is also the case 
with TTTS as all 4 studies that investigated maternal serum sFlt-1 levels at diagnosis 
of TTTS in the second trimester have reported significantly higher sFlt-1 in TTTS 
pregnancies compared to uncomplicated MC twin pregnancies. As sFlt-1 is anti-
angiogenic, it may be that these effects are more apparent in the second trimester 
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when the pregnancy is established, as opposed to in the first trimester where 
vasculogenesis plays an important role (Flamme 1997). Or it may be that unlike in 
pre-eclampsia whereby the mother exhibits pathophysiological abnormalities, for 
example changes in maternal blood pressure and maternal kidneys, TTTS and 
sIUGR are fetal conditions and do not affect the mother, therefore although there 
may be fetal changes, these may not be reflected in maternal serum. Particularly as 
in pregnancy there is obvious capillary growth within the placenta villi but little 
angiogenesis occurs in maternal tissue (Clark 1998). There is the suggestion that the 
major role for sFlt-1 is through systemic effects on maternal circulation rather than on 
the local placental vasculature (Hirashima 2003) thus effects are seen in pre-
eclampsia but not TTTS or sIUGR. This is compounded in MC twin pregnancy 
complications as the pathophysiological processes are often discordant between the 
twins for example with a hypervolaemic recipient twin, and hypovolaemic donor twin 
in TTTS. When placental villi from recipient and donor twins were compared sFlt-1 
mRNA was upregulated in the donor villi, but not the recipient villi which the authors 
hypothesise is due to hypoperfusion of the donor villi and subsequent hypoxia and 
ischaemia (Kumazaki 2002). Thus the donor and recipient twins may contribute 
different amounts of sFlt-1 to the maternal circulation and the level may not appear 
abnormal. An alternative explanation is that genetic variants in the offspring genome 
may play a role. A recent study of 4,380 women with pre-eclampsia demonstrated 
certain genetic variants near the FLT1 gene are associated with an increased risk of 
pre-eclampsia (McGinnis 2017), thus it may be that a genetic susceptibility is needed 
for pre-eclampsia and the associated abnormal sFlt-1 levels, which may not have 
been present in this TTTS group. 
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3.6.8 Strengths and limitations 
This is the first study to explore the individual prognostic value of first trimester 
maternal serum AFP, PlGF and sFlt-1 for predicting adverse outcome in MC twins. It 
is also the largest study to evaluate first trimester β-hCG and PAPP-A, and to 
investigate the independent prognostic value of first-trimester NT and CRL % 
discordance using such robust statistical methodology, to the authors’ knowledge. 
The potential prognostic factors were examined as continuous data, without the use 
of non-evidence based, non-validated cut-offs making the study more statistically 
robust compared to other studies. The study was designed and analysed according 
to a vigorous prognostic research methodology; and has been reported in-keeping 
with REMARK which is a great strength of this study. The results were adjusted using 
a comprehensive list of existing prognostic factors and whilst the evidence was 
sparse for some adjustment factors, the adjusted and unadjusted results are 
presented. Sample size was an issue with this study due to the relative scarcity of 
MCDA twins in the UK and Australian general obstetric populations, however there 
were a sufficient number of events (n=94) if you apply the widely accepted rule of 
thumb of requiring 10 events for each 7 potential prognostic factors being examined 
(Peduzzi 1996), and there was little missing data. The rate of fetal adverse outcome 
composite (94/177 pregnancies, 53.1%)) demonstrates how high-risk MCDA twin 
pregnancies are, and how important research in this area is, particularly given the 
potentially fatal outcome of these complications. Although the use of a composite 
outcome is less desirable than individual outcomes, they were created to enable 
meaningful statistical analysis within this relatively specialised area of obstetrics. The 
conditions included in the primary outcome of the fetal adverse outcome composite 
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are monitored in the same way: with at least 2-weekly ultrasound scans, and the 
potential sequelae of TTTS, TAPS and growth restriction are the same: IUFD. The 
conditions were examined individually as well, but if viewed pragmatically, the clinical 
action for being higher-risk for one of the conditions in the fetal adverse outcome 
composite group could be similar for all conditions, for example increased monitoring, 
and a lower threshold to refer to a tertiary fetal medicine centre. As the study 
included women who underwent antenatal care at 28 different UK maternity units, the 
results are generalisable to the UK obstetric population and possibly to other high-
income countries, however the study should be repeated in other cohorts to account 
for different obstetric populations. The results may be less applicable to those in 
developing countries, who lack the resources to conduct prognostic testing and such 
intensive antenatal surveillance.  
Another major strength of this study is that the potential prognostic factors evaluated 
were evaluated by appropriately accredited NHS laboratories, and the assays are 
readily accessible, easily and reliably measurable on an automated platform, and 
only require a small amount of maternal blood thus presenting no risk to the mother 
or fetuses. The ultrasound measurements used are easily calculable and although 
ultrasound may be subject to inter-operator variability, all health care professionals 
performing these assessments require additional certification, which is a national 
programme in the UK and thus the variability should be negligible. Consequently any 
prognostic factors with sufficient predictive ability would be clinically useful and 
feasible to measure at a national level, as with first trimester aneuploidy screening. 
Examining maternal blood in twin pregnancy does present some problems. The main 
issue is that maternal blood contains biomarkers from both twins and each twin may 
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be affected differently by the same adverse outcome, therefore abnormal levels of a 
biomarker from one twin may be disguised by the levels of the other twin. This was 
an issue with aneuploidy screening but has been overcome by using the most 
accurate cut-offs for twin pregnancies (Wald 2005) as opposed to simply doubling 
singleton values (Muller 2003). However this screening test is still less accurate than 
in singletons. Cell-free fetal DNA testing for aneuploidy in twin pregnancy was also 
less accurate than in singleton pregnancy when it was initially introduced, however 
the technology has improved and the test accuracy is now comparable to singletons 
(Mackie 2018).  
One of the main issues with this study was the absence of internationally agreed 
definitions and outcomes for multiple pregnancies, particularly with regards to 
abnormal growth. Therefore pragmatic decisions were made, based on clinical utility, 
and how patients would be managed if factors were found to be prognostic. Since 
performing this study, a Delphi consensus was published to focus definitions and 
outcomes in fetal growth restriction in twins (Khalil 2018), but this requires validation 
and was published too late to be used in this study. Although the growth restriction 
definitions were as pragmatic as possible, different pathophysiological mechanisms 
(Lewi 2008a) may be included as the sample size was too small to do further sub-
group analysis, possibly explaining why biomarkers were not significant for the 
growth restriction outcomes. It may also be that “true” or “confirmed” growth 
restriction was not represented due to the discrepancy between antenatally- and 
postnatal-detected growth restriction not being concordant, although the growth 
restriction definitions were chosen as the antenatal measurements are those that 
guide clinicians’ management decisions. Whether to include isolated BWD as an 
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outcome was a dilemma. Interestingly, the experts who participated in the Delphi 
process included BWD in the list of potential parameters to define fetal growth 
restriction in DC twins, but not MC twins, thus supporting that BWD is not important in 
MC twin pregnancies. A recent meta-analysis reported that BWD ≥20% in MC twins 
is not associated with an increased risk of NND (D'Antonio 2017b), but is associated 
with an increased risk of IUFD compared to concordant MC twins. This risk increased 
further when at least one of the twins was SGA, although the authors do not 
comment on how many pregnancies developed isolated BWD with the absence of 
antenatal signs of growth restriction, therefore it is not possible to know how many of 
these higher risk pregnancies would have been detected antenatally, and thus would 
have been included in the growth restriction outcomes. The authors also do not state 
whether they included pregnancies affected by sIUFD which will affect the results and 
it is not possible to delineate if they have included or excluded these pregnancies as 
they have not presented their 2x2 data. As only 2/177 pregnancies in this current 
cohort developed isolated BWD it is unlikely they would have a substantial impact on 
the findings, but it was thought more appropriate not to include these pregnancies in 
the fetal adverse outcome composite or postnatally-detected growth restriction group 
given the dearth of evidence demonstrating that it is clinically significant. 
LBW was included in the PGR and fetal adverse outcome composite outcomes as 
the reported accuracy of predicting fetal growth restriction on ultrasound using 
Hadlock’s formula in twin pregnancies is sub-optimal with a sensitivity of 70.1% 
(95%CI 62.2, 77.1), specificity of 86.4% (95%CI 82.5, 89.6), positive predictive value 
of 67.9% (95%CI 60.1, 75.0) and negative predictive value of 87.5% (95%CI 83.7, 
90.7). Therefore by including LBW this would allow the inclusion of pathologically 
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growth restricted babies who were missed on ultrasound scan, thus allowing 
complete reporting of pathology (Harper 2013). If viewed pragmatically, it was felt 
that if a prognostic factor was able to predict which pregnancies would result in a 
LBW (<9th centile), antenatally this pregnancy would be managed differently to a 
pregnancy with no signs of abnormal growth. 
The neonatal outcomes were difficult to collect due to in-utero and ex-utero transfers, 
and the results are difficult to interpret due to the myriad of confounding factors 
involved in neonatal outcomes. The latter point is also true of PTB and the maternal 
composite with a plethora of confounding factors that were beyond the scope of this 
study to adjust for, and may explain why none of the potential prognostic factors were 
predictive of these outcomes. 
There is debate as to whether these biomarkers, particularly those related to 
angiogenesis, should be measured in serum or plasma (Levine 2004a, Staff 2005, 
Romero 2008) as it is thought that free VEGF released from platelets may affect sFlt-
1 levels in serum (Jelkmann 2001). However many studies have used serum and 
have demonstrated a difference in pre-eclamptic pregnancies (Koga 2003, Maynard 
2003, Tsatsaris 2003, Levine 2004b, Staff 2005). Serum was used in this study for 
several reasons: the assays that the laboratories use and that are recommended by 
NICE require serum samples, the VEGF levels were not measured which is the focus 
of concern regarding the use of plasma or serum samples, and the stored first 
trimester aneuploidy screening samples were serum samples.  
 
  
210 
 
3.6.9 Clinical implications and future research 
The aim of this study was to identify individual prognostic factors of complications in 
MC twin pregnancies. For those markers where there was a statistically significant 
association with adverse outcome translating this into clinical scenarios using 
common values demonstrated that the clinical utility of individual biomarkers was 
poor i.e. the change in risk of adverse outcome in an individual was not clinically 
useful to allow a change in management. The RCOG MC twin pregnancy guidance 
recommends that “screening for TTTS by first trimester nuchal translucency 
measurements should not be offered” (Kilby 2016) and the findings of this study 
support that NT % discordance, and individual NT measurements alone should not 
be used to predict TTTS. 
Although the changes in individual biomarkers do not accurately predict outcome, 
and their individual predictive ability was thought to be too low to justify combination 
in a prognostic model, the findings are exciting from a pathophysiological perspective 
as they suggest that physiological changes occur before the appearance of the 
ultrasound signs of polyhydramnios and oligohydramnios, and IUFD. This supports 
that first trimester prognostic factors may exist, and warrant further investigation. 
Interestingly no potential prognostic factors affected both growth restriction and TTTS 
supporting that they have different pathological mechanisms. The lack of animal 
models and scarcity of MCDA twin pregnancies makes the pathophysiology difficult 
to investigate. No longitudinal studies have been performed prospectively recruiting 
women with MCDA pregnancies in the first trimester, prior to the appearance of the 
clinical signs of MC twin complications, and comparing those who subsequently 
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develop a complication. This would help determine whether the differences in the 
biomarkers are because the biomarker is abnormal earlier in pregnancy, or that it 
does not increase.  
 
3.7 Conclusion 
 
This study has demonstrated the predictive ability of individual first trimester 
ultrasound measurements and maternal serum biomarkers. Individually the 
prognostic factors have insufficient ability to predict complications in MC twin 
pregnancies, but the findings suggest that physiological changes occur in the first 
trimester, before the appearance of clinical signs, thus further research is warranted. 
  
212 
 
CHAPTER 4 FIRST AND SECOND TRIMESTER 
MATERNAL SERUM AFP, PLGF AND SFLT-1 IN 
UNCOMPLICATED MONOCHORIONIC TWIN 
PREGNANCIES 
 
 
4.1 Overview 
 
First trimester maternal serum AFP, PlGF and sFlt-1 levels were evaluated as 
potential prognostic factors of complications in MC twin pregnancies in CHAPTER 3 
because differences had been demonstrated in these biomarkers between MC twins 
with TTTS and uncomplicated MC twins in the second trimester. When first trimester 
concentrations of these biomarkers were evaluated in CHAPTER 3 AFP was found to 
have a borderline significant association with adverse outcome in MC twin 
pregnancies, PlGF was found to have a significant association with adverse outcome, 
and sFlt-1 was found to have no association. Consequently it was hypothesised that 
the first trimester may be too early to see changes in the biomarkers. As stated in 
CHAPTER 3 there is little research examining AFP, PlGF and sFlt-1 levels in MC 
twins longitudinally, thus this chapter will explore AFP, PlGF and sFlt-1 levels at 12, 
16 and 20 weeks gestation in prospectively recruited women with MC twin 
pregnancies.   
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4.2 Background  
 
4.2.1 AFP, PlGF, sFlt-1 
Detailed information on these biomarkers can be found in sections 3.2.5, 3.2.6 and 
3.2.7. 
 
4.2.2 Aims 
The aims of this study are to investigate the maternal serum concentrations of AFP, 
PlGF and sFlt-1 in MC twin pregnancies at 12, 16 and 20 weeks gestation.  
 
Hypotheses 
In the context of repeated blood sampling at 12, 16 and 20 weeks in MC twin 
pregnancies: 
1) AFP will increase over time. 
2) PlGF will increase over time. 
3) sFlt-1 will increase over time. 
 
4.3 Methods 
 
4.3.1 Participants 
All women with MCDA twin pregnancies who booked at BWH were approached 
about the study. The recruitment period was 1 July 2015 – 31 December 2017. 
Women were approached either in antenatal clinic or in the West Midlands Fetal 
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Medicine Department if they were attending for first trimester aneuploidy screening. 
Recruitment was prospective. Women were eligible if they booked at less than 14 
weeks gestation. Chronicity had to have been determined in the first trimester based 
on: a single placental mass, a thin inter-twin membrane, the presence of the ‘T’ sign 
and absence of Lambda sign (Sepulveda 1996). If the twins were a different sex, or 
postnatally the pregnancy was diagnosed as DC based on placental assessment, 
these pregnancies were excluded. As participants in the study had MCDA 
pregnancies, the majority were spontaneous conceptions therefore dates relating to 
ART could not be used. Consequently, the gestational age was calculated based on 
the largest twin CRL, as this is the measurement advised by various national bodies 
(Morin 2011, NICE 2011, Khalil 2016b, Kilby 2016), and is the gestational age upon 
which clinicians will have based management decisions. Women were not eligible for 
inclusion if they had a: miscarriage prior to 14 weeks gestation, MCMA pregnancy, 
higher order multiple pregnancy. Women with pregnancies affected by serious 
structural or congenital anomalies were also excluded, whether concordant or 
discordant, as the aetiology of their adverse outcomes, such as growth restriction, 
PTB or IUFD would be different to pregnancies not affected by structural or 
congenital anomalies, consequently increasing heterogeneity within the cohort. If a 
structural or chromosomal abnormality was diagnosed later in pregnancy, the woman 
was withdrawn from the study and none of her data were included. MCDA twin 
pregnancies at BWH were cared for in a specialised multiple pregnancy antenatal 
clinic, and managed according to the most recent NICE and RCOG guidance (NICE 
2011, Kilby 2016). There was a specific local proforma detailing the risks of MCDA 
pregnancies, including TTTS, sIUGR and preterm labour, which clinicians completed 
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in the booking appointment i.e. the first appointment in antenatal clinic in the first 
trimester. After completing the proforma, the clinician asked if the participant would 
allow the researcher to discuss the study with them; if so the researcher explained 
the study and recruited participants who provided written informed consent (see 
Appendix 10.12 and 10.13 for patient information sheet and consent form). 
Depending on gestation, blood sampling was performed then, or at a later date. 
Serial blood sampling was performed at 12, 16 and 20 weeks gestation and 
coincided with antenatal clinic appointments.  
MCDA twin pregnancies were monitored with ultrasound assessment of fetal growth, 
liquor volume and umbilical artery Doppler at least every 2 weeks from 16 weeks 
gestation. Some participants were also recruited to the STOPPIT-2 trial (ISRCTN 
98835694) (Norman 2018) and underwent a cervical length scan. Based on the 
results of the cervical length scan the woman may have been randomised to an 
Arabin pessary or normal management. As PTB was not an outcome in this study, 
being in both studies was not an issue. Postnatal outcome data were collected until 
discharge from hospital (see Appendix 10.3 for data collection form). No further 
follow-up data were collected. Anonymised data were collated, imputed and coded in 
an Excel spreadsheet by a single researcher. 
 
4.3.2 Sample collection and storage 
Maternal venous blood samples were collected in 7.5ml serum gel tubes (Sarstedt, 
Nümbrecht, Germany) from the antecubital fossa, allowed to clot for 1 hour at room 
temperature, centrifuged at 3000g for 10 minutes at room temperature, and 
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sediment-free serum aliquots were stored immediately at -80°C prior to analysis. 
Serum sample aliquots were stored for a maximum of 32 months prior to analysis. 
 
4.3.3 Biomarkers (alpha-fetoprotein, placental growth factor and soluble fms-like 
tyrosine kinase-1) 
The biomarkers were measured as described in section 3.4.4. 
 
4.3.4 Adjustment factors 
Measurements were not adjusted as the aim of the work is to demonstrate the normal 
values for the cohort across time. 
 
4.3.5 Missing data 
To be eligible for inclusion, all participants had to have provided a blood sample at all 
3 time points, with measurable levels of AFP, PlGF and sFlt-1. The only missing data 
was the smoking status of one participant which was assumed to be the modal status 
of non-smoker. No other imputations were performed. 
 
4.3.6 Statistical analysis 
All statistical analysis was performed in Stata (Stata, 2015 Release 13.1 StataCorp, 
Texas, USA). As this was a sample of convenience, no power calculation was 
performed. 
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The skewing and kurtosis of the data was assessed using the sktest command 
(StataCorp. 2013i), and the Shapiro-Wilk test of normality was performed using the 
swilk command (StataCorp. 2013k). Descriptive data are reported as medians and 
IQRs.  
 
A line plot was generated using the twoway connected command (StataCorp. 2013d) 
to visually display the data for each biomarker longitudinally. To assess any 
difference between the three time points, the Shapiro-Wilk test of normality was 
performed, and the presence of outliers was examined using box plots. All data were 
not normally distributed consequently the Kruskall-Wallis test was performed using 
the kwallis command (StataCorp. 2013e). If a significant difference was found, this 
was investigated by Dunn’s test using the dunntest command (Dinno 2015). 
 
4.3.7 Ethical approval 
Ethical approval was granted from East Midlands – Derby REC (15/EM/0244) on 01 
July 2015 and the 1st amendment to include all MC twin pregnancies not just those 
undergoing first trimester aneuploidy screening was approved on 28 September 
2015, the 2nd amendment to include parental attachment and depression assessment 
in the complicated sub-group was approved on 22 December 2015, the 3rd 
amendment to extend the study period was approved on 08 March 2017. This work is 
part of a larger study, which was registered on 22nd April 2016: ISRCTN 13114861 
(www.isrctn.com/ISRCTN13114861). The protocol was published prior to analysis 
(Mackie 2017). 
  
218 
 
4.4 Results  
 
Fifty-six women with MCDA twin pregnancies were approached to participate in the 
study, 43/56 (76.8%) consented to participate (Figure 4.1). Of the participants, 24 
had blood sampling at all 3 time points, and 19/24 (79.2%) women had 
uncomplicated pregnancies. Five women developed complications antenatally (3 
growth restriction, 1 TTTS, 1 spontaneous sIUFD of unknown cause) and were thus 
not included in the study. No woman was included twice. 
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4.4.1 Maternal demographic data  
All data were able to be collected except for one participant’s smoking status. The 
demographic data are displayed in Table 4.1. 
 
Approached to participate in study 
n=56 
Declined participation n=13 
Agreed to participate 
n=43 
<3 samples collected n= 19 
All 3 blood samples collected 
n=24 
Developed complications n=5 
Uncomplicated pregnancy 
n=19 
Figure 4.1 Flow diagram of patient inclusion 
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Table 4.1 Maternal demographic data 
(n=19 pregnancies). Gestation in weeks+days. 
 
 Uncomplicated MC twin 
pregnancies 
Maternal age; median (IQR) years 28 (26, 33) 
Maternal BMI; median (IQR) kg/m2 25 (22, 29) 
Maternal smoking status; n (%) 
 Never 
 Current smoker 
 Ex-smoker 
 
14 (73.7) 
3 (15.8) 
2 (10.5) 
Maternal ethnicity; n (%) 
 White 
 Mixed 
 Oriental 
 South Asian 
 African-Caribbean 
 
11 (57.9) 
2 (10.5) 
1 (5.3) 
3 (15.8) 
2 (10.5) 
Parity; n (%) 
 0 
 1 
 2 
 ≥3 
 
9 (47.4) 
6 (31.6) 
3 (15.8) 
1 (5.3) 
Assisted conception; n (%) 1 (5.3) 
Gestation at 1st blood collection median (IQR)  12+5 (12+0, 13+4) 
Gestation at 2nd blood collection median (IQR) 16+1 (15+6, 16+4) 
Gestation at 3rd blood collection median (IQR) 20+1 (19+6, 20+4) 
Gestation at delivery; median (IQR) 36+2 (36+0, 36+3) 
 
4.4.2 Biomarkers at each time point  
The median values of each of the 3 biomarkers are displayed in Table 4.2. As 
demonstrated by the individual line plots (Figure 4.2, Figure 4.3 and Figure 4.4) and 
the IQRs in Table 4.2, the spread of concentrations of each biomarker appears to 
increase at each time point. 
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Table 4.2 Alpha-fetoprotein, placental growth factor and soluble fms-like 
tyrosine kinase-1 levels in the first and second trimester in monochorionic twin 
pregnancies  
(n=19 pregnancies) 
 
Biomarker, time point at 
blood sampling 
Median (IQR) 
AFP (U/mL) 
12 weeks 30.9 (19.25, 38.97) 
16 weeks 64.6 (49.48, 94.14) 
20 weeks 102.3 (86.89, 143.15) 
PlGF (pg/mL) 
12 weeks 65.29 (54.36, 129) 
16 weeks 284.10 (183.5, 443) 
20 weeks 558.3 (428.5, 1011) 
sFlt-1 (pg/mL) 
12 weeks 2231 (1918, 3363.5) 
16 weeks 2271 (1837.5, 3466) 
20 weeks 2552 (1892, 3696) 
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4.4.3 Alpha-fetoprotein 
There was a significant change in AFP over time using the Kruskal Wallis test, 
χ2(2)=36.424, p=0.0001 (Figure 4.2). Post hoc Dunn’s test revealed a significant 
increase in AFP concentrations at each time point. 
 
 
Figure 4.2 Line plot of individual maternal serum AFP concentrations at 
12, 16 and 20 weeks 
(n=19 women with uncomplicated monochorionic twin pregnancies) p=0.0001 
12 vs 16 weeks, p=0.0000 12 vs 20 weeks, p=0.0174 16 vs 20 weeks 
 
 
0
50
10
0
15
0
20
0
  12 weeks      16 weeks          20 weeks 
Gestational age at blood sampling 
M
at
er
na
l s
er
um
 A
FP
 c
on
ce
nt
ra
tio
n 
(U
/m
L)
 
  
223 
 
4.4.4 Placental growth factor 
There was a significant change in PlGF over time using the Kruskal Wallis test, 
χ2(2)=34.709, p=0.0001 (Figure 4.3). Post hoc Dunn’s test revealed a significant 
increase in PlGF concentrations at each time point. 
 
 
0
10
00
20
00
30
00
40
00
50
00
1 2 3
Timepoint
  12 weeks       16 weeks        20 weeks 
Gestational age at blood sampling 
M
at
er
na
l s
er
um
 P
lG
F 
co
nc
en
tra
tio
n 
(p
g/
m
L)
 
Figure 4.3 Line plot of individual maternal serum PlGF concentrations at 
12, 16 and 20 weeks  
(n=19 women with uncomplicated monochorionic twin pregnancies) p=0.0002 12 
vs 16 weeks, p=0.0000 12 vs 20 weeks, p=0.0093 16 vs 20 weeks 
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4.4.5 Soluble fms-like tyrosine kinase 
There was no significant change in sFlt-1 over time using the Kruskal Wallis test, 
χ2(2)=0.819, p=0.664 (Figure 4.4). 
 
 
 
 
 
 
 
Figure 4.4 Line plot of individual maternal serum sFlt-1 concentrations at 
12, 16 and 20 weeks  
(n=19 women with uncomplicated monochorionic twin pregnancies) No 
significant difference seen.  
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4.5 Discussion 
 
4.5.1 Alpha-fetoprotein and placental growth factor 
The increase in AFP and PlGF over time echoes the increases seen in singleton 
pregnancies. The concentrations reported in this work are substantially higher than 
reported in studies of singleton pregnancies (Bredaki 2015, Faupel-Badger 2015), 
supporting that singleton levels cannot be used for twin pregnancies. 
 
4.5.2 Soluble fms-like tyrosine kinase-1 
There was no significant change in sFlt-1 over time which is interesting given its 
relationship with PlGF, and that PlGF did significantly increase over time. This is 
supported by a study by Faupel-Badger et al. who demonstrated a greater increase 
in sFlt-1 between 26 weeks to 35 weeks gestation, compared to 10-17 weeks 
gestation in both singleton and twin pregnancies (Faupel-Badger 2015).  
 
4.5.3 Strengths and limitations 
This is the first piece of work to perform repeated measures of AFP, PlGF and sFlt-1 
in uncomplicated MC twin pregnancies at 12, 16 and 20 weeks gestation. The 
biomarker concentrations were not adjusted for factors known to affect measures 
such as ethnicity which is a limitation of this work, however as the focus of the work 
was to look at the pattern in the biomarkers overtime, these factors will have 
remained the same at each time point.  
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4.5.4 Clinical implications and future research 
The findings have no immediate clinical implications as this is only a descriptive 
study, and further research is required. The work should be repeated in a larger 
cohort of MC twins in order to recruit sufficient numbers of uncomplicated MC twin 
pregnancies to power the study, and also complicated MC twin pregnancies which 
will then allow comparison between the two groups. Longitudinal analysis of the 
biomarkers complements the work on first trimester maternal serum biomarkers as it 
may provide gestational cut-offs for when each biomarker can be accurately 
measured. It may also improve knowledge surrounding the pathogenesis of MC twin 
complications as by recruiting complicated MC twin pregnancies this will enable 
investigation as to whether the biomarkers are low only in the first trimester, or 
remain low throughout the first and second trimester when signs and symptoms 
begin to appear. It would be interesting to compare these levels in DC twin 
pregnancies, although this may have less clinical utility as DC twins develop fewer, 
and different complications as MC twins. As the IQRs increase over time, this would 
support that first trimester measures of the biomarkers may be best as there is less 
deviation from the median.  
 
4.6 Conclusion 
 
This study improves knowledge of the longitudinal pattern of maternal serum AFP, 
PlGF and sFlt-1 in MC twin pregnancies in the first and second trimester. Further 
work is required, including recruiting a sufficient number of women with complicated 
MC twin pregnancies so as to compare the change over time and delineate whether 
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the association between AFP and PlGF and adverse outcome is due to a lower 
concentration of these factors only in the first trimester, or throughout pregnancy.  
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CHAPTER 5 AMNIOTIC FLUID METABOLITES IN 
TWIN-TWIN TRANSFUSION SYNDROME AND 
ASSOCIATION WITH FETAL CARDIAC FUNCTION 
 
• These findings were presented as a platform poster at British Maternal and Fetal 
Medicine Society 17th Annual Conference, London, UK, and as an oral 
presentation at the 26th World Congress on Ultrasound in Obstetrics and 
Gynaecology, Rome, Italy, where Dr F Mackie won the prize for best free 
communication.  
• These findings have been published in abstract form [Dunn WB, Shek NW, Fox 
CE, Mackie FL, Van Mieghem T and Kilby MD (2015). “Non-targeted 
metabolomics in recipient amniotic fluid of monochorionic twin pregnancies 
complicated by severe twin to twin transfusion syndrome (TTTS) and treated by 
fetoscopic laser ablation (FLA).” BJOG 122(S2):8.] and [Mackie FL, Dunn WB, 
Allwood JW, Van Mieghem T, Morris RK, Fox CE and Kilby MD (2016). 
“Metabolomic changes in amniotic fluid from Twin–twin transfusion syndrome 
recipient twins in relation to treatment and fetal cardiovascular risk.” Ultrasound 
Obstet Gynecol 48(S1):16-17.] 
• These findings have also been published in full article form [Dunn WB, Allwood 
JW, Van Mieghem T, Morris RK, Mackie FL, Fox CE and Kilby MD (2016). 
“Carbohydrate and fatty acid perturbations in the amniotic fluid of the recipient 
twin of pregnancies complicated by twin-twin transfusion syndrome in relation to 
treatment and fetal cardiovascular risk.” Placenta 44(8):6-12.] 
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5.1 Overview 
 
In addition to the existing prognostic factors examined in CHAPTER 3 and CHAPTER 
4, new potential biomarkers were sought by attempting to learn more about the 
pathophysiology of TTTS. This chapter explores the possibility of using metabolomics 
in the context of TTTS. Work examining the relationship between amniotic fluid 
metabolites and cardiac function in recipient twins is described. The reasons why 
amniotic fluid was chosen are outlined in the discussion. There was a focus on 
cardiac function as TTTS is predominantly a cardiovascular disease, and mortality of 
the recipient twin may be related to cardiac dysfunction. There is still a lot that is not 
known regarding the pathophysiology of TTTS, including the associated cardiac 
dysfunction, therefore a non-targeted metabolomics study was performed. 
 
5.2 Metabolomics 
 
As described in section 1.10.4 metabolomics investigates the final downstream 
product of the interaction between the genotype and its environment and has not 
been explored in the setting of TTTS before. Metabolomics has been used to explore 
cardiovascular disease in non-pregnant adults and does demonstrate functional and 
metabolic changes in heart failure (Deidda 2015, Wang 2015). Metabolomics have 
also been investigated in first trimester maternal serum samples to predict congenital 
heart disease (Bahado-Singh 2014) which demonstrated that abnormal lipid 
metabolism appears to play a role. In twin pregnancies only one metabolomics study 
has been published in humans (Cosmi 2013). This study used liquid 
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chromatography-high resolution mass spectrometry to examine the metabolome in 
cord blood from 4 sIUGR MC pregnancies and compared it to the metabolome of 4 
appropriately grown MC twins (Cosmi 2013). They reported a trend of increased 
phenylalanine, and decreased isoleucine, proline, tryptophan and valine in sIUGR 
twins, and theorise that the results did not reach statistical significance due to the 
small sample size.  
 
5.2.1 Aims 
The aims of this study are to investigate if in amniotic fluid samples taken from the 
recipient twin affected by TTTS there is a: 
1) difference in the metabolomic profile pre-FLA and post-FLA. 
2) relationship between the recipient twin cardiovascular function at diagnosis 
of TTTS (pre-FLA) and metabolomic profile. 
 
Hypotheses 
The metabolomic profile of the amniotic fluid may reflect the severity of cardiac 
dysfunction in the recipient twin in TTTS. As the amniotic fluid profile of TTTS 
pregnancies has not been explored before, this is hypothesis-generating work and no 
specific metabolites were specified. 
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5.3 Methods 
 
5.3.1 Participants 
Women with MCDA twin pregnancies attending the West Midlands Fetal Medicine 
Centre between August 2011-June 2012 for assessment and treatment of TTTS were 
consecutively recruited by Dr Caroline Fox as part of her MD (Fox 2013). TTTS was 
diagnosed and prospectively staged according to the Quintero definitions (Quintero 
1999) as previously outlined (Section 1.2.2). Those who required amnio-infusion prior 
to and/or during FLA were not included as the concentration of the metabolites would 
have been affected. 
 
5.3.2 Sample collection 
At FLA to treat TTTS an amniotic fluid sample (10ml) was taken at insertion of the 
trocar into the recipient amniotic sac. The post-FLA amniotic fluid sample (10ml) was 
removed at the end of the FLA, prior to amniodrainage. Samples were stored at  
-80°C before preparation and analysis in March 2015. 
 
5.3.3 Cardiac function assessment 
High-resolution fetal echocardiography was performed in the recipient twin with 
curvilinear array transducers (7–3.5 MHz) on a Siemens S3000 ultrasound machine 
(Siemens Ltd, Erlangan, Germany) by a single operator (Professor Mark Kilby). The 
MPI was calculated for each ventricle by adding the isovolumetric contraction time to 
the isovolumetric relaxation time, and dividing by ventricular ejection time (Tsutsumi 
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1999, Van Mieghem 2009c). A higher score indicated worse cardiac function. Cardiac 
dysfunction was indicated by the presence of tricuspid regurgitation, reversed flow in 
the DV during atrial contraction, and a tricuspid early passive/atrial contraction (E/A) 
ratio of >95% CI outside the normal limits for gestation. This was performed 24 hours 
prior to FLA, and repeated within 6 hours post-FLA. 
 
5.3.4 Fetoscopic laser ablation (FLA)  
Prophylactic tocolysis (indomethacin 100mg per rectum) was given 2 hours before 
FLA and intravenous cefuroxime (1.5g) was given peri-operatively. FLA was 
performed using local anaesthesia (1% lignocaine skin/myometrial infiltration) and 
maternal Remifentanil sedation by one operator (Professor Mark Kilby). Using 
continuous ultrasound guidance a 3.3mm port with trocar was inserted and a 2.0mm 
curved or straight fetoscope (Storz, Germany) was introduced, depending on 
placental site. The vasculature on the placental surface was carefully mapped and 
inter-twin anastomoses identified. A selective sequential FLA technique using a 
Diode laser system (30–50 W) was used, with an additional “Solomon” procedure in 
cases that were recruited to the Solomon Trial (Slaghekke 2014b). Amnio-infusion 
was not performed due to affecting the concentration of the metabolites. Women 
undergoing repeat FLA were not included. 
 
5.3.5 Sample preparation  
Sample preparation, ultra-high performance liquid chromatography-mass 
spectrometry (UHPLC-MS) and biostatistical data analysis were performed by 
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Professor Warwick Dunn and Dr William Allwood at the Birmingham Phenome 
Centre. All samples were randomised to ensure the order of preparation was not 
affected by the subject, TTTS severity or date of sample collection. Deproteinisation 
was performed by vortex-mixing 250μL of amniotic fluid with 1000μL of methanol for 
15 seconds to precipitate proteins and DNA. Centrifugation (15 minutes, 13,000 g) 
drying to induce metabolite stability was performed and the samples were stored at  
-80°C prior to analysis. A pooled quality control (QC) sample was prepared by 
combining 80μL aliquots of each of the 38 amniotic fluid samples as is standard 
practice (Dunn 2011). The pre-FLA samples were used to assess the relationship 
with cardiac dysfunction. 
 
5.3.6 UHPLC-MS analysis 
All chemicals and solvents applied were of HPLC analytical grade (JT. Baker, UK). 
UHPLC-MS analysis of amniotic fluid extracts and QC samples was performed by 
passing the samples through a Dionex™ UltiMate™ 3000 metabolite separation 
system coupled to an electrospray LTQ-FT Ultra™ mass spectrometer (Thermo 
Scientific Ltd. UK), a hybrid of the Linear Ion Trap mass spectrometer (LTQ) and 
Fourier Transform (FT) mass spectrometer. Samples were reconstituted in 100µL of 
50:50 methanol:water, vortex-mixed for 15 seconds, centrifuged (15 minutes, 13,000 
g) and transferred to vials with 200µL fixed inserts (Thermo-Fisher Ltd UK). All 
samples were stored in the autosampler at 5°C and analysed separately in negative 
and positive electrospray ionisation (ESI) modes within 72 hours of reconstitution. 
UHPLC separations were performed applying a Hypersil Gold C18 reversed phase 
column (100 x 2.1mm, 1.9µm) at a flow rate of 400µL.min-1, at a column temperature 
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of 40°C, and with two solvents: solvent A (HPLC grade water + 0.1% formic acid) and 
solvent B (HPLC grade methanol + 0.1% formic acid). A gradient elution was 
performed as follows: hold 100% A 0-1.5 min, 100% A - 100% B 1.5-6 min curve 3, 
hold 100% B 6-12 min, 100% B – 100% A 12-13 min curve 3, hold 100% A 13-15 
min. Injection volume was 5µL. UHPLC eluent was introduced directly in to the 
electrospray LTQ-FT Ultra™ mass spectrometer with source conditions as follows: 
spray voltage -4.5 kV (ESI-) and +5 kV (ESI+), sheath gas 30 arbitrary units, aux gas 
15 arbitrary units, capillary voltage 35 V, tube lens voltage -100 V (ESI-) and +90 V 
(ESI+), capillary temperature 280°C, ESI heater temperature 300°C. Data were 
acquired in the FT mass spectrometer in the mass/charge ratio (m/z) range 100-1000 
at a mass resolution of 50,000 (FWHM defined at m/z 400), with a scan speed of 0.4 
sec and an AGC setting of 1x106. Analysis order was composed of 10 QC sample 
injections for system conditioning followed by a QC sample injection every 6th 
injection with two QC sample injections at the end of the analytical run. Amniotic fluid 
extracts for each subject were analysed in a random order, but the pre-FLA and post-
FLA samples for each participant were analysed sequentially.  
 
5.3.7 Data pre-processing  
UHPLC-MS raw data profiles were converted into a Network Common Data Form 
(NetCDF) format within the Xcalibur™ (Thermo Fisher Scientific) software's File 
Converter program. Each NetCDF based three-dimensional data matrix (intensity × 
m/z × retention time [one per sample]) was converted into a vector of peak 
responses, defined as the “sum of intensities over a window of specified mass and 
time range” using the freely available XCMS software 
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(http://masspec.scripps.edu/xcms/xcms.php) as described previously (Dunn 2008). 
Data were exported from XCMS as a .csv file for further data analysis. Metabolite 
annotation was performed applying the PUTMEDID_LCMS workflow 
(www.mcisb.org/resources/putmedid.html) as previously described (Brown 2011). All 
metabolite annotations are reported at level 2 (putatively annotated compounds) 
according to Metabolomics Standards Initiative (MSI) reporting standards (Sumner 
2007). In cases where a single metabolite is detected as multiple metabolite features 
(i.e. where multiple types of ions are detected for the same metabolite thus 
overestimating the number of metabolites detected (Brown 2009)), only a single 
feature is reported that was chosen as having a p-value nearest to 0.05).  
 
5.3.8 Statistical analysis  
As no existing studies have explored metabolomics and TTTS, untargeted 
metabolomics was performed, for which a sample of convenience is considered 
acceptable, so no power calculation was performed (Nyamundanda 2013). Medians 
and IQRs were described. Intergroup comparisons for continuous variables with a 
non-parametric distribution were made using the Mann-Whitney U test to determine 
significant differences between the data sets. Categorical data were analysed using 
Fisher's exact test and OR and 95%CI were reported. Metabolomics processed data 
were analysed in ‘R’ (R: A language and environment for statistical computing. R 
Foundation for Statistical Computing, Vienna, Austria) applying the unsupervised 
multivariate principal components analysis (PCA), supervised multivariate Partial 
Least Squares-Discriminant Analysis (PLS-DA), univariate non-parametric Wilcoxon 
Signed Rank test and Spearman rank correlation analysis. The fold change (median 
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peak area pre-FLA/median peak area post-FLA) was calculated including 95%CI. 
Metabolites were manually clustered into classes defining similar chemical structure 
or metabolic pathway to identify biologically relevant and robust metabolic changes. 
Results were considered significant if p<0.05. 
 
5.3.9 Ethical approval 
Ethical approval was granted by Birmingham Black Country Local Research Ethics 
Committee (No: 06/Q2702/71 accepted in 2006) with written consent obtained from 
all participants. 
 
5.4 Results 
 
5.4.1 Participant characteristics 
Amniotic fluid samples from 19 women with MCDA twins complicated by TTTS 
undergoing FLA were collected and analysed. The characteristics of the women at 
TTTS diagnosis are reported in Table 5.1. The Quintero stage at FLA was: stage I 
1/19 (5.2%), stage II 3/19 (15.8%), and stage III 15/19 (79%).  
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Table 5.1 Demographic and clinical data for all participants  
(n=19 TTTS pregnancies; n=38 fetuses) BMI: body mass index, EFW: estimated fetal 
weight, IUFD: intra-uterine fetal death. *Perinatal survival defined as total number of 
survivors (all fetuses) who survived until at least 28 days of age 
 
Patient characteristics Median (IQR) 
Maternal age (years) 29.0 (25.0, 31.5) 
Maternal BMI 24.4 (21.5, 26.65) 
Gestational age at FLA (weeks) 20+2 (19+4, 21+3) 
Inter-twin difference in EFW at FLA (%) 25.2 (19.2, 30.5) 
Fetoscopic laser ablation (FLA) variables Median (IQR) 
Duration of FLA (minutes) 19 (13, 25) 
Number of arteriovenous anastomoses ablated 8 (7.5 – 8.5) 
Amniodrainage post-FLA (ml) 2600 (2250, 3100) 
Pregnancy outcome  
Gestational age at delivery (weeks, days) Median 
(IQR)  
32+3 (29+6, 34+0) 
At least one survivor n (%) 18/19 (94.7) 
Two survivors n (%) 12/19 (63.2) 
Single IUFD n (%) 6/19 (31.5) 
Double IUFD n (%) 1/19 (5.3) 
Perinatal survivor at 28 days n (%) (total fetuses) 30/38 (78.9) 
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5.4.2 Recipient twin cardiac function 
The cardiac function measurements of the recipient twin are reported in Table 5.2. 
 
Table 5.2 Recipient twin cardiac function 
DV: ductus venosus, E/A: early passive/atrial contraction, EFW: estimated fetal 
weight, IUFD: intra-uterine fetal death, FLA: fetoscopic laser ablation, LV: left 
ventricle, MPI: myocardial performance index, RV: right ventricle. *p<0.05 pre-FLA vs 
post-FLA 
 
 Pre-FLA Post-FLA 
RV MPI (z-score) Median  
(IQR) 
4.96  
(3.36, 6.31) 
2.90 
 (1.71, 4.50)* 
LV MPI (z-score) Median  
 (IQR) 
2.74  
(1.78, 3.73) 
2.07  
(0.56, 3.22)* 
Absent/reversed “A-wave” in DV n 
(%) 
7/19  
(36.8) 
2/19  
(10.5) 
Tricuspid regurgitation n  
(%) 
15/19  
(78.9) 
12/19  
(63.2) 
RV E/A ratio >95%CI for gestation 
n (%) 
11/19  
(57.9) 
6/19  
(31.2) 
 
 
Pre-FLA the recipient twin right ventricle (RV) and left ventricle (LV) MPI was 
elevated (>95%CI for gestation) in 89.4% (17/19) and 73.7% (14/19) respectively 
(Figure 5.1(a) and Figure 5.1(b). Of the two recipient twins with a RV MPI within 
95%CI for gestation, one was Quintero stage I and one stage III. In the 5 recipient 
twins with a LV MPI within 95%CI for gestation, all had stage III.  
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Figure 5.1(a) Right ventricular myocardial performance index (RV-MPI) (b) 
Left ventricular myocardial performance index (LV-MPI) in recipient fetuses 
at diagnosis of twin-twin transfusion syndrome 
The graph demonstrates individual fetal values against gestational age. The solid 
black line depicts the median MPI for uncomplicated monochorionic twins, and 
the dashed line depicts the upper 95% confidence interval (Van Mieghem 2009c). 
 
(a) 
 
 
 
 
 
 
(b) 
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The recipient twins’ RV MPI (p=0.02) and LV MPI (p=0.03) decreased significantly 
after FLA Figure 5.2(a) and Figure 5.2(b).  
 
 
 
(a) 
 
 
 
 
 
(b) 
Figure 5.2 Changes in recipient twin (a) Right Ventricular Myocardial 
Performance Index (RVMPI) and (b) Left Ventricular Myocardial Performance 
Index (LVMPI) pre- and post-fetoscopic laser ablation 
RV and LV MPI z-scores before and 6 hours post- fetoscopic laser ablation 
(individual matched data shown). 
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5.4.3 Metabolome of recipient twin amniotic fluid 
38 paired amniotic fluid samples were collected pre- and post-FLA. Following quality 
assurance of the data, 2694 and 1510 metabolite features remained in positive and 
negative ion modes respectively.  
 
5.4.4 Metabolomic changes pre- and post-FLA 
There was a significant difference in the relative concentration of 200 metabolites 
when the pre-FLA amniotic fluid samples were compared to the matched post-FLA 
samples (p<0.005). There was no difference if the Solomon FLA technique was used 
(data not shown). Figure 5.3 visually displays these data as a “heat map” of relative 
concentration changes pre-FLA and post-FLA for all metabolite classes containing 
three or more metabolites. 
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There were 13 metabolite “classes” consisting of ≥3 metabolites which demonstrated 
significant fold changes: acyl carnitines, acyl glycerides, amino acid metabolism, 
carbohydrate metabolism, cholesterol esters, ceramides and sphingolipids, fatty acid 
Figure 5.3 Heat map showing the distribution of concentrations for 
individual metabolites (rows) for samples collected pre- and post-
fetoscopic laser ablation (FLA) (columns) 
Green represents a low concentration whereas red represents a high 
concentration in the range of concentrations for each metabolite. Abbreviations 
are: amino acid metabolism (AA), acyl carnitines (AC), acyl glycerides (AG), 
carbohydrates (C), cholesterol esters (CE), ceramides and sphingolipids (CS), 
fatty acids (FA), glycerophospholipids (GPL), haem metabolism (H), 
nucleotides (N), oxidised fatty acids (OFA), oxidative phosphorylation (OP) and 
thyroid/steroid hormones (TSH) 
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metabolism, glycerophospholipids, haem metabolism, nucleosides, oxidised fatty 
acids, oxidative phosphorylation (electron transport chain) and thyroid/steroid 
hormone metabolism. Particularly interesting findings include higher levels of 
carbohydrates pre-FLA compared to post-FLA, and higher levels of fatty acids 
(shown by higher levels of acyl carnitines, acyl glycerides, fatty acids, oxidised fatty 
acids and TCA/oxidative phosphorylation metabolites) post-FLA compared to pre-
FLA (Appendix10.5).  
 
5.4.5 Association between recipient twin pre-FLA metabolites and cardiac 
function 
There were 102 pre-FLA amniotic fluid metabolites significantly correlated with the 
recipient twin RV MPI (Appendix 10.6), and 118 metabolites significantly correlated 
with the LV MPI (Appendix 10.7). A summary of the findings grouped according to 
metabolite class are displayed in Table 5.3.  
When the individual metabolites were grouped into metabolite classes, the overall 
correlation of each class to the RV or LV MPI was calculated. The acyl carnitines, 
acyl glycerides, ceramides, sphingolipids, glycerophospholipids, fatty acids and 
oxidised fatty acids classes were negatively correlated with the RV and LV MPI, 
meaning that an increased concentration in these classes was associated with better 
cardiac function. Carbohydrates were positively correlated with the RV and LV MPI 
cardiac function meaning that an increased concentration in these classes was 
associated with worse cardiac function. Two oxidative phosphorylation metabolites 
were negatively correlated with LV MPI alone and not RV MPI; no metabolites were 
correlated just with the RV MPI and not LV MPI. 
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Table 5.3 Correlation of recipient twin amniotic fluid metabolic profiles and 
cardiac function according to metabolite class  
LV: left ventricle, MPI: myocardial performance index, RV: right ventricle.  
The metabolites identified as having a significant association with RV MPI or LV MPI 
(denoted as ‘+’ correlation coefficient shows that as MPI increases so does the 
metabolite concentration) or a negative correlation (denoted as ‘-‘ shows that as MPI 
increases the metabolite concentration decreases). *The range reported is for all 
individual metabolites grouped in the class. 
 
 
 
5.5 Discussion 
 
5.5.1 Metabolome of recipient twin amniotic fluid 
This work has demonstrated that it is possible to perform metabolomics on amniotic 
fluid taken during FLA from the recipient twin amniotic sac. There are no other 
studies on the amniotic fluid metabolome in twin pregnancies to compare the 
findings, and for ethical and practical reasons outlined below it was not possible to 
recruit a MC twin control group. 
Metabolite Class RV MPI LV MPI 
Number of 
Metabolites 
Correlation 
coefficient 
range* 
Number of 
Metabolites 
Correlation 
coefficient 
range* 
Acyl amino acids 2 +0.30 to +0.37 2 +0.34 to +0.39 
Acyl carnitine 6 -0.43 to -0.31 5 -0.46 to +0.41 
Acyl glycerides 9 -0.49 to +0.60 12 -0.52 to +0.54 
Bile acid metabolism 3 +0.31 to +0.36 3 -0.38 to +0.44 
Carbohydrates 4 -0.33 to +0.45 3 -0.57 to +0.65 
Ceramides & sphingolipids 9 -0.49 to +0.42 8 -0.43 to -0.30 
CoA metabolism 2 -0.40 to -0.30 2 -0.34 to +0.36 
Fatty acid metabolism 13 -0.52 to +0.46 10 -0.67 to +0.54 
Glycerophospholipids 28 -0.64 to +0.51 41 -0.53 to +0.50 
Nucleoside 4 -0.36 to +0.54 3 -0.48 to +0.34 
Oxidised fatty acids 7 -0.48 to +0.57 4 -0.31 to -0.30 
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5.5.2 Metabolomic changes pre- and post-FLA 
Following FLA, a variety of different metabolite classes were different in the recipient 
twin amniotic fluid. Post-FLA, higher levels of fatty acids and lower levels of 
carbohydrates were seen compared to pre-FLA suggesting that there is a switch from 
fetal or placental use of fatty acids as precursors for energy metabolism to 
carbohydrates post-FLA. Of five acyl carnitines, it is the medium chain derivatives 
(hexanoyl, octanoyl and decanoyl) that dominated the increase seen in acyl 
carnitines post-FLA, suggesting a specific perturbation in medium chain fatty acid 
oxidation. Also changes related to oxidative phosphorylation were noted, again 
supporting that a switch in energy production. Another change seen post-FLA was a 
decrease in the concentrations of thyroid and steroid hormones, potentially related to 
an attenuated “stress” response post- FLA as it is known that FLA may temporarily 
worsen the cardiac function for example. A final noteworthy finding was that 
pseudouridine was 20% higher pre-FLA compared to post-FLA. This metabolite is 
increased in heart failure in adults and is considered as good a marker as BNP for 
cardiac failure (Dunn 2007). Interestingly pseudouridine is also raised in renal failure 
(Dzúrik 1992) and it may be that the level in the recipient twin decreases post-FLA as 
the high pseudouridine levels in the donor twin can no longer be transferred to the 
recipient twin through the ablated anastomoses.  
As alluded to, the metabolite changes seen pre- and post-FLA may be related to 
changes in cardiac function as a significant decrease in the RV and LV MPI was seen 
post-FLA compared to pre-FLA, and correlations were found between metabolites 
and MPI. 
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5.5.3 Association between recipient twin pre-FLA metabolites and cardiac 
function  
The shift from fatty acids to carbohydrates pre- to post-FLA may be related to 
recipient twin cardiac function (as measured by LV and RV MPI) as fatty acids are 
negatively correlated and carbohydrates are positively correlated with increasing MPI 
score. Put another way, this means that pre-FLA, when the MPI is higher and cardiac 
function is worse, more fatty acids are used for energy metabolism, so the fatty acids 
concentrations are low and carbohydrates concentrations are high because the 
carbohydrates are not being metabolised. Post-FLA, when the MPI decreases and 
cardiac function improves, metabolism switches so carbohydrates are low and fatty 
acids are high. These results do not confirm causality, but a link is apparent. 
Interestingly, metabolic modulators prescribed in adult cardiac disease, including 
hypertrophic cardiomyopathy which is also observed in recipient twins, aim to shift 
the use of fatty acids as substrates for metabolism to glucose (Drury 2015) as it is a 
more efficient way to produce energy, and produce symptomatic improvement 
(Abozguia 2010).Ceramides, sphingolipids and glycerophospholipids were also 
negatively correlated with MPI score and warrant further investigation due to their 
known involvement in adult cardiac failure (Park 2012). Changes in N,N-
dimethylarginine and the structurally similar N,N-diacetylspermine are also worthy of 
further investigation as N,N-dimethylarginine is a known inhibitor of nitrous oxide 
synthesis from arginine and therefore reduces vasodilation which is believed to play a 
role in the pathogenesis of TTTS. Symmetrical and asymmetrical N,N-
dimethylarginine are implicated in cardiac function and cardiovascular health 
(Gorenflo 2001, Gore 2013). 
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5.5.4 Strengths and limitations 
In this relatively small cohort study a substantial proportion of the recipient twins had 
evidence of cardiac dysfunction with an elevated LV and RV MPI. Such data are 
consistent with those previously described in the literature (Van Mieghem 2010) thus 
the cohort represents a general TTTS population. The rapid improvement in the 
recipient RV and LV MPI post-FLA has also been previously reported in the literature 
(Papanna 2011) suggesting that FLA was effective, as is also demonstrated by the 
high survival rate. Another strength is that the cardiac function assessments were 
only performed by a single observer, thus avoiding inter-observer variability. 
Significant differences have been found, however it is difficult to delineate whether 
the source of the metabolites is fetal or placental as at that gestation amniotic fluid is 
derived from fetal and placental metabolite secretion. As amniotic fluid sampling was 
repeated after a median time of 19 minutes, it is possible that the changes seen 
when the pre-FLA samples were compared to the post-FLA samples are secondary 
to a combination of trophoblast/vessel destruction from the ablation and recipient twin 
cardiovascular change, but there is some biological plausibility in the findings. It is 
important to consider that maternal metabolites may be present in amniotic fluid. 
Although the mechanism is not known, ‘maternal mirror syndrome’, maternal oedema 
in the presence of fetal oedema, can occur in TTTS Quintero Stage IV or V and thus 
it may be that maternal metabolites are present amniotic fluid, however there were no 
pregnancies with TTTS Stage IV or V at FLA included in the cohort thus it is unlikely 
to have affected the results. Due to the sample size, it was not possible to adjust for 
the Quintero Stage of TTTS, as Stages I-III may have different effects on the 
metabolome. There is also the possibility multiple testing has affected the findings, 
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which is an issue with all –omics technologies due to the large amount of data 
produced (Broadhurst 2006). As this was untargeted mechanistic discovery work, no 
statistical correction for a false discovery rate was applied as this can increase the 
number of false negatives, restricting biological interpretation and mean that 
potentially important metabolites are missed and not investigated in future work 
(McDonald 2014). Instead, individual metabolites were grouped together according to 
metabolic function, pathway or structure; thus if multiple individual metabolites are 
significant in the same group, the pathway can be considered mechanistically 
significant, as opposed to a random finding due to statistical chance.  
 
When designing a metabolomics study, one important consideration is the choice of 
biofluid and timing of sample collection. As the focus was to explore the 
pathophysiology of cardiac dysfunction in TTTS prior to FLA treatment which can 
affect cardiac function, amniotic fluid was chosen because it is the most ethically-
acceptable fetal biofluid able to be collected at the time of TTTS diagnosis. In-utero 
fetal blood sampling has serious associated risks. Amniotic fluid comprises mainly of 
fetal urine at this gestation and thus is reflective of fetal metabolism (Palmas 2016). 
Ideally a gestationally-matched MC twin control group would be recruited, however it 
is rare to perform an invasive procedure in normal MC twins at this gestation thus it 
was not possible. It was also not possible to collect donor twin amniotic fluid as it 
would be technically too difficult and dangerous and often the recipient twin has 
worse cardiac function than the donor twin. As this is the first work to be conducted in 
this area, samples were collected at diagnosis of TTTS in the second trimester. To 
collect first trimester samples would have meant the recruitment and collection of 
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many MC twin samples because the condition is relatively rare. Although 
metabolomics could have been performed on first trimester or second trimester 
maternal serum samples, as it is the first time the technology has been used in TTTS 
and there is little known about metabolomics in twin pregnancies, amniotic fluid was 
chosen to decrease the risk of maternal metabolites affecting the results.  
 
5.5.5 Clinical implications and future research  
These findings represent preliminary mechanistic work but cannot be used clinically 
at present. The results need to be validated, ideally by another metabolomics centre, 
with amniotic fluid samples from different pregnancies. It would be interesting to 
collect amniotic fluid samples and placental samples at delivery and to correlate 
these samples with fetal cardiac function prior to delivery. However this would be 
difficult as the Fetal Medicine Centre treats patients from a wide geographical area, 
and the majority of patients will deliver at their local centre. Additionally many 
pregnancies treated by FLA will have a spontaneous PTB and caesarean section is 
the best way to collect “clean” amniotic fluid at delivery. The study would also require 
a large sample number as cardiac function often normalises after FLA (Van Mieghem 
2009c).  
In adults with cardiac failure, prediction of survival is improved when cardiac 
ultrasound measurements are combined with serum-derived biomarkers (Latini 
2007). In recent years there has been a move to a metabolomic approach for profiling 
functional and metabolic changes in adults with heart failure (Deidda 2015). This 
could be applicable in fetal cardiac disease in TTTS, with ultrasound measurements 
being combined with other biomarkers to improve prognostic ability (Van Mieghem 
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2010). The work presented here suggests that metabolomics may identify candidate 
biomarkers worthy of future prognosis research. Future work should include targeted 
metabolomics to evaluate specific individual metabolites and assess their prognostic 
ability. 
 
5.6 Conclusion 
 
This study has demonstrated a difference in the recipient twin’s amniotic fluid 
metabolome pre- and post-FLA, suggesting that it is affected by FLA. A relationship 
between recipient twin cardiac function at diagnosis of TTTS (pre-FLA) and 
metabolomic profile has been reported, and hypotheses have been generated. The 
correlation of the balance between fatty acid and carbohydrate use in energy 
metabolism and measures of recipient twin cardiac dysfunction warrant further 
investigation. The limitations in assessing in-utero fetal metabolism have been 
discussed. Further targeted metabolomics studies in different biofluids and tissues 
are now required to improve mechanistic knowledge, and identify potential prognostic 
‘biomarkers’. 
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CHAPTER 6 MICRORNA CHANGES IN MATERNAL 
SERUM FROM PREGNANCIES COMPLICATED BY 
TWIN-TWIN TRANSFUSION SYNDROME: A 
DISCOVERY STUDY  
 
• These findings were presented as a poster presentation at the Royal College of 
Obstetricians and Gynaecologists Annual Academic Meeting, February 2018, 
London, by F Mackie. 
 
6.1 Overview 
 
In addition to the prognostic factors examined in CHAPTER 3, new potential 
prognostic factors were sought by attempting to learn more about the 
pathophysiology of TTTS. This chapter explores the possibility of using miRNA in the 
context of TTTS. The miRNA profiles of maternal serum samples taken at diagnosis 
of TTTS are compared to matched maternal serum samples taken from women with 
uncomplicated MC twin pregnancies. The reasons why maternal serum samples 
were used, and why the samples were taken at diagnosis of TTTS, are outlined. As 
this is the first time that miRNAs have been explored in TTTS, an array was 
performed, and the results were validated in a different cohort. 
 
6.2 microRNA  
 
As described in section 1.10.2 miRNA are a sub-group of transcriptomics as they are 
involved in the translation of genes for protein synthesis. miRNAs are highly 
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ubiquitous noncoding RNAs, consisting of a single strand of around 21–25 
nucleotides that are conserved across many species (Ke 2003). They are involved in 
post-transcriptional regulation of gene expression and function through base-pairing 
with the 3’ untranslated region (UTR) of the complementary mRNA molecules, which 
then silences the mRNA by degradation of the target mRNA, or repression of 
translation (Lai 2002, Bartel 2004). These endogenous regulatory miRNAs are 
present in many human bodily fluids and tissues, including human placenta (Maccani 
2011, Flor 2012, Morales-Prieto 2012, Wang 2012b, Chen 2013b, Higashijima 2013, 
Wen 2017). Their potential role as biomarkers in detecting and defining prognosis in 
heart disease and cancer, among many other diseases, has been reported (Wang 
2008). There is less miRNA research in pregnancy, particularly twin pregnancy, 
however changes have been demonstrated.  
 
In pregnancy, changes in miRNAs may be in placenta-specific miRNAs i.e. those 
expressed only in the placenta, or non-placental-specific miRNAs. There is a group of 
miRNAs, known collectively as the chromosome 19 miRNA cluster (C19MC), that are 
expressed almost exclusively in the placenta (Noguer-Dance 2010). These miRNAs 
are some of the most abundant miRNAs in maternal serum and human placental 
tissue (Mouillet 2010, Donker 2012). Placental miRNA are present, and stable, in 
maternal blood (Chim 2008), and are believed to be released from the 
syncytiotrophoblast and carried in plasma in at least two forms: protein-bound miRNA 
and vesicular miRNA (Mouillet 2015). They are cleared from the maternal circulation 
soon after delivery (Morisaki 2015) and consequently may act as biomarkers for 
diseases related to pregnancy. miRNA changes in pregnancy conditions are not only 
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seen in placenta-specific miRNA, but also in non-placental specific miRNA. These 
changes will be outlined below.  
A variety of biofluids and tissues are used to investigate changes in miRNA in 
pregnancy-related conditions, including placental tissue, maternal plasma, maternal 
serum, chorioamniotic membrane, cervical cells, and in-vitro cell lines including 
HUVEC and BeWo cells. miRNA changes within the same woman may be different 
depending on the tissue/biofluid sampled (Timofeeva 2018), thus when interpreting 
miRNA studies, it is imperative that findings are compared with those in the same 
tissue type, and also the same animal species (Barchitta 2017). Logically, some 
pregnancy miRNA investigative work is performed on placental tissue and cell lines in 
order to better understand pathophysiological mechanisms. However, changes seen 
in placental tissue do not necessarily translate to changes in maternal blood 
(Timofeeva 2018), thus it is vital to consider the aim of the miRNA work and 
acknowledge that differences seen in placental tissue have limited clinical utility as a 
prognostic factor due to the risk of obtaining a placental sample antenatally. As the 
aim of this work is to explore future potential prognostic factors, maternal serum was 
chosen, and the background information in this section will focus on miRNA changes 
in human maternal serum samples where possible. This is different to the 
metabolomics work in CHAPTER 5 as placenta-specific miRNA are identifiable in 
maternal serum, however metabolites in maternal serum are not placenta-specific as 
there is a combination of maternal and placental metabolites present in maternal 
serum. Additionally it was not possible to compare amniotic fluid samples from 
pregnancies with TTTS to those without TTTS for ethical reasons, however by using 
maternal serum it is possible to compare those with TTTS and those without TTTS 
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and thus the presence of maternal miRNAs in maternal serum can be compared 
between the two groups. 
 
The majority of miRNA work in pregnancy has been performed in singleton 
pregnancies, with a particular focus on pre-eclampsia, but miscarriage, PTB, LBW, 
and macrosomia have also been explored as reviewed by Barchitta et al (Barchitta 
2017). A cornucopia of studies has demonstrated miRNA changes in maternal serum 
and plasma taken at various time points in pre-eclampsia (Gunel 2011, Yang 2011, 
Agarwal 2012, Hromadnikova 2012, Wu 2012, Zhang 2012, Li 2013, Ura 2014, 
Akehurst 2015, Munaut 2016, Sandrim 2016b, Gunel 2018), including in miRNAs 
related to angiogenesis. Certain miRNAs, including plasma hsa-miR-195-5p, may be 
linked to the increase in sFLT-1 seen in pre-eclamptic pregnancies (Sandrim 2016a). 
Thus miRNAs may act as ‘biomarkers’ of placental and vascular function in 
pregnancy. A recent proof of concept study has shown that miRNA changes in the 
buffy coat removed from first trimester maternal plasma samples may be able to 
predict pre-eclampsia in singleton pregnancies (Winger 2018).  
 
Studies have also demonstrated miRNA changes in various tissues including 
placental tissue in pre-eclampsia (Zhang 2010, Choi 2013, Lykoudi 2018), 
miscarriage (Wang 2012c, Dong 2014, Li 2016) and LBW (Song 2013, Wang 2014); 
the chorioamniotic membrane (Montenegro 2009, Enquobahrie 2016), and cervical 
cells (Elovitz 2014, Sanders 2015) in PTB, but as mentioned previously the focus of 
this work is on maternal serum samples. 
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Care should be taken when translating findings in singleton pregnancies to twin 
pregnancies. There are significant differences in types and quantities of third 
trimester maternal plasma miRNA in uncomplicated twin pregnancies, compared to 
uncomplicated singleton pregnancies (Ge 2011). Differences have also been 
demonstrated in spent blastocyst medium from ART procedures between twin and 
singleton pregnancies (Noli 2016), and in singleton and twin pregnancy sheep 
undernutrition models (Lie 2016). However there is a dearth of research looking at 
miRNA differences in complications in twin pregnancies. Wen et al. examined 
placental tissue from 14 MC twin pregnancies with sIUGR and found a difference in 
14 miRNAs when the miRNA profile of the larger twin was compared to the smaller 
twin, thus miRNA may play a role in the pathology of MC twin pregnancy 
complications, however the authors did not look at MC twin pregnancies without 
sIUGR or maternal serum samples (Wen 2017). No other studies were found looking 
at growth restriction in twin pregnancy, and there have been no reports of miRNAs in 
TTTS pregnancies, in any bodily fluid. As changes in miRNAs associated with 
trophoblast proliferation, angiogenesis and fetal growth have been demonstrated (Fu 
2013, Zhao 2013b) this suggests that miRNAs are important in human placentation, 
and related conditions, and thus warrant investigation in TTTS. 
 
6.2.1 Aims 
The aim of this study is to investigate if there is a difference in the miRNA profile of 
maternal serum samples taken at the time of diagnosis of TTTS compared to 
matched maternal serum samples from women with uncomplicated MCDA twin 
pregnancies. 
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Hypothesis 
There is a difference in human maternal serum miRNAs in pregnancies complicated 
with TTTS compared to uncomplicated matched MCDA twin pregnancies. 
 
6.3 Methods 
 
6.3.1 Participants 
No woman was included in both the investigation and validation cohorts. 
 
Investigation cohort 
Patients were recruited prospectively as part of the OMMIT study (Mackie 2017). 
Maternal blood samples were obtained the day prior to FLA from patients attending 
the West Midlands Fetal Medicine Centre for FLA for the treatment of TTTS from 
August 2015 to August 2017. TTTS was defined as a MPD >8cm in the recipient twin 
at <20 weeks gestation, or MPD >10cm at >20 weeks gestation, in combination with 
a MPD <2cm in the donor twin. Patients were prospectively staged using the 
Quintero classification (Quintero 1999). A control group of pregnant women with 
uncomplicated MCDA twin pregnancies who booked at BWH were recruited over the 
same time period. The control group underwent serial maternal blood sampling at 12, 
16 and 20 weeks gestation to coincide with their antenatal clinic appointments (see 
section 4.3.1 for more details of the participants). Chorionicity was confirmed by the 
presence of the ‘T’ sign on first trimester ultrasound (Sepulveda 1996). Women 
whose pregnancies were affected by chromosomal/structural anomalies were not 
eligible for inclusion. Participants in the control group had no serious adverse 
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maternal or fetal outcome and delivered two healthy babies which did not require 
NNU admission. Patients were matched based on: maternal age, ethnicity, parity, 
BMI, gestation at blood sampling, and fetal sex.  
 
Validation cohort 
The validation cohort was recruited as part of the same OMMIT study within the 
same time period. Women whose pregnancies were complicated by TTTS were 
matched to women with uncomplicated MC twin pregnancies, based as on the same 
factors as in the investigation cohort. No woman was included twice.  
 
6.3.2 Sample collection and storage 
Venous blood samples were collected in 7.5ml serum gel tubes (Sarstedt, 
Nümbrecht, Germany) from the antecubital fossa, allowed to clot for 1 hour at room 
temperature, centrifuged at 3000g for 10 minutes at room temperature, and 
sediment-free serum aliquots were stored immediately at -80°C prior to analysis and 
during transit. Serum sample aliquots were stored for a maximum of 13 months prior 
to analysis in the investigation cohort, and a maximum of 31 months for the validation 
cohort, which is considered acceptable practice in a recent best practice paper (Khan 
2017). Serum was chosen as it has higher miRNA concentrations than plasma 
(Wang 2012a). 
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6.3.3 RNA extraction for profiling array 
Total RNA was extracted from serum using the miRCURY™ RNA Isolation Kit – 
Biofluids (Exiqon, Vedbaek, Denmark). Serum was thawed on ice to room 
temperature and centrifuged at 3000g for 5 minutes. 200μL of supernatant from each 
sample was transferred to new tubes, and 62.5μL of a well-mixed master mix of Lysis 
buffer (60μL), RNA Spike-in template mixture (1μL) (miRCURY LNA™ Universal RT 
microRNA PCR, RNA Spike-in kit [Exiqon]) and carrier-RNA (1.5μL) (MS2 RNA, 
[Roche, West Sussex, UK]) was added. The samples were vortexed and incubated 
for 3 minutes at room temperature. The Protein Precipitation Solution BF (20μL) was 
added to each sample, the samples were vortexed and incubated for 1 minute at 
room temperature, then centrifuged at 11,000g for 3 minutes. The clear supernatant 
was then transferred to a new tube and isopropanol (270μL) was added, and the 
sample vortexed to adjust the binding conditions. A miRNA Mini Spin Column BF was 
placed in a collection tube and the sample loaded onto the column, incubated for 2 
minutes at room temperature and centrifuged at 11,000g for 30 seconds. The flow-
through was discarded and the column placed back in the collection tube. To remove 
residual DNA which may affect downstream applications, Wash Solution 2 BF 
(700μL) was added to the spin column BF and centrifuged at 11,000g for 30 
seconds. The flow-through was discarded and the column returned to the collection 
tube. This was repeated with 250μL Wash Solution 2 and was centrifuged at 11,000g 
for 2 minutes. rDNase (50μL) was added to the membrane of the spin column and 
incubated for 15 minutes at room temperature to aid digestion of the DNA. The 
columns were washed with Wash Solution 1 BF (100μL), then Wash Solution 2 BF 
(700μL), then Wash Solution 2 BF (250μL). Following each wash the samples were 
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centrifuged at 11,000g for 30 seconds, apart from the final wash following which the 
samples were centrifuged for 2 minutes, to ensure complete drying of the membrane. 
The spin column was placed in a new collection tube and RNase free H2O (50μl) was 
added directly onto the membrane, incubated for 1 minute at room temperature, and 
centrifuged at 11,000g for 1 minute to elute the samples. The extracted RNA was 
stored at -80°C prior to transfer to Exiqon, Denmark, 2 months later, on dry ice. 
 
6.3.4 Quality control of profiling array samples 
Haemolysis was assessed by 2 miRNAs known to correlate with the degree of 
haemolysis: hsa-miRNA-451 which is expressed on red blood cells, and hsa-miRNA-
23a which is not affected by haemolysis. A ratio >7.0 of those 2 miRNAs indicates 
that the sample may be affected by haemolysis. Spike-ins were added to each 
sample as technical controls: UniSp2 and UniSp4 are RNA isolation controls and 
assess RNA extraction; and UniSp6 is a complementary DNA (cDNA) synthesis 
control to assess reverse transcription and qPCR. A negative control, “blank” sample, 
was included in the reverse transcription step to detect RNA contamination. 
 
6.3.5 Quantitative RT-PCR miRNA profiling array 
miRNA profiling was performed by Exiqon using the miRCURY LNA™ Universal RT 
microRNA PCR Human panel I+II. These panels contain primer sets for the 752 
human miRNA most commonly differentially expressed in disease and/or cited in the 
scientific literature, including miRNAs associated with cardiovascular disease, renal 
disease, angiogenesis, and placenta-specific miRNA, in-keeping with the 
  
260 
 
pathophysiological mechanisms of TTTS (see Appendix 10.8 for full list of miRNAs 
tested). All the miRNAs were polyadenylated and reverse transcribed into cDNA. The 
cDNA and ExiLENT SYBR® Green master mix were transferred to the qPCR panels 
with 384 well plates pre-loaded with the specified primers, using a pipetting robot. 
The amplification was performed in a Lightcycler® 480 Instrument (Roche).  
 
6.3.6 Identification of candidate miRNAs 
The candidate miRNAs were decided upon based on: 
• Being significantly different in the TTTS compared to control samples, prior to 
Benjamini-Hochberg correction for multiple testing. 
• Being present in all investigation cohort samples, irrespective of whether they 
were TTTS or control samples. 
• Having validated targeted functional genes with strong evidence of microRNA-
Target Interaction (MTI) reported on MiRTarBase (version 7.0) (Chou 2018). 
• Biological plausibility for association with TTTS based on a literature search using 
keywords: placenta, pregnancy, twin, maternal, gestation, cardio-$, renal-$, 
vascul-$, angio-$, trophoblast, fetal. 
• Including a mixture of upregulated and downregulated miRNAs. 
 
6.3.7 Validation with RT-PCR of candidate miRNAs 
The validation of the candidate miRNAs was performed by Dr Andrew Beggs and 
Miss Agata Stodolna at the University of Birmingham. miRNA was extracted from 
serum with miRNeasy Serum/Plasma Kit (Qiagen, Manchester, UK) according to 
  
261 
 
manufacturer’s instructions (see Appendix 10.9). The quality and the concentration of 
the samples was investigated with High Sensitivity RNA TapeStation (Agilent, 
Stockport, UK). Two endogenous controls were used: miR-361-5p and miR-451a. 
Samples were converted to cDNA, and miRNA was amplified using TaqMan 
Advanced miRNA cDNA Synthesis Kit (Applied Biosystems, Thermo Fisher Scientific, 
Warrington UK) according to the manufacturer’s instructions. RT-PCR was performed 
with TaqMan Advanced miRNA Assays (Applied Biosystems) according to the 
manufacturer’s instructions. 5µl of 1:10 dilution of cDNA template was used for the 
RT-PCR reaction with 10µl of 2X TaqMan Fast Advanced Master Mix (Applied 
Biosystems), 1µl of 20X TaqMan Advanced miRNA Assay and 4µl of RNase-free 
water. The reaction was run on the QuantStudio 5 instrument (Applied Biosystems) 
under conditions: 1 cycle for 20 seconds at 95ºC, then 40 cycles of 1 second at 95ºC 
and 20 seconds at 60ºC.  
 
6.3.8 Statistical analysis 
Normalisation was performed based on the average of the assays detected in all 10 
samples. A Heatmap with red denoting miRNA expression above the mean and 
green denoting miRNA expression below the mean, and a PCA plot were drawn to 
assess the miRNA expression profiles of the samples by depicting the normalised 
dCq values for the top 50 miRNAs with the widest variation in expression in the 
samples. If any samples appeared to be outliers, this was further investigated as to 
whether the cause was due to pathology, sample quality, an error in processing, or 
natural miRNA variation. To compare the miRNAs in different groups, a volcano plot 
was drawn to allow easy identification of miRNAs upregulated and downregulated in 
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each group. To quantitatively compare the groups, normality of the data was 
assessed using the Shapiro-Wilk test. The t-test was used when data were 
parametric, and the Wilcoxon test or Mann-Whitney U test was used when data were 
non-parametric to compare matched samples, or groups accordingly. Benjamini-
Hochberg correction was applied to control for the false discovery rate in the context 
of multiple testing. p<0.05 was considered significant. In order to further investigate 
the differential expression differences and correct for population substructure, raw 
dCt data on a probe wise level was imported into R 3.3.1 (R Core Team (2013). R: A 
language and environment for statistical computing (R Foundation for Statistical 
Computing, Vienna, Austria) and multivariate logistic regression analysis was 
performed with case control as the outcome and age, ethnicity, gestation, parity and 
maternal BMI as independent variables along with dCt using limma. Moderated t-
statistics were then calculated using Empirical Bayesian shrinkage (eBayes) and the 
topTable command used to rank significant probes by descending Bayes Factor (BF). 
To assess the validation cohort, individual data points were plotted using the dotplot 
command on Stata (StataCorp. 2013b). The ΔΔCts of the control group were 
compared to the matched ΔΔCts of the TTTS group by the Wilcoxon Signed Rank 
test using the signrank command on Stata (StataCorp. 2013h). Findings with p<0.05 
were considered significant. 
 
For the initial profiling array no power calculation was performed as it was discovery 
work, thus a sample size of 10 is considered adequate, based on existing literature. 
The results of the investigation cohort were used to perform a power calculation 
based on the observed dCt values, standard deviations and correcting for multiple 
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testing (using Stata 12.1) and revealed that 16 samples (n=8 TTTS, n=8 control) are 
needed in the validation cohort to demonstrate a statistically significant difference 
between the TTTS and uncomplicated MC twin pregnancy samples, with close 
matching of demographic variables in subjects, as in the investigation cohort. 
 
6.3.9 Ethical approval 
This study received ethical approval from East Midlands Research Ethics Committee 
(15/EM/0244) in July 2015 and all patients provided written informed consent (see 
Appendix 10.12 and 10.13 for patient information sheet and consent form). 
 
6.4 Results  
 
6.4.1 Participant characteristics  
Investigation cohort 
Five patients were included in the TTTS group, and were matched to five from the 
control group. 2001 was paired with 2047, 2002 with 2020, 2018 with 2027, 2022 
with 2039, 2043 and 2023 (Table 6.1). TTTS patients were selected pragmatically 
and matched as closely with the control group as possible. The median gestational 
age at blood sampling in the TTTS group was 20+0 weeks (IQR 19+4-20+0 weeks) 
compared to 20+2 weeks (20+0-20+2 weeks) in the control group. 
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Table 6.1 Patient demographic data of investigation profiling array cohort 
†This patient was excluded from analysis as a biological outlier due to natural variation in maternal miRNA. BMI: body mass index, 
GA: gestational age, TTTS: twin-twin transfusion syndrome 
 
Patient 
number 
Complication 
(Quintero stage) 
Maternal age 
(years) 
Maternal ethnicity Parity Maternal BMI 
(kg/m2) 
GA at blood 
sampling (weeks) 
Fetal 
sex 
2001 Nil 24 White European 0 31.9 19+1 Female 
2047 TTTS (Stage II) 29 White European 1 29.4 20+0 Female 
2002 Nil 27 White European 1 25.2 19+4 Female 
2020 TTTS (Stage IIIR) 33 White European 1 15.8 19+5 Female 
2018 Nil 24 White European 0 24.7 20+0 Female 
2027 TTTS (Stage IIIR) 23 White European 1 32 20+3 Male 
2022† Nil 28 White European 0 29.4 20+0 Female 
2039 TTTS (Stage II) 28 White European 0 19.6 20+2 Female 
2043 Nil 29 White European 0 18.5 21+1 Male 
2023 TTTS (Stage II) 35 White European 0 25.1 20+2 Male 
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Validation cohort 
An independent cohort of 19 women in total was included in the validation cohort. 
The sample from participant 2124 was used as the reference sample as it most 
closely matched the median characteristics of the validation control group. Samples 
2102 and 2013 (TTTS samples) were removed from analysis as there was 
insufficient miRNA in the samples, thus there were 8 control samples and 8 TTTS 
samples (Table 6.2). 2015 was paired with 2067, 2045 with 2025, 2068 with 2071, 
2094 with 2069, 2104 with 2012, 2108 with 2101, 2112 with 2009, 2086 and 2017. 
TTTS patients were selected to match the control group as closely as possible. The 
median gestational age at blood sampling in the TTTS group was 20+1 weeks (IQR 
19+6-20+5 weeks) compared to 20+2 weeks (20+0-20+6 weeks) in the control group. 
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Table 6.2 Demographic data of participants included in the validation cohort 
†Patient excluded from analysis as insufficient miRNA. BMI: body mass index, GA: gestational age, TTTS: twin-twin transfusion 
syndrome 
 
Patient 
number 
Complication  
(Quintero stage) 
Maternal 
age 
(years) 
Maternal ethnicity Parity Maternal BMI 
(kg/m2) 
GA at blood 
sampling (weeks) 
Fetal 
sex 
2015 Nil 42 White European 4 44.5 20+0 Female 
2067 TTTS (Stage III) 27 White European 1 35.7 19+4 Female 
2045 Nil 20 White European 2 19.0 21+5 Male 
2025 TTTS (Stage II) 22 White European 2 18.3 20+4 Male 
2068 Nil 36 White European 1 25.5 19+6 Female 
2071 TTTS (Stage I) 35 White European 1 22.7 20+0 Female 
2094 Nil 30 White European 0 27.1 20+3 Female 
2069 TTTS (Stage III) 28 White European 1 23.5 20+1 Female 
2104 Nil 36 White European 1 25.6 20+4 Male 
2012 TTTS (Stage III) 27 White European 3 23.5 20+1 Male 
2108 Nil 34 White European 0 29.1 19+2 Male 
2101 TTTS (Stage II) 24 White European 1 23.9 21+0 Female 
2112 Nil 36 White European 1 24.6 20+0 Male 
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Patient 
number 
Complication 
(Quintero stage) 
Maternal 
age 
(years) 
Maternal ethnicity Parity Maternal BMI 
(kg/m2) 
GA at blood 
sampling (weeks) 
Fetal 
sex 
2009 TTTS (Stage II) 24 White European 1 27.6 19+4 Male 
2086 Nil 34 White ‘Other’ 0 22.4 21+3 Female 
2017 TTTS (Stage III) 28 White European 4 29.8 21+3 Female 
2124 
(reference) 
Nil 28 White European 1 31.7 20+2 Female 
2102† TTTS (Stage III) 21 White European 0 28.6 19+1 Male 
2013† TTTS (Stage III) 20 White European 1 19.8 19+5 Female 
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6.4.2 Quality control of profiling array samples 
There was a low level of haemolysis in all 10 samples as demonstrated by the 
hsa−miR−23a−3p to hsa−miR−451a ratio being less than 7.0 in all the samples 
(Figure 6.1). The steady level of spike-ins in the samples (Figure 6.2) demonstrates 
high quality input RNA and successful reverse transcription and qPCR. The similar 
level in the blank sample demonstrates no RNA contamination in the PCR. 
 
Figure 6.1 hsa−miR−23a−3p to hsa−miR−451a ratio as an indicator of 
haemolysis in all individual profiling array samples 
 
Patient number 
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Figure 6.2 Spike-in raw Cq-values in all individual profiling array samples 
 
 
 
From the Heatmap, and PCA plot of the top 50 miRNA with largest variation in 
expression across all samples (Figure 6.3 and Figure 6.4), sample 2022 (control) 
appeared to be an outlier. When this was further investigated, the quality of the 
sample was the same as the other samples and there was no clinical reason why this 
sample should be different, therefore the difference was believed to be due to 
biological variation, and the sample was excluded from further analysis. 
 
Patient number 
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Figure 6.3 Heatmap of miRNA expression in all profiling array samples 
Maternal serum samples from pregnancies with twin-twin transfusion syndrome 
(TTTS) (n=5) compared to matched controls with uncomplicated monochorionic 
diamniotic twin pregnancies (n=5) 
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Figure 6.4 Principal Component Analysis (PCA) plot of top 50 miRNA with 
largest variation in expression across all maternal serum samples from 
pregnancies with twin-twin transfusion syndrome (TTTS) compared to 
matched controls with uncomplicated monochorionic diamniotic twin 
pregnancies 
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6.4.3 miRNA profiling array differences between TTTS and uncomplicated 
monochorionic twin pregnancies  
555/752 miRNAs were detected. 185 miRNAs were identified in all samples, with a 
mean of 313 miRNAs detectable per sample. In the PCA there was a trend towards 
bimodal clustering of the 9 samples (excluding 2022), depending on whether they 
were TTTS or control samples which suggests there may be a difference between 
the groups, although there was still dispersion. The volcano plot demonstrated a 
number of significantly different miRNA, some were upregulated and some 
downregulated (Figure 6.5).  
 
 
  
273 
 
 
 
Figure 6.5 Volcano plot comparing fold change of miRNA expression in 
maternal serum samples from pregnancies with twin-twin transfusion 
syndrome (TTTS) compared to matched controls with uncomplicated 
monochorionic diamniotic twin pregnancies 
1 biological outlier excluded. Red denote miRNAs with statistically significant fold 
change difference in TTTS, blue denotes miRNAs with no significant difference 
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31 miRNAs were significantly different in the TTTS compared to control group (see 
Appendix 10.9 for all miRNAs, and Table 6.3 for ‘Top 5’). 17 miRNAs were 
upregulated in the TTTS samples, in order of statistical significance: hsa-miR-107, 
hsa-miR-519c-3p, hsa-let-7b-5p, hsa-miR-517a-3p, hsa-miR-33a-3p, hsa-let-7c-5p, 
hsa-miR-519d-3p, hsa-miR-519a-3p, hsa-miR-30b-5p, hsa-miR-518c-3p, hsa-miR-
26b-5p, hsa-miR-517c-3p, hsa-miR-99a-5p, hsa-miR-20b-5p, hsa-miR-519b-3p, hsa-
miR-144-3p, hsa-miR-17-5p; and 14 were downregulated: hsa-miR-551a, hsa-miR-
361-5p, hsa-miR-140-5p, hsa-miR-9-5p, hsa-miR-135a-5p, hsa-miR-128-3p, hsa-
miR-450a-5p, hsa-miR-582-3p, hsa-miR-26b-3p, hsa-miR-151a-5p, hsa-let-7d-3p, 
hsa-miR-556-3p, hsa-miR-223-3p, hsa-miR-543. They did not remain significant 
following the Benjamini-Hochberg correction for multiple testing. 
 
A Bayesian model technique was used to examine the differential expression 
between TTTS and control (Table 6.4), both unadjusted and with adjusted for 
maternal age, BMI, ethnicity, parity and gestational age at blood sampling. Neither 
adjusted nor non-adjusted models demonstrated any significant differential 
expression between TTTS and control groups by Bayes factor.  
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Table 6.3 ‘Top 5’ significantly upregulated miRNAs, and downregulated 
miRNAs in profiling array 
Prior to Benjamini-Hochberg correction, in maternal serum samples from pregnancies 
complicated by twin-twin transfusion syndrome (TTTS), compared to matched 
controls with uncomplicated monochorionic diamniotic twin pregnancies 
 
Assay Average 
dcq TTTS 
(SD) 
Average 
dcq 
Control 
(SD) 
ddcq 
TTTS - 
Control 
Fold change 
TTTS / 
Control 
t-test p-
value 
hsa-miR- 
107 
2.581 
(-0.305) 
1.765 
(0.209) 
0.816 1.761 0.002 
hsa-miR-
519c-3p 
-3.212 
(0.551) 
-4.600 
(0.373) 
1.388 2.618 0.003 
hsa-miR- 
551a 
-2.259 
(0.560) 
-1.098 
(0.219) 
-1.160 -2.235 0.007 
hsa-let- 
7b-5p 
3.219 
(0.366) 
2.299 
(0.409) 
0.919 1.891 0.012 
hsa-miR- 
361-5p 
1.196 
(0.175) 
1.611 
(0.191) 
-0.416 -1.334 0.014 
hsa-miR- 
140-5p 
0.493 
(0.145) 
1.303 
(0.359) 
-0.810 -1.753 0.015 
hsa-miR- 
9-5p 
-6.594 
(0.567) 
-4.768 
(0.529) 
-1.826 -3.545 0.015 
hsa-miR-
135a-5p 
-6.030 
(0.900) 
-4.501 
(0.331) 
-1.529 -2.886 0.016 
hsa-miR-
517a-3p 
0.695 
(0.522) 
-0.228 
(0.404) 
0.923 1.896 0.020 
hsa-miR- 
33a-3p 
-4.193 
(0.483) 
-5.326 
(0.608) 
1.133 2.193 0.024 
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Table 6.4 Bayesian Model of significant miRNAs in profiling array in pregnancies complicated by twin-twin transfusion 
syndrome, compared to uncomplicated monochorionic diamniotic twin pregnancies 
*Adjusted for maternal age, BMI, ethnicity, parity and gestational age at blood sampling  
 
(a) Unadjusted 
      
  
Log Fold 
Count 
Average 
Expression t P value 
Adjusted  
P Value B 
hsa-miR-494-3p 10.78839 7.202803 5.912049 0.000116 0.01834 -0.02452 
hsa-miR-204-5p 9.935406 6.635394 5.731394 0.00015 0.01834 -0.15169 
hsa-miR-520c-3p 8.480225 4.711236 5.070715 0.0004 0.01834 -0.66378 
hsa-miR-411-5p 9.925229 7.538905 4.817742 0.000592 0.01834 -0.88045 
hsa-miR-181a-2-3p 10.45718 8.027257 4.742297 0.000667 0.01834 -0.94735 
hsa-miR-381-3p 10.75888 8.367614 4.601182 0.000834 0.01834 -1.07533 
hsa-miR-518d-3p 10.82702 8.443192 4.579189 0.000864 0.01834 -1.09561 
hsa-miR-369-5p 10.26154 7.965421 4.576583 0.000868 0.01834 -1.09802 
hsa-miR-517-5p 10.31679 8.030072 4.552294 0.000902 0.01834 -1.12054 
hsa-miR-10a-5p 10.44629 8.173513 4.503198 0.000976 0.01834 -1.16638 
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(b) Adjusted*  
      
  
Log Fold 
Count 
Average 
Expression t P value 
Adjusted  
P Value B 
hsa-miR-379-5p -186.379 6.396119 -9.89661 0.002952 0.574946 -4.59509 
hsa-miR-9-5p -197.243 7.054207 -9.77597 0.003053 0.574946 -4.59509 
hsa-let-7c-5p -81.7966 7.004665 -7.37649 0.006547 0.574946 -4.59509 
hsa-miR-577 205.4049 3.385849 6.465976 0.009306 0.574946 -4.59509 
hsa-miR-503-5p -190.476 6.641287 -5.89464 0.011881 0.574946 -4.59509 
hsa-miR-589-3p 210.6642 7.959102 5.791917 0.012443 0.574946 -4.59509 
hsa-miR-365b-5p -79.0397 2.389523 -5.55616 0.013871 0.574946 -4.59509 
hsa-miR-877-3p -81.4977 2.40734 -5.14132 0.016964 0.574946 -4.59509 
hsa-miR-219a-2-3p 83.26375 1.219888 5.016209 0.018075 0.574946 -4.59509 
hsa-miR-548d-5p 82.48287 1.208447 4.997538 0.018249 0.574946 -4.59509 
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6.4.4 Identification of candidate miRNAs for validation 
Eight miRNAs were identified for validation (Table 6.5). All miRNAs were 
detected in all samples in the investigation cohort. No MTI studies were found in 
maternal serum in pregnancy. See Appendix 10.11 for more information on the 
biological plausibility of the candidate miRNAs.
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Table 6.5 Candidate miRNAs for validation 
MTI: microRNA-Target Interaction. *according to miRTarBase (Chou 2018)
 
miRNA Fold 
change in 
investigation 
cohort 
Change in TTTS 
maternal serum 
compared to 
control 
Number of 
papers with 
strong 
evidence of 
functional MTI* 
Functional 
MTI target 
genes* 
TTTS biological plausibility 
hsa-let-7b-5p 1.89 
 
Upregulated 42 34 Upregulated in congestive heart failure 
hsa-miR-17-5p 1.37 
 
Upregulated 120 80 Associated with angiogenesis 
hsa-miR-107 1.76 
 
Upregulated 49 38 Upregulated in congestive heart failure, 
same gene targets as those involved in 
pre-eclampsia and spiral artery remodelling 
hsa-miR-140-5p -1.75 
 
Downregulated 37 30 Downregulated in congestive heart failure  
hsa-miR-223-3p -1.59 
 
Downregulated 64 48 Downregulated in Stage 3 and 4 chronic 
kidney disease 
hsa-miR-517a-3p 1.90 
 
Upregulated 2 2 Placenta-specific miRNA 
hsa-miR-519a-3p 2.48 
 
Upregulated 12 9 Placenta-specific miRNA 
hsa-miR-519c-3p 2.62 
 
Upregulated 8 6 Placenta-specific miRNA 
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6.4.5 Validation of candidate miRNAs 
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Figure 6.6 Validation of candidate miRNAs 
No significant difference between groups (n=8 controls, n=8 TTTS pregnancies) 
(Wilcoxon signed-rank test) Line represents median. miR-451a used as reference. 
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There was no significant difference in miRNA expression between the TTTS group 
and the control group (Figure 6.6). It was not possible to perform RT-PCR of 
miR519a-3p or miR519c-3p and the validation results should be interpreted with 
caution as the concentration of the RNA, as quantified by the RNA integrity number 
(RIN) was low. 
 
6.5 Discussion 
 
6.5.1 miRNA profiling array differences between TTTS and uncomplicated 
monochorionic twin pregnancies  
The initial miRNA profiling array suggested that there was a difference in the miRNA 
profiles of maternal serum taken from TTTS and uncomplicated MC twin 
pregnancies. Although the results were not significant following statistical correction 
for multiple testing, the thresholds for these corrections are naturally conservative 
and it was possible the small sample size for the profiling array was associated with a 
type II statistical error, thus candidate miRNAs were investigated and validated. 
 
6.5.2 Validation of candidate miRNAs 
None of the candidate miRNAs were confirmed as being significantly different in the 
validation cohort. There are no other studies on maternal serum miRNA in TTTS to 
compare the findings. However, the quality control of the validation work was low and 
although some of the assays were able to be performed, the two placenta-specific 
miRNA were unable to be assessed. 
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One reason why the results may not have been significant is that maternal circulating 
miRNA may come from different sources (fetus, placenta or maternal endothelium) 
and the pathophysiology of TTTS may affect miRNAs from each source differently. 
Even if it was possible to identify the source of the miRNA and which were maternal 
and which were fetal, an added complication with exploring miRNA in maternal serum 
in MCDA twin pregnancies is that although they are monozygotic with the same 
germline and same environmental influences in-utero, discordant conditions still 
occur antenatally (Machin 2009, Saffery 2012). In the case of TTTS, there may be 
different epigenetic mechanisms at play in each fetus, due to the different problems 
the donor and recipient fetuses develop. It is possible that the epigenetic changes in 
one twin could “mask” a difference in the other twin, and therefore changes will not 
be seen in maternal serum. In-utero inter-twin miRNA differences in fetal circulation 
have not been described; practically and ethically it would be difficult to obtain 
individual fetal blood samples, as an invasive procedure would be required, which 
would increase the risk of miscarriage in a clinical scenario that is already highly 
morbid.  
 
Inter-twin miRNA differences have been explored in adults; in adults discordant for 
non-alcoholic fatty liver disease (4 monozygotic twin pairs, 2 dizygotic twin pairs), a 
difference in miRNAs was seen (Zarrinpar 2016), which persisted when sub-group 
analysis was performed on the monozygotic twins. Another study looking at 
monozygotic twins with discordant life expectancies, defined as a difference in age of 
death of at least 5 years, found a difference in miRNA in plasma samples taken at 
age 44-51 years in the twin pairs (Wu 2016), but this difference did not remain 
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significant following Bonferroni correction for multiple testing. Therefore there 
remains a lot to be elucidated regarding miRNAs in monozygotic twin pairs, 
particularly antenatally. 
 
It may be that as we were unable to recruit pregnancies with TTTS all at the same 
Quintero stage, that miRNA expression is affected by different stages, but 
unfortunately it was not possible to investigate this further. Another reason why there 
may not be a significant difference in miRNA in maternal serum in TTTS pregnancies 
is that TTTS is a disease which affects the placenta and fetuses, but rarely causes 
additional extra-uterine symptoms, such as maternal proteinuria and hypertension 
which characterise pre-eclampsia, therefore miRNA changes in TTTS may not be 
seen in the maternal circulation. There is a rare condition called ‘maternal mirror 
syndrome’ which describes maternal oedema in the presence of fetal oedema 
(Hayashi 2006, Chai 2014, Chang 2014) and is associated with changes in the 
maternal serum (Prefumo 2010), thus one could hypothesise that there may be 
changes in miRNA in maternal serum in TTTS. However mirror syndrome is only 
associated with Quintero Stage IV and V and none of the participants had Stage IV 
or V TTTS prior to FLA when blood sampling was performed. It is interesting to note 
that whilst miRNA changes are seen in both maternal plasma and placental tissue in 
conditions which clinically affect both the mother and the fetus, such as GDM (Zhao 
2011, Zhao 2014), and pre-eclampsia (Akehurst 2015); in conditions which only 
affect the fetus, such as fetal growth restriction, it is not as clear. Studies by 
Hromadnikova et al. have found conflicting results in changes in miRNA in maternal 
plasma, with miRNA differences apparent at 12-16 weeks gestation (Hromadnikova 
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2012), but not at 10-13 weeks (Hromadnikova 2017). In two studies from the same 
group in which the gestation at blood sampling was not stated but is assumed to be 
at a later gestation, no difference in miRNA in maternal plasma samples was seen in 
placenta-specific miRNA i.e. those only produced by placental tissue but able to be 
transferred to maternal blood (Hromadnikova 2013), but a significant difference was 
seen in miRNAs associated with cardiovascular and cerebrovascular disease 
(Hromadnikova 2016).  
 
Changes have been demonstrated in miRNA in placental tissue from fetal growth 
restricted pregnancies (Maccani 2011), but again the picture is not clear. Higasijima 
et al. (Higashijima 2013) looked at placental tissue and maternal plasma in the same 
study and demonstrated changes in placental tissue, but not maternal plasma, 
despite miRNAs being able to cross into the maternal circulation, whereas Mouillet et 
al. found no difference in maternal plasma, or placental tissue, although they only 
looked at miRNAs associated with hypoxia (Mouillet 2010). Therefore, the significant 
miRNAs for TTTS may not be placenta-specific, despite the condition being placental 
in origin. The panels used in this work did include the cardiovascular and 
cerebrovascular miRNAs which Hromadnikova found to be significantly different, as 
one may hypothesise they would also be different in TTTS, given the cardiovascular 
sequelae in the fetuses, however no significant difference in these miRNAs were 
seen.  
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6.5.3 Strengths and limitations 
This is the first study to compare human maternal serum miRNAs in pregnancies 
complicated with TTTS, with uncomplicated MCDA twin pregnancies and it has 
demonstrated that it is possible to measure miRNA in maternal serum taken prior to 
FLA for TTTS. An attempt was made to match the samples as closely as possible as 
demographic factors including maternal age, BMI and ethnicity affect miRNA 
expression (Morales-Prieto 2012, Enquobahrie 2017, Timofeeva 2018), and this is 
vital in miRNA research (Barchitta 2017). The sample size did not allow the 
examination of the impact of other factors such as stage of TTTS, pregnancy 
outcome following TTTS, maternal age, BMI, parity, fetal sex on miRNA in TTTS 
which may have provided further information, although a Bayesian model was 
produced in the investigation cohort to adjust for these factors, and the samples were 
matched as closely as possible. This does mean that one limitation of this work is 
that only white European women were examined because of the patient population, 
and thus the results may not be generalisable to other ethnicities. 
 
Another strength is that there was good technical performance in the profiling 
experiment as demonstrated by the RNA spike-in and no template control. Due to the 
high risk nature of MCDA twins, it was not possible to find a group of control MCDA 
patients with no comorbidities, therefore a pragmatic approach was taken and 
included 2 patients with comorbidities (isolated polyhydramnios in 1 twin at 34 weeks, 
pregnancy-induced hypertension at 34 weeks) in the control group in the 
investigation cohort which is not believed to have affected the study results as they 
are unrelated to TTTS. In the control group in the validation cohort 3 patients had 
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comorbidities (1 patient developed mild pre-eclampsia at 33 weeks, 1 patient 
developed moderate pre-eclampsia at 35 weeks, and 1 patient developed 
chorioamnionitis at 30+6 weeks following spontaneous rupture of membranes at 
30+3 weeks) but they are unlikely to have affected the study results. 
 
RT-PCR was used for validation as opposed to Next Generation Sequencing as PCR 
is the only platform able to generate absolute quantification, and this is the most 
frequently used method of validation, and is considered an acceptable approach 
(Barchitta 2017, Moldovan 2017). Both methods are comparable, but when detecting 
pre-selected miRNAs, RT-PCR provides a higher sensitivity and requires a smaller 
amount of biofluid (Blondal 2017). 
 
6.5.4 Clinical implications and future research 
These findings cannot be used clinically yet as this was initial discovery work and 
more research is required. Due to poor quality control in the validation work, this work 
should be repeated in a different cohort. Although no difference was seen in the 752 
miRNAs compared, it may be that the differences in TTTS occur in miRNAs 
transferred in exosomes as exosome-specific RNA extraction was not performed, 
and exosomal miRNAs have recently been shown to be important in the regulation of 
angiogenesis in the maintenance of normal pregnancy (Jia 2018), or that changes 
may occur in miRNAs which have not yet been discovered. miRNAs were first 
discovered in 1993, and since then PubMed cites over 75,000 publications on 
miRNAs, and more than 1880 human miRNAs have been reported (Chiofalo 2017) 
therefore there are more miRNAs to explore in future research. However, to do this, 
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and investigate those which have not yet been discovered would be costly and 
require Next Generation Sequencing (Ge 2011). 
 
Another area to focus on would be to examine miRNA expression in placentas of 
pregnancies complicated by TTTS, particularly as it was not possible to get the RT-
PCR of maternal serum to work to validate miR519a-3p or miR519c-3p which are 
placenta-specific miRNAs, however, there are a couple of issues with using placental 
tissue. The collection of TTTS placentas is logistically difficult as most patients whom 
are treated with FLA return to their referring unit to deliver, and as placentas need to 
be collected and sampled within an hour of delivery, given the large geographical 
area from which referrals are received, this will not be possible. There is also the 
question regarding if the TTTS resolves following FLA, whether collecting placentas 
at delivery will demonstrate any changes, as miRNAs are transient and the miRNA 
profile may have returned to normal, or if changes are present this may be a cause of 
TTTS, a consequence of TTTS, or an effect of FLA. Alternatively, placentas could be 
collected from pregnancies from the extreme end of the TTTS spectrum: which have 
ended in a dIUFD, however even if it was possible to collect the placenta, there is the 
issue of whether the miRNA changes were due to TTTS, FLA or IUFD. Cord blood at 
delivery may offer an alternative solution, but again presents the same problems as 
with placental collection and sampling. Alternatively, analysing amniotic fluid taken 
prior to FLA may provide a way to assess fetal miRNA changes. Ideally one would 
sample the recipient, and the donor twin, but it would be technically very difficult, and 
potentially dangerous to sample amniotic fluid from the donor twin sac due to the 
oligohydramnios.  
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6.6 Conclusion 
 
This is the first study to look at miRNAs in maternal serum from pregnancies 
complicated by TTTS. Although the initial profiling array demonstrated a difference in 
miRNAs in pregnancies complicated by TTTS compared to control MCDA 
pregnancies, these finding were not confirmed in the validation cohort. Further 
investigation using alternative biofluids, particularly placental tissue samples, would 
be interesting, but pragmatically difficult to obtain. 
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CHAPTER 7 PROGNOSIS OF THE CO-TWIN 
FOLLOWING SPONTANEOUS SINGLE 
INTRAUTERINE FETAL DEATH IN TWIN 
PREGNANCIES: SYSTEMATIC REVIEW AND META-
ANALYSIS 
 
• These findings were presented as a poster presentation at the British Maternal 
and Fetal Medicine Society 19th Annual Conference, April 2018, Brighton. 
• These findings have published in full article form [Mackie FL, Rigby A, Morris RK 
and Kilby MD (2018). “Prognosis of the co-twin following spontaneous single 
intrauterine fetal death in twin pregnancies: a systematic review and meta-
analysis.” BJOG; 126:569-78.] 
 
7.1 Introduction 
 
Twin pregnancies are associated with increased perinatal morbidity and mortality 
compared to singletons. The prevalence of sIUFD is up to 6% in twin pregnancies, 
making it a common adverse event (Pharoah 2000). Monochorionic (MC) twins with 
placental inter-twin anastomoses conjoining the fetal circulations are associated with 
an increased risk of sIUFD and consequential fetal morbidity (Bajoria 1999b, 
D'Antonio 2017b). Many are first trimester fetal losses, but sIUFD after 14 weeks 
gestation is associated with greatest adverse effect on the surviving fetus 
(Malinowski 2001). Sequelae of sIUFD in twin pregnancy include: co-twin IUFD, PTB 
(spontaneous or iatrogenic), and long term comorbidity; most commonly ante- or 
postnatal brain injury. A critical appraisal and interpretation of the literature is 
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complicated by significant heterogeneity in the incidence and management in 
reported studies (Ong 2006). In 2011, our group completed a systematic review and 
meta-analysis of co-twin prognosis following sIUFD, with outcomes stratified by 
chorionicity. In the 22 included manuscripts there were 343 cases of sIUFD reported 
in 6225 twin pregnancies (Hillman 2011). A meta-analysis of event rates was not 
undertaken as there was a high risk of heterogeneity and low number of events within 
each study. A summary point estimate was produced with a simple binomial 
confidence interval, thus not allowing for the non-independence of the different 
studies. This manuscript demonstrated an increased OR of co-twin death and 
neurodevelopmental morbidity after sIUFD in MC compared to DC twin pregnancies. 
The management of multiple pregnancies in general, and MC pregnancies in 
particular, has received considerable attention since 2011 with national and 
international guidelines being published by international professional bodies (Morin 
2011, NICE 2011, ACOG 2016, Khalil 2016b, Kilby 2016, RANZCOG 2017). 
Importantly the 2011 review included twin pregnancies that had undergone 
intervention for TTTS and IUGR, thus confounding factors will have affected the 
prognosis (Morris 2010). This review will focus on spontaneous sIUFD only and will 
not include pregnancies that have undergone treatment for TTTS or IUGR. 
 
7.1.1 Objectives 
To determine the prognosis of the surviving co-twin following spontaneous sIUFD. 
The outcomes explored will be: co-twin IUFD, PTB, abnormal postnatal brain imaging 
and neurodevelopmental comorbidity as analysed in the previous systematic review 
and meta-analysis, and the additional outcomes of abnormal antenatal brain imaging 
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and NND will also be examined. This review will allow inclusion of the recent 
literature informing clinical practice to aid counselling patients and highlight areas of 
future research. 
 
7.2 Materials and methods 
 
The systematic review was performed according to an a priori protocol and complied 
with recommended guidance including MOOSE and PRISMA guidelines (Stroup 
2000, Moher 2009). Ethical approval was not required. 
 
7.2.1 Eligibility criteria 
The gestation of the initial sIUFD must have been after 14 weeks. Twin chorionicity 
had to be defined but studies did not have to include both MC and DC twin 
pregnancies in the same study. Studies were excluded if the following conditions 
could not be removed for analysis i.e. if the following cases were not identifiable in 
analysis: selective termination, higher order multiple pregnancies, twin reversed 
arterial perfusion (TRAP) sequence, structural or chromosomal anomalies, conjoined 
twins, monoamniotic twins, or first-trimester miscarriages associated with twins. As 
the objective of the study was to assess spontaneous IUFD, IUFDs which occurred 
following an intervention for TTTS or sIUGR, including FLA or BCO, were not 
included in the analysis as there are confounding factors that may affect the outcome 
of the pregnancy, including surgeon experience, which make this group 
heterogeneous (Morris 2010). As FLA dichorionises the placenta and this was 
considered to have more of an effect on outcome, whereas amniodrainage was not 
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considered an intervention which would affect the prognosis in the co-twin as the 
main reason for IUFD following amniodrainage is likely due to TTTS itself, rather than 
a complication of the procedure, thus these pregnancies remained in the analysis. All 
study designs were included, although case series needed to include at least 5 cases 
of sIUFD in twin pregnancies. 
 
7.2.2 Outcomes 
There is no core outcome set for multiple pregnancy, particularly sIUFD co-twin 
survivors, thus the outcomes assessed were the outcomes in the previous review, 
with the addition of antenatal brain imaging and NND. The outcomes were defined a 
priori as: 
• Co-twin IUFD >14 weeks gestation but prior to delivery. 
• PTB, defined as a live birth of the surviving co-twin, irrespective of whether the 
birth was spontaneous or iatrogenic which will be explored as a sub-group 
analysis, between 24+0-34+0 weeks gestation as some MCDA twins are 
routinely delivered at <36 weeks, and with little long-term consequence.  
• Abnormal antenatal brain imaging. There was no limit on timing of imaging 
post-IUFD or type of imaging due to no consensus guidance existing at the 
time of this review. 
• Abnormal postnatal brain imaging. There was no limit on imaging modality. 
• Neurodevelopmental comorbidity, defined as per study, as there is no 
standard test to assess this in sIUFD. 
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• NND, defined as death within 28 days of live birth. 
 
7.2.3 Information sources 
The search was performed according to previously published methods (Hillman 
2011). In brief, Medline, Embase, Web of Science, Cochrane Library and British 
Nursing Index were searched. Due to including the new outcomes of abnormal 
antenatal brain imaging, and NND, the searches were run from 1980 in keeping with 
the introduction of ultrasound into clinical practice, to 9th June 2017.  
 
7.2.4 Search strategy 
Keywords and variants of “intrauterine” “death” and “twin” were used (see Appendix 
10.14 for search strategy). Bibliographies were manually checked and there was no 
restriction on language.  
 
7.2.5 Study selection and data extraction 
Three investigators (FLM, AR and RKM) independently extracted the data needed to 
assess the quality of the studies and form a 2x2 contingency table, using piloted data 
collection forms (Appendix 10.15). Data from the previous systematic review by 
Hillman (Hillman 2011) was re-extracted by FLM and RKM. Any discrepancies were 
resolved by MDK. If clarification was required authors were contacted. 
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7.2.6 Quality assessment of included studies 
The quality of the studies was assessed according to the STROBE checklist (von Elm 
2007). 
 
7.2.7 Assessment of heterogeneity 
Heterogeneity between the studies was assessed visually using forest plots and 
statistically using the I2 statistic. An I2 statistic ≥50% indicated a high-risk of 
heterogeneity. Heterogeneity was investigated via sub-group and sensitivity analysis. 
 
7.2.8 Assessment of reporting bias 
If >10 studies were included in a meta-analysis, a funnel plot was generated using 
the metafunnel command (Sterne 2003) in Stata (Stata, 2015 Release 13.1, 
StataCorp. Texas, USA) and Egger’s test was performed using the metabias 
command (Harbord 2009), with p<0.05 considered a significant risk of small-study 
effects publication bias. 
 
7.2.9 Data synthesis 
With the additional 20 studies, a summary event rate statistic was produced which 
has allowed for the non-independence of different studies when the data is pooled, 
as is appropriate in a meta-analysis. This was calculated using the metan command 
(Harris 2009). ORs with random effects were calculated to compare the risk in MC 
twin pregnancies with DC twin pregnancies using the metan command. 0.5 was 
added to 0 cells in all analyses to allow inclusion of more studies (Sankey 1996). If a 
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study only included MC twin pregnancies, the study was used to calculate the 
summary event rate for MC twins only, and was not included in the DC summary 
event rate or OR calculation of MC vs. DC twins, and vice versa if a study only 
included DC twin pregnancies. Sub-group analysis, in analyses of ≥3 studies, was 
planned to evaluate the effect of factors identified as potential causes of 
heterogeneity prior to commencing analysis: gestational age of sIUFD <28 weeks, 
TTTS (managed conservatively meaning no intervention but continued surveillance), 
IUGR (managed conservatively), year of publication pre-and post-2011. Twenty-eight 
weeks was chosen as a cut-off to distinguish between trimesters as there is no 
research to determine an evidence-based cut-off. PTB as an outcome was also 
divided by iatrogenic and spontaneous where possible. Antenatal and postnatal brain 
imaging were divided by imaging modality, and the postnatal outcomes were also 
divided by PTB where possible, the latter irrespective of whether the PTB was 
iatrogenic or spontaneous. The sub-group summary event rate was reported as the 
rate of the outcome (e.g. co-twin IUFD) in women with or without that factor (e.g. 
sIUFD at <28 weeks, TTTS, IUGR) to enable maximum clinical utility for counselling 
women in each scenario. ORs were calculated to compare the summary event rate 
for each factor in MC and DC twin pregnancies. 
 
7.3 Results 
7.3.1 Study selection 
The search revealed 2966 citations potentially eligible for inclusion, of which 2629 
were excluded on the title or abstract, 337 full papers were assessed, and 42 full 
papers were eligible for inclusion (Hagay 1986, Szymonowicz 1986, Cherouny 1989, 
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Fusi 1990, Gaucherand 1994, Ishimatsu 1994, Kilby 1994, Santema 1995, Jou 1996, 
Tordjeman 1996, Sebire 1997, Krayenbuhl 1998, van Heteren 1998, Axt 1999, 
Bajoria 1999b, Lin 1999, Petersen 1999, Saito 1999, Malinowski 2000, Wang 2000, 
Woo 2000, Baghdadi 2003, Malinowski 2003, Gratacós 2004, Barigye 2005, 
Gratacós 2008, Jelin 2008, Lewi 2008, Chelli 2009, Fichera 2009, Dias 2011, 
Mahony 2011, Farah 2012, McPherson 2012, Deveer 2013, Hoffmann 2013, Griffiths 
2015, van Klink 2015, Wang 2016, D'Antonio 2017b, Robinson 2017, Rustico 2017) 
(Figure 7.1).  
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Figure 7.1 Study selection from initial search 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7.3.2 Studies not included in meta-analyses 
Although Woo 2000, Wang 2000 and Wang 2016 were eligible for inclusion in the 
systematic review, it was not possible to include them in meta-analysis (Wang 2000, 
Woo 2000, Wang 2016). In Woo, once the cases with insufficient information were 
removed, the number of sIUFD cases was reduced to 4 therefore this study was not 
Citations excluded by title 
(n=1892) or abstract (n=737) 
Studies excluded based on full article n=295 
Not divided by chorionicity n=141 
Not divided by sIUFD and dIUFD n=39 
Case reports<5 n=28 
Gestational age of sIUFD not stated n=26 
Included pregnancies undergoing FLA, BCO or 
selective reduction n=22 
Unobtainable n=13 
Included pregnancies with fetal anomalies n=11 
First trimester sIUFD n=5 
No sIUFDs n=5 
No twin pregnancies included n=3 
Does not report prognosis of co-twin n=8 
Overlapping data with another paper n=2 
       
     
       
      
Studies included in 
systematic review n=42 
Citations retrieved for detailed 
evaluation of full article n=337 
Potentially relevant citations 
identified by search strategy 
(1980-June 2017) n=2966 
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included in analysis, unlike in the previous review. Wang 2000 was not able to be 
included as all 9 sIUFD pregnancies had TTTS, 8/9 women were delivered 
prematurely to avoid dIUFD, they were unable to report on the presence of congenital 
anomalies and the authors limited their cohort to third trimester sIUFDs. In Wang 
2016 6/16 (38%) cases of sIUFD who had TTTS had undergone FLA and could not 
be removed for analysis. This proportion of heterogeneous sIUFDs was felt to be too 
high to include the study in meta-analysis. The 10 DC pregnancies in Fichera 2009 
were not included as a high proportion 3/10 (30%) had chromosomal anomalies, 
although the MC pregnancies are included in analysis (Fichera 2009).  
Six studies were not included in the co-twin IUFD outcome: 2 studies did not report 
this outcome (Jelin 2008, D'Antonio 2017b) and 4 studies focused on neonatal 
outcomes thus dIUFDs were excluded by the authors (Szymonowicz 1986, van 
Heteren 1998, Lin 1999, Saito 1999). It was not possible to include Chelli 2009 in the 
PTB outcome as the authors defined PTB as 26-33 weeks which was not in-keeping 
with the definition used in this review (Chelli 2009).  
  
7.3.3 Study characteristics 
The characteristics of the included studies are described in Table 7.1 which 
summarises the study design, study population, and details of abnormal brain 
imaging and neurodevelopmental comorbidity. 10/42 studies were published in the 5 
years prior to June 2017 when the search was performed. The oldest study was from 
1986. 40 studies were cohort studies, 2 studies were case-controls. The majority of 
studies performed retrospective data collection (n=32), 7 performed prospective data 
collection, and it was not clear in 3 studies. Enrolment was consecutive in 17 studies, 
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not stated in 24 studies, and random in 1 study. 28 groups of patients were from 11 
European countries, the UK being the commonest (n=9), 3 from the USA, 3 from 
Taiwan, 2 from Japan, 2 from Australia, 2 from Israel, 1 from Hong Kong and 1 from 
China. The longest study ran for 16 years, with the modal time period being 4 years 
and shortest being 21 months. The smallest study analysed 9 sIUFDs, and the 
largest analysed 62 sIUFDs. The previous review included 22 studies (Hagay 1986, 
Szymonowicz 1986, Fusi 1990, Jou 1993, Gaucherand 1994, Ishimatsu 1994, Kilby 
1994, Santema 1995, Krayenbuhl 1998, van Heteren 1998, Axt 1999, Bajoria 1999b, 
Lin 1999, Petersen 1999, Saito 1999, Malinowski 2000, Wang 2000, Woo 2000, 
Baghdadi 2003, Malinowski 2003, Chelli 2009, Fichera 2009). Of the 42 studies, 39 
were included in the meta-analysis (for details of excluded studies see section 7.3.2). 
The additional outcomes of antenatal brain imaging and NND were reported by 6 
studies, and 19 studies respectively. The imaging modalities used were ultrasound 
and fetal magnetic resonance imaging (fMRI) antenatally, CT scan was also used 
postnatally. 
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Table 7.1 Characteristics of studies eligible for inclusion  
Reproduced from Hillman et al. (Hillman 2011)  
Abbreviation: FLA: fetoscopic laser ablation, FU: follow-up, IUGR: intrauterine growth restriction, IVH: intraventricular haemorrhage, 
MCDA: monochorionic diamniotic, MA: monoamniotic, MRI: magnetic resonance imaging, NA: not applicable, PTB: preterm birth, 
PVH: periventricular haemorrhage, sIUFD: spontaneous intrauterine fetal death, sIUGR: selective intrauterine growth restriction, 
TRAP: twin reversed arterial perfusion sequence, TTTS: twin-twin transfusion syndrome, USS: ultrasound scan 
†: new study added 
 
Author  
(year) 
Study 
design, data 
collection, 
enrolment 
Study population (location, years, inclusion 
description, PTB information, additional information) 
Details of abnormal 
brain imaging 
Details of 
neurodevelop-
mental 
comorbidity 
Follow-up 
 
Axt 
(1999) (Axt 
1999) 
Cohort, 
retrospective, 
not reported  
Location: Germany 
Year: 1992-1998 
Description: 185 twin pregnancies. 7 twin pregnancies 
with sIUFD but we excluded 1 due to structural 
anomalies to fit our own criteria. Death of twin confirmed 
by USS. Placenta examined histologically to confirm 
chorionicity. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic stated.  
Additional: Confounders of TTTS although no mention of 
intervention, fetal anomaly, IUGR and maternal illness 
recorded 
Mode of imaging: 
postnatal USS and 
MRI 
When imaged: “after 
birth” 
Definition of 
abnormal imaging: 
Periventricular 
leukomalacia, 
multiple small cystic 
lesions in white 
matter 
Mild delay in gross 
motor development 
and muscle rigidity. 
No details of 
method of 
assessment given. 
Different for 
individual 
infants. From 
hospital 
discharge – 1.5 
years of age. 
Baghdadi 
(2003) 
(Baghdadi 
2003) 
Cohort, 
prospective, 
consecutive 
Location: UK 
Year: 1996-1998 
Description: 252 twin pregnancies, authors excluded 14 
cases as either; fetal anomaly on USS, loss to FU or 
mother’s medical condition, therefore 238 in cohort. 13 
cases of sIUFD included. Placenta examined 
histologically to confirm chorionicity. 
PTB information: gestational age at delivery reported 
NA NA 11 cases lost to 
follow up out of 
252 (4.4%) 
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individually thus sub-group possible. Spontaneous or 
iatrogenic not clear. 
Additional. Kaplan –Meir analysis of survival. 
Confounders of TTTS although no mention of 
intervention, fetal anomaly and maternal illness 
recorded. All 4 NNDs were in fetuses delivered <24 
weeks 
Bajoria 
(1999) (Bajoria 
1999b) 
Cohort, 
retrospective, 
not reported  
Location: UK 
Year: 1980-1998 
Description: 3 hospitals included. 101 cases of twin 
pregnancy, 9 cases excluded as type of 
anastomoses/neonatal data not present therefore 92 
pregnancies analysed. Also excluded if had abortion, 
acardiac twin, FLA for TTTS, or delivered before 20 
weeks. Histological confirmation of chorionicity recorded. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear. 
Additional: Information on confounders TTTS including 4 
who underwent amniodrainage, IUGR and maternal 
illness were recorded but not congenital anomaly. 
Mode of imaging: 
postnatal USS 
When imaged: 
neonatal 
Definition of 
abnormal imaging: 
IVH, periventricular 
leukomalacia, 
subependymal 
haemorrhage. 
Excludes transient 
echo-dense areas. 
Obtained from the 
neonatal notes. 
Only information on 
major neurological 
handicaps such as 
cerebral palsy, 
blindness and 
paralysis was 
obtained. 
“Long-term 
follow-up” 
duration not 
specified. 
† Barigye 
(2005) (Barigye 
2005) 
Case-control, 
retrospective, 
not reported 
Location: UK 
Year:1992-2004 
Description: 151 uncomplicated MCDA pregnancies, 7 
with sIUFD after 24 weeks.  
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear.  
Additional: excluded TTTS, IUGR, structural anomalies, 
TRAP, HOM, MA, conjoined twins. Maternal illness not 
recorded. 
NA NA Not reported 
Chelli 
(2009) (Chelli 
2009) 
Cohort, 
retrospective, 
not reported 
Location: France 
Year:2000-2008 
Description: 1107 twin pregnancies. 33 with sIUFD after 
26 weeks, but only 28 with chorionicity determined. 
Mode of imaging: 
postnatal USS 
When imaged: day 7 
of life 
NA USS at day 7 
post-delivery in 
100% survivors 
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Histological confirmation of chorionicity recorded. 
PTB information: could only extract 26-33 weeks due to 
way grouped therefore unable to include in analysis, 
spontaneous or iatrogenic not clear. One monoamniotic 
twin pregnancy included as unable to remove for 
analysis. 
Additional: Information on confounders TTTS including 1 
who had amniodrainage, IUGR, maternal illness and 
congenital anomaly recorded. 
Definition of 
abnormal imaging: 
IVH, periventricular 
hyperechogenicity, 
Subependymal 
haemorrhage 
† Cherouny 
(1989) 
(Cherouny 
1989) 
Cohort, 
retrospective, 
consecutive 
Location: USA 
Year: 1980-1987 
Description: 20 multiple pregnancies with sIUFD >20 
weeks or birthweight >350g. We excluded 1 which was a 
triplet pregnancy, 4 which were MA, and 3 which 
chorionicity was not determined therefore 12 
pregnancies were analysed. Histological confirmation of 
chorionicity recorded. 
PTB information: NA 
Additional: Confounders of TTTS and IUGR recorded, 
fetal anomaly and maternal illness not recorded 
NA NA Not reported 
† D’Antonio 
(2017) 
(D'Antonio 
2017b) 
Cohort, 
retrospective, 
consecutive 
Location: UK 
Year: 2000-2010 
Description: 3013 twin pregnancies, of which 65 had a 
sIUFD and the authors excluded 3 with dIUFD but 
provided insufficient details to include in co-twin IUFD 
outcome. The authors excluded TTTS, TOP, 
chromosomal anomalies, MA, HOM, miscarriage <24 
weeks, dIUFD and sIUFD >34 weeks therefore we only 
included the study in PTB analysis. Histological 
confirmation of chorionicity recorded. 
PTB information: grouped to <34, <32 and <28 weeks 
therefore first group used for analysis. Spontaneous or 
iatrogenic not clear. 
Additional: Information on confounder maternal illness 
not recorded. 
NA NA Not reported 
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† Deveer (2013) 
(Deveer 2013) 
Cohort, 
prospective, 
not reported 
Location: Turkey 
Year: Not reported, but over 21 months 
Description: 47 IUFDs but 9 women discontinued follow-
up after diagnosis of IUFD therefore not included, 13 
IUFDs diagnosed in the first trimester and therefore not 
included, 25 cases 2nd and 3rd trimester IUFDs included. 
Chorionicity determined on USS. 
PTB information: no definition given therefore could not 
include 
Additional: Information on confounders TTTS but no 
mention of intervention, maternal illness and congenital 
anomaly recorded. 1 fetus with a congenital anomaly 
included, but unable to identify and remove from 
analysis, therefore included. 
NA “neurological 
impairment” no 
further details 
given, did not report 
on whole cohort, 
just TTTS patients 
therefore could not 
include 
Not reported 
† Dias (2011) 
(Dias 2011) 
Cohort, 
retrospective, 
consecutive 
Location: UK 
Year: 1997-2008 
Description: 147 MCDA pregnancies. 19 with sIUFD but 
we excluded 1 TRAP, 1 who underwent FLA for TTTS, 
and 1 with a congenital malformation, therefore 16 
included in analysis. Placenta examined histologically to 
confirm chorionicity. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear.  
Additional: Confounders of TTTS and IUGR recorded, 
but maternal illness not. 
NA NA Not reported 
† Farah (2012) 
(Farah 2012) 
Cohort, 
retrospective, 
not reported 
Location: Southern Ireland 
Year: 1999-2007 
Description: 208 uncomplicated MCDA twin 
pregnancies, 9 twin pregnancies included with sIUFD. 
Placenta examined histologically to confirm chorionicity. 
Authors excluded TTTS, IUGR, growth discordance, 
TRAP and structural anomalies. 
PTB information: NA 
Additional: Confounder of maternal illness not recorded 
NA NA Not reported 
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Fichera (2009) 
(Fichera 2009) 
 
 
 
Cohort, 
retrospective, 
not reported 
Location: Italy 
Year: 2001-2006 
Description: 23 twin pregnancies with sIUFD, we 
excluded 1 who underwent termination of pregnancy, 
and did not include the DC twin pregnancies as a high 
proportion (3/10) had chromosomal anomalies. Study 
also excluded MCMA twins and sIUFD in first trimester. 
Chorionicity determined by USS. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear. 
Additional: Confounder of TTTS with 1 patient 
undergoing FLA and 4 amniodrainage was recorded 
although it was not possible to remove the pregnancy 
which underwent FLA. sIUGR and maternal illness also 
recorded. 
Mode of imaging: 
antenatal and 
postnatal USS 
When imaged: 
‘prenatal’ or 
‘neonatal’ 
Definition of 
abnormal imaging: 
severe IVH, bilateral 
ventriculomegaly, 
PVH, periventricular 
hyperechogenicities, 
calcifications and 
multilocular cysts on 
pavements of normal 
ventricles 
Assessed by 
neuropediatric 
specialist according 
to Dubowitz 
method, Prechtl 
evaluation, or 
Griffith’s Mental 
Developmental 
Scales as 
appropriate.  
Follow up of 
surviving twin in 
18/20 cases 
(85%). Follow 
up ranged from 
12-56 months 
Fusi 
(1990) (Fusi 
1990) 
 
 
Cohort, 
retrospective, 
not reported 
Location: UK 
Year: 1977-1988 
Description: 485 twin pregnancies. 11 cases of sIUFD 
included from first hospital. An additional 5 cases from a 
second hospital, however 1 MCMA therefore excluded 
from analysis. Authors excluded if death occurred during 
labour or within a week of delivery. Death of twin 
confirmed by USS. Placenta examined histologically to 
confirm chorionicity 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear. 
Additional: Maternal illness and IUGR as confounders 
were recorded but TTTS not mentioned. 
NA Cerebral atrophy, 
spastic quadriplegia 
Not reported 
Gaucherand 
(1994) 
(Gaucherand 
1994) 
 
Cohort, 
retrospective, 
not reported 
Location: France 
Year: 1985-1992 
Description: 248 multiple pregnancies. The authors 
excluded 3 cases of dIUFD because they were affected 
by TTTS thus 10 cases of sIUFD but we excluded the 1 
Mode of imaging: 
postnatal USS 
When imaged: not 
stated but postnatal  
Definition of 
Tetraplegia and 
convulsions, no 
further information 
given. 
Not reported 
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selective termination of pregnancy for Down’s syndrome 
and 1 triplet pregnancy. 8 cases included. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear. 
Additional: Data on maternal illness, IUGR and TTTS as 
potential confounders included but definition of latter not 
clear. 
abnormal imaging: 
porencephaly 
† Gratacós 
(2004) 
(Gratacós 
2004) 
Cohort, 
prospective, 
consecutive 
Location: not stated 
Year: not stated 
Description: 50 MC twin pregnancies. Authors excluded 
8 as underwent cord occlusion, 6 sIUFDs all of which 
had sIUGR. Chorionicity confirmed on US. Pregnancies 
with TTTS were excluded. 
PTB information: NA 
Additional: Confounders of fetal anomaly and maternal 
illness not recorded. 
Mode of imaging: 
postnatal USS  
When imaged: all 
twins at or before 4 
days and 28 +/- 7 
days of life  
Definition of 
abnormal imaging: 
suggestive of 
parenchymal brain 
damage, particularly  
periventricular 
leukomalacia. “The 
latter was classified 
as follows: (I) 
transient 
periventricular 
echodensities for ≥7 
days; (II) 
periventricular 
echodensities 
evolving into small 
localised 
frontoparietal 
cystic lesions; (III) 
periventricular 
densities evolving 
NA Not reported 
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into 
extensive 
periventricular cystic 
lesions; (IV) densities 
extending into the 
deep white matter 
evolving into 
extensive cystic 
lesions” 
† Gratacós 
(2008) 
(Gratacós 
2008) 
Cohort, 
retrospective, 
consecutive 
Location: Spain and Belgium 
Year: 2003-2006 
Description: 49 MC twin pregnancies with sIUGR Type 
III. 31 had expectant management of which 9 had a 
sIUFD. We did not include the 18 who underwent laser 
treatment. 
PTB information: NA 
Additional: Confounders of fetal anomaly and maternal 
illness not recorded 
NA NA Not reported 
† Griffiths 
(2015) (Griffiths 
2015) 
Cohort, 
retrospective, 
not reported 
Location: UK 
Year: 2004-2013 
Description: 68 monochorionic IUFDs who underwent 
fetal MRI. Birth outcome data available for 64. Cohort 
divided into spontaneous IUFD (n=41) and IUFD post-
FLA for TTTS (n=27). We only included spontaneous 
IUFD group, of which we excluded 2 first-trimester 
losses and 10 with no pregnancy outcome data. 29 
sIUFDs included. Chorionicity determined by USS. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear. 
Additional: Data on congenital anomaly as confounder 
included, but not maternal illness. 
Mode of imaging: 
antenatal USS and 
MRI in all 
pregnancies 
When imaged: 1-12 
weeks post-IUFD  
Definition of 
abnormal imaging: 
encephalomalacia, 
ventriculomegaly 
NA Not reported 
Hagay 
(1986) (Hagay 
1986) 
Cohort, not 
reported, not 
reported 
Location: Israel 
Year: 1969-1983 
Description: 1192 multiple pregnancies. 21 cases of 
NA NA Not reported 
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sIUFD recorded 1 set triplets and 20 twins. We excluded 
the 1 case of triplets, 2 MCMA pregnancies, and 7 
further cases (2 MC, 5 DC) where the gestational age of 
sIUFD was not recorded therefore we analysed 11 
cases. Placenta examined histologically to confirm 
chorionicity. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear. 
Additional: Data on maternal illness and congenital 
anomaly was recorded but not TTTS. 
† Hoffmann 
(2013) 
(Hoffmann 
2013) 
Cohort, 
prospective, 
not reported 
Location: Israel 
Year: 2007-2010 
Description: 34 monochorionic IUFDs who underwent 
fetal MRI. 18 were a consequence of selective reduction 
and 10 underwent FLA for TTTS and were excluded 
from our analysis. In the 6 with a spontaneous IUFD, we 
excluded 2 from the co-twin death and PTB outcome as 
they decided to terminate the pregnancy following 
antenatal scan. Chorionicity determined by USS. 
Authors included only included those with sIUFD after 1st 
trimester. In-utero transfusion was performed in 1 twin 
included in analysis 
PTB information: NA 
Additional: Information on maternal illness and 
congenital anomalies not reported. 
Mode of imaging: 
antenatal USS and 
MRI 
When imaged: within 
6 days of sIUFD 
Definition of 
abnormal imaging: 
acute ischemic 
lesions 
Information 
obtained from 
hospital charts and 
telephone 
interviews with 
parents. Sequelae 
of prematurity and 
asphyxia. No 
further information 
given. 
Not reported 
Ishimatsu 
(1994) 
(Ishimatsu 
1994) 
Cohort, not 
reported, not 
reported 
Location: Japan 
Year: 1986-1992 
Description: 100 twin pregnancies. 15 cases of sIUFD 
included. Death of twin confirmed by USS. Histological 
assessment placental chorionicity in all cases. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear. 
Additional: Information on congenital anomaly recorded 
Mode of imaging: 
postnatal USS and 
CT 
When imaged: 
neonatal 
Definition of 
abnormal imaging: 
periventricular 
leukomalacia, 
Cerebral palsy or 
mental retardation. 
Assessment 
methods not 
described. 
Not reported 
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but not TTTS or maternal illness. intracranial 
haemorrhage, 
microcephaly, brain 
atrophy 
† Jelin (2008) 
(Jelin 2008) 
Cohort, 
retrospective, 
consecutive 
Location: USA 
Year: 1997-2007 
Description: 47 MC twin pregnancies with sIUFD 
undergoing fMRI, The authors excluded 25 who 
underwent radiofrequency ablation or placental ablation, 
and the 1 case with no antenatal USS with which to 
compare the fMRI, therefore 21 sIUFDs in the study. We 
excluded 2 TRAP pregnancies, and 1 1st trimester loss, 
thus 18 in our analysis. Due to not reporting the outcome 
of the pregnancy, this study was only included in the 
antenatal brain imaging outcome. 
PTB information: NA  
Additional: Confounders of TTTS, fetal anomaly and 
maternal illness recorded 
Mode of imaging: 
antenatal USS and 
MRI in all 
pregnancies 
When imaged: 0-12 
weeks post sIUFD 
Definition of 
abnormal imaging: 
ventriculomegaly, 
abnormal sylvian 
fissures, evidence of 
cerebral injury, cystic 
changes, 
haemorrhage 
NA Doesn’t report 
on outcome of 
pregnancy after 
antenatal MRI. 
Jou 
(1996) (Jou 
1996) 
 
Cohort 
prospective, 
consecutive 
Location: Taiwan 
Year: 1991-1995 
Description: Monochorionic pregnancies with sIUFD 
after 20 weeks, 14 cases in cohort. sIUFD confirmed by 
USS. Authors excluded 2 cases where 2nd twin was 
terminated following sIUFD, therefore 12 cases included 
in analysis. Placenta chorionicity determined 
histologically. 6 pregnancies with TTTS underwent 
amniodrainage but were included in our analysis. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear. 
Additional: Presence of TTTS was noted but congenital 
anomaly and maternal illness was not. 
NA Spastic cerebral 
palsy 
Not reported 
Kilby 
(1994) (Kilby 
1994) 
Cohort, 
retrospective, 
not reported 
Location: UK 
Year: 1988-1993 
Description: 342 twin pregnancies 20 cases of sIUFD 
NA, results not 
divided by 
chorionicity 
NA, results not 
divided by 
chorionicity 
Not reported 
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with surviving twin born after 20 weeks; we excluded 5 
with congenital anomalies. sIUFD confirmed by USS. 
Placentas examined histologically for chorionicity. 
PTB information: NA 
Additional: Details on congenital anomaly, karyotyping 
and maternal illness recorded. 1 case of mild TTTS 
reported but included in our analysis. 
Krayenbuhl 
(1998) 
(Krayenbuhl 
1998) 
Cohort, 
retrospective, 
not reported 
Cohort 
Location: Switzerland 
Year: 1984-1994 
Description: 541 twin pregnancies. 19 cases of sIUFD 
included. Chorionicity determined histologically. sIUFD 
in first trimester excluded. 
PTB information: NA 
Additional: Data on TTTS (n=5 cases) but no mention of 
treatment, and congenital anomaly but not maternal 
illness. Two pregnancies with congenital anomalies 
included, but unable to remove as doesn’t report the 
chorionicity of the 2 cases. 
NA NA Not reported 
† Lewi (2008) 
(Lewi 2008)  
Cohort, 
retrospective, 
consecutive 
Location: Belgium, Germany 
Year: 2002-2007 
Description: 202 MCDA twin pregnancies, excluded 
HOM, 1 TRAP sequence, 1 1st trimester dIUFD, 1 with 
sirenomelia. 45 had sIUFD but we excluded those who 
underwent FLA, cord occlusion or termination of 
pregnancy for TTTS, therefore 13 included in analysis. 
Placenta examined histologically to confirm chorionicity. 
PTB information: NA 
Additional: Confounders of TTTS, IUGR and fetal 
anomaly and recorded, but not maternal illness. 
Mode of imaging: not 
stated 
When imaged: 
postnatally 
Definition of 
abnormal imaging: 
not stated 
NA Not reported 
Lin (1999) (Lin 
1999) 
 
 
Cohort, 
retrospective, 
not reported 
Location: Taiwan 
Year: 1988-1997 
Description: 302 twin pregnancies. 17infant survivors of 
sIUFD included. We excluded 5 cases as chorionicity 
was not known, 2 did not undergo neurological 
assessment. The study did not include dIUFD therefore 
Mode of imaging: not 
stated 
When imaged: 
postnatally 
Definition of 
abnormal imaging: 
Cerebral palsy Not reported 
  
310 
 
not included in co-twin IUFD outcome.  
PTB information: NA 
Additional: No data on confounders TTTS, congenital 
anomaly and maternal illness. 
IVH, periventricular 
echogenicity, 
encephalomalacia 
† Mahony 
(2011) (Mahony 
2011) 
Cohort, 
retrospective, 
consecutive 
Location: Ireland 
Year:1997-2006 
Description: 1178 twin pregnancies. 22 sIUFD 
pregnancies included. Only included IUFDs after 23+6 
weeks. Placenta examined histologically to confirm 
chorionicity. Authors excluded pregnancies with fetal 
anomalies. 
PTB information: NA 
Additional: data on TTTS reported with several who 
underwent amniodrainage but were kept in for analysis, 
IUGR also reported, but not maternal illness. 
NA NA Not reported 
Malinowski 
(2000) 
(Malinowski 
2000) 
Cohort, 
prospective, 
consecutive 
 
Location: Poland 
Year: 1989-1999 
Description: 11 cases of sIUFD recorded, we excluded 3 
as 1st trimester sIUFD and 2 with congenital 
malformations. Placenta examined histologically to 
confirm chorionicity. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear. 
Additional: Data on TTTS but no mention of intervention, 
congenital anomaly recorded but not maternal illness. 
NA NA Not reported 
Malinowski 
(2003) 
(Malinowski 
2003) 
 
 
Cohort 
Multi-centre, 
retrospective, 
not reported 
Location: Poland 
Year: 1995-1999 
Description: 295 twin pregnancies. 12 cases of sIUFD  
PTB information: NA 
Additional: Pregnancies all in the third trimester. Data on 
congenital anomaly, TTTS but no mention of 
intervention, and maternal illness recorded. 
NA NA Not reported 
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† McPherson 
(2012) 
(McPherson 
2012) 
Cohort, 
retrospective, 
consecutive 
Location: USA 
Year: 1990-2008 
Description: 2454 twin pregnancies. 77 twin pregnancies 
with sIUFD included. Authors excluded MA, TTTS, 
higher order multiples and IUFD <20 weeks. Placenta 
examined histologically to confirm chorionicity. 
PTB information: NA 
Additional: Confounders of TTTS, fetal anomaly and 
maternal illness recorded 
NA NA Not reported 
Petersen 
(1999) 
(Petersen 1999) 
 
Cohort, 
retrospective, 
not reported 
Location: Denmark 
Year: 1991-1995 
Description: 310 twin pregnancies. sIUFD occurred in 28 
multiple pregnancies. We excluded 6 as they were a 1st 
trimester loss, 9 because they were from selective fetal 
reduction, 1 because the chorionicity was not 
determined,1 with Fallot’s tetralogy, and 1 set of triplets, 
therefore 10 cases were analysed. Histopathological 
examination of chorionicity for all cases.  
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic was reported. 
Additional: Information on TTTS, IUGR, congenital 
anomaly and maternal illness as potential confounders 
recorded.  
NA Psychomotor 
development 
commented on, but 
no further details 
given. 
4 out of 8 
surviving twins 
(50%) at mean 
of 19 months, 
range 8-51 
months. 
† Robinson 
(2017) 
(Robinson 
2017) 
Cohort, 
retrospective, 
not reported 
Location: Australia 
Year: 2007-2016 
Description: 33 complicated MC twin pregnancies that 
had fetal MRIs, 10 of which were spontaneous sIUFDs. 
Pregnancies with structural anomalies were excluded. 
We excluded 2 from the co-twin death and PTB outcome 
as they decided to terminate the pregnancy following 
antenatal scan. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear Additional: Confounders of TTTS, 
Mode of imaging: 
antenatal USS and 
MRI in all 
pregnancies 
When imaged: 2 
weeks post IUFD, 
usually after 24 
weeks gestation 
Definition of 
abnormal imaging: 
IVH, 
NA Not reported 
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IUGR, fetal anomaly and maternal illness recorded ventriculomegaly, 
infarction, abnormal 
cranial biometry 
† Rustico 
(2017) (Rustico 
2017) 
Cohort, 
retrospective, 
consecutive 
Location: Italy 
Year: 2004-2012 
Description: 140 MC twin pregnancies with sIUGR. 18 
twin pregnancies included with sIUFD. TTTS and TAPS 
excluded. We did not include the 20 who had cord 
occlusion or 5 who had a termination of pregnancy 
PTB information: NA. 
Additional: Confounders of fetal anomaly and maternal 
illness not recorded 
NA Detailed 
assessment 
outlined in article 
All surviving 
infants were 
followed up as 
per Italian 
protocol by 
paediatric 
neurologist-
psychiatrists. 
The range of 
follow up in the 
study was 1-7 
years (median 2 
years) 
Saito 
(1999) (Saito 
1999) 
Cohort, 
retrospective, 
not reported 
Location: Japan 
Year: 1971-1997 
Description: 481 cases of twins. 30 cases of sIUFD of 
which we have excluded 3 MCMA and 2 with fetal 
anomalies. Method of determining chorionicity and 
gestational age of twin demise not recorded. 
Amniodrainage performed for TTTS in some cases but 
not clear which. As the aim of the study was to assess 
the neonatal outcome of sIUFD twins, the study was not 
included in the co-twin IUFD outcome as dIUFD were 
not included. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear Additional: Confounders such as 
TTTS congenital anomaly and maternal illness recorded. 
NA Cerebral palsy, 
assessment 
method not stated. 
Not reported 
Santema 
(1995) 
(Santema 1995) 
 
Case-control, 
prospective, 
consecutive 
 
Location: The Netherlands 
Year: 1973-1993 
Description: 531 twin pregnancies. 29 cases of sIUFD, 
confirmed by USS with sIUFD >20 weeks, and >12h 
NA NA 3/22 (16%) lost 
to follow-up. 
Median age of 
FU 4years and 2 
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before delivery. Control group was normal twin 
pregnancies, used to compare outcomes but not include 
in our analysis. Placentas were examined histologically 
to determine chorionicity.  
PTB information: NA 
Additional: Data on congenital anomaly, maternal illness 
recorded but not TTTS. 
months range 2 
months to 18 
years 
† Sebire (1997) 
(Sebire 1997) 
Cohort, 
retrospective, 
not reported 
Location: UK 
Year: 1992-1996 
Description: 486 twin pregnancies. 27 twin pregnancies 
included with sIUFD. Placenta examined histologically to 
confirm chorionicity. The authors excluded chromosomal 
anomalies but analysis included 1 MC twin with 
gastroschisis, and 1 DC twin with arthrogryposis  
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear Additional: Confounders of TTTS 
recorded although intervention not mentioned. 
NA NA Not reported 
Szymonowicz 
(1986) 
(Szymonowicz 
1986) 
 
Cohort, 
retrospective, 
not reported 
Location: Australia 
Year: not stated 
Description: 6 cases of MCDA sIUFDs. How chorionicity 
determined is not recorded. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear 
Additional: Data on TTTS, congenital anomaly and 
maternal illness not recorded 
Mode of imaging: 
USS and CT 
When imaged: Not 
stated whether 
antenatal or 
postnatal therefore 
not included in 
analysis  
Definition of 
abnormal imaging: 
parietal / occipital / 
cerebellar / cortical / 
parietal-occipital 
infarcts, 
hydranencephaly,  
hydrocephalus. 
Cerebral palsy and 
mental retardation, 
no other 
information given. 
2 out of 2 cases 
that survived 
(100%) at 3 and 
5 years of age 
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† Tordjeman 
(1996) 
(Tordjeman 
1996) 
Cohort, 
retrospective, 
not reported 
Location: France 
Year: 1984-1994 
Description: 21 pregnancies with sIUFD, we excluded 3 
triplets, 1 quadruplet, 2 MCMA twins, 3 with congenital 
anomalies, 2 termination of pregnancy for haemophilia A 
and TTTS. 10 twin pregnancies included with sIUFD. 
Placenta examined histologically to confirm chorionicity. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear 
Additional: Confounders of TTTS, IUGR, fetal anomaly 
and maternal illness recorded 
Mode of imaging: 
postnatal USS  
When imaged: not 
stated but know is 
postnatal  
Definition of 
abnormal imaging: 
severe multicystic 
encephalopathy 
NA Not reported 
van Heteren 
(1998) (van 
Heteren 1998) 
Cohort, 
retrospective, 
consecutive 
Location: The Netherlands 
Year: 1990-1996 
Description: Only included sIUFD in MC twin 
pregnancies with TTTS but did not undergo intervention. 
11 cases included. Chorionicity was determined by 
placental histological. Not included in co-twin IUFD as 
aim of paper to look at outcomes for child, therefore not 
dIUFDs included. 
PTB information: gestational age at delivery reported 
individually thus sub-group possible. Spontaneous or 
iatrogenic not clear Additional: Data on TTTS, congenital 
anomaly were recorded but not concurrent maternal 
illness. Did change management for last 2/9 
pregnancies due to high comorbidity rate: delivered as 
soon as possible after sIUFD when compatible with 
neonatal survival. 
Mode of imaging: 
postnatal USS 
When imaged: 
neonatal but does 
not state specifically 
Definition of 
abnormal imaging: 
periventricular 
leukomalacia, 
(transient) 
periventricular 
echodensities, 
multicystic 
encephaloleucomala
cia 
Taken from 
neonatal notes. 
Psychomotor 
retardation and 
spastic tetraplegia. 
Spastic diplegia. 
Further information 
re mode of 
assessment not 
stated. 
FU of the eight 
survivors 
(100%) at  
1.5-3 years of 
age. 
† van Klink 
(2015) (van 
Klink 2015) 
Cohort, 
retrospective, 
consecutive 
Location: The Netherlands 
Year: 2002-2013 
Description: 49 MC pregnancies with sIUFD. Authors 
excluded sIUFD post-FLA, selective feticide, dIUFD on 
same day. There was 1 case of triplets that we excluded 
from all 4 outcomes (co-twin death, antenatal brain 
imaging, postnatal brain imaging, NND), 5 MCMA twins 
Mode of imaging: 
antenatal and 
postnatal USS and 
MRI 
When imaged: 
antenatal diagnosis 
made at median 26.5 
NA 28/47 had 
postnatal US, of 
whom 11/28 had 
MRI as well. All 
cerebral imaging 
performed up to 
1 year of age 
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that we were only able to exclude from co-twin death, 1 
with congenital anomalies that we were only able to 
exclude from co-twin death, and 2 with a termination of 
pregnancy that were excluded from co-twin death, 
postnatal brain imaging and NND. 6 underwent in-utero 
transfusions, but included in analysis as it was not 
possible to remove them. 
PTB information: NA 
Additional: Data on TTTS and congenital anomalies 
reported, but no record of maternal illness. 
weeks (IQR 22.3-
30.8), postnatal 
imaging performed 
up to 1 year of age, 
not all pregnancies 
scanned 
Definition of 
abnormal imaging: 
IVH, parenchymal 
haemorrhage, cystic 
periventricular 
leukomalacia, 
porencephalic cyst, 
ventricular dilatation, 
infarction and 
hypoxic-ischemic 
injury of basal 
ganglia, thalamus 
and/or cortex. 
Severe cerebral 
injury was defined as 
at least one of: 
IVH≥Grade III, 
cPVL≥Grade II, 
ventricular 
dilatation≥97th 
percentile, 
porencephalic 
cyst, arterial or 
venous infarction, 
basal ganglia, 
thalamic 
and/or cortical injury 
or other severe 
cerebral lesions 
reported. 
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associated with an 
adverse neurological 
outcome. 
Wang 
(2000) (Wang 
2000) 
Cohort, 
retrospective, 
consecutive 
Location: Taiwan 
Year: 1993-1998 
Description: 9 cases of MC twin with sIUFD. All had a 
sIUFD associated with TTTS but intervention was 
delivery therefore the study could not be included in 
analysis. Not recorded how chorionicity or gestation of 
sIUFD was derived.  
PTB information: NA 
Additional: No record of potential confounders, maternal 
illness and congenital anomaly 
NA NA Not reported 
† Wang (2016) 
(Wang 2016) 
Cohort, 
retrospective, 
random 
enrolment 
Location: China 
Year: not stated 
Description: 47 cases of sIUFD, although the study 
excluded 1st trimester miscarriages and selective 
reductions, the study did include 2 MCMA pregnancies, 
2 terminations of pregnancies and 7/16 cases of TTTS 
who underwent FLA therefore the study could not be 
included in analysis. 
PTB information: NA 
Additional: Did report potential confounders of maternal 
illness, but not congenital anomaly 
Mode of imaging: 
postnatal USS 
When imaged: 
neonatal but does 
not state specifically 
Definition of 
abnormal imaging: 
IVH, 
ventriculomegaly 
NA FU average of 
32 months 
(range 12-37 
months) 
Woo 
(2000) (Woo 
2000) 
 
 
 
Cohort, not 
reported, not 
reported  
Location: Hong Kong 
Year: 1993-1997 
Description: 182 twin pregnancies. 7 cases of sIUFD 
included. We excluded 3 as the chorionicity was not 
recorded in one case and the gestation of sIUFD was 
not recorded in 2 cases, therefore the study could not be 
included in analysis. Chorionicity was confirmed 
histologically. 
PTB information: NA 
Additional: Confounders; TTTS, maternal illness and 
congenital anomaly were recorded 
NA NA All 6 surviving 
twins were FU 
(100%) but 
timings of FU 
were not 
recorded. 
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7.3.4 Risk of bias of included studies 
The quality of the included studies is displayed in Figure 7.2. All the studies reported 
study design and the number of outcome events. None of the studies explained how 
their sample size was determined and it is likely that a sample of convenience was 
used. The poor reporting of enrolment methods mean that selection bias is not clear.. 
The number of participants at each stage of the study was reported in 20/42 (47.6%) 
studies which may be that selective reporting and attrition bias occurred in some 
studies and results should be interpreted with caution as it is possible that adverse 
outcomes were over reported. Only 15/42 (35.7%) studies reported which data were 
missing, and 19/42 (45.2%) adequately reported the limitations of their study. The 
funnel plots and Egger’s test results are reported in Appendix 10.17; some analyses 
did suggest small-study effects publication bias which is important when interpreting 
the results as caution should be heeded. 
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Figure 7.2 Quality assessment of included studies according to ‘Strengthening 
The Reporting of Observational studies in Epidemiology’ (STROBE) checklist 
 
7.3.5 Synthesis of results 
As some studies only included MC, or DC twin pregnancies, these studies could only 
be included in the summary event rate calculation and not in the comparison of MC 
with DC twin pregnancies. The extracted 2x2 data used to calculate the summary 
0 5 10 15 20 25 30 35 40
Funding sources and roles
Generalisability
Cautious overall interpretation
Limitations of study and potential bias
Summarises key results
Other analyses
Translates relative risk to absolute risk
Category boundaries
Unadjusted and adjusted estimates
Number of outcome events
Summarises follow-up time
Number of participants with missing data
Participant characteristics
Patient flow diagram
Reasons for non-participation
Participants at each stage of study
Sensitivity analyses
Addresses loss to follow-up
Addresses missing data
Sub-group analysis
Statistical methodology
How quantitative variables analysed
Study size calculation
Addresses potential sources of bias
Defines all variables
Defines all outcomes
Matching criteria
Eligibility criteria and selection methodolgy
Setting, recruitment period, data collection
Key elements of study design
Specific objectives/hypotheses
Scientific background/rationale
Informative abstract
Study design in title or abstract
Number of papers 
Yes No Unclear Not applicable
 319 
 
event rates, and the forest plots not included in the main text comparing MC with DC 
twin pregnancies for each adverse outcome are in Appendix 10.16. Reasons why 
data have not been included in analysis are described in Table 7.1. 
 
7.3.6 Summary event rates 
 
Table 7.2 Summary event rates and odds ratio of adverse outcome in surviving 
co-twin following sIUFD in monochorionic and dichorionic twin pregnancies 
fMRI: fetal magnetic resonance imaging, NP: not possible to calculate odds ratios. p 
value in the OR column denotes the significance of OR=1. Statistically significant 
results are in bold. 
 
Adverse 
outcome 
Monochorionic  
event rate 
Dichorionic  
event rate 
Odds ratio [95%CI] 
comparing MC v DC 
Co-twin intra-
uterine fetal 
death 
41.0% [95%CI 33.7, 
49.9] I2=44.2%, 32 
studies, 379 
pregnancies 
22.4% [95%CI 16.2, 
30.9] I2=21.7%, 20 
studies, 255 
pregnancies 
2.06 [95%CI 1.14, 
3.71] p=0.016, 
I2=0.0%, 19 studies, 
441 pregnancies 
Preterm birth 58.5% [95%CI 48.2, 
70.9] I2=11.7%, 20 
studies, 202 
pregnancies 
53.7% [95%CI 40.8, 
70.6] I2=0.0%, 12 
studies, 107 
pregnancies 
1.42 [95%CI 0.67, 
2.99] p=0.356, I2=1.5%, 
10 studies, 167 
pregnancies 
Abnormal 
antenatal 
brain fMRI  
20.0% [95%CI 12.8, 
31.1] I2=21.9%, 6 
studies, 116 
pregnancies 
 
NP 
 
NP 
Abnormal 
postnatal 
brain imaging 
43.0% [95%CI 32.8, 
56.3] I2=12.4%, 12 
studies, 140 
pregnancies 
21.2% [95%CI 10.6, 
42.4] I2=0.7%, 7 
studies, 75 
pregnancies 
5.41 [95%CI 1.03, 
28.58] p=0.047, 
I2=45.8%, 7 studies, 
142 pregnancies 
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Adverse 
outcome 
Monochorionic  
event rate 
Dichorionic  
event rate 
Odds ratio [95%CI] 
comparing MC v DC 
Neuro-
developmental 
comorbidity 
28.5% [95%CI 19.0, 
42.7] I2=0.0%, 13 
studies, 103 
pregnancies 
10% [95%CI 3.9, 
27.7] I2=0.0%, 8 
studies, 62 
pregnancies 
3.06 [95%CI 0.88, 
10.61] p=0.08, I2=0.0%, 
8 studies, 129 
pregnancies 
Neonatal 
death 
27.9% [95%CI 21.1, 
36.9] I2=0.0%, 18 
studies, 206 
pregnancies 
21.2% [95%CI 14.5, 
31.2] I2=0.0%, 12 
studies, 130 
pregnancies 
1.95 [95%CI 1.00, 
3.79] p=0.051, I2=0.0%, 
11 studies, 232 
pregnancies 
 
The co-twin survivor in MC twin pregnancies was at significantly higher risk of co-twin 
IUFD (Table 7.2, Figure 7.3) and abnormal postnatal brain imaging than co-twin 
survivors in DC twin pregnancies. No significant difference was found between MC 
and DC twin pregnancies in the rate of PTB, neurodevelopmental comorbidity or 
NND, although the latter outcome was borderline significant. The rate of abnormal 
antenatal brain imaging in MC twin pregnancies was 20%, but as no studies were 
found reporting this outcome in DC twin pregnancies, the OR was not calculated. 
Additional forest plots and extracted 2x2 data are shown in Appendix 10.16. 
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Figure 7.3 Forest plot comparing the risk of co-twin intrauterine fetal death (co-
twin IUFD) following single intrauterine fetal death in monochorionic (MC) and 
dichorionic (DC) twin pregnancies 
 
7.3.7 Sub-group analysis 
Sub-group analysis demonstrated that in MC twin pregnancies, those with an sIUFD 
<28 weeks were significantly more likely to have a co-twin IUFD than those with an 
sIUFD ≥28 weeks. The pathologies of TTTS and IUGR were not associated with an 
increased risk of co-twin IUFD (Table 7.3). Pregnancies complicated by TTTS were 
significantly more likely to have a PTB than twin pregnancies without TTTS. It was 
not possible to calculate ORs to examine if there was a significant difference in the 
proportion of PTB which were spontaneous or iatrogenic as the proportions were not 
known for the births which were not preterm, however the summary event rates may 
suggest a difference (Appendix 10.16). When PTB was divided according to whether 
it was iatrogenic or spontaneous, in MC twins the summary event rate of iatrogenic 
PTB was 60.4% ([95%CI 33.5, 109.1] I2=0.0%, 3 studies, 7 pregnancies) compared 
 .05 .1         .5   1    2     5  10   25     100 
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to a spontaneous PTB rate of 37.1% % ([95%CI 20.5, 66.9] I2=24.1%, 3 studies, 4 
pregnancies). In DC twins the summary event rate of iatrogenic PTB was 32.4% 
([95%CI 14.6, 72.1] I2=32.7%, 3 studies, 6 pregnancies) compared to a spontaneous 
PTB rate of 70.7% ([95%CI 31.8, 157.4] I2=0.0%, 3 studies, 6 pregnancies), although 
the wide 95% CIs and low numbers of included pregnancies should be noted. Other 
sub-group analysis in DC twins was limited due to small numbers, but the following 
analyses were possible, none of which found a significant difference: sIUFD <28 
weeks did not affect co-twin IUFD, PTB, abnormal postnatal brain imaging, 
neurodevelopmental comorbidity or NND; IUGR did not affect co-twin IUFD or PTB, 
neurodevelopmental comorbidity or NND; PTB did not affect abnormal postnatal 
brain imaging, neurodevelopmental comorbidity or NND. 
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Table 7.3 Significant results for sub-group analysis of adverse outcomes in surviving co-twin following single intrauterine 
fetal death in monochorionic twin pregnancies  
Summary event rates for each sub-group are presented, and the significant odds ratio (OR) comparing the two sub-groups  
fMRI: fetal magnetic resonance imaging, GA: gestational age, IUGR: intrauterine growth restriction, NA: not applicable as a sub-
group for outcome, NP: not possible to calculate odds ratio, NS: not statistically significant, PTB: preterm birth, TTTS: twin-twin 
transfusion syndrome, USS: ultrasound scan. p value in the OR column denotes the significance of OR=1. Note TTTS and IUGR 
were conservatively managed. Statistically significant results are in bold. 
 
Adverse outcome GA of sIUFD <28 weeks TTTS IUGR PTB versus no PTB 
Co-twin intra-uterine 
fetal death 
60.6% ([95%CI 45.8, 
80.2] I2=30.4%, 14 
studies, 114 
pregnancies) 
29.6% ([95%CI 19.2, 
45.6] I2=0.0%, 15 
studies, 85 pregnancies) 
OR 2.31 ([95%CI 1.02, 
5.25] p=0.046, I2=0.0%, 
12 studies, 184 
pregnancies) 
NS NS NA 
 324 
 
Adverse outcome GA of sIUFD <28 weeks TTTS IUGR PTB versus no PTB 
Preterm birth NS 
74.9% ([95%CI 54.0, 
103.8] I2=0.0%, 6 
studies, 36 pregnancies) 
43.3% ([95%CI 32.5, 
57.6] I2=76.0%, 7 
studies, 47 pregnancies) 
OR 3.48 ([95%CI 1.17, 
10.84] p=0.03, I2=0.0%, 
6 studies, 80 
pregnancies) 
NS NA 
Abnormal antenatal 
brain imaging NP NP NP NA 
Abnormal postnatal 
brain imaging NS NP NS NS 
Neurodevelopmental 
comorbidity NS NS NS NS 
Neonatal death 
55.0% ([95%CI 36.4, 
83.1] I2=0.0%, 10 
studies, 47 pregnancies) 
25.2% ([95%CI 15.9, 
40.0] I2=0.0%, 12 
studies, 76 pregnancies) 
OR 2.84 ([95%CI 1.18, 
6.77] p=0.019, I2=0.0%, 
10 studies, 117 
pregnancies) 
NS 
34.5% ([95%CI 23.5, 
50.6] I2=68.5%, 7 
studies, 26 pregnancies) 
25.3% ([95%CI 19.2, 
33.4] I2=0.0%, 7 studies, 
50 pregnancies) 
OR 4.83 ([95%CI 1.14, 
20.47] p=0.03, I2=0.0%, 
6 studies, 60 
pregnancies) 
41.9% (95%CI 33.6, 
52.3] I2=19.4%, 12 
studies, 79 pregnancies) 
11.3% (95%CI 8.6, 15.0] 
I2=24.1%, 11 studies, 49 
pregnancies) 
OR 4.95 ([95%CI 1.71, 
14.30] p=0.003, I2=0.0%, 
11 studies, 124 
pregnancies) 
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All six MC twin pregnancy studies which reported antenatal brain imaging compared 
fMRI with fetal ultrasound in the same pregnancy (Jelin 2008, Fichera 2009, 
Hoffmann 2013, Griffiths 2015, van Klink 2015, Robinson 2017). Ultrasound “missed” 
6/19 (31.5%) lesions detected on fMRI in 3 studies (Jelin 2008, Hoffmann 2013, 
Robinson 2017) although this difference was not statistically significant. The other 3 
studies demonstrated concordance between the two imaging modalities (Fichera 
2009, Griffiths 2015, van Klink 2015). In abnormal postnatal brain imaging, it was not 
possible to perform sub-group analysis based on the imaging modalities of MRI or CT 
scan as 2 studies used ultrasound and MRI (Gaucherand 1994, van Klink 2015), 1 
study used ultrasound and CT (Lin 1999), and 2 studies did not state the mode of 
imaging (Gratacós 2004, Lewi 2008). The rate of NND was higher in MC twin 
pregnancies where the initial sIUFD occurred <28 weeks gestation, in those with 
IUGR, and those with a PTB. No factors affected the risk of adverse outcome in DC 
twin survivors. It was not possible to calculate ORs for the year of publication sub-
group analysis. 
 
7.3.8 Publication bias 
The funnel plots for co-twin IUFD, PTB, abnormal postnatal brain imaging and 
neurodevelopmental comorbidity appear asymmetrical and Egger’s test suggests 
small-study effects publication bias may exist in MC and the DC twins (Appendix 
10.17).  
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7.4 Discussion 
 
7.4.1 Main findings 
Abnormal antenatal brain imaging following sIUFD has not previously been meta-
analysed; this review reports a rate of 1 in 5 surviving MC co-twins demonstrating 
abnormal antenatal brain imaging, which doubled on postnatal brain imaging. NND 
was another novel outcome in this review with a rate of almost 3 in 10 surviving MC 
co-twins resulting in a NND, and 2 in 10 DC co-twins being reported. In MC twins, if 
the initial sIUFD occurred at <28 weeks gestation, this significantly increased the rate 
of co-twin IUFD and NND compared to pregnancies in which the initial sIUFD 
occurred >28 weeks. The presence of TTTS was associated with a significant 
increase in the rate of PTB, but no other adverse outcome.  
 
7.4.2 Strength and limitations 
This rigorous and robust systematic review provides clinicians and parents with the 
most up to date rates of complications in the surviving twin following spontaneous 
sIUFD as reported by the literature. It also allows more tailored counselling, for 
example, depending on the gestation of the initial sIUFD. According to international 
guidance (Morin 2011, NICE 2011, ACOG 2016, Khalil 2016b, Kilby 2016, 
RANZCOG 2017), MC twins should be scanned at a minimum frequency of every 2 
weeks, and DC twins every 4 weeks, therefore it is possible that some cases of co-
twin IUFD have been missed by studies as there may appear to be a double IUFD at 
the subsequent ultrasound scan, although the surviving co-twin may have been alive 
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for a substantial period following the initial sIUFD. Some of the sub-group analysis 
was limited because these data were not reported by the included studies. For 
example it was not possible to perform the sub-group analysis based on year of 
publication, thus the inclusion of older studies with different antenatal care guidance 
and neonatal care provision may increase the risk of heterogeneity. Ideally for the 
PTB outcome, further analysis would have been performed using cut-offs of 24-28, 
28-32 weeks etc. as the review definition of <34 weeks was somewhat crude, 
however there were insufficient numbers of pregnancies to do this. It would also be 
more clinically useful if the gestation of sIUFD could be more specific than before or 
after 28 weeks, but this would require individual patient data. There was a myriad of 
differences between studies reporting brain imaging findings, including different 
referral criteria, different timing of antenatal imaging which varied from 0-12 weeks 
post IUFD, different imaging modalities, antenatal imaging findings were rarely linked 
to postnatal imaging findings and neurodevelopmental comorbidity, follow-up was 
poor and no studies were found reporting antenatal brain imaging in DC twins. 
Different methods of assessing neurodevelopment were used, making interpretation 
difficult. The results of this meta-analysis are not applicable to women in low-income 
countries as most studies include populations from developed countries. 
 
7.4.3 Interpretation 
When co-twin IUFD is viewed in the context of the summary event rates, the rate 
appears higher in both MC and DC twins compared to the previous review from 2011 
(Hillman 2011). Caution is advised when interpreting this result as it is possibly an 
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overestimate. This may be because of the existence of small-study effects publication 
bias in this outcome, and it is likely that there is selective bias as authors are more 
likely to report adverse outcomes than normal outcomes. Nevertheless, these event 
rates are the most recent data available and 10 additional studies have been 
published since the previous review. The smaller 95%CI when comparing co-twin 
IUFD between chorionicities suggests that the most recent results are more realistic, 
and the increased rate seen in MC twins compared to DC twins is to be expected 
given the presence of vascular anastomoses in the former. The significant difference 
may also be a consequence of an improved ability to determine chorionicity, better 
knowledge, and changes in monitoring over time. The lack of difference in adverse 
outcome, including co-twin IUFD, in TTTS pregnancies may be because of excluding 
TTTS pregnancies undergoing FLA or BCO, thus there was a higher proportion of 
milder cases of TTTS. This was different to the previous review but as the treatment 
for TTTS has advanced dramatically, its use is more widespread since 2011, and 
there are different confounding factors compared to in spontaneous sIUFD, it was 
important to include this restriction. TTTS was associated with an increased PTB 
rate, although it was not possible to determine if they were spontaneous or 
iatrogenic. No difference was found in PTB between MC and DC surviving co-twins, 
suggesting that the mechanism of PTB in these cases is not inherent to chorionicity 
or vascular anastomoses, but to factors common to all twin pregnancies. With 
regards to abnormal antenatal and postnatal brain imaging, these results are difficult 
to interpret for reasons previously outlined. The higher rate of abnormal postnatal 
brain imaging in MC twins compared to DC twins was expected as it is believed that 
 329 
 
when one MC twin dies, acute transfusional events through inter-twin placental 
anastomoses occur (as reviewed by Mackie 2016) resulting in cerebral injury 
detectable on postnatal brain imaging in the surviving co-twin. Whereas in DC twins 
the cause of the cerebral pathology is more likely a result of the pathological 
condition which killed the other twin, rather than a consequence of the sIUFD. The 
similarity between chorionicities and sub-group analysis in the neurodevelopmental 
comorbidity outcome may be due to small study size or a reflection of there being no 
difference in PTB between the chorionicities. The borderline-significantly higher rate 
of NND in MC twins compared to DC twins was to be expected, particularly as if the 
initial sIUFD was <28 weeks, or IUGR or PTB was involved, the rate of NND was 
significantly higher in MC twins. It would have been interesting to explore the 
relationship between these factors further, but it was not possible. 
 
7.5 Conclusion 
 
These results will help clinicians counsel parents with a sIUFD and give information 
based upon chorionicity. The high rate of adverse outcomes highlights the 
importance of close antenatal surveillance, particularly in MC surviving co-twins, and 
those in which the sIUFD has occurred at <28 weeks. PTB was the commonest 
adverse outcome and clinicians and parents should be aware of the high risk of PTB 
in these pregnancies, and the potential NNU admission. Outcomes regarding brain 
imaging and neurodevelopmental comorbidity are an important area for future 
research as this outcome is important to parents and will affect the quality of life of 
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not only the surviving twin, but also other family members. The high rate of 20% of 
co-twins with an abnormal antenatal fMRI highlights that parents should always be 
offered antenatal brain imaging. In line with these findings, and those of the 
MERIDIAN study, the imaging modality should be fMRI not ultrasound (Griffiths 
2017). A study is needed examining antenatal and postnatal brain imaging and 
neurodevelopmental comorbidity in the same surviving co-twins, in a standardised 
manner, with adequate follow-up. The studies included in this meta-analysis were 
small and small study effects were shown to exist, consequently the authors have 
recognised the need to perform a large population-based study and are in the 
process of conducting a study using data from UKOSS. This will be the largest study 
of complications in the surviving co-twin in a population cared for using the same 
national guidance (for further details see (UKOSS 2016)).  
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CHAPTER 8 PARENTAL ATTACHMENT AND 
DEPRESSIVE SYMPTOMS IN PREGNANCIES 
COMPLICATED BY TWIN-TWIN TRANSFUSION 
SYNDROME  
 
• These findings have been accepted for publication in full article form [Mackie FL, 
Pattison H, Jankovic J, Morris RK, Kilby MD (2019). “Parental attachment and 
depressive symptoms in pregnancies complicated by twin-twin transfusion 
syndrome.” BMC Pregnancy Childbirth] 
 
8.1 Overview 
 
There has been little research on the psychological impact of TTTS on mothers and 
fathers antenatally and postnatally. As the disease process is so morbid, it is 
probable that there are emotional effects for both parents, antenatally and postnatally 
but these have been poorly described. This chapter will investigate maternal and 
paternal antenatal fetal attachment and postnatal infant attachment in pregnancies 
complicated by TTTS. Parental depression will also be explored in this setting, and 
an association between parental attachment and depression will be evaluated. 
 
8.1.1 Psychological and emotional issues in TTTS pregnancies 
Twin pregnancies are known to generate complex emotional and practical demands 
on parents compared to singleton pregnancies even in the absence of complications 
(Nys 1998, Beretta 2007, Wenze 2015). However, TTTS is a highly morbid condition 
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that carries a risk of neurological comorbidity, and dIUFD or sIUFD, even with 
antenatal treatment (see section 1.2.6). These risks continue throughout pregnancy 
which is why MC twin pregnancies are closely monitored. Regular sequential 
ultrasound monitoring may reassure parents by allowing timely detection of 
abnormality, but conversely can cause concern that a complication is going to be 
detected (Laxton-Kane 2002, Righetti 2005, Yarcheski 2009, Atluru 2012). The 
unusual scenario where both twins are at risk, often to varying degrees, and one twin 
may die and one twin may survive, or one or both may be handicapped even after 
FLA means that parents may face difficult paradoxical situations. Studies performed 
on parents of MC twin pregnancies affected by sIUFD have reported that as MC 
twins are identical they find it difficult to cope with grieving for one twin whilst caring 
for the other, with the reminder of the deceased twin in the surviving twin (Swanson 
2009, Richards 2015, Jordan 2018). Consequently women with pregnancies affected 
by TTTS are at risk of altered materno-fetal attachment and symptoms of depression 
and anxiety, both antenatally and postnatally, compared to women with 
uncomplicated MC twins and DC twins (Beauquier-Maccotta 2016, Falletta 2018). 
There have been no studies examining these potential emotional impacts of TTTS on 
fathers. 
 
8.1.2 Maternal and paternal antenatal and postnatal attachment 
As Mercer states: “The purpose of studying the developing mother-infant relationship 
is to identify determinants of sensitive, competent mothering that foster healthy child 
development, and vulnerable populations for intervention” (Mercer 1993a). Laxton-
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Kane describes that: “Pre- and postnatal attachment may require different conceptual 
frameworks” as there is reciprocation with postnatal attachment, which may affect 
both maternal and paternal attachment to the fetus/infant (Laxton-Kane 2002). Fetal 
attachment is known to occur antenatally in mothers and fathers through fantasy 
before the infant is born, and to increase with gestational age and continue into the 
postnatal period (Leifer 1977, Cranley 1981, Heidrich 1989, Raphael-Leff 2001, 
Condon 2013), with a positive correlation reported between maternal antenatal 
attachment and subsequent maternal postnatal attachment (Müller 1996, van Bussel 
2010, Dubber 2015). In fathers, antenatal attachment has been demonstrated to be 
the strongest predictor of postnatal attachment, with paternal depression thought to 
be the second strongest predictor of decreased attachment (Ferketich 1995b, 
Hjelmstedt 2008). Conflicting results have been reported when comparing levels of 
attachment in mothers and fathers. Some studies report higher levels of attachment 
in mothers compared to fathers (Mercer 1988, Lorensen 2004, Ustunsoz 2010, Kaur 
2017), particularly antenatally, with speculation that the difference may be due to the 
mother being able to feel physical cues from the fetus, whereas for the father the 
absence of the ’real’ child may affect his ability to form a bond with the fetus (Colpin 
1998). Other studies have reported higher attachment in fathers (Schodt 1989, White 
1999) and one study reported no difference in antenatal or postnatal maternal and 
paternal attachment (Wilson 2000). 
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8.1.3 Importance of parental attachment 
Materno-fetal attachment positively influences maternal health choices antenatally 
including dietary, smoking, alcohol and drug-taking decisions, and thus may affect 
neonatal outcome (Alhusen 2008). Parento-fetal and parento-infant attachment is 
important as it shapes parental postnatal behaviour (Siddiqui 2000, Condon 2013); in 
the short term improving early infant development (Ard 2000, Damato 2000, Alhusen 
2008). In the long term parental attachment is associated with the child’s feeling of 
self-worth, ability to explore and deal with their environment, and their future 
capability of forming relationships (Ainsworth 1979, Bowlby 1982, Egeland 1984, 
Damato 2000).  
 
8.1.4 Parental attachment in TTTS pregnancies 
A high-risk pregnancy may decrease the mother’s ability to make psychologically 
adaptive changes to the pregnancy, thus preventing antenatal attachment for fear the 
fetus may not survive (Moore 1983, Kemp 1987, Stainton 1992). This protective 
mechanism may exist in pregnancies affected by TTTS. Only one study has explored 
materno-fetal attachment in TTTS pregnancies (Beauquier-Maccotta 2016). 
Beauquier-Maccotta et al. compared pregnancies with TTTS to uncomplicated MC 
twins, and DC twins in France. They found that materno-fetal antenatal attachment 
increased during pregnancy in mothers with uncomplicated MC and DC twins, but not 
in mothers with pregnancies complicated by TTTS. Postnatal attachment was not 
examined, and the investigators did not distinguish between the 22 women with 
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TTTS pregnancies with 2 survivors, and 9 women with TTTS pregnancies with 1 
survivor. 
 
8.1.5 Maternal and paternal antenatal and postnatal depression 
Parents of twins are generally reported to have higher rates of postnatal depressive 
symptoms compared to parents of singletons (Wenze 2015). Fewer studies have 
explored parental antenatal depression in twin pregnancy, and results are conflicting 
when mothers and fathers of twins are compared to singletons (Wenze 2015). When 
mothers and fathers of twins were compared to each other, mothers appear to 
experience higher postnatal distress, and lower well-being levels than fathers 
(Zanardo 1998, Baor 2004) although little research has been conducted in the 
antenatal period, and in comparing parents of MC and DC twins. It is interesting to 
note that fathers whose partners scored highly on the Edinburgh Postnatal 
Depression Scale (EPDS) i.e. reported greater depressive symptoms, scored more 
highly than fathers whose partners scored lower on the EPDS (Lovestone 1993, 
Morgan 1997, Matthey 2001, Paulson 2010, Underwood 2017) suggesting there is a 
link between maternal and paternal postnatal depression in couples (see section 
8.2.2 for more information on the EPDS). The most important risk factor for postnatal 
depression, in mothers and fathers, is believed to be antenatal depression (Becker 
2016). 
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8.1.6 Importance of parental depression 
Maternal postnatal depression affects 10-15% of the general obstetric population, 
and can lead to self-harm, suicide and infanticide (Palumbo 2017). Antenatally, 
maternal depression and anxiety can have effects on the fetus as well as the mother 
as they are associated with LBW, PTB, and pre-eclampsia (Bonari 2004, Grote 2010, 
Grigoriadis 2013) thus compounding the increased background risk MC twin 
pregnancies have of these complications. In the longer term maternal antenatal and 
postnatal depression is negatively associated with child development, and an 
increased number of behavioural problems (Murray 1992, Cummings 1994, Bonari 
2004, Grigoriadis 2013). Paternal postnatal depression is associated with 
behavioural problems, with children of fathers with depression displaying significantly 
more hyperactivity and conduct disorders at 3.5 years of age compared to children 
whose fathers were not depressed, including when maternal depression was 
adjusted for (Ramchandani 2005). Paternal postnatal depression has an important 
impact on the whole family, and there is a tendency of high attrition rates of fathers in 
postnatal depression studies meaning evidence is lacking (Ramchandani 2008, 
Oladosu 2012).  
 
8.1.7 Parental depression in TTTS pregnancies 
There is a dearth of research on parents of TTTS pregnancies and depression, 
particularly fathers. Beauquier-Maccotta et al. reported at 20 weeks gestation when 
TTTS was diagnosed, the total mean EPDS score of the mothers in the TTTS group 
(mean 12.06 +/- 5.58) was significantly higher than the score of mothers in 
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gestationally-matched uncomplicated MC (5.68 +/- 5.00) and DC twin (5.40 +/- 4.64) 
pregnancy groups, with 72% of the TTTS group scoring above the cut-off of 11 for 
major depressive symptoms in French speaking women (Beauquier-Maccotta 2016) 
(Table 8.1). At 30 weeks gestation there was no significant difference between the 
groups, and the percentage of mothers with TTTS pregnancies who scored above 
the cut-off decreased to 9%. At 3 months postnatally the TTTS group reported the 
highest rate of depression again, with an increase to 33%. Sub-group analysis was 
not performed according to pregnancy outcome.  
 
Table 8.1 Percentage of women with Edinburgh Postnatal Depression Scale 
scores >11 at each time point 
Comparing TTTS pregnancies with uncomplicated monochorionic (MC) and 
dichorionic (DC) twin pregnancies (taken from (Beauquier-Maccotta 2016)). The 
number of women in each group at each time point is not clear, hence only able to 
provide percentages, but there were 77 women in the study in total. 
 
 
Another study reported high rates of depressive symptoms in 350 women in the USA 
with a pregnancy complicated by TTTS: 11.4% of women reported ‘some’ or ‘serious’ 
depressive symptoms before pregnancy, 66.0% during pregnancy, and 67.7% after 
 At 
diagnosis 
of TTTS 
20 weeks 
gestation 
26 weeks 
gestation 
30 weeks 
gestation 
3 months 
postnatal 
TTTS 
 
68 72 25 9 33 
Uncomplicated 
MC 
NA 20 22 33 25 
Uncomplicated 
DC 
NA 5 11 11 9 
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pregnancy (Falletta 2018). However, one limitation of this study was the retrospective 
design as participants were recruited following completion of their TTTS pregnancy, 
as the authors highlighted, a prospective study is warranted. A recent study from 
Belgium which surveyed 92 women at a median of 7 years post-FLA for TTTS self-
reported a higher rate of “psychological and emotional” problems compared to 
mothers of uncomplicated MCDA twin pregnancies (n=107) (Vergote 2018). These 
problems were defined as “anxiety concerning health of the baby, fear for repetition; 
grieving the loss of a child, feelings of guilt”; and there was another group described 
as “others”. They did not demonstrate a significant difference in “depressed mood” 
between the 2 groups, although as the authors state, one limitation of their study was 
the self-reported nature of their survey and lack of standardised tools for assessing 
depressive symptoms. 
 
8.1.8 Parental depression in TTTS pregnancies according to pregnancy outcome 
The American TTTS cohort was divided by outcome and they found that the highest 
percentage of women with depressive symptoms during pregnancy were those with a 
sIUFD (46/57, 80.7%) (Falletta 2018). The rate of depression in the sIUFD women 
increased postnatally (52/57, 92.1%), however the highest percentage of women with 
depressive symptoms postnatally were those with a dIUFD (48/49, 98.0%). 
Interestingly, even in the double survivor group there were high rates of mothers who 
experienced depressive symptoms during pregnancy following diagnosis of TTTS 
(132/199, 66.2%), which remained high (107/199, 53.8%) postnatally, much higher 
than before pregnancy, indicating that TTTS is associated with depression, 
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irrespective of pregnancy outcome. These rates are substantially higher that those 
reported in uncomplicated twin pregnancies (Wenze 2015). There have been no 
studies looking at this in fathers. 
 
8.1.9 Association between maternal and paternal attachment and depression 
Depression has a negative impact on antenatal materno-fetal attachment (Condon 
1997, Martins 2000, Alhusen 2008) and postnatal materno-infant attachment 
(Goecke 2012, Dubber 2015) in low-risk singleton pregnancies. Colpin et al. 
demonstrated that a higher quality of antenatal materno-fetal attachment was 
associated with a higher “psychosocial wellbeing” as measured by the General 
Health Questionnaire (GHQ-30) in women with twin pregnancies (Colpin 1998), 
though this was not the case in the fathers. Other studies have demonstrated a 
relationship between paternal postnatal depression and paternal postnatal 
attachment, although there has been little research exploring this (Ferketich 1995a). 
In TTTS pregnancies, there was no difference in materno-fetal attachment between 
mothers with and without depressive symptoms at diagnosis of TTTS (Beauquier-
Maccotta 2016). In mothers with depressive symptoms there was no correlation 
between antenatal attachment and EPDS scores in any group at any gestation. 
Postnatal attachment in fathers was not investigated. 
 
8.1.10 Aims 
The aims of this study are to investigate in a cohort of parents with pregnancies 
complicated by TTTS if: 
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1) There is a difference in parental attachment, and depressive symptoms, in 
mothers compared to fathers. 
2) Parental attachment, and maternal and paternal depressive symptoms change 
at diagnosis of TTTS, following FLA, and postnatally. 
3) There is a difference in parental attachment, and depressive symptoms, in 
mothers and fathers who have a past/current history of mental health 
problems. 
4) There is an association between parental attachment and depressive 
symptoms. 
 
Hypotheses 
In the context of pregnancies complicated by TTTS: 
1) Mothers will report higher levels of parental attachment, and more depressive 
symptoms, than fathers, particularly antenatally. 
2) Parental attachment will increase, and depressive symptoms will decrease, 
antenatally to postnatally. 
3) Mothers and fathers who have a past/current history of mental health 
problems will report lower parental attachment and greater depressive 
symptoms than those with no past/current history of mental health problems. 
4) There will be an inverse relationship between parental attachment and 
depressive symptoms in mothers and fathers. 
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8.2 Methods 
 
8.2.1 Participants 
Women with MCDA twin pregnancies, and their partners, who were referred to the 
West Midlands Fetal Medicine Centre for FLA for TTTS at <24 weeks gestation were 
prospectively and consecutively recruited between 28/1/2016 and 5/9/2017, and 
follow-up continued to 1/2/2018. Both the woman and her partner had to provide 
individual written informed consent to participate. If a woman attended the initial 
consultation or came for FLA without her partner, they were not eligible for 
recruitment as the couple were recruited as a pair. Participants had to be able to read 
English due to needing to understand the follow-up postal questionnaires. Women 
with higher order pregnancies, or whose pregnancies were affected by 
chromosomal/structural anomalies were not eligible for inclusion. If a couple suffered 
a dIUFD or sIUFD prior to FLA, meaning that FLA would not be performed, they were 
not eligible for recruitment. Recruits received no compensation for participation. 
 
8.2.2 Measures 
In this work, parental attachment refers to either maternal or paternal attachment to 
the fetus(es) or infant(s) depending on whether the child is in-utero or has been born. 
The maternal and paternal scores were never combined. 
 342 
 
1. Parental Attachment Scale questionnaires 
Parental attachment was assessed using four self-reported Attachment Scales 
created by Condon et al. (Condon 1998, Condon 2013, Condon 2015b, Condon 
2015a): 
• Maternal Antenatal Attachment Scale (MAAS) 19 items, range of scores 19-95, 
sub-groups of ‘quality’ and ‘intensity’ of attachment.  
• Paternal Antenatal Attachment Scale (PAAS) 16 items, range of scores 16-80, 
sub-groups of ‘quality’ and ‘intensity’ of attachment. 
• Maternal Postnatal Attachment Scale (MPAS) 19 items, range of scores 19-95, 
sub-groups of ‘quality of attachment’, ‘absence of hostility’ and ‘pleasure in 
interaction’. 
• Paternal Postnatal Attachment Scale (PPAS) 19 items, range of scores 19-95, 
sub-groups of ‘patience and tolerance’, ‘pleasure in interaction’ and ‘affection and 
pride’. 
A higher score denotes greater attachment. These attachment tools have acceptable 
internal consistency, test-retest reliability, construct validity and have been 
demonstrated to be a valid measure of parento-fetal attachment and parento-infant 
attachment in numerous countries, including English-speaking countries as in this 
study (Condon 1998, Condon 2013). No studies were found using these 
questionnaires in twin pregnancies or TTTS due to little research having been 
conducted in this area, but it was favoured over the Prenatal Attachment Inventory 
(PAI) (Muller 1993) which although it has been used in twin pregnancies, the PAI has 
been used less in fathers than the PAAS and PPAS which was believed to be more 
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important than being validated in twin pregnancy. The PAI is also believed to focus 
more on attitudes towards pregnancy and motherhood, whereas the scales created 
by Condon et al. are more of a reflection of attitudes towards the fetus/infant 
(Alhusen 2008). 
 
No cut-offs were used as low parental attachment is not recognised as a pathological 
condition, and there are no validated cut-offs. As the antenatal and postnatal sub-
groups were different, longitudinal comparison could not be performed between sub-
groups. Participants were asked to complete the Attachment Scales per pregnancy, 
not per fetus/infant, and in the pre-FLA and post-FLA questionnaires the time point of 
“since the diagnosis of TTTS” was specified, as opposed to the last two weeks as 
stated in the original questionnaires, thus the wording was amended to reflect this. 
The reworded questionnaires were piloted on couples with twin pregnancies for 
sense prior to use in the actual study (see Appendix 10.19 for questionnaires).  
 
2. Edinburgh Depression Scale (EDS) and Edinburgh Postnatal Depression Scale 
(EPDS) 
Depressive symptoms were assessed antenatally and postnatally using the EDS and 
EPDS respectively, which will be referred to as ‘EPDS’ irrespective of whether it was 
used antenatally or postnatally. The EDS and EPDS both consist of the same 10 
questions and a 4-point self-rated scale of depressive symptoms. The response to 
each question corresponds to a score of 0-3, with a total lowest score possible of 0, 
and maximum score of 30 (Cox 1987). A higher score denotes greater depressive 
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symptoms. A cut-off of 15 or more was used for maternal antenatal depression to 
give a sensitivity of 91% and specificity of 95% for indicating major depressive 
disorders in English speaking women, and 13 or more for maternal postnatal 
depression (Matthey 2006). Although the questionnaire is validated for use in fathers 
antenatally a cut-off for major depressive disorders has not been validated (Matthey 
2006) so a cut-off of 12 or more was used for paternal antenatal depression as in 
Ramchandani et al. and Buist et al. (Buist 2003, Ramchandani 2008). A cut-off of 10 
or more was used for paternal postnatal depression to give a sensitivity of 71.4% and 
specificity of 93.8% (Matthey 2001). The EPDS has been validated for use in mothers 
and fathers antenatally and postnatally including English-speaking parents as in this 
study (Cox 1987, Murray 1990, Cox 1996, Matthey 2001, Matthey 2006). Due to the 
rapid disease progression of TTTS, patients are referred to the Fetal Medicine Centre 
for treatment the following day, thus the pre-FLA and post-FLA EPDS questionnaires 
were amended to ask about time “since the diagnosis of TTTS” as opposed to in the 
last 7 days. The postnatal questionnaire asked about the last 7 days. 
 
3. Mental health history questionnaire 
Participants were asked to complete several questions on current and past mental 
health problems, including questions regarding diagnoses, medication and therapy 
(see Appendix 10.19). At the postnatal time point, participants were asked if they had 
received any new psychiatric diagnoses, and if they were taking any additional 
medication or undergoing therapy for any mental health problems since the diagnosis 
of TTTS. 
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8.2.3 Procedure 
Women and their partners were approached by a trained researcher after they had 
been consented for FLA by the Fetal Medicine Consultant. This was the day before 
FLA. The woman and her partner were asked to complete the questionnaire on 
parento-fetal attachment and depressive symptoms separately. The Attachment and 
EPDS questionnaires were completed at three time points: 
• Pre-FLA: the day prior to FLA (MAAS, PAAS, maternal and paternal EPDS, 
mental health history) 
• Post-FLA: one month following FLA (MAAS, PAAS, maternal and paternal EPDS) 
• Postnatal: 6–10 weeks following delivery (MPAS, PPAS, maternal and paternal 
EPDS, mental health history).  
As the West Midlands Fetal Medicine Centre treats patients from a large 
geographical area, the follow-up questionnaires were posted to participants, with a 
stamped addressed envelope enclosed. If follow-up questionnaires were not 
received, a reminder was sent in the post, and contact with the couple was attempted 
by telephone. The timing of the questionnaires was related to medical care as 4 
weeks post-FLA is when a fMRI is advised to assess for brain injury, and 6-10 weeks 
postnatal allows time for NNU admission if required. If FLA was planned but was not 
possible intra-operatively, the initial pre-FLA questionnaires were included in 
analysis, but the post-FLA and postnatal questionnaires were not sent out. If 
following FLA the couple suffered a dIUFD, double NND, or terminated the whole 
pregnancy, the post-FLA and/or postnatal questionnaires were not sent out according 
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to the timing of the double IUFD/NND or termination. This was because the 
Attachment Scales would no longer be relevant. Those with a sIUFD or single NND 
were still eligible and were asked to complete the follow-up questionnaires. If a 
participant was considered at high-risk of suicide based on the answers of the 
questionnaire, the participant and general practitioner (GP) were contacted. 
Completed questionnaires were stored in a secure place, and data were anonymised 
prior to data entry onto the statistical package. 
 
8.2.4 Missing data 
If a participant only completed the Attachment Scale, or EPDS portion of the 
questionnaire, their answers were included for the completed portion. Where one 
person in the couple did not complete the questionnaire, the answers of the other 
person were included in the analysis examining either mothers or fathers individually, 
but the couple was not included in the comparison between mothers and fathers. For 
single missing answers, median substitution was performed as indicated in Table 8.3, 
no other imputations were performed. 
 
8.2.5 Statistical analysis 
All statistical analysis was performed in Stata (Stata, 2015 Release 13.1 StataCorp, 
Texas, USA). As this was a sample of convenience, no power calculation was 
performed. 
The skewing and kurtosis of the data were assessed using the sktest command 
(StataCorp. 2013i), and the Shapiro-Wilk test of normality was performed using the 
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swilk command (StataCorp. 2013k). Descriptive data are reported as medians and 
IQRs. As the maximum total score of the PAAS was different to the MAAS, MPAS 
and PPAS, the scores were converted into percentages of the maximum total score 
to allow comparison. 
Box plots were generated using the graphbox command (StataCorp. 2013c). The 
Wilcoxon rank-sum test was performed to compare the maternal and paternal scores 
at each time point, and those with and without mental health problems, using the 
ranksum command (StataCorp. 2013f). Fisher’s exact test was used to compare the 
proportion of mothers and fathers above the EPDS cut-off at each time point, using 
the exact command (StataCorp. 2013f).  
A line plot was generated using the twoway connected command (StataCorp. 2013d) 
to visually display the data longitudinally. To assess any difference between the three 
time points within the mothers or fathers who completed questionnaires at all 3 time 
points, the Shapiro-Wilk test of normality was performed, and the presence of outliers 
was examined using box plots. All data were normally distributed except the paternal 
pre-FLA EPDS score, and the only outliers were 2 paternal attachment scores pre-
FLA. Consequently one-way repeated-measures analysis of variance (ANOVA) was 
performed using the anova command (StataCorp. 2013a) to assess maternal 
attachment and EPDS scores over time. If a significant difference was found, this 
was investigated by linear regression using the regress command (StataCorp. 
2013g). Paternal attachment and EPDS scores were examined by the Kruskall-Wallis 
test using the kwallis command (StataCorp. 2013e). 
 348 
 
To evaluate if there was an association between attachment and EPDS scores 
Kendall’s rank correlation coefficients were calculated using the ktau command 
(StataCorp. 2013j). Sub-group analysis was planned to assess the effect of those 
with past/current mental health problems, and those with one survivor compared to 
two survivors. A post-hoc sub-group analysis was performed to assess the effect of 
participants who did not complete the pre-FLA questionnaires before FLA and 
completed it immediately after FLA instead. 
 
8.2.6 Ethical approval 
This study received ethical approval from East Midlands Research Ethics Committee 
(15/EM/0244) and all participants gave written informed consent (see Appendix 10.12 
for patient information sheet and Appendices 10.13 and 10.18 for the consent forms). 
 
8.3 Results 
 
8.3.1 Participant characteristics 
Fifty-four women, under 24 weeks gestation, were booked for FLA for TTTS at the 
West Midlands Fetal Medicine Centre during the 19 month recruitment period, of 
which 27 couples were approached, and 27 couples (100%) consented and agreed 
to participate. One couple was missed in the screening process. The other 26/54 
women were ineligible to participate for the following reasons: no partner present at 
appointment (n=16), seen by researcher the morning of FLA therefore insufficient 
time to complete questionnaire (n=7), dIUFD the following morning/prior to 
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commencing FLA (n=1), unable to read English (n=1), declined to talk to researcher 
(n=1). Two couples did not complete the questionnaire prior to FLA and when asked 
about the questionnaires immediately following FLA stated that they had “forgotten” 
and were unable to complete them, thus the data presented here are for 25 couples 
(25 mothers, and 25 fathers). The demographic information is given in Table 8.2. 
There were no same-sex couples. All mothers and fathers who participated were 
couples at the time of recruitment, but not all were married or co-habiting and 
biological parental status was not confirmed. One couple was local and was booked 
at Birmingham Women’s and Children’s NHS Foundation Trust thus was already 
undergoing routine antenatal care at the same hospital as the West Midlands Fetal 
Medicine Centre. The other 24 couples were booked at other hospitals and had to 
travel for FLA. 
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Table 8.2 Participant demographic information 
Maternal characteristics (n=25)  
Maternal age median (IQR) years 28.76 (26-32) 
Parity n (%) 
 Nulliparous 
 Multiparous 
 
16 (64) 
9 (36) 
Maternal ethnicity n (%) 
 White European 
 
26 (100) 
Quintero staging at FLA median (IQR) 3 (2-3) 
Gestation at FLA median (IQR) weeks 19+3  
(18+2-20+6) 
Gestation 1 month following FLA median (IQR) 
weeks 
23+5  
(22+4-25+1) 
 
23/25 (92%) couples completed all sections of the pre-FLA questionnaire (Table 8.3), 
although 6/25 (24%) of couples completed the pre-FLA questionnaires immediately 
following FLA. In one couple, neither the mother nor father completed the EPDS: the 
mother had current mental health problems, and the father had a history of mental 
health problems. In another couple the father did not complete the pre-FLA 
questionnaires, and in another couple the father did not complete the post-FLA 
questionnaire although his partner did, therefore these couples were not included in 
the mother to father comparisons. All pregnancy outcomes for those who underwent 
FLA were collected: 9/23 (39.1%) pregnancies resulted in a double survivor, 8/23 
(34.8%) resulted in a single survivor and 6/23 (26.1%) in no survivors. FLA was 
unable to be performed in 2 pregnancies therefore these couples were not eligible for 
follow-up. The questionnaire return rate from eligible couples post-FLA was 8/18 
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(44.4%), and postnatal was 5/17 (29.4%) with one reminder due to the tight time 
frame of the follow-up and progressing pregnancy. The postnatal questionnaires 
were completed when baby(ies) had been discharged from the NNU as they were 
posted out 6 weeks after their planned delivery date of 36 weeks. 
 
8.3.2 Mental health history of participants 
At diagnosis of TTTS, one mother reported a current mental health problem (anxiety), 
and 6 mothers reported a combination of previous mental health problems (5 anxiety, 
2 with concurrent depression, 1 postnatal depression, 1 post-traumatic stress 
disorder, 1 anorexia nervosa). Five fathers reported a current mental health problem 
at diagnosis of TTTS (1 depression, 4 anxiety, 2 with concurrent depression, 1 
obsessive compulsive disorder), and 2 fathers reported a past mental health problem 
(1 anxiety, 1 depression). There were no new mental health problems diagnosed 
during the study. 
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Table 8.3 Questionnaires received at each time point and pregnancy outcome 
Study 
ID 
Pre-
FLA 
Post-
FLA 
Post-
natal Pregnancy outcome Issues with questionnaire completion 
2033 y y y 2 survivors born at 32w None 
2036 y y  
1 survivor born at 35w, sIUFD at 
20w Father did not complete post-FLA 
2039 y   0 survivors, dIUFD at 23w None 
2040 y   1 survivor born at 26w, 1 NND None 
2041 y   1 survivor None 
2042 y y  2 survivors born at 30w 
Maternal and paternal pre-FLA completed just after 
FLA 
2047 y y y 2 survivors born at 30w None 
2054 y   2 survivors born at 32w None 
2055 y y y 1 survivor born at 36w, sIUFD 17w None 
2066 y   
1 survivor born at 28w, sIUFD at 
18w Answer MAAS 1.3 missing (median substitution) 
2069 y   2 survivors born at 30w None 
2071 y y y 2 survivors None 
2078 y   0 survivors, dIUFD at 21w None 
2095 y   1 survivor born at 31w None 
2097 y y y 2 survivors Maternal and paternal pre-FLA completed just after FLA 
2098 y   1 survivor born at 34w None 
2101 y   Unable to perform FLA 
Maternal and paternal pre-FLA completed just after 
FLA. No maternal or paternal EPDS completed 
2102 y   0 survivors, sIUFD at 19w then TOP None 
2105 y   Unable to perform FLA Answer MAAS 1.14 missing (median substitution) 
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Study 
ID 
Pre-
FLA 
Post-
FLA 
Post-
natal Pregnancy outcome Issues with questionnaire completion 
2107 y   0 survivors, dIUFD None 
2116 y   
0 survivors, PPROM at 18w then 
TOP 
Father did not complete pre-FLA. Answer MAAS 1.16 
missing (median substitution) 
2118 y   
1 survivor born at 30w, sIUFD at 
30w 
Maternal and paternal pre-FLA completed just after 
FLA 
2119 y   2 survivors born at 31w 
Maternal and paternal pre-FLA completed just after 
FLA 
2123 y y  2 survivors born at 29w  
Maternal and paternal pre-FLA completed just after 
FLA 
2125 y   0 survivors, dIUFD at 21w Answer MAAS 1.15 missing (median substitution) 
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8.3.3 Maternal and paternal attachment  
 
Table 8.4 Maternal and paternal attachment pre-fetoscopic laser ablation (FLA), 
post-FLA and postnatally 
NA: not applicable as sub-group does not exist in questionnaire. Median and IQR 
presented. 
 
 Maternal 
pre-FLA 
(n=25) 
Maternal 
post-
FLA 
(n=8) 
Maternal 
postnatal 
(n=5) 
Paternal 
pre-FLA 
(n=24) 
Paternal 
post-
FLA 
(n=7) 
Paternal 
postnatal 
(n=5) 
Total 
Attachment 
Scale score 
79 
(74-82) 
82 
(70.5-
86.5) 
86.8 
(74.4-
88.2) 
63.5 
(55-67) 
65 
(58-68) 
82.1 
(77.4-
84.8) 
Total 
Attachment 
Scale score 
as 
percentage of 
maximum 
possible 
83.2 
(77.9-
86.3) 
86.3 
(74.2-
91.1) 
91.4 
(78.3-
92.8) 
79.4 
(68.8-
83.8) 
81.3 
(72.5-85) 
86.4 
(81.5-
89.3) 
Sub-groups of Attachment Scales 
Quality of 
attachment 
43 
(40-45) 
44 
(40-46.5) 
42.2 
(42.2-
42.2) 
35 
(32-36.5) 
34 
(32-37) 
NA 
Intensity of 
attachment 
30 
(29-34) 
33 
(26-34) 
NA 20 
(15-21.5) 
21 
(16-22) 
NA 
Pleasure in 
interaction 
NA NA 24 
(21-25) 
NA NA 27.2 
(26.9-
27.3) 
Absence of 
hostility 
NA NA 19.6 
(17.6-21) 
NA NA NA 
Patience and 
tolerance 
NA NA NA NA NA 36.2 
(30.1-
37.2) 
Affection and 
pride 
NA NA NA NA NA 20 
(19-20) 
 
There was no significant difference between maternal and paternal attachment 
scores at each time point (Table 8.4, Figure 8.1). When maternal and paternal 
attachment in the 5 couples who completed questionnaires at all 3 time points was 
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examined over time, ANOVA demonstrated a significant difference in maternal 
attachment, F(2, 4)=7.86, p=0.0258 with Greenhouse and Geisser correction of 
sphericity (ε=0.7359) (Greenhouse 1959). Post hoc linear regression revealed a 
significant increase in maternal attachment from pre-FLA to postnatal (p=0.004) 
(Figure 8.2 (a)). This result should be interpreted with caution as only 5 couples were 
able to be included in this analysis and the antenatal score at diagnosis of TTTS may 
be more of a reflection of adjustment to the diagnosis of TTTS than of antenatal 
attachment. There was no significant change in paternal attachment over time using 
the Kruskal Wallis test, χ2(2)=2.414, p=0.30 (Figure 8.2(b)). It was not possible to 
compare couples with 1 survivor to those with 2 survivors due to insufficient numbers. 
However, it was interesting to note that the one couple with a sIUFD who completed 
the questionnaires at all 3 time points reported the lowest attachment scores pre-FLA 
and postnatally (Figure 8.2(a) and Figure 8.2(b)). 
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Figure 8.1 Box and whisker plots of maternal and paternal Attachment Scale 
scores as percentages of total maximum score pre-fetoscopic laser ablation 
(FLA), post-FLA and postnatally  
(n=25 mothers, n=25 fathers) No significant difference was found between mothers 
and fathers. Median and IQR presented. 
 357 
 
 
 
 
 
 
 
 
 
60
70
80
90
10
0
M
at
er
na
l a
tta
ch
m
en
t s
co
re
 (%
)
1 1.5 2 2.5 3
Timepoint
2055 2033
2097 2017
2047
60
70
80
90
10
0
Pa
te
rn
al
 a
tta
ch
m
en
t s
co
re
1 1.5 2 2.5 3
Timepoint
2055 2033
2097 2017
2047
Figure 8.2 Line plot of individual (a) maternal (b) paternal Attachment 
Scale scores as a percentage of the maximum possible score pre-
fetoscopic laser ablation (FLA), post-FLA and postnatally 
(n=5 couples included at all 3 time points) The bottom dark blue line with circle 
markers is the couple with 1 survivor, the other 4 couples had 2 survivors. 
p<0.05 maternal attachment pre-FLA to postnatal 
 
M
at
er
na
l t
ot
al
 a
tta
ch
m
en
t s
co
re
 (%
) 
 Pre-FLA    Post-FLA        Postnatal 
2071 
P
at
er
na
l t
ot
al
 a
tta
ch
m
en
t s
co
re
 (%
) 
Pre-FLA    Post-FLA    Postnatal 
71 
(a) 
 
 
 
 
 
 
 
 
(b) 
 358 
 
When the cohort was divided based on mental health problems, there were no 
statistically significant differences between those with and without mental health 
problems (Table 8.5). Mothers with a history of mental health problems reported a 
trend of lower attachment scores at all time points than mothers with no history of 
mental health problems, but there was only one mother in the postnatal group with a 
history of mental health problems. The opposite was true in fathers: fathers with 
current or a past mental health problems reported a trend of higher attachment 
scores than fathers with no history of mental health problems, but there was only one 
father with current mental health problems, and one father with past mental health 
problems who completed the pre-FLA and post-FLA questionnaires. 
 
Table 8.5 Total parental attachment scores as a percentage of the maximum 
possible score pre-fetoscopic laser ablation (FLA), post-FLA and postnatally 
according to presence of mental health problems 
NA: not applicable as no participants in the sub-group. Median and IQR presented. 
 
 Maternal 
pre-FLA 
 
Maternal 
post-FLA 
 
Maternal 
postnatal 
 
Paternal 
pre-FLA 
 
Paternal 
post-
FLA 
 
Paternal 
postnatal 
 
Current 
mental 
health 
problems 
85.26 
n=1 
NA 
n=0 
 
NA 
n=0 
 
81.25 
(71.25-
83.75) 
n=5 
87.50 
n=1 
96.00 
n=1 
Past 
mental 
health 
problems 
78.95 
(76.32-
82.37) 
n=6 
71.58 
(68.95-
74.21) 
n=2 
78.32 
n=1 
85.00 
(83.13-
86.88) 
n=2 
83.75 
n=1 
89.26 
n=1 
No history 
of mental 
health 
problems 
83.68 
(79.21-
87.11) 
n=18 
89.47 
(85.26-
91.32) 
n=6 
92.11 
(87.68-
94.00) 
n=4 
77.50 
(67.50-
82.50) 
n=17 
76.25 
(72.50-
81.25) 
n=5 
81.47 
(79.42-
83.95) 
n=3 
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There was no significant difference between those who completed the pre-FLA 
attachment questionnaire before FLA, and those who completed it immediately after 
FLA (data not shown). 
 
8.3.4 Maternal and paternal depressive symptoms  
There was a significant difference between the maternal and paternal EPDS scores 
pre-FLA and post-FLA, but not postnatally (Table 8.6, Figure 8.3). When the scores 
were translated into the number of participants above the cut-off for major depressive 
disorders there was no significant difference between the mothers and fathers at 
each time point. The time point with the highest proportion of mothers above the cut-
off was post-FLA (4/8, 50.0%). Postnatally no mothers had an EPDS score above the 
cut-off, irrespective of pregnancy outcome. The time point with the highest proportion 
of fathers above the cut-off was pre-FLA (6/23, 26.1%). Postnatally 1/5 (20%) fathers 
had an EPDS score above the cut-off, which interestingly was the pregnancy with 1 
survivor whereas the other 4/5 pregnancies had 2 survivors. When EPDS scores in 
the 5 couples who completed questionnaires at all 3 time points were examined over 
time, ANOVA demonstrated a significant difference in maternal depressive symptoms 
F(2, 4)=8.03, p=0.0308 with Greenhouse and Geisser correction of sphericity 
(ε=0.6552) (Greenhouse 1959). Post hoc linear regression revealed a significant 
decrease in maternal EPDS score from pre-FLA to postnatal (p=0.006) Figure 8.4(a). 
This result should be interpreted with caution as only 5 couples were able to be 
included in this analysis and as previously highlighted this may be more of an acute 
adjustment reaction to the diagnosis of TTTS rather than antenatal depression. There 
was no significant change in paternal depressive symptoms over time using the 
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Kruskal Wallis test, χ2(2)=2.738, p=0.25 Figure 8.4(b). It was not possible to formally 
compare couples with 1 survivor to those with 2 survivors due to insufficient numbers. 
However, the couple with a sIUFD who completed the questionnaires at all 3 time 
points reported the highest EPDS scores postnatally (Figure 8.4(a) and Figure 
8.4(b)). 
 
Table 8.6 Maternal and paternal Edinburgh Postnatal Depression Scale (EPDS) 
scores pre-fetoscopic laser ablation (FLA), post-FLA and postnatally 
*p=0.01 pre-FLA: maternal vs paternal, †p=0.02 post-FLA: maternal vs paternal 
 
 
 
 
 
 
 
 
 
 Maternal 
pre-FLA 
(n=24) 
Maternal 
post-
FLA 
(n=8) 
Maternal 
postnatal 
(n=5) 
Paternal 
pre-FLA 
(n=23) 
Paternal 
post-
FLA 
(n=7) 
Paternal 
postnatal 
(n=5) 
Total 
EPDS 
score 
median 
(IQR) 
12.5* 
(7-17) 
12.5† 
(9.5-
17.5) 
4 
(3-7) 
8* 
(5-11.5) 
6† 
(4.5-9.5) 
3 
(2-9) 
Number of 
participants 
above cut-
off n/N (%) 
10/24 
(41.7) 
4/8 
(50.0) 
0/5 
(0.0) 
6/23 
(26.1) 
1/7 
(14.2) 
1/5 
(20.0) 
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Figure 8.3 Box and whisker plots of maternal and paternal Edinburgh 
Postnatal Depression Scale (EPDS) scores pre-fetoscopic laser ablation 
(FLA), post-FLA and postnatally  
(n=24 mothers, n=24 fathers) *p<0.05 pre-FLA, and post-FLA, when mothers 
were compared to fathers. Median and IQR presented. 
* 
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Figure 8.4 Line plot of individual (a) maternal (b) paternal Edinburgh 
Postnatal Depression Scale (EPDS) scores pre-fetoscopic laser ablation 
(FLA), post-FLA and postnatally 
(n=5 couples included at all 3 time points) The bottom dark blue line with circle 
markers (2055) is the couple with 1 survivor, the other 4 couples had 2 survivors. 
p<0.05 maternal EPDS total pre-FLA to postnatal 
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When the cohort was divided based on mental health problems, mothers with a 
history of mental health problems reported significantly greater depressive symptoms 
post-FLA than mothers with no mental health problems (Table 8.7). 
Fathers with current mental health problems reported significantly greater depressive 
symptoms pre-FLA than fathers with no history of mental health problems. However, 
these increases in EPDS score did not translate into a significant difference in the 
proportion of mothers and fathers above the cut-offs. There was a trend of greater 
depressive symptoms pre-FLA in mothers with a history of mental health problems 
compared to mothers with no mental health problems, and in fathers with current 
mental health problems compared to fathers with no mental health problems. It is not 
possible to draw conclusions regarding postnatal depression because of insufficient 
numbers. 
 
There was a significant difference (p=0.03) in the median maternal EPDS scores 
between those who completed the pre-FLA questionnaire before the FLA (10.5 [IQR: 
7-16.75] 18 mothers) and those who completed it immediately after FLA (19 [IQR: 
4.75-22.5] 6 mothers). This did not translate to a difference in the proportion of 
mothers who scored above the cut-off. There was no difference in the fathers (data 
not shown). 
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Table 8.7 Total maternal and paternal Edinburgh Postnatal Depression Scale 
(EPDS) scores pre-fetoscopic laser ablation (FLA), post-FLA and postnatally 
according to presence of mental health problems 
*p<0.05 maternal post-FLA: past mental health problems vs no mental health 
problems †p<0.05 paternal pre-FLA: current mental health problems vs no mental 
health problems. NA: not applicable as no participants in the sub-group. Median 
(IQR) presented. 
 
 Maternal 
pre-FLA 
 
Maternal 
post-
FLA 
 
Maternal 
postnatal 
 
Paternal 
pre-FLA 
 
Paternal 
post-
FLA 
Paternal 
postnatal 
 
Current 
mental 
health 
problems  
NA NA NA 12† 
(10-15) 
9 2 
Above cut-off 
n/N (%) 
0/0 0/0 0/0 3/5 
(60) 
0/1 
(0) 
0/1 
(0) 
Past mental 
health 
problems  
17 
(11-20) 
23.5* 
(20.75-
26.25) 
3 6 3 1 
Number of 
participants 
above cut-off 
n/N (%) 
4/6 
(66.6) 
2/2 
(100) 
0/1 
(0) 
0/1 
(0) 
0/1 
(0) 
0/1 
(0) 
No history of 
mental 
health 
problems  
10 
(7-16.75) 
10* 
(9.25-
13.75) 
 
5.5 
(3.5-7.5) 
7† 
(4-9) 
6 
(6-10) 
9 
(6-10.5) 
Number of 
participants 
above cut-off 
n/N (%) 
6/18 
(33.33) 
2/6 
(33.33) 
0/4 
(0) 
3/17 
(17.65) 
1/5 
(20) 
1/3 
(33.33) 
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8.3.5 Association between parental attachment and depressive symptoms 
There was no association between parental attachment and depressive symptoms in 
mothers or fathers, at any time point (Table 8.8, scatter plots not shown). 
 
Table 8.8 Correlation between maternal and paternal attachment scores and 
Edinburgh Postnatal Depression Scale (EPDS) scores pre-fetoscopic laser 
ablation (pre-FLA), post-FLA and postnatally. 
 
 
8.4 Discussion 
 
8.4.1 Maternal and paternal attachment  
There was no significant difference between maternal and paternal attachment 
scores at each time point. This may be because the fathers who were more attached 
were more likely to attend the Fetal Medicine Centre, and agree to participate in the 
study, or may be reflective of small sample size. Although results are conflicting in 
other studies regarding whether mothers or fathers report higher levels of attachment 
there is a dearth of recent studies (Ustunsoz 2010), and very few in the UK, thus it 
could be that as fathers have become more involved in family life, paternal 
 
 Maternal 
pre-FLA 
(n=24) 
Maternal 
post-FLA 
(n=8) 
Maternal 
postnatal 
(n=5) 
Paternal 
pre-FLA 
(n=24) 
Paternal 
post-
FLA 
(n=8) 
Paternal 
postnatal 
(n=5) 
Kendall’s 
tau-b 
correlation 
coefficient 
-0.28 -0.47 -0.40 -0.15 -0.39 -0.60 
p value 0.07 0.13 0.46 0.35 0.29 0.22 
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attachment levels have increased. Another explanation is that mothers with TTTS 
pregnancies decrease their attachment to the fetuses in the antenatal period as a 
protective mechanism (Damato 1998), consequently mothers are no longer more 
attached than fathers. The employment of a protective mechanism in mothers of 
high-risk pregnancies has been reported by other studies (Penticuff 1982, Moore 
1983, Stainton 1992, Feldman 1999), and is supported in this study by the level of 
maternal attachment increasing from at time of diagnosis of TTTS to postnatally, but 
there being no significant increase at the post-FLA time point when the fetuses are 
still in danger. This is supported by Beauquier-Maccotta et al. who also reported no 
increase in antenatal maternal attachment in TTTS pregnancies (Beauquier-Maccotta 
2016). Alternatively, the increase in maternal attachment over time may be a 
reflection of the general increase in maternal attachment in relation to gestational 
age, as in other studies (Leifer 1977, Cranley 1981, Heidrich 1989, Raphael-Leff 
2001, Condon 2013). No change over time was seen in the fathers which may reflect 
that fathers vary in the way they cope with stressful situations, with some fathers 
employing protective mechanisms and others not. It is important to highlight that the 
time period for the MAAS and PAAS was changed to “since the diagnosis of TTTS” 
as opposed to “over the past 2 weeks” thus the pre-FLA MAAS and PAAS should be 
interpreted with caution as the score may be more reflective of an acute adjustment 
reaction. Unfortunately it was not possible to assess the effect that time from 
diagnosis/suspicion of TTTS had on attachment as 24/25 couples underwent 
antenatal care in other hospitals and may have had discordant liquor volumes prior to 
referral to the West Midlands Fetal Medicine Centre. 
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8.4.2 Maternal and paternal depression 
Mothers reported significantly greater depressive symptoms than fathers at diagnosis 
of TTTS, and 1 month post-FLA, but there was no difference in postnatal depressive 
symptoms between mothers and fathers. This may link to the guilt and responsibility 
that mothers feel as it is them who are growing the fetuses inside them, and who may 
blame themselves for the pregnancy being complicated by TTTS. Another interesting 
finding was from the post-hoc analysis of mothers who forgot to complete the pre-
FLA questionnaire before the FLA and completed it immediately after FLA who 
reported significantly greater depressive symptoms than mothers who completed the 
questionnaire pre-FLA. This may be because the mothers were too nervous or 
depressed to remember to complete the questionnaire prior to FLA. No difference 
was seen in the fathers, but mothers had the additional stress of being the ones 
physically going through the FLA. 
 
Maternal depressive symptoms decreased from diagnosis of TTTS to postnatally. In-
keeping with the results of this study, Beauquier-Maccotta et al. also reported a lower 
rate of maternal depressive symptoms postnatally than at the diagnosis of TTTS 
which fits with the pregnancy continuing to be at risk throughout the antenatal period 
and mothers experiencing relief at the delivery of the survivor(s) (Beauquier-Maccotta 
2016). The mean EPDS score reported by Beauquier-Maccotta et al. at the diagnosis 
of TTTS was 12.06 (SD 5.58) which is comparable to the median score of 12.5 (IQR: 
7-17) in this study, however they used a cut-off of 11.5 for their French cohort 
(compared to a validated cut-off of 15 and above in English speaking cohort) and 
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therefore they reported a higher proportion of mothers scoring above the cut-off at 
the diagnosis of TTTS compared to in this study (72% vs 41.7% respectively).  
Although in the current study there were significant changes in the EPDS scores, this 
did not translate into changes in the proportion of participants above the cut-offs. The 
rate of 0/5 (0%) women in the postnatal period with an EPDS score above the cut-off, 
is likely to be an underestimate due to insufficient numbers. There was no change 
over time in fathers which may reflect that fathers experience potentially high-risk 
situations in a more variable way than mothers. Multiple studies have reported that 
fathers believe their role is to provide support to the mother and to stay in control of 
the situation, and consequently do not feel able to express their emotions (Due 
2017). Alternatively it could be that mental health history played a part as fathers with 
current mental health problems reported significantly greater depressive symptoms at 
diagnosis of TTTS than fathers with no history of mental health problems. Another 
explanation is that other confounding factors including quality of relationship with 
their partner and low social support, that are known to affect paternal depressive 
symptoms (Wee 2011), were not accounted for in this study due to the small 
numbers, and were beyond the scope of the current study. It is important to highlight 
that the time period for the maternal and paternal pre-FLA EPDS was changed to 
“since the diagnosis of TTTS” as opposed to “in the past seven days” thus the pre-
FLA EPDS should be interpreted with caution as the score may be more reflective of 
an acute adjustment reaction. Unfortunately it was not possible to assess the effect 
that time from diagnosis/suspicion of TTTS had on depressive symptoms as 24/25 
couples underwent antenatal care in other hospitals and may have had discordant 
liquor volumes prior to referral to the West Midlands Fetal Medicine Centre. 
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8.4.3 Effect of number of survivors on attachment and depression 
It was not possible to formally assess if the number of survivors affected parental 
attachment, but the one couple with one survivor who completed the questionnaires 
at all three time points did report the lowest attachment score at diagnosis of TTTS 
and postnatally, and the highest postnatal depression scores. As the attachment 
scores were lowest at diagnosis of TTTS prior to the sIUFD, it may be that the mother 
and father in this couple naturally have a lower attachment tendency, or they may 
have already employed a protective mechanism prior to assessment at the Fetal 
Medicine Centre. 
It was interesting that postnatally they both had the lowest attachment scores and 
highest depression scores. This suggestion that parents of twins with sIUFD report 
greater depressive symptoms than those with 2 survivors is supported by Falletta 
2018 (Falletta 2018), and may reflect the difficulty these parents have in caring for a 
new-born, whilst grieving the loss of the other twin, with the surviving twin acting as a 
reminder of the deceased identical twin (Swanson 2009, Richards 2015, Jordan 
2018).  
 
8.4.4 Effect of mental health problems on attachment and depression 
When participants with mental health problems were examined as a sub-group, 
although no statistically significant difference was found with parental attachment, 
interestingly a trend did appear of mental health history having opposing effects on 
maternal and paternal attachment: fathers with past and current mental health 
problems reported higher attachment scores than fathers with no mental health 
problems at all three time points, whereas mothers with past mental health problems, 
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including previous postnatal depression, reported lower attachment scores than 
mothers with no history of mental health problems. As mentioned previously, this may 
be a reflection of protective mechanisms being employed by mothers, but not fathers. 
When perinatal depressive symptoms were examined in the context of mental health 
problems, mothers with a history of mental health problems reported significantly 
greater depressive symptoms 1 month post-FLA than mothers with no mental health 
problems, and fathers with current mental health problems reported significantly 
greater depressive symptoms at diagnosis of TTTS than fathers with no history of 
mental health problems. This is in-keeping with what is reported in the literature with 
antenatal depression being linked to existing mental health problems (Cox 2005, 
Becker 2016). It was difficult to draw conclusions regarding postnatal depression 
because of insufficient numbers.  
 
8.4.5 Association between parental attachment and depression 
Parental attachment was not associated with depressive symptoms in mothers or 
fathers. In the context of TTTS pregnancies, the maternal findings are supported by 
Beauquier-Maccotta et al., but the relationship between paternal attachment and 
depressive symptoms has not been explored before (Beauquier-Maccotta 2016). 
Studies in various countries have shown that decreased maternal attachment is 
associated with increased maternal depression in singleton pregnancies (Taylor 
2005, Goecke 2012), although paternal attachment does not appear to be associated 
with paternal depression (Kunkle 2003). Findings in twin pregnancies, particularly 
those complicated by TTTS may differ from singletons as attachment in twin 
pregnancies is different to in singleton pregnancies (Abbink 1982, Van der Zalm 
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1995, Damato 2004). The diagnosis of a twin pregnancy can cause conflicting 
feelings as not all mothers and fathers are happy with the diagnosis of a twin 
pregnancy (Nys 1998, Beretta 2007) as the diagnosis carries with it not only 
implications for pregnancy risk, but there are physical implications in terms of 
potentially needing to move house, and other additional financial implications such as 
buying a new car. Consequently when the fetuses are in danger, this can cause 
contradictory feelings. In a Danish study of 61 women with twin pregnancies, half of 
women (54%, 33/61) reported happiness at the diagnosis of a twin pregnancy, 34% 
(21/61) reported shock/negative feelings, and 33% (20/61) were uncertain whether 
they were capable of parenting two infants at the same time (Nys 1998). At 27 weeks 
gestation, the percentage of women who reported happiness increased to 70% 
(43/61), and those with shock/negative feelings decreased to 2% (1/61), but those 
uncertain of their parenting ability remained high at 31% (19/61). The chorionicity of 
the twins in the study was not reported, but one would imagine that there would be a 
difference between parents of MC and DC twins due to MC twins being considered 
higher-risk than DC twins. Anxiety also seems to play a role in parental attachment 
and depression (Condon 1997, Kunkle 2003, van Bussel 2010, Dubber 2015) and 
therefore warrants further investigation in TTTS pregnancies, particularly as fathers 
are more likely to report anxiety symptoms than depressive symptoms (Matthey 
2001), and Beauquier-Maccotta et al. reported significantly higher anxiety symptoms 
in mothers with TTTS pregnancies than those with uncomplicated MC or DC twin 
pregnancies (Beauquier-Maccotta 2016).  
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8.4.6 Strengths and limitations 
This is the first time attachment and depression has been explored in a UK cohort of 
mothers and fathers whose pregnancies have been affected by TTTS. All participants 
approached were willing to take part, and there was a good return of pre-FLA 
questionnaires (92.6%), but the proportion of returned post-FLA questionnaires 
(44.4%) and postnatal questionnaires (29.4%) was lower than the generally agreed 
acceptable survey response rate of 60% (Livingston 2012). Consequently, this work 
is at risk of sampling bias as substantial proportions of the population have not been 
represented. The amount of missing data in the returned questionnaires was 
acceptable and is a problem common to postal questionnaire studies. Importantly 
sub-group analysis was performed according to past/current mental health problems 
which have been shown to be one of the biggest predictors of lower parental 
attachment and greater depression symptoms. By only including parents with twin 
pregnancies affected by TTTS, it meant that the confounding factor of including DC 
twins was ameliorated as mothers of DC twins have demonstrated thinking differently 
about their twins compared to mothers of MC twins. Mothers of DC twins defined 
each baby with different characteristics, whereas MC twin mothers think of each baby 
as being in a pair (Van der Zalm 1995). As maternal scores were compared with 
paternal scores, this also decreased the role of other potential confounding founders 
such as household income, due to the couple acting as an internal control in some 
analyses. Although ethnicity was not an exclusion criteria, only one ethnicity was able 
to be included in this cohort which may be seen as a limitation on one hand because 
the results are not generalisable to other ethnicities and cultures, but it does mean 
that ethnicity was not a confounding factor either, and there was no effect of cultural 
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bias (Matthey 2001). Another strength of this study was the use of a validated 
depression screening tool specific to pregnancy that has been used in twin 
pregnancy before. Although the EPDS does not provide a definitive diagnosis of a 
depressive disorder according to the DSM-IV criteria, it does have a high sensitivity 
and specificity and is therefore considered an acceptable screening tool, and is used 
in routine clinical care. It was decided to explore attachment per total surviving 
number of fetuses/infants, and not per fetus which is believed to be a unique 
characteristic of this study. Although mothers in a study of 214 low- and high-risk 
twins reported a significantly higher attachment score in the second born twin, the 
actual difference in the score was not believed to have a practical impact on 
attachment, and no reference was made to chorionicity which is known to affect 
attachment (Damato 2000). When Beauquier-Maccotta et al. asked mothers to 
complete a Prenatal Attachment Inventory (PAI) for each twin fetus from TTTS 
pregnancies there was no significant difference between the twins at any time point 
(20, 26, 32 weeks gestation) including no difference depending on whether the twin 
was the donor or recipient (Beauquier-Maccotta 2016).  
 
There were several limitations to this study. One was the geographical spread of 
patients who are treated at the West Midlands Fetal Medicine Centre, which may 
have meant that fewer participants completed the follow-up questionnaires than if 
they had had their antenatal follow-up care at the Fetal Medicine Centre. Only one 
couple was local whereas the other 24 couples had to travel for FLA, which one 
could hypothesise may affect how parents cope psychologically with TTTS. How 
couples are counselled at the start of a MC twin pregnancy may also differ between 
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units, with some parents reporting not having heard of the condition until they were 
diagnosed with it, and others being aware of the risk from their booking appointment.  
The issue of geographical patient spread is a problem with all studies of FLA for 
TTTS as FLA needs to be performed by experienced operators, and thus treatment 
has to be centralised (Morris 2010). This also meant that interviews to delineate the 
reasons behind the questionnaire responses were not possible within this study. 
However there is a benefit to using questionnaires as respondents are believed to be 
more truthful when answering questionnaires than in face to face interviews (Leedy 
2001) as ‘acceptability influence’ is a known issue of self-report questionnaires 
(Edwards 1957). This could have been a potential issue with this study as Condon et 
al. explains that participants may answer attachment questions in the way that they 
believe reflects well on them, and in the way that they perceive society expects them 
to answer (Condon 1998). However, one way to view it is that if the ‘average person’ 
embellishes their answers to appear more socially desirable, the whole distribution of 
the cohort’s responses will shift, which has a minimal effect when the scores are 
converted to standardised scores (Nunnally 1970). As the study was not concerned 
with absolute attachment scores, but the comparison between mothers and fathers, 
and the change in scores over time, the ability to discriminate between the low- and 
high-attachment groups is more important than the absolute scores, and the MAAS, 
PAAS, MPAS, PPAS do discriminate between the groups (Condon 1998, Condon 
2013). 
 
By the nature of the study the results are not generalisable to all parents with a 
pregnancy complicated by TTTS. It was not possible to include couples who did not 
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read English who may have a different cultural background and thus may be 
psychologically affected by TTTS differently. It was also not possible to include 
couples in which the father did not attend the Fetal Medicine Centre (16/54, 29.6%) 
which would be an interesting group to assess as it may be that not being at the 
appointment affects paternal attachment and depression, particularly in the antenatal 
period. Additionally, it may be that not having the paternal support during the 
procedure impacts maternal psychological well-being. Another group who are 
important to evaluate are those with a dIUFD, but as the attachment questionnaires 
would not be relevant they were not included in this study. There is a risk of selection 
bias as those very distressed may be less willing to participate, leading to an 
underestimate of the negative reactions in these circumstances, and they may also 
be less likely to return follow-up questionnaires. Performing interviews may be a way 
to explore this further. The missing outcomes for some pregnancies may mean that 
confounding factors such as an abnormal fMRI, or neonatal comorbidity were unable 
to be accounted for. 
 
No studies in twin pregnancies were found that have used the Attachment Scales by 
Condon et al. which is a limitation of the study. The majority of questions on the scale 
seemed appropriate, although 1 question in the MAAS and PAAS was difficult to 
interpret in the context of TTTS: “Since the diagnosis of TTTS when I think about the 
babies inside me I get feelings which are:” the responses vary from “Very sad” to 
“Very happy”. As the pregnancy is in danger at this point the question may not be 
able to discriminate between parents with high and low fetal attachment. The scoring 
of this question was not altered, in line with other studies which have used the MAAS 
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in high-risk pregnancies (White 2008, Pisoni 2015). Some wording of the 
questionnaires was amended to reflect twin pregnancies, and the time over which 
parents were asked to think back over, as due to the rapid disease progression of 
TTTS and the necessity for treatment, the pre-FLA and post-FLA questionnaires 
were changed to “since diagnosis of TTTS” from “over the last 7 days”. The postnatal 
questionnaires were not changed. There is also no validated cut-off for the paternal 
antenatal EPDS score (Matthey 2001) but 12 and above was used as a cut-off, akin 
to 2 other studies that investigated antenatal paternal depression using the EPDS. 
This cut-off was 2 points higher than the validated postnatal cut-off, which is the 
difference between the maternal antenatal and postnatal cut-offs (Matthey 2006), but 
it is important to highlight that the paternal antenatal depressive symptoms cut-off 
may not be reflective of pathology. 
Demographic data on mothers were collected but not fathers, and results were not 
adjusted for demographic factors. The main limitation is the sample size, particularly 
in the longitudinal analyses as only 5 couples completed questionnaires at all 3 time 
points thus the results should be interpreted with caution. 
 
Research into the relationship between attachment and demographic 
variables/potential confounding factors such as: IVF, whether pregnancy was 
planned or not, parental educational level, and family income has been conflicting 
(Damato 2004). The majority of evidence does not support any association with 
these factors (Kemp 1987, Laxton-Kane 2002, Lahann 2008). Lahann et al. (Lahann 
2008) reported a significant relationship between maternal antenatal attachment in 
twin pregnancy and maternal age, parity and known gender of fetuses, but these 
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variables were not adjusted for as these findings conflict with other studies which did 
not find a significant difference (Mercer 1993b, Siddiqui 2000). The only factors that 
have been consistently reported to affect attachment are gestational age (Damato 
2004, Beauquier-Maccotta 2016), and the ability to feel fetal movements 
(‘quickening’) which have demonstrated an association with increased maternal 
attachment (Lerum 1989, Bloom 1995, Damato 2004). These factors were 
incorporated in this study as attachment over time was explored, and the pre-FLA 
and post-FLA time points represent pre- and post-‘quickening’. 
 
8.4.7 Clinical implications and future research 
This work demonstrates that a high proportion of mothers with TTTS pregnancies 
score above the EPDS cut-off, particularly 1 month after FLA (50%). Therefore 
referral centres providing on-going antenatal care for these women after FLA should 
be aware of this risk and screen and refer for additional psychological support as 
necessary. The clinical team in France routinely offer all women referred to their 
centre for FLA psychological follow-up, although the effect of this follow-up has not 
been evaluated. In light of the findings of this study, psychological follow-up should 
be considered in the UK patient population, (Beauquier-Maccotta 2016). Patients and 
health care professionals can be reassured that generally maternal depressive 
symptoms decrease in the postnatal period although it has been highlighted that the 
maternal postpartum depression rate may be an underestimate. With regards fathers, 
health care practitioners should be aware of the variable way fathers experience 
TTTS, and although the EPDS has been validated as a screening tool for fathers, 
there is not a validated antenatal cut-off for depressive disorders, and fathers may 
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not always feel able to express their emotions. Health care professionals should be 
particularly aware of mothers and fathers who have a history of mental health 
problems, and those whose pregnancy has resulted in 1 survivor. A recent study 
found that psychological issues thought to be a result of a TTTS pregnancy persist 
for at least 7 years following FLA (Vergote 2018), and that the loss of a child in a 
previous pregnancy impacts subsequent pregnancies (O’Leary 2004) thus health 
care professionals should be aware of this when caring for women in pregnancies 
subsequent to their TTTS pregnancy. 
Continued research in this area, with larger cohorts in different countries and 
ethnicities using translated questionnaires with appropriate validation is required. 
Future research should include the exploration of anxiety symptoms, and their 
relationship with parental attachment and depression, particularly in fathers. 
Qualitative interviews are important to ascertain reasons behind the scores on the 
questionnaires, and confirm the diagnosis of depression. Parental attachment scores 
in TTTS pregnancies should be validated with another measure of attachment, and a 
cut-off for paternal antenatal depression using the EPDS is required. Future studies 
should ensure that pregnancy outcome and current and past mental health problems 
are considered. Other potential confounding factors should be investigated in a TTTS 
pregnancy context, including paternal demographic data, and partner relationship 
satisfaction (Condon 1997, Colpin 1998, van Bussel 2010, Goecke 2012). It would 
also be interesting to assess fathers who were unable to attend the Fetal Medicine 
Centre, but due to the rapid progression of TTTS and the large geographical referral 
area, it would be difficult to consent these fathers. Different methods of improving 
survey response rate should be explored. 
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8.5 Conclusion 
 
In this small preliminary study of parental antenatal and postnatal attachment and 
depression in TTTS pregnancies, maternal attachment increases in the postnatal 
period, and maternal depressive symptoms decrease in the postnatal period, 
whereas paternal scores do not appear to change over time. The study has also 
highlighted the importance of health care professionals in referral centres monitoring 
mothers and fathers following FLA for depressive symptoms, particularly those with a 
history of mental health problems, and in TTTS pregnancies which involve fetal loss 
and the possible requirement of additional psychological support for high-risk 
pregnancies undergoing invasive procedures. Further work is needed in this area in 
larger cohorts.  
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CHAPTER 9 DISCUSSION 
 
9.1 Overview 
 
This thesis has explored the prediction, diagnosis and management of complications 
in MC twin pregnancies. MC twin pregnancies are high risk and adverse outcomes 
can have devastating effects on families. They are closely monitored antenatally as 
stipulated in international guidance (NICE 2011, Khalil 2016b, Kilby 2016) because it 
is not possible to predict which pregnancies will develop complications. Following this 
guidance necessitates health care professionals’ time and resources, in addition to 
the effects it has on parents’ time and anxiety. The ability to predict which 
pregnancies will develop complications may allow more tailored antenatal care for 
women with MC twin pregnancies, and allow clinicians to practice stratified medicine. 
Additionally, it may enable the development of new treatments for complications and 
inform future research studies (Riley 2013).  
Although this thesis did not find any maternal serum biomarkers with sufficient 
predictive ability to be used clinically, this thesis has progressed knowledge in the 
field of MC twin pregnancies and the findings do have clinical implications.  
 
9.1.1 How this thesis has progressed knowledge of MC twin pregnancies 
So-called ‘negative’ findings are still valid and important findings. In CHAPTER 3 the 
OMMIT study found that first trimester inter-twin NT discordance, CRL discordance, 
and first trimester maternal serum β-hCG, PAPP-A, AFP, PlGF and sFlt-1 were 
unable to predict adverse outcomes as individual prognostic factors. However, the 
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results are exciting from a pathophysiological perspective as some associations with 
adverse outcomes were found, and they suggest that pathophysiological changes 
may occur in the first trimester, prior to the appearance of the ultrasound signs of 
polyhydramnios and oligohydramnios, and IUFD. This supports that first trimester 
prognostic factors may exist; warranting further investigation. Interestingly no 
potential prognostic factors affected both growth restriction and TTTS supporting that 
they have different pathological mechanisms. 
As changes in these markers were demonstrated in the second trimester at 20 weeks 
gestation by previous work, but not at 12 weeks gestation in this work, the 
concentrations in maternal serum were measured longitudinally over the first and 
second trimester in women with uncomplicated MC twin pregnancies in CHAPTER 4. 
The patterns of these markers have not been measured before in MC twin 
pregnancies and may improve understanding of the pathophysiology of TTTS. 
The discovery of changes in the amniotic fluid metabolome from the recipient twin 
pre- and post-FLA; and a relationship between cardiac function in the recipient twin 
and a switch from fatty acid to carbohydrate metabolism was demonstrated in 
CHAPTER 5. These are thrilling new findings, suggesting that metabolomics may 
play a role in the pathophysiology of TTTS and provide other potential prognostic 
factors and therapeutic targets to explore in future work.  
The work on miRNA in second trimester maternal serum from pregnancies 
complicated by TTTS in CHAPTER 6 is the first time that miRNA has been 
investigated in this context. The finding of no significant difference in the 6 candidate 
miRNAs which were validated increases knowledge surrounding TTTS and suggests 
that maternal serum may not reflect possible miRNA changes in TTTS.   
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The systematic review in CHAPTER 7 reported updated and more detailed 
prognoses of the surviving co-twin after spontaneous sIUFD, demonstrating that 
pregnancies in which the sIUFD occurred at 14-28 weeks are at higher risk. The rate 
of abnormal antenatal brain imaging and NND were calculated for the first time in this 
context which also adds to existing knowledge.  
The preliminary study of parento-fetal antenatal and postnatal attachment and 
depression in TTTS pregnancies in CHAPTER 8 is the first time these outcomes 
have been explored in mothers in a UK cohort, and in fathers in the World. This 
thesis found that maternal attachment increased postnatally and depressive 
symptoms decreased, whereas paternal scores did not change, and a higher-risk 
group for developing adverse psychological outcome was identified. 
 
9.1.2 Strengths and limitations 
A major strength of this thesis is that it is the first time many factors have been 
explored in MC twin pregnancies, and especially in those with TTTS. The lack of 
animal models makes it difficult to investigate the pathophysiology, thus impeding 
advances in this area. However, collaborations were formed, and pragmatic choices 
were made, to maximise what could be learned in this area. The methodologies and 
statistical analyses used were robust and as five of the seven chapters have been 
accepted for publication/are published to date this indicates that the scientific 
community believes the work is relevant and important. 
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One of the main limitations of the work was the sample size, which was unsurprising 
given the relative scarcity of MCDA twin pregnancies in the general obstetric 
population. As discussed in CHAPTER 3, the general rule of thumb for powering 
investigation of individual prognostic factors is at least ten events for every candidate 
prognostic factor of interest, consequently a fetal adverse outcome composite was 
used. If the study was to be powered to demonstrate a difference in TTTS alone, the 
number of cases of TTTS would have to be 70. Given that TTTS affects 10-15% of 
MCDA twin pregnancies, this would equate to needing to recruit approximately 700 
MCDA twin pregnancies. If a recruitment rate of 75% was used, as was found in 
CHAPTER 4, this would mean approximately 935 women with MC twin pregnancies 
would need to be approached, which would take roughly 43 years if women were 
recruited from BWH alone (a tertiary referral unit with 8,000 deliveries/year), therefore 
collaboration is essential, and biobanking for rare conditions is important. The sample 
size was adequate for the hypothesis generating untargeted metabolomics work, and 
according to the power calculation performed in the miRNA work. Although the initial 
recruitment rate to the psychological work was good, the return rate of follow-up 
questionnaires was sub-optimal. 
Recruiting appropriate controls was also a limitation, and is particularly hindered 
when invasive techniques are needed to obtain tissue samples. There are many 
options for future research and research resources and time could be, in my opinion, 
better spent in other ways (see Section 9.4). 
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9.1.3 Clinical implications for clinicians and patients 
The main clinical implication from the first trimester potential prognostic factors work 
is that, in line with the RCOG MC twin pregnancy guidance, NT % discordance, and 
individual NT measurements alone should not be used to predict TTTS (Kilby 2016). 
New knowledge has been synthesised to produce a more personalised risk 
prediction for parents with a sIUFD, which has the clinical implications of improving 
patient counselling and decision making. The high risk of preterm birth in DC and MC 
twins should prompt clinicians to discuss with patients the possibility of NNU 
admission, and to have a low threshold to seek medical advice if they have concerns 
that they are going into preterm labour. The importance of offering antenatal brain 
imaging to parents follow sIUFD in MC twin pregnancies has also been highlighted 
and the rate of 20% may help parents decide whether to undergo imaging. 
Additional knowledge has been obtained to help referring centres identify mothers 
and fathers who may need additional psychological support following FLA. Patients 
and health care professionals can be reassured that generally maternal depressive 
symptoms decrease in the postnatal period although it has been highlighted that the 
maternal postpartum depression rate may be an underestimate. With regards fathers, 
health care practitioners should be aware of the variable ways fathers experience 
TTTS, and although the EPDS has been validated as a screening tool for fathers, 
there is not a validated antenatal cut-off for depressive disorders, and fathers may 
not always feel able to express their emotions. Health care professionals should be 
particularly aware of mothers and fathers who have a history of mental health 
problems, and those whose pregnancy has resulted in 1 survivor. The findings in this 
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thesis should prompt them to ask them to complete an EPDS, and advise either 
referral to a specialist perinatal mental health team, or to seek advice from their GP.  
 
9.1.4 Future research 
A wealth of research ideas has been generated from this thesis. An overriding issue 
highlighted in this thesis was the lack of a core outcome set for twin pregnancy 
research, thus pragmatic decisions were made. The importance of a core outcome 
set has been recognised by other groups, and this work is currently being performed. 
As previously stated, sample size was an issue, but in order to power the work to 
look at specific adverse outcomes, such as TTTS, it would take a long time to recruit 
an adequately sized cohort, thus collaboration would be better. What would be more 
helpful would be to explore other biomarkers, but to continue examining outcomes as 
a composite. Careful consideration would be needed of what the action would be 
following the output from the eventual prognostic model. For example if a high risk 
outcome from the prognostic model is calculated, the action may be to increase 
ultrasound surveillance, and it would be appropriate to combine sIUGR, TTTS and 
sIUFD together, but if it was to identify which pregnancies to give a new prophylactic 
treatment for TTTS, the use of a composite would not be appropriate. Ideally new 
biomarkers to be explored in maternal blood would be identifiable as fetal material 
rather than maternal, such as cffDNA, as TTTS and sIUGR are considered 
placental/fetal diseases.  
The longitudinal work in CHAPTER 4 exploring maternal serum biomarkers in the first 
and second trimester should be repeated in a larger cohort of MC twins, and with the 
inclusion of complicated MC twin pregnancies, to allow comparison between the two 
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groups, and provide gestational cut-offs for when each biomarker can be accurately 
measured. It may also improve knowledge surrounding the pathogenesis of MC twin 
complications as by recruiting complicated MC twin pregnancies this will enable 
investigation as to whether the biomarkers are low only in the first trimester, or 
remain low throughout the first and second trimester when signs and symptoms 
begin to appear. It would be interesting to compare these levels in DC twin 
pregnancies, although this may have less clinical utility as DC twins develop fewer, 
and different complications compared to MC twins.  
The results of the metabolomics work in CHAPTER 5 need to be validated, ideally by 
another metabolomics centre, with amniotic fluid samples from different MC twin 
pregnancies. Following this, the biological function of the significantly different 
metabolites should be investigated by performing targeted assays to assess the 
phenotype and identify candidate biomarkers worthy of future prognosis research. 
The biomarkers could be used to predict outcome following FLA, and could also be 
explored prior to the appearance of clinical signs of TTTS. It would be interesting to 
collect amniotic fluid samples and placental samples at delivery and to correlate 
these samples with fetal cardiac function prior to delivery.  
As this is the first time miRNA has been explored in TTTS there is a lot of future 
work. The work should be repeated in a different cohort to ensure that the negative 
findings of the validation work are true and that miRNA is not incorrectly discounted. 
Exosomal miRNAs should be explored, and other new miRNAs could be examined 
using Next Generation Sequencing. Another captivating area to focus on is miRNA 
expression in placentas of pregnancies complicated by TTTS, particularly as it was 
not possible to get the RT-PCR of maternal serum to work to validate miR519a-3p or 
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miR519c-3p which are placenta-specific miRNAs. This could be extended to 
placentas from uncomplicated MC and DC twin pregnancies, and twins with sIUGR 
and sIUFD. The miRNA work could be repeated in amniotic fluid samples, and cord 
blood to investigate possible inter-twin differences.  
The systematic review on sIUFD prognosis in CHAPTER 7 revealed a dearth of 
research regarding antenatal brain imaging in DC twins, and very little research 
linking antenatal brain imaging with postnatal brain imaging. As it can be difficult to 
counsel patients on their baby’s/babies’ quality of life based on antenatal brain 
imaging, investigating this in the context of follow-up postnatal brain imaging and 
standardised long-term neurodevelopmental follow-up assessment is vital. The 
studies included in this meta-analysis were small and small study effects were shown 
to exist, thus a large population-based study has been performed using data from 
UKOSS. This will be the largest study of complications in the surviving co-twin in a 
population cared for using the same national guidance (for further details see 
(UKOSS 2016)).  
The psychological work should be continued in a larger cohort with additional 
strategies to improve questionnaire return rates. It would be fascinating to perform 
qualitative interviews to confirm the diagnosis of depression, and delineate the 
reasons behind the answers on the questionnaires. Interviews would also enable 
further investigation as to how couples can be best supported, and allow health care 
professionals to provide holistic care. It is important to repeat this research in 
different countries and ethnicities using translated questionnaires with appropriate 
validation. Future research should also include the exploration of anxiety symptoms, 
and their relationship with parental attachment and depression, particularly in fathers. 
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Parental attachment scores in TTTS pregnancies should be validated with another 
measure of attachment, and a cut-off for paternal antenatal depression using the 
EPDS is required. Future studies should ensure that pregnancy outcome and current 
and past mental health problems are considered. Other potential confounding factors 
should be investigated, including paternal demographic data, and partner relationship 
satisfaction (Condon 1997, Colpin 1998, van Bussel 2010, Goecke 2012). It would 
also be interesting to assess fathers who were unable to attend the Fetal Medicine 
Centre, but due to the rapid progression of TTTS and the large geographical referral 
area, it would be difficult to consent these fathers. Different methods of improving 
survey response rate should be explored. 
 
9.2 Conclusion 
 
This thesis has explored the prediction, diagnosis and management of complications 
in MC twin pregnancies. Stimulating findings have been reported, some of which 
have direct clinical implications, others excitingly advance knowledge regarding 
complications of MC twin pregnancies. Conducting further research in this group is 
essential as complications are associated with high rates of morbidity, however there 
are various obstacles that make research in this field difficult. Pragmatic solutions 
must be found and collaborations formed.  
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CHAPTER 10 APPENDICES 
 
 
10.1 Early prognostic factors of outcomes in monochorionic twin 
pregnancy systematic review search strategy 
 
1. fetofetal blood transfusion or fetofetal transfusion or twin twin transfusion 
syndrome or twin to twin transfusion syndrome or twin-twin transfusion syndrome or 
twin-to-twin transfusion.mp. 
2. twin anemia* polycythemia* sequence or TAPS.mp. 
3. twin oligohydramnios-polyhydramnios sequence or TOPS.mp. 
4. fetal death or intrauterine death or intrauterine demise or single twin demise or 
perinatal mortality or perinatal outcome* or neonatal mortality.mp. 
5. small-for-gestational age or lbw or small for gestational age or sgr or small for 
date* or small for gestation* or fgr or iugr or intrauterine growth retard* or intrauterine 
growth restrict* or fetal growth retard* or fetal growth restrict* or growth restrict* or 
growth retard* or “Fetal growth retardation” or “Infant, Low Birthweight” or low 
birthweight.mp. 
6. Diseases in Twins/ 
7. amniotic fluid or amniotic fluid metabolism.mp. 
8. placenta* or placental circulation or placental metabolism or placental blood 
supply or amnion or chorion.mp. 
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9. alpha-fetoprotein* or angiogenesis inducing agents or biological markers or 
chorionic gonadotropin, beta subunit or angiogenesis inducing agents or 
metabolomics* or vascular endothelial growth factor* or placental growth factor.mp. 
10. neck/ultrasonography or nuchal translucency.mp. crown-rump length.mp. or 
biometry.mp or blood flow velocity.mp. or regional blood flow.mp. or umbilical 
arteries*.mp. or umbilical veins*.mp. or Doppler.mp. or ductus venosus.mp. 
11. predictive value or tests* or risk assessment or risk factors* or prognostic* 
factors* or predictive* factors* or prognostic model or prognosis* or prediction* or 
predictor or formula or algorithm.mp. 
12. twins*.mp. 
13. monochorionic*.mp. 
14. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 
15. 12 and 13 and 14 
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10.2 Early prognostic factors of outcomes in monochorionic twin 
pregnancy systematic review data collection form 
Section A: Study Information 
1)Ref ID:  4)Publication year:  
2)Rev name:  5)First Author:  
3)Country:  6)Language:  
7) Authors 
contacted? 
Yes □1   No □2   Not required □3   
 
Section B: Population 
8) Number of participating centres: __________  
9) Setting: tertiary referral centre □1 DGH □2 Other _______________________________ 
13) What was the chorionicity / amnionicity of the (case) group? 
Monochorionic/diamniotic □1 Monochorionic/monoamniotic □2 Dichorionic/diamniotic □3  
Unreported □4 
13.ii) Was chorionicity / amnionicity appropriately assessed? Yes □1 No □2 Unreported  □3 
13.iii) How was chorionicity assessed?  
 
 
 
14) Were all patients primigravid? 
Yes □1  No □2      Unreported  □3 
15) List other eligibility/ in-/exclusion criteria e.g. chromosomal abnorm, Quintero staging 
 
 
 
 
 
14.i) Were eligibility/in-/exclusion criteria appropriate? Yes □1  No □2  Unclear  □3 
 
USS? 
Placental postnatal assessment? 
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15) Study population: (describe age (mean +/- SD or median/range), ethnicity, smoking, BMI 
etc.) 
 
 
 
 
16) Start of patient inclusion (year) :               Unreported □1  
17) End of patient inclusion (year) :      Unreported □1 
18) Study Design:   
cohort □1 case control □2 RCT/CCT □3 cross sectional □4 before and after □5 case series □6 (n=___)   
other ___________________□7 
19) Data collection: prospective □1   retrospective  □2   unreported □3    other □4 
20) Enrolment: consecutive □1    arbitary (random) □2   unreported □3    other □4 
21) Blinding: single □1 double □2 none □3 not reported □4 
 
1st Predictive factor (use separate section for each factor)  
10.i) Which predictive factor evaluated?  
NT □1 CRL □2 Ductus venosus □3 Cord insertion □4 Plasma biochemical markers □5 Amniotic 
biochemical markers □6   Other ____________________________________ 
10.ii) More detail (eg. if USS how calculated, if biomarker which and normal values)  
 
 
 
 
 
 
 
11.i) Gestation at time of predictive factor measured 
<11 weeks □1 11-13+6 weeks □2 14-24 weeks □3 24+1-37 weeks □4 Unreported □5 Other ________ 
 
11.i) Mean (range)_________________Unreported □1 
11.iii) Median (range) _______________Unreported □1 
12) Indication for predictive factor: 
Routine clinical care □1 Down’s screening □2 No clinical reason □3 Unreported □4   
Other _____________________________________   
 
 
 393 
 
2nd Predictive factor (use separate section for each factor)  
10.i) Which predictive factor evaluated?  
NT □1 CRL □2 Ductus venosus □3 Cord insertion □4 Plasma biochemical markers □5 Amniotic 
biochemical markers □6   Other ____________________________________ 
10.ii) More detail (eg. if USS how calculated, if biomarker which and normal values)  
 
 
 
 
 
 
 
11.i) Gestation at time of predictive factor measured 
<11 weeks □1 11-13+6 weeks □2 14-24 weeks □3 24+1-37 weeks □4 Unreported □5 Other ________ 
 
11.i) Mean (range)_________________Unreported □1 
11.iii) Median (range) _______________Unreported □1 
12) Indication for predictive factor: 
Routine clinical care □1 Down’s screening □2 No clinical reason □3 Unreported □4   
Other _____________________________________     
  
 
3rd Predictive factor (use separate section for each factor)  
10.i) Which predictive factor evaluated?  
NT □1 CRL □2 Ductus Venosus □3 Cord insertion □4 Plasma biochemical markers □5 Amniotic 
biochemical markers □6   Other ____________________________________ 
10.ii) More detail (eg. if USS how calculated, if biomarker which and normal values)  
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11.i) Gestation at time of predictive factor measured 
<11 weeks □1 11-13+6 weeks □2 14-24 weeks □3 24+1-37 weeks □4 Unreported □5 Other ________ 
 
11.i) Mean (range)_________________Unreported □1 
11.iii) Median (range) _______________Unreported □1 
12) Indication for predictive factor: 
Routine clinical care □1 Down’s screening □2 No clinical reason □3 Unreported □4   
Other _____________________________________ 
 
    
22) Numbers: 
 
 
 
 
 
 
 
 
 
 
 
23) Completeness of Verification: 
(= E / C x 100 = %) 
> 90% □1   81-90% □2   < 81% □3 
Outcome(s) 
11.i) Outcome(s) assessed by predictive factor: 
TTTS □1 sFGR □2 Fetal death □3 TAPS □4 TOPS □5 Discordant fetal anomalies □6  Pre-term 
labour  □7  Neurological comorbidity  □8  Birth weight  □9  Other □10 
Other ___________________________________ 
 
B Reasons ________________ 
 
   
A Eligible 
Patients 
n=  
C Predictive 
factors assessed  
n=  
E Outcome data 
collected 
n=  
D Post Enrolment 
Exclusions 
n= 
B Excluded 
Patients 
n=  
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11.ii) Definition of outcome:  
 
 
 
24.i) Adequate □1 Inadequate □2 Unclear □3 
 
25) Follow-up details (e.g. mode, frequency, length) 
 
 
 
 
 
 
 
24.i) Adequate □1 Inadequate □2 Unclear □3 
 
 
 
 
 
 
 
 
 
 
 
 
Results 
Predictive factor: 
Predictive: Yes □1 No □2  
Reasons given for being predictive: 
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10.3 OMMIT data collection form 
Woman’s Demographic Details 
 
Study number (OMMIT1 ____  ____  ____) (see patient list for study number) 
 
Date of birth ______________________ 
 
Marital status  single / married or CP / Partner / Separated / Divorced / 
Widowed 
 
Was the woman in paid employment at booking?    Yes / No 
If Yes, what is her occupation? ____________________________________ 
What is her partner’s (if any) occupation ________________________ 
 
Smoking status    never smoked / current smoker / ex-smoker 
If ex-smoker, date gave up _____________ 
 
Ethnicity of mother of baby _____________________________________ 
 
Ethnicity of father of baby _____________________________________ 
 
Height at booking (cm) _______ 
 
Weight at booking (kg) _______ 
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Previous Obstetric History 
 
Number of completed pregnancies beyond 24 weeks ______ 
 
Number of pregnancies less than 24 weeks ______ 
2.2.a) If pregnancy <24 weeks, please specify gestation of each pregnancy 
________________________________________________________________ 
 
2.3 Any history of previous preterm birth      Yes / No 
2.3a) If yes, please specify number of pregnancies and gestation at delivery of 
each._________________________________________________ 
 
2.4 Any history of neonatal death:       Yes / No 
If yes, please specify gestation at delivery and age at death if known 
________________________________________________________________ 
 
Did the women have a previous history of multiple pregnancy?  Yes / No 
2.5a If yes, please give details 
________________________________________________________________ 
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Did the woman have any other previous pregnancy problems   Yes / No 
If Yes, please specify details 
Problem Yes Details e.g. medication 
Ovarian hyperstimulation syndrome 
 
  
Hyperemesis requiring admission 
 
  
Gestational diabetes 
 
  
Severe infection e.g. pyelonephritis 
 
  
Pregnancy induced hypertension 
 
  
Pre-eclampsia 
 
  
Eclampsia 
 
  
Placenta praevia 
 
  
Placental abruption 
 
  
Post-partum haemorrhage requiring 
transfusion 
  
Surgical procedure in pregnancy 
 
  
Puerperal psychosis 
 
  
Thrombotic event 
 
  
Amniotic fluid embolism 
 
  
 399 
 
Problem Yes Details e.g. medication 
Stillbirth 
 
  
Baby with a major congenital 
abnormality 
  
Small for gestational age (SGA) 
infant 
  
Large for gestational age (LGA) 
infant 
  
Other (please specify: 
 
  
 
Previous Medical History 
Did the woman have any pre-existing medical problems   Yes / No 
If Yes, please specify details 
Problem Yes Details 
Cardiac disease (congenital or 
acquired) 
  
Renal disease 
 
  
Endocrine disorders  
e.g. hypo or hyperthyroidism 
  
Psychiatric disorders 
 
  
Haematological disorders  
e.g. sickle cell disease, diagnosed 
thrombophilia 
  
Inflammatory disorders  
e.g. inflammatory bowel disease 
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Problem Yes Details e.g. medication 
Autoimmune diseases 
 
  
Cancer 
 
  
HIV 
 
  
Other (please specify): 
 
 
  
 
This Pregnancy 
 
Estimated date of delivery (EDD) (Use the best estimate (ultrasound scan or date 
of last menstrual period [based on a 40 week gestation]) ______________ 
 
Was this an assisted conception pregnancy?    Yes / No 
4.2a) If yes specify type of artificial reproductive technique e.g. IVF, ICSI, clomiphene 
etc. 
 
Was there evidence of any fetal complications of monochorionic pregnancy?  
Yes / No 
4.3a) If yes, please complete the table below 
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Growth discordance 
between twins (>20% 
difference) 
Diagnosis 
present? 
  
Description of severity of 
complication  
 
Antenatal 
management 
instituted?  
Did the woman have an 
antenatal ultrasound or MRI 
to look for neurological 
damage? 
(If yes, please provide 
details indicated in 
boxes to the right) 
Yes / No 
Date of 
diagnosis: 
 
Gestation at 
first 
diagnosis: 
 
Greatest estimated fetal weight 
discordance (%):  
 
Gestation of greatest 
discordance: 
 
Which twin smallest: Twin 1 / 2 
 
Did the growth plot below the 10th 
centile: twin 1 / twin 2 / neither 
 
Umbilical artery Doppler end-
diastolic flow in twin 1: positive / 
constant absent or reversed / 
intermittent absent or reversed 
 
Umbilical artery Doppler end-
diastolic flow in twin 2: positive / 
constant absent or reversed / 
intermittent absent or reversed 
 
Any other details: 
 
 
 
 
Yes / No 
Type of intervention: 
 
 
Date of procedure: 
Yes / No 
Type of imaging: 
 
Date of imaging: 
 
Findings (please continue on 
separate sheet): 
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Twin to twin 
transfusion 
syndrome (TTTS) 
Diagnosis 
present? 
 
Description of severity of 
complication by Quintero 
stage*.  
 
Antenatal 
management 
instituted? 
Did the woman have an 
antenatal ultrasound or MRI 
to look for neurological 
damage? 
(If yes, please provide 
details indicated in 
boxes to the right) 
Yes / No 
Date of 
diagnosis: 
 
Donor twin: Twin 1 / 2 
Recipient twin: Twin 1 / 2 
Quintero staging* (see end of data 
collection form for classification):  
 
Yes / No 
Type of intervention: 
 
Date of procedure: 
Yes / No 
Type of imaging: 
 
Date of imaging: 
 
Findings (please continue on 
separate sheet): 
 
 
 
Intrauterine death Diagnosis 
present? 
Description of complication 
 
Antenatal 
management 
instituted? 
Did the woman have an 
antenatal ultrasound or MRI 
to look for neurological 
damage? 
(If yes, please provide 
details indicated in 
boxes to the right) 
 
 
 
Twin 1: Yes / 
No 
Date of 
diagnosis: 
Twin 2: Yes / 
No 
Date of 
diagnosis: 
 
Cause (if known?): 
 
 
Any other details: 
Yes / No 
Type of intervention: 
 
Date of procedure: 
Yes / No 
Type of imaging: 
 
Date of imaging: 
 
Findings (please continue on 
separate sheet): 
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Chromosomal 
anomaly 
Diagnosis 
present? 
 
Description of chromosomal 
anomaly 
 
Antenatal 
management 
instituted? 
Did the woman have an 
antenatal ultrasound or MRI 
to look for neurological 
damage? 
(If yes, please provide 
details indicated in 
boxes to the right) 
Twin 1: Yes / 
No 
Twin 2: Yes / 
No 
Date of 
diagnosis: 
 
Twin 1: 
 
 
 
Twin 2: 
Yes / No 
Type of intervention: 
 
Date of procedure: 
Yes / No 
Type of imaging: 
 
Date of imaging: 
 
Findings (please continue on 
separate sheet): 
 
 
 
Structural anomaly Diagnosis 
present? 
 
Description of structural 
anomaly 
 
Antenatal 
management 
instituted?  
Did the woman have an 
antenatal ultrasound or MRI 
to look for neurological 
damage? 
(If yes, please provide 
details indicated in 
boxes to the right) 
Twin 1: Yes / 
No 
Twin 2: Yes / 
No 
Date of 
diagnosis: 
 
Twin 1: 
 
 
 
Twin 2: 
Yes / No 
Type of intervention: 
 
Date of procedure: 
Yes / No 
Type of imaging: 
 
Date of imaging: 
 
Findings (please continue on 
separate sheet): 
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Other problem e.g. 
TOPS, TAPS 
Diagnosis 
present? 
 
Description of complication Antenatal 
management 
instituted? 
Did the woman have an 
antenatal ultrasound or MRI 
to look for neurological 
damage? 
(If yes, please provide 
details indicated in 
boxes to the right) 
 
 
 
 
 
 
 
 
Twin 1: Yes / 
No 
Twin 2: Yes / 
No 
Date of 
diagnosis: 
 
Twin 1: 
 
 
 
Twin 2: 
Yes / No 
Type of intervention: 
 
Date of procedure: 
Yes / No 
Type of imaging: 
 
Date of imaging: 
 
Findings (please continue on 
separate sheet): 
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Were there any other problems in this pregnancy?     Yes / No 
If Yes, please specify details 
Problem Yes Details 
Ovarian hyperstimulation syndrome 
 
  
Hyperemesis requiring admission 
 
  
Dehydration requiring admission 
 
  
Gestational diabetes 
 
  
Severe infection e.g. pyelonephritis 
 
  
Pregnancy induced hypertension 
 
  
Pre-eclampsia 
 
  
Eclampsia 
 
  
HELLP 
 
  
Placenta praevia 
 
  
Significant placental abruption 
 
  
Post-partum haemorrhage requiring 
intevention 
 
  
Surgical procedure in pregnancy 
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Problem Yes Details 
Puerperal psychosis 
 
  
Thrombotic event 
 
  
Cerebrovascular accident 
 
  
Amniotic fluid embolism 
 
  
Adult respiratory distress syndrome 
 
  
Disseminated intravascular 
coagulopathy 
  
Pulmonary oedema 
 
  
Mendelson’s syndrome 
 
  
Renal failure 
 
  
Septicaemia 
 
  
Maternal death 
(if yes, please state date of death, 
and primary cause of death as 
stated on the death certificate)  
  
Other (please specify: 
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Did she receive any of the following treatments?    Yes / No 
Medication Yes Gestation 
given 
Reason given 
Steroids for fetal lung 
maturation 
 
  Routine elective caesarean section 
At risk of spontaneous preterm delivery 
At risk of iatrogenic preterm delivery 
Other (please specify): 
 
 
Magnesium Sulphate   Prevention of maternal fitting 
 
Fetal neuroprotection 
 
Other (please specify): 
Tocolysis 
(please list agents): 
 
 
 
   
Other preterm labour 
prevention agents 
(may be part of a 
research study) e.g. 
Arabin pessary, 
Cervical cerclage, 
Progesterone 
pessary 
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Delivery (this pregnancy) 
 
Did this woman have a miscarriage?       Yes / No 
If Yes, please specify date ______________ 
 
Did this woman have a termination of pregnancy?    Yes / No 
If Yes, please specify date _____________ 
 
Has this women delivered?        Yes / No 
 
If she has not delivered, will she receive the rest of her antenatal care from 
your hospital?          Yes / No 
If No, please indicate name of hospital providing future care  
___________________________________________________________ 
 
Will she be delivered at your hospital?       Yes / No 
If No, please indicate name of hospital where she will be delivered 
___________________________________________________________ 
 
Did this woman have a routine Category 4 Elective Caesarean Section?  
Yes / No 
If Yes, please specify date ________________  
If Yes, please specify indication _________________ 
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What was the onset of labour?  Spontaneous / Induced / Did not labour   
     
5.7a) If induced, please state indication _________________________  
   
Did the woman reach full dilatation?       Yes / No 
 
What was mode of delivery? (please tick all that apply) 
 
Mode of delivery Twin 1 Twin 2 
Caesarean section cat 1   
Caesarean section cat 2   
Caesarean section cat 3   
Instrumental delivery   
Normal vaginal delivery   
 
 
 
 
 
 
If delivery was by Emergency Caesarean section (category 1, 2 or 3), please state 
the indication: 
________________________________________________________________ 
 
 
RCA/RCOG/CEMACH/CNST Classification for urgency of caesarean section: 
1  Immediate threat to life of woman or fetus 
2  Maternal or fetal compromise which is not immediately life-threatening 
3  Needing early delivery but no maternal or fetal compromise 
4  At a time to suit the woman and maternity team 
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Which anaesthesia was used? Regional / General / Both  
 
5.11a) If general anaesthesia, indication: ___________________________ 
 
Outcomes: Maternal 
 
Was the woman admitted to HDU or ITU?     Yes / No 
6.1a) If Yes, please state indication for admission 
_________________________________________________________________ 
6.1b) specify duration of stay (days) _____ 
6.1c) Or Tick if woman is still in HDU or ITU ___ 
6.1d) Or Tick if woman was transferred to another hospital ___ 
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Outcomes: Infants 
Outcome Twin 1 Twin 2 
Date of delivery  
Time of delivery   
Gestation at delivery  
Birthweight (g)   
Sex of infant M / F / Indeterminate M / F / Indeterminate 
Condition at birth Live / Stillborn Live / Stillborn 
If stillborn, date of death   
Timing of stillbirth Antenatal / 
Intrapartum 
Antenatal / 
Intrapartum 
Presumed cause of death   
Apgar @ 5 mins   
Cord gas (venous)   
Cord gas (arterial)   
NNU admission? Y / N Y / N 
Date of NNU admission   
Reason for NNU admission 
 
 
 
 
 
 
 
 
Were the babies transferred to a 
different NNU? 
Y / N Y / N 
If transferred, which NNU were 
they transferred to? 
  
Discharge date from hospital to 
home 
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Did any major infant complications occur?    Yes / No 
If Yes, please tick 
Problem Twin 1 - Yes Twin 2 - yes 
Respiratory distress syndrome   
Intraventricular haemorrhage or other brain 
injury? 
  
Necrotising enterocolitis   
Neonatal encephalopathy   
Chronic lung disease   
Severe jaundice requiring phototherapy   
Major congenital anomaly   
Severe infection e.g. septicaemia, meningitis   
Exchange transfusion   
Did this infant die? Y / N / still in 
NNU 
Y / N / still in 
NNU 
  If yes, what was the primary cause of death 
as stated on the death certificate? (please 
state if not known) 
 
  
Other complications (please specify): 
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Are there any signs of potential long-term damage?   Yes / No 
If yes, please tick and provide details 
 
Problem Twin 1 Twin 2 
Ultrasound evidence of 
neurological damage 
postnatally? 
Y / N / test not performed Y / N / test not performed 
  If yes, date of imaging   
  Type of abnormality  
 
 
MRI evidence of 
neurological damage 
postnatally? 
Y / N / test not performed Y / N / test not performed 
  If yes, date of imaging   
  Type of abnormality 
(please continue on 
separate page if required) 
 
 
 
Abnormal neurological 
signs noted in the 
neonatal period prior to 
discharge? 
Y / N / Not known Y / N / Not known 
  If yes, please detail 
 
 
 
  
Evidence of cardiac 
impairment? 
Y / N / Not known Y / N / Not known 
  If yes, please detail 
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Section 8: The end 
Name of person completing the form: 
Designation:  
Today’s date: 
 
You may find it useful in the case of queries to keep a copy of this form. 
 
If posting forms back, please send to: 
Dr Fiona Mackie 
3rd Floor O&G Academic Department 
Birmingham Women’s Hospital 
Mindelsohn Way 
Edgbaston 
Birmingham 
B15 2TG 
 
Email:  (if patient sensitive information) 
 
Twin to twin transfusion syndrome, please state which twin donor and which twin 
recipient and then state Quintero stage: 
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10.4 OMMIT scatter plots  
The scatterplots and lines of best fit demonstrate the spread of data points for each 
potential prognostic factor. An uncomplicated pregnancy was defined as no adverse 
outcome and the delivery of 2 healthy twins after 34 weeks gestation. A complicated 
pregnancy was defined as being affected by at least one outcome in the fetal 
adverse outcome composite (TTTS, TAPS, IUFD, growth restriction). 
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PlGF 
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10.5 Post-FLA compared to pre-FLA metabolites 
All metabolites are grouped into classes of chemical structure or metabolic pathway. Fold change is calculated as the median 
(pre-treatment)/median (post-treatment) and the 95% confidence intervals are included in brackets. 
Mass/ 
charge 
ratio 
Retention 
time 
Ion 
Mode 
Metabolites Metabolite 
class 
P value Fold 
change 
(pre/post) 
129.9757 820 Negative Nitrate and/or Peroxynitrite Inorganic ionic 
metabolites 
0.00270 0.74 
(0.55,0.98) 
186.1134 242 Negative 8-Amino-7-oxononanoate Biotin 
metabolism 
0.00162 0.39 
(0.21,0.89) 
202.0337 215 Negative 8-Hydroxy-7-methylguanine and/or Adenine Nucleosides 0.00270 0.69 
(0.52,0.89) 
259.0137 230 Negative D-Galactose 6-sulfate and/or D-Glucose 6-
sulfate and/or O3-Sulfonylgalactose and/or 
O4-Sulfonylgalactose 
Carbohydrates 0.00079 0.81 
(0.58,1.10) 
410.1620 816 Negative (4E,8E,10E-d18:3) Sphingosine Ceramides 
and 
sphingolipids 
0.00468 0.61 
(0.50,0.73) 
424.0174 36 Negative D-4'-Phosphopantothenate CoA 
metabolism 
0.00134 0.74 
(0.60,0.91) 
523.1454 38 Negative Fucosyllactose Carbohydrates 0.00389 0.80 
(0.44,1.39) 
532.2874 484 Negative Glycocholic acid Sterols and 
steroids 
0.00270 0.70 
(0.55,0.88) 
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539.1405 38 Negative (1->3)-beta-D-Galactopyranans and/or (2,6-
beta-D-Fructosyl)n and/or 1,3-beta-D-
Oligoglucan and/or 1,6-beta-D-Glucan and/or 
1-alpha-D-(1,4)-alpha-D-Glucosyl(n-1)-alpha-
D-glucopyranoside and/or 1F-beta-D-
Fructosylsucrose and/or 1-kestotriose and/or 
3-Galactosyllactose and/or 6-alpha-D-(1,4-
alpha-D-Glucano)-glucan and/or 6-alpha-
Maltosylglucose and/or 6F-alpha-D-
Galactosylsucrose and/or 6G-kestotriose 
and/or 6-kestotriose and/or beta-D-
Fructofuranosyl O-beta-D-glucopyranosyl-(1-
6)-alpha-D-glucopyranoside and/or beta-D-
Glucan and/or Cellotriose and/or Dextrin 
and/or D-Gal alpha 1->6D-Gal alpha 1->6D-
Glucose and/or fagopyritol B2 and/or 
Galactomannan and/or Isomaltotriose and/or 
Laminarin and/or Levan and/or Maltotriose 
and/or manninotriose and/or Melezitose 
and/or Panose and/or Polysaccharide and/or 
Raffinose and/or Umbelliferose 
Carbohydrates 0.00058 0.79 
(0.63,0.98) 
565.9458 35 Negative 8-hydroxydeoxyguanosine 5'-triphosphate 
and/or GTP and/or Guanosine-3'-
Monophosphate-5'-Diphosphate 
Nucleosides 0.00451 0.73 
(0.57,0.92) 
573.3282 506 Negative PC(20:4) Glycero- 
phospholipids 
0.00468 0.67 
(0.35,1.07) 
604.0563 37 Negative CDP-ribitol Carbohydrates 0.00134 0.78 
(0.52,1.14) 
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612.5577 531 Negative DG(34:0) Acyl glycerides 0.00228 1.53 
(1.04,2.39) 
666.6060 567 Negative DG(38:1) Acyl glycerides 0.00047 2.11 
(1.34,3.71) 
668.6194 573 Negative DG(38:0) Acyl glycerides 0.00228 1.59 
(1.07,2.57) 
677.1417 453 Negative 2-Acetyl-Protoporphyrin I Heme 
metabolism 
0.00468 0.85 
(0.65,1.09) 
680.6215 580 Negative DG(39:1) Acyl glycerides 0.00389 1.64 
(1.10,2.63) 
680.8807 30 Negative 3'-Phosphoadenylylselenate Other class 0.00286 0.71 
(0.51,0.96) 
692.1633 37 Negative 3'-Sialyllactose and/or 6'-Sialyllactose and/or 
Lactose Sialic Acid 
Carbohydrates 0.00270 0.74 
(0.61,0.89) 
692.6215 570 Negative DG(40:2) Acyl glycerides 0.00047 2.27 
(1.38,4.37) 
694.6371 593 Negative DG(40:1) Acyl glycerides 0.00047 2.05 
(1.32,3.57) 
700.5307 533 Negative PE(16:0/dm18:1) and/or PE(16:1/dm18:0) 
and/or PE(18:1/dm16:0) 
Glycero- 
phospholipids 
0.00031 1.47 
(1.03,2.21) 
 421 
 
701.1941 40 Negative 1,3-alpha-D-Mannosyl-1,2-alpha-D-
mannosyl-1,2-alpha-D-mannosyl-D- 
mannose and/or 1,6-kestotetraose and/or 
1F-alpha-D-Galactosylraffinose and/or 3F-
alpha-D-Galactosylraffinose and/or 6G,6-
kestotetraose and/or alpha-D-Galactosyl-(1-
6)-alpha-D-galactosyl-(1-6)-beta-D-fructosyl- 
(2-1)-alpha-D-glucoside and/or Cellotetraose 
and/or fagopyritol B3 and/or Glycogen and/or 
Lychnose and/or Maltotetraose and/or 
Stachyose 
Carbohydrates 0.00010 0.67 
(0.45,0.99) 
719.4780 464 Negative DG(38:3) Acyl glycerides 0.00286 0.86 
(0.60,1.14) 
722.5140 516 Negative PE(18:3/dm18:1) and/or PE(18:4/dm18:0) 
and/or PE(20:4/dm16:0) and/or 
PE(16:0/dm18:1) and/or PE(16:1/dm18:0) 
and/or PE(18:1/dm16:0) 
Glycero- 
phospholipids 
0.00228 1.32 
(0.96,1.90) 
732.1963 40 Negative 3-Sialyl-N-acetyllactosamine and/or 6-Sialyl-
N-acetyllactosamine and/or alpha-N-
Acetylneuraminyl-2,6-beta-D-galactosyl-1,4-
N-acetyl-beta-D- glucosamine 
Carbohydrates 0.00006 0.66 
(0.53,0.81) 
744.4982 33 Negative PE(18:3/dm18:1) and/or PE(18:4/dm18:0) 
and/or PE(20:4/dm16:0) 
Glycero- 
phospholipids 
0.00162 0.52 
(0.38,0.68) 
750.5382 510 Negative PC(15:0/dm18:1) and/or PE(18:0/dm18:1) 
and/or PE(18:1/dm18:0) and/or 
PE(20:1/dm16:0) 
Glycero- 
phospholipids 
0.00389 1.27 
(0.96,1.75) 
776.5459 513 Negative PC(32:1) and/or PE(35:1) Glycero- 
phospholipids 
0.00047 1.86 
(1.26,3.12) 
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778.5610 526 Negative PC(32:0) and/or PE(35:0) Glycero- 
phospholipids 
0.00016 1.44 
(0.94,2.02) 
779.5651 526 Negative PC(32:0) and/or PE(35:0) Glycero- 
phospholipids 
0.00004 1.60 
(1.08,2.67) 
780.5686 526 Negative PC(32:0) and/or PE(35:0) Glycero- 
phospholipids 
0.00091 1.16 
(0.83,1.71) 
788.5466 580 Negative PS(36:1) and/or PC(33:2) and/or PE(36:2) Glycero- 
phospholipids 
0.00058 1.85 
(1.16,3.36) 
803.5655 517 Negative PT(36:1) Glycero- 
phospholipids 
0.00027 1.93 
(1.27,3.37) 
804.5769 529 Negative PS(37:0) Glycero- 
phospholipids 
0.00010 1.74 
(1.15,2.92) 
812.5823 524 Negative PC(18:2/dm18:1) and/or PC(18:3/dm18:0) 
and/or PC(20:3/dm16:0) 
Glycero- 
phospholipids 
0.00389 1.39 
(0.94,2.26) 
826.5633 513 Negative PC(36:4) Glycero- 
phospholipids 
0.00027 2.30 
(1.49,4.17) 
828.5775 519 Negative PC(36:3) Glycero- 
phospholipids 
0.00047 2.00 
(1.26,3.71) 
832.6086 548 Negative PC(36:1) Glycero- 
phospholipids 
0.00027 1.73 
(1.12,3.00) 
838.6000 529 Negative PC(20:3/dm18:1) and/or PC(20:4/dm18:0) 
and/or PC(22:4/dm16:0) 
Glycero- 
phospholipids 
0.00389 1.51 
(0.99,2.61) 
852.5793 516 Negative PC(38:5) Glycero- 
phospholipids 
0.00079 1.94 
(1.22,3.60) 
854.5957 528 Negative PC(38:4) Glycero- 
phospholipids 
0.00047 1.96 
(1.28,3.52) 
859.6930 596 Negative SM(d18:0/24:1) and/or SM(d18:1/24:0) Ceramides 
and 
sphingolipids 
0.00270 1.74 
(1.17,2.99) 
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878.5944 524 Negative PC(40:6) Glycero- 
phospholipids 
0.00134 1.63 
(0.98,3.12) 
884.5509 510 Negative PC(O-17:0/18:1) and/or PE(20:0/dm18:0) 
and/or PE(22:0/dm16:0) 
Glycero- 
phospholipids 
0.00018 1.48 
(1.05,2.31) 
888.6808 539 Negative PC(O-19:0/22:0) Glycero- 
phospholipids 
0.00228 1.74 
(1.23,2.57) 
951.5361 510 Negative PI(40:4) Glycero- 
phospholipids 
0.00134 1.38 
(1.03,1.99) 
971.5852 482 Negative PE(44:2) Glycero- 
phospholipids 
0.00270 0.62 
(0.46,0.82) 
982.6173 482 Negative PE(44:5) Glycero- 
phospholipids 
0.00468 0.73 
(0.50,1.00) 
127.0359 66 Positive Hydroxybutyric acid Oxidised fatty 
acids 
0.00451 1.13 
(0.89,1.44) 
132.1018 69 Positive Isoleucine and/or L-Leucine Amino acid 
metabolism 
0.00001 1.31 
(0.98,1.78) 
138.0524 69 Positive Proline Amino acid 
metabolism 
0.00001 1.41 
(1.17,1.72) 
142.9387 92 Positive Sulfate Inorganic ionic 
metabolites 
0.00468 1.19 
(0.98,1.44) 
147.1128 48 Positive Lysine Amino acid 
metabolism 
0.00001 1.36 
(1.08,1.73) 
155.0681 362 Positive Hydroxyhexanoic acid Oxidised fatty 
acids 
0.00058 1.27 
(0.98,1.66) 
156.0765 55 Positive Histidine Amino acid 
metabolism 
0.00097 1.45 
(1.14,1.86) 
186.0732 60 Positive Norvaline and/or Valine Amino acid 
metabolism 
0.00016 1.45 
(1.20,1.78) 
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203.1502 67 Positive N,N-dimethylarginine Acyl amino 
acids and 
related 
metabolites 
0.00058 1.19 
(0.93,1.54) 
204.1230 68 Positive Acetylcarnitine Acyl carnitines 0.00010 1.22 
(1.01,1.48) 
228.0636 365 Positive Methoxyindoleacetate Other class 0.00010 1.35 
(1.14,1.62) 
230.0783 394 Positive N-Acetyl-phenylalanine Acyl amino 
acids and 
related 
metabolites 
0.00228 1.11 
(0.76,1.61) 
241.1418 399 Positive Decanoate Fatty acid 
metabolism 
0.00010 1.30 
(1.04,1.66) 
243.1338 414 Positive Dodecenoic acid Fatty acid 
metabolism 
0.00016 1.46 
(1.10,1.98) 
249.0593 379 Positive Dimethylxanthine and/or Theobromine and/or 
Theophylline 
Other class 0.00286 1.17 
(0.96,1.43) 
260.1857 396 Positive Hexanoylcarnitine Acyl carnitines 0.00001 1.37 
(1.06,1.78) 
267.0587 68 Positive Pseudouridine and/or Uridine Nucleosides 0.00058 1.20 
(0.93,1.56) 
267.1191 394 Positive S-Acetyldihydrolipoamide Oxidative 
phosphory- 
lation 
0.00053 1.23 
(0.87,1.85) 
272.2586 575 Positive Hexadecenoic acid Fatty acid 
metabolism 
0.00058 0.92 
(0.85,0.99) 
282.1198 64 Positive Methyladenosine and/or Methyl-
deoxyguanosine 
Nucleosides 0.00004 1.27 
(1.11,1.46) 
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287.2442 57 Positive N,N-Diacetylspermine Acyl amino 
acids and 
related 
metabolites 
0.00001 1.36 
(0.98,1.93) 
289.2204 453 Positive Octanoylcarnitine Acyl carnitines 0.00010 1.36 
(0.97,1.95) 
290.2473 603 Positive 5a-Androst-3-en-17-one Thyroid and 
steroid 
hormones 
0.00286 0.91 
(0.72,1.12) 
301.1411 585 Positive Hydroxydodecanoic acid Oxidised fatty 
acids 
0.00001 0.50 
(0.43,0.60) 
305.0841 62 Positive Methylinosine Nucleosides 0.00027 1.27 
(1.09,1.49) 
313.2740 643 Positive Oxo-nonadecanoic acid Oxidised fatty 
acids 
0.00270 1.62 
(1.09,2.33) 
316.2484 495 Positive Decanoylcarnitine Acyl carnitines 0.00010 1.32 
(0.95,1.86) 
318.3004 509 Positive 4-hydroxysphinganine and/or 
Phytosphingosine 
Ceramides 
and 
sphingolipids 
0.00286 0.91 
(0.85,0.98) 
325.2732 610 Positive 11(R)-HEDE and/or 11S-HEDE and/or 
15(R)-HEDE 
Oxidised fatty 
acids 
0.00286 0.86 
(0.70,1.06) 
357.1956 560 Positive Octadecenoic acid Fatty acid 
metabolism 
0.00058 1.63 
(0.64,2.65) 
368.1528 70 Positive Estrone sulfate Thyroid and 
steroid 
hormones 
0.00058 1.36 
(1.13,1.64) 
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370.2571 685 Positive (13E)-11alpha-Hydroxy-9,15-dioxoprost-13-
enoate and/or (5e,13e)-9,15-Dihydroxy-11-
Oxoprosta-5,13-Dien-1-Oicacid and/or (5Z)-
(15S)-11alpha-Hydroxy-9,15-
dioxoprostanoate and/or (5Z,13E)-(15S)-11-
alpha,15-dihydroxy-9-oxoprosta-5,13-
dienoate and/or (5z,13e)-(15s)-6,9-alpha-
epoxy-11-alpha,15-dihydroxyprosta-5,13-
dienoate and/or (5Z,13E)-(15S)-
9alpha,11alpha-epoxy-15-
hydroxythromboxa-5,13-dienoate and/or 
(5Z,13E)-(15S)-9alpha,15-Dihydroxy-11-
oxoprosta-5,13-dienoate and/or 
(6Z,8E,10E,14Z)-(5S,12R)-5,12,20-
Trihydroxyicosa-6,8,10,14- tetraenoate 
and/or 11beta-PGE2 and/or 13,14-dihydro-
15-keto-PGD2 and/or 13,14-dihydro-15-oxo-
lipoxin A4 and/or 15-epi-lipoxin A4 and/or 15-
epi-lipoxin B4 and/or 15-Keto-prostaglandin 
F2alpha and/or 15-oxo-PGE1 and/or 15R-
PGD2 and/or 15R-PGE2 and/or 20-OH-
hepoxilin A3 and/or 20-OH-Leukotriene B4 
and/or 20-OH-Leukotriene B4 and/or 
5,12,20-TriHETE and/or 5,14,15-trihydroxy-
6,8,10,12-Eicosatetraenoic acid and/or 
5S,6S-Lipoxin A4 and/or 5-trans-PGE2 
and/or 8-iso-15-keto-PGF2a and/or 8-iso-
PGF3a and/or 8-isoprostaglandin E2 and/or 
D17 PGE1 and/or delta-12-PGD2 and/or 
Dinoprostone (JAN/USP/INN) and/or 
Oxidised fatty 
acids 
0.00010 1.66 
(1.14,2.52) 
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Epoprostenol (USAN/INN) and/or 
Levuglandin D2 and/or Levuglandin E2 
and/or Lipoxin A4 and/or Lipoxin B4 and/or 
Narbonolide and/or PGE2 and/or PGK1 
and/or Prostaglandin E2 and/or 
Prostaglandin F3alpha and/or Prostaglandin 
H2 and/or Prostaglandin I2 and/or 
prostaglandin-H2 and/or Thromboxane A2 
and/or w-hydroxyl leukotriene B4 
386.3996 607 Positive dimethyl-docosanoic acid and/or methyl-
tricosanoic acid and/or tetracosanoate 
Fatty acid 
metabolism 
0.00027 1.30 
(0.61,2.95) 
395.1381 536 Positive QH2 Oxidative 
phosphory- 
lation 
0.00010 0.23 
(0.17,0.33) 
400.4154 612 Positive Pentacosanoic acid Fatty acid 
metabolism 
0.00157 1.24 
(0.58,2.85) 
401.2579 655 Positive Methyl-eicosanoic acid and/or Heneicosanoic 
acid 
Fatty acid 
metabolism 
0.00286 0.74 
(0.55,0.93) 
405.2759 513 Positive Tetracosatetraenoic acid Fatty acid 
metabolism 
0.00004 0.38 
(0.31,0.47) 
406.1446 539 Positive Poly-L-glutamate Amino acid 
metabolism 
0.00270 0.23 
(0.17,0.36) 
414.4314 617 Positive Hexacosanoic acid Fatty acid 
metabolism 
0.00004 1.22 
(0.56,2.88) 
427.2670 536 Positive 1(3)-glyceryl-PGD2 and/or 1(3)-glyceryl-
PGE2 and/or 1(3)-glyceryl-PGH2 and/or 2-
glyceryl-PGD2 and/or 2-glyceryl-PGE2 
and/or 2-glyceryl-PGH2 
Oxidised fatty 
acids 
0.00011 0.02 
(0.01,0.03) 
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459.1296 383 Positive FMNH Oxidative 
phosphory- 
lation 
0.00010 1.37 
(1.12,1.70) 
496.3403 596 Positive LysoPC(16:0) Glycero- 
phospholipids 
0.00010 1.76 
(1.25,2.49) 
504.4365 655 Positive Ceramide (d18:1/12:0) Ceramides 
and 
sphingolipids 
0.00468 1.89 
(1.26,2.62) 
509.1768 439 Positive Estriol-glucuroinide Thyroid and 
steroid 
hormones 
0.00058 1.23 
(0.94,1.62) 
510.4886 683 Positive N-(Tetradecanoyl)-sphing-4-enine Ceramides 
and 
sphingolipids 
0.00011 1.48 
(1.01,2.17) 
522.2863 526 Positive Chenodeoxycholoyltaurine and/or 
Taurochenodeoxycholate and/or 
Taurodeoxycholic acid and/or 
Tauroursodeoxycholic acid 
Bile acid 
metabolism 
0.00058 1.3 
(0.83,2.09) 
522.3579 598 Positive LysoPC(18:1) Glycero- 
phospholipids 
0.00097 1.82 
(1.27,2.65) 
524.3708 617 Positive LysoPC(18:0) Glycero- 
phospholipids 
0.00010 1.68 
(1.24,2.25) 
529.2423 521 Positive 11-hydroxyprogesterone 11-glucuronide Thyroid and 
steroid 
hormones 
0.00058 1.20 
(0.63,2.11) 
535.4343 693 Positive DG(28:0) Acyl glycerides 0.00286 1.33 
(1.09,1.61) 
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539.5236 700 Positive N-Palmitoylsphingosine Ceramides 
and 
sphingolipids 
0.00001 1.57 
(1.14,2.20) 
541.2332 695 Positive Leukotriene D4 Oxidised fatty 
acids 
0.00010 1.54 
(1.18,2.10) 
542.2777 543 Positive Octadecenoyl carnitine Acyl carnitines 0.00286 1.26 
(0.96,1.67) 
542.3224 581 Positive LysoPC(20:5) and/or LysoPC(18:2) Glycero- 
phospholipids 
0.00451 1.47 
(1.05,2.04) 
545.2362 416 Positive 13-cis-retinoyl-beta-D-glucuronide and/or all-
trans-Retinoyl-beta-glucuronide 
Other class 0.00134 1.23 
(0.79,1.98) 
562.5149 700 Positive Cer(d18:0/16:0) Ceramides 
and 
sphingolipids 
0.00001 1.37 
(1.03,1.84) 
563.2452 460 Positive Tetrahydroaldosterone-3-glucuronide Thyroid and 
steroid 
hormones 
0.00010 1.37 
(1.04,1.81) 
564.2495 510 Positive LysoPE(22:6) Glycero- 
phospholipids 
0.00010 1.42 
(1.08,1.87) 
565.4355 612 Positive PC(O-3:1/O-18:1) Glycero- 
phospholipids 
0.00004 1.78 
(1.11,2.89) 
568.5664 727 Positive Cer(d18:0/18:0) Ceramides 
and 
sphingolipids 
0.00091 1.29 
(0.91,1.85) 
575.4666 670 Positive DG(33:4) and/or DG(31:1) Acyl glycerides 0.00006 2.11 
(1.19,3.74) 
583.4003 618 Positive Hentriacontanoic acid Fatty acid 
metabolism 
0.00468 1.44 
(1.09,1.88) 
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585.4814 696 Positive Tritriacontanoic acid Fatty acid 
metabolism 
0.00468 1.57 
(0.98,2.48) 
594.5827 745 Positive Ceramide (d18:1/20:0) Ceramides 
and 
sphingolipids 
0.00006 1.41 
(0.99,2.01) 
595.3468 441 Positive Urobilin Heme 
metabolism 
0.00031 1.37 
(0.90,2.18) 
601.4813 662 Positive DG(35:5) and/or DG(33:2) Acyl glycerides 0.00010 2.05 
(1.22,3.34) 
609.2601 614 Positive 2-hydroxyestrone-1-S-glutathione Thyroid and 
steroid 
hormones 
0.00286 1.26 
(0.99,1.62) 
614.2843 572 Positive LysoPE(22:4) Glycero- 
phospholipids 
0.00270 1.27 
(0.90,1.80) 
628.3592 682 Positive LysoPC(19:0) and/or PC(3:0/O-16:0) and/or 
PC(O-16:0/3:0) and/or PC(O-17:0/2:0) and/or 
PC(O-18:0/1:0) 
Glycero- 
phospholipids 
0.00286 0.79 
(0.65,0.96) 
633.4487 633 Positive PA(31:1) Glycero- 
phospholipids 
0.00058 1.41 
(1.07,1.88) 
634.5399 612 Positive DG(36:4) Acyl glycerides 0.00097 1.37 
(1.15,1.63) 
636.4600 633 Positive PC(25:0) and/or PE(28:0) Glycero- 
phospholipids 
0.00001 2.04 
(1.17,3.57) 
641.5126 733 Positive DG(38:6) and/or DG(36:3) Acyl glycerides 0.00058 1.54 
(1.15,2.03) 
643.5279 753 Positive DG(38:5) and/or DG(36:2) Acyl glycerides 0.00058 1.63 
(1.22,2.17) 
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644.5958 777 Positive Ceramide (d18:1/22:0) Ceramides 
and 
sphingolipids 
0.00058 1.34 
(0.90,1.97) 
647.4595 763 Positive DG(35:4) Acyl glycerides 0.00058 0.82 
(0.72,0.93) 
651.6487 803 Positive Cer(d18:0/24:1) Ceramides 
and 
sphingolipids 
0.00468 1.06 
(0.67,1.94) 
651.7983 483 Positive Triiodothyronine Thyroid and 
steroid 
hormones 
0.00058 1.24 
(0.97,1.59) 
652.6011 761 Positive Episteryl palmitoleate and/or fecosteryl 
palmitoleate 
Fatty acid 
metabolism 
0.00053 1.26 
(0.82,1.99) 
658.6116 797 Positive Tricosanamide Fatty acid 
metabolism 
0.00010 1.51 
(1.06,2.19) 
667.5279 752 Positive DG(40:7) and/or DG(38:4) and/or DG(36:1) Acyl glycerides 0.00010 1.78 
(1.22,2.72) 
670.6115 770 Positive Ceramide (d18:1/24:1) Ceramides 
and 
sphingolipids 
0.00001 1.82 
(1.19,2.97) 
675.5445 688 Positive SM(d18:1/14:0) Ceramides 
and 
sphingolipids 
0.00001 1.63 
(1.18,2.34) 
689.5604 709 Positive CE(18:1) Cholesterol 
esters 
0.00001 1.62 
(1.15,2.40) 
690.5638 719 Positive N-(2-hydroxyhenicosanoyl)-4,8-
sphingadienine 
Ceramides 
and 
sphingolipids 
0.00010 1.75 
(1.22,2.70) 
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690.6378 801 Positive N-(24-hydroxytetracosanyl)sphinganine 
and/or N-tetracosanylphytosphingosine 
Ceramides 
and 
sphingolipids 
0.00270 1.27 
(0.92,1.79) 
695.5107 672 Positive SM(d18:0/12:0) Ceramides 
and 
sphingolipids 
0.00027 1.53 
(1.05,2.29) 
700.4900 694 Positive PE(33:3) and/or PC(28:0) and/or PE(31:0) Glycero- 
phospholipids 
0.00011 1.54 
(1.07,2.34) 
700.5603 55 Positive PC(O-14:0/O-16:0) Glycero- 
phospholipids 
0.00047 1.35 
(1.00,1.82) 
701.5604 693 Positive Episteryl oleate and/or fecosteryl oleate 
and/or lanosteryl palmitoleate 
Fatty acid 
metabolism 
0.00001 1.61 
(1.14,2.37) 
704.5794 712 Positive N-(2-hydroxydocosanoyl)-4,8-sphingadienine Ceramides 
and 
sphingolipids 
0.00001 1.43 
(1.07,1.96) 
707.5434 697 Positive TG(36:0) Acyl glycerides 0.00058 1.46 
(1.05,2.11) 
713.5494 701 Positive 3-demethylubiquinone-8 Oxidative 
phosphory- 
lation 
0.00016 1.81 
(1.23,2.80) 
717.5915 715 Positive CE(20:1) Cholesterol 
esters 
0.00001 1.48 
(1.04,2.21) 
718.5754 701 Positive PC(14:0/dm18:0) and/or PC(16:0/dm16:0) 
and/or PC(O-14:0/18:1) 
Glycero- 
phospholipids 
0.00058 1.49 
(1.09,2.13) 
720.5549 726 Positive PC(31:0) and/or PE(34:0) Glycero- 
phospholipids 
0.00002 1.44 
(1.01,2.16) 
726.5614 702 Positive SM(d18:1/16:0) Ceramides 
and 
sphingolipids 
0.00001 1.46 
(1.07,2.05) 
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727.1948 487 Positive Dehydroisocoproporphyrinogen Heme 
metabolism 
0.00468 1.36 
(0.72,2.53) 
727.5681 713 Positive Coenzyme Q8 and/or ubiquinone-8 Oxidative 
phosphory- 
lation 
0.00001 1.42 
(1.06,1.95) 
729.2107 517 Positive Coproporphyrin and/or Uroporphyrin Heme 
metabolism 
0.00468 1.09 
(0.85,1.41) 
731.6074 728 Positive SM(d18:0/18:1) Ceramides 
and 
sphingolipids 
0.00001 1.53 
(1.13,2.14) 
733.5858 775 Positive PC(14:0/dm18:1) and/or PC(14:1/dm18:0) 
and/or PC(16:1/dm16:0) 
Glycero- 
phospholipids 
0.00468 1.28 
(0.86,1.84) 
738.5995 781 Positive DG(44:8) Acyl glycerides 0.00468 1.26 
(0.87,1.82) 
739.5508 677 Positive DG(40:5) Acyl glycerides 0.00001 1.60 
(1.18,2.19) 
742.5731 734 Positive PC(16:1/dm18:1) and/or PC(18:2/dm16:0) Glycero- 
phospholipids 
0.00010 1.39 
(0.97,2.06) 
748.4906 61 Positive PC(32:4) and/or PE(35:4) Glycero- 
phospholipids 
0.00058 1.66 
(1.15,2.53) 
748.5861 755 Positive PC(33:0) and/or PE(36:0) Glycero- 
phospholipids 
0.00270 1.18 
(0.77,1.98) 
752.5602 729 Positive PE(20:3/dm18:1) and/or PE(20:4/dm18:0) 
and/or PE(22:4/dm16:0) and/or PE(O-
16:0/22:5) and/or PE(O-18:0/20:5) and/or 
PE(O-18:1/20:4) 
Glycero- 
phospholipids 
0.00286 1.58 
(1.13,2.31) 
753.5817 727 Positive Ubiquinol 8 Oxidative 
phosphory- 
lation 
0.00010 1.46 
(1.07,2.06) 
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755.5405 710 Positive CE(20:5) Cholesterol 
esters 
0.00010 1.44 
(1.08,1.98) 
759.4971 687 Positive DG(44:11) Acyl glycerides 0.00016 1.54 
(1.13,2.17) 
759.5735 717 Positive PC(34:2) Glycero- 
phospholipids 
0.00010 1.57 
(1.14,2.22) 
760.5863 738 Positive PC(34:1) and/or PE(37:1) Glycero- 
phospholipids 
0.00010 1.45 
(1.10,1.97) 
766.4087 597 Positive PS(32:4) and/or PE(32:5) Glycero- 
phospholipids 
0.00010 0.86 
(0.76,0.97) 
766.5732 750 Positive PC(18:3/dm18:1) and/or PC(18:4/dm18:0) 
and/or PC(20:4/dm16:0) 
Glycero- 
phospholipids 
0.00001 1.59 
(1.11,2.43) 
768.5534 726 Positive PC(35:4) and/or PE(38:4) Glycero- 
phospholipids 
0.00058 1.46 
(1.12,1.97) 
770.5698 670 Positive PC(35:3) and/or PE(36:0) Glycero- 
phospholipids 
0.00010 1.70 
(1.23,2.38) 
772.5887 747 Positive PC(35:2) Glycero- 
phospholipids 
0.00079 1.35 
(1.08,1.78) 
774.5422 724 Positive PE(22:6/dm18:1) Glycero- 
phospholipids 
0.00286 1.51 
(1.10,2.15) 
774.6011 698 Positive PC(35:1) and/or PE(38:1) Glycero- 
phospholipids 
0.00468 1.59 
(1.07,2.49) 
777.6960 485 Positive O-(4-Hydroxy-3,5-diidophenyl)-3,5-diiodo-L-
tyrosine and/or thyroxine 
Thyroid and 
steroid 
hormones 
0.00162 1.21 
(0.96,1.53) 
781.6198 734 Positive SM(d18:1/20:0) Ceramides 
and 
sphingolipids 
0.00001 1.52 
(1.11,2.14) 
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785.6545 764 Positive SM(d18:1/22:1) Ceramides 
and 
sphingolipids 
0.00010 1.60 
(1.13,2.35) 
787.6053 740 Positive PC(36:2) Glycero- 
phospholipids 
0.00010 1.55 
(1.12,2.22) 
787.6698 793 Positive SM(d18:1/22:0) Ceramides 
and 
sphingolipids 
0.00001 1.59 
(1.10,2.39) 
796.5841 739 Positive PC(37:4) and/or PE(40:4) and/or PE(38:1) Glycero- 
phospholipids 
0.00001 1.56 
(1.11,2.32) 
813.5459 734 Positive PS(36:1) and/or PG(38:6) and/or PC(33:2) 
and/or PE(36:2) 
Glycero- 
phospholipids 
0.00286 1.46 
(1.06,1.97) 
813.6855 798 Positive SM(d18:1/24:1) Ceramides 
and 
sphingolipids 
0.00016 1.63 
(1.08,2.60) 
816.5653 56 Positive PE(20:0/dm18:1) and/or PE(20:1/dm18:0) 
and/or PE(22:1/dm16:0) 
Glycero- 
phospholipids 
0.00097 1.51 
(1.05,2.31) 
818.6050 731 Positive PC(22:5/dm18:1) and/or PC(22:6/dm18:0) 
and/or PC(20:2/dm18:1) and/or 
PC(20:3/dm18:0) 
Glycero- 
phospholipids 
0.00001 1.62 
(1.13,2.45) 
821.5239 689 Positive PG(36:1) Glycero- 
phospholipids 
0.00270 1.52 
(1.06,2.39) 
825.0334 703 Positive Diguanosine diphosphate Nucleosides 0.00157 1.54 
(1.03,2.33) 
828.5073 733 Positive PC(O-15:0/20:4) and/or PE(20:2/dm18:1) 
and/or PE(20:3/dm18:0) 
Glycero- 
phospholipids 
0.00058 1.26 
(0.98,1.59) 
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833.6522 768 Positive SM(d18:0/22:0) Ceramides 
and 
sphingolipids 
0.00010 1.62 
(1.16,2.36) 
836.5374 721 Positive PS(36:0) and/or PE(38:4) and/or PE(36:1) Glycero- 
phospholipids 
0.00010 1.52 
(1.15,2.06) 
837.5403 726 Positive PG(36:0) Glycero- 
phospholipids 
0.00027 1.45 
(1.11,1.94) 
842.6039 744 Positive PC(22:4/dm18:1) and/or PC(22:5/dm18:0) 
and/or PC(37:0 and/or PE(40:0) 
Glycero- 
phospholipids 
0.00053 1.30 
(0.95,1.83) 
844.5390 712 Positive PC(18:1/dm18:1) and/or PC(18:2/dm18:0) 
and/or PC(20:2/dm16:0) 
Glycero- 
phospholipids 
0.00010 1.68 
(1.21,2.42) 
854.6703 745 Positive GlcCer(d18:0/22:0) Ceramides 
and 
sphingolipids 
0.00053 1.41 
(1.07,1.88) 
868.6010 411 Positive PC(37:2) and/or PE(40:2) Glycero- 
phospholipids 
0.00286 1.23 
(0.91,1.68) 
872.5699 756 Positive PC(20:1/dm18:1) and/or PC(20:2/dm18:0) 
and/or PC(22:2/dm16:0) 
Glycero- 
phospholipids 
0.00006 1.53 
(1.09,2.24) 
875.6235 742 Positive PC(42:8) Glycero- 
phospholipids 
0.00011 1.45 
(1.05,2.06) 
901.6392 750 Positive PC(44:9) Glycero- 
phospholipids 
0.00016 1.56 
(1.09,2.34) 
910.5107 704 Positive PC(42:11) Glycero- 
phospholipids 
0.00006 1.56 
(1.07,2.34) 
912.5263 735 Positive PC(42:10) Glycero- 
phospholipids 
0.00010 1.68 
(1.21,2.43) 
916.5281 717 Positive PC(44:12) Glycero- 
phospholipids 
0.00011 1.54 
(1.14,2.11) 
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918.5439 735 Positive PC(44:11) Glycero- 
phospholipids 
0.00016 1.59 
(1.16,2.26) 
923.5036 716 Positive PI(38:5) Glycero- 
phospholipids 
0.00004 1.46 
(1.09,1.99) 
924.5716 733 Positive PC(42:9) Glycero- 
phospholipids 
0.00389 1.36 
(0.97,1.92) 
938.6262 407 Positive PE(44:3) Glycero- 
phospholipids 
0.00451 1.24 
(0.92,1.71) 
944.2437 664 Positive Decanoyl-CoA CoA 
metabolism 
0.00468 0.89 
(0.78,1.01) 
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10.6 Metabolites correlated with RV MPI pre-FLA 
All metabolites listed demonstrated a Spearman Rank correlation between -1.0 to -0.3 or +0.3 to +1.0 and are grouped into 
classes of chemical structure or metabolic pathway. 
Mass/ 
charge 
ratio 
Retention 
time 
Ion 
mode 
Metabolite Metabolite Class Correlation 
Coefficient 
203.1502 67 Positive N,N-dimethylarginine Acyl amino acids 0.30 
287.2442 57 Positive N,N-Diacetylspermine Acyl amino acids 0.37 
542.2777 543 Positive Octadecenoyl carnitine Acyl carnitine -0.43 
204.1230 68 Positive Acetylcarnitine Acyl carnitine -0.40 
184.0943 56 Positive Carnitine Acyl carnitine -0.36 
232.1543 75 Positive Butanoylcarnitine Acyl carnitine -0.33 
289.2204 453 Positive Octanoylcarnitine Acyl carnitine -0.32 
260.1857 396 Positive Hexanoylcarnitine Acyl carnitine -0.31 
547.4343 635 Positive DG(29:1) Acyl glycerides -0.49 
739.5508 677 Positive DG(40:5) Acyl glycerides -0.40 
707.5434 697 Positive TG(36:0) Acyl glycerides -0.37 
713.5494 701 Positive DG(40:3) Acyl glycerides -0.34 
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633.4487 633 Positive DG(36:7);DG(34:4) Acyl glycerides -0.33 
745.5988 751 Positive DG(40:2) Acyl glycerides -0.31 
957.6695 391 Positive TG(56:10) Acyl glycerides 0.32 
429.1987 580 Positive MG(14:0) Acyl glycerides 0.41 
953.6869 399 Positive TG(55:10) Acyl glycerides 0.60 
339.0221 346 Positive Vanillactic acid Aromatic metabolites -0.41 
532.2909 338 Negative Glycocholic acid Bile acid metabolism 0.31 
651.2658 335 Negative Taurallocholic acid;Tauroursocholic acid Bile acid metabolism 0.31 
570.2418 531 Positive Deoxycholic acid disulfate Bile acid metabolism 0.36 
187.0577 59 Positive 1,5-Anhydro-D-glucitol;Deoxy-
galactose;Deoxy-
glucose;Fucose;Rhamnose; Rhamnulose 
Carbohydrates -0.33 
275.0655 36 Negative 1-Amino-1-deoxy-scyllo-inositol 4-
phosphate;Glucosamine 1-
phosphate;Aminofructose 6-
phosphate;Galactosamine 1-
phosphate;Galactosamine 6-
phosphate;Glucosamine-4-
Phosphate;Glucosamine-1-Phosphate 
Carbohydrates 0.30 
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673.2322 41 Negative 3-Sialyl-N-acetyllactosamine;6-Sialyl-N-
acetyllactosamine 
Carbohydrates 0.35 
634.2114 37 Negative 3'-Sialyllactose;6'-Sialyllactose Carbohydrates 0.45 
867.6750 750 Positive SM(d18:1/25:0) Ceramides and sphingolipids -0.49 
792.5794 736 Positive Cer(d18:1/26:1) Ceramides and sphingolipids -0.41 
660.5699 766 Positive Cer(d18:1/22:0) Ceramides and sphingolipids -0.38 
510.4886 683 Positive N-(Tetradecanoyl)-sphing-4-enine Ceramides and sphingolipids -0.37 
654.4016 733 Positive N-(2-hydroxypentadecanoyl)-4,8-
sphingadienine 
Ceramides and sphingolipids -0.36 
340.2821 519 Positive 4-hydroxysphinganine; Phytosphingosine Ceramides and sphingolipids -0.33 
539.5236 700 Positive N-Palmitoylsphingosine Ceramides and sphingolipids -0.30 
458.2247 606 Positive Sphinganine-1-phosphate Ceramides and sphingolipids 0.40 
738.6497 693 Positive Cer(d18:0/26:0) Ceramides and sphingolipids 0.42 
912.0391 378 Positive Formyl-CoA CoA metabolism -0.40 
242.0998 82 Positive Pantothenic acid CoA metabolism -0.30 
201.1111 433 Positive Decenedioic acid Fatty acid metabolism -0.52 
213.1101 407 Positive Octanoic acid Fatty acid metabolism -0.45 
374.3033 592 Positive Anandamide (20:2, n-6) Fatty acid metabolism -0.43 
357.1956 560 Positive Octadecenoic acid Fatty acid metabolism -0.41 
 441 
 
583.4003 618 Positive Hentriacontanoic acid Fatty acid metabolism -0.40 
451.3777 625 Positive Pentacosanoic acid Fatty acid metabolism -0.35 
377.3224 594 Positive Anandamide (20:l, n-9) Fatty acid metabolism -0.32 
160.1335 317 Positive Aminooctanoic acid;Octenoic acid Fatty acid metabolism -0.30 
467.2860 596 Positive Docosanoic acid Fatty acid metabolism 0.32 
401.1641 270 Negative Docosahexaenoic acid Fatty acid metabolism 0.32 
289.2932 515 Positive Methyl-hexadecanoic acid;Heptadecanoic 
acid 
Fatty acid metabolism 0.33 
266.2085 551 Positive Amino-tetradecanoic acid Fatty acid metabolism 0.38 
608.6364 33 Negative Docosanyl octadecanoate;eicosanyl 
icosanoate;hexadecyl 
tetracosanoate;octadecyl 
docosanoate;tetracosanyl 
hexadecanoate;tetradecyl 
hexacosanoate;; 
Fatty acid metabolism 0.46 
880.5985 450 Positive PC(36:0) Glycerophospholipids -0.64 
720.5549 726 Positive PE(34:0) Glycerophospholipids -0.45 
872.6479 801 Positive PC(22:0/dm18:1);PC(22:1/dm18:0);PC(2
4:1/dm16:0) 
Glycerophospholipids -0.45 
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614.2843 572 Positive LysoPE(22:6) Glycerophospholipids -0.44 
748.5861 755 Positive PE(36:0) Glycerophospholipids -0.42 
742.5731 734 Positive PC(16:1/dm18:1);PC(18:2/dm16:0);PC(O
-16:0/18:3);PC(P-16:0/18:2) 
Glycerophospholipids -0.42 
791.5685 731 Positive PE(22:6/dm18:1) Glycerophospholipids -0.42 
718.5394 715 Positive PE(34:1) Glycerophospholipids -0.41 
888.5360 736 Positive PC(18:0/dm18:1);PC(18:2/O-
18:0);PC(20:1/dm16:0);PC(P-18:0/18:1) 
Glycerophospholipids -0.40 
842.6039 744 Positive PE(40:0) Glycerophospholipids -0.39 
649.3451 516 Positive PG(24:0) Glycerophospholipids -0.38 
958.7256 440 Positive PE(48:1) Glycerophospholipids -0.38 
837.5403 726 Positive PG(36:0) Glycerophospholipids -0.36 
700.4900 694 Positive PC(28:0) Glycerophospholipids -0.36 
932.6470 405 Positive PC(44:4) Glycerophospholipids -0.35 
747.5136 717 Positive PG(34:2) Glycerophospholipids -0.35 
767.5788 750 Positive PC(18:3/dm18:1);PC(18:4/dm18:0);PC(2
0:4/dm16:0);PC(O-16:0/20:5);PC(P-
16:0/20:4) 
Glycerophospholipids -0.35 
923.5036 716 Positive PI(38:5) Glycerophospholipids -0.32 
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752.5602 729 Positive PE(20:3/dm18:1);PE(20:4/dm18:0);PE(22
:4/dm16:0) 
Glycerophospholipids -0.32 
590.3300 492 Positive LysoPI(16:0) Glycerophospholipids -0.32 
818.6050 731 Positive PC(22:5/dm18:1);PC/dm18:0);PC(P-
18:0/22:6);PC(20:2/dm18:1;PC(20:3/dm1
8:0);PC(O-16:0/22:4);PC(O-18:0/20:4) 
Glycerophospholipids -0.32 
844.6192 713 Positive PC(22:4/dm18:0);PC(O-
18:0/22:5);PC(20:0/dm18:1);PC(20:1/dm1
8:0);PC(22:1/dm16:0) 
Glycerophospholipids -0.31 
718.5754 701 Positive PC(14:0/dm18:0);PC(16:0/dm16:0);PC(O
-14:0/18:1) 
Glycerophospholipids -0.31 
912.5263 735 Positive PC(42:10) Glycerophospholipids -0.30 
982.6173 482 Negative PE(44:2) Glycerophospholipids 0.31 
573.3282 506 Negative PC(20:4) Glycerophospholipids 0.31 
834.5431 33 Negative PE(40:3) Glycerophospholipids 0.36 
511.1917 415 Positive PG(12:0) Glycerophospholipids 0.51 
695.2615 775 Positive Protoporphyrinogen IX Heme metabolism -0.34 
355.2245 479 Positive Dihydroxy-stearic acid;methyl-
hexadecanoic acid 
Mixed class -0.59 
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331.0182 57 Positive 2-deoxyglucose-6-
phosphate;Glycerophosphoglycerol 
Mixed class 0.46 
306.0926 64 Positive Orotidine Nucleoside -0.36 
667.1006 632 Positive 2'-Deoxycytidine-2'-Deoxyadenosine-
3',5'-Monophosphate 
Nucleosides -0.50 
385.0209 363 Positive 2',3'-Dehydro-2',3'-Deoxy-Thymidine 5'-
Diphosphate 
Nucleosides -0.34 
565.9458 35 Negative 8-hydroxydeoxyguanosine 5'-
triphosphate;Guanosine triphosphate 
Nucleosides 0.54 
743.5405 695 Positive Cholesteryl 11-hydroperoxy-
eicosatetraenoate 
Other class -0.43 
263.0796 419 Positive Hydroxynicotine;Nicotine-N-oxide Other class -0.41 
450.0877 209 Negative Succinyladenosine Other class 0.32 
420.2155 604 Positive S-Octyl GSH Other class 0.38 
511.0943 506 Positive CDP-choline Other class 0.57 
604.0563 37 Negative CDP-ribitol Other class 0.71 
579.2165 486 Positive Leukotriene D5 Oxidised fatty acids -0.48 
187.1328 401 Positive Hydroxydecenoic acid;Oxodecanoic acid Oxidised fatty acids -0.40 
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398.2885 731 Positive PGF2alpha-EA;;16,16-dimethyl-
PGD2;16,16-dimethyl-PGE2;1a,1b-
dihomo-PGD2;1a,1b-dihomo-PGE2;20-
ethyl-PGE2 
Oxidised fatty acids -0.31 
346.3319 535 Positive Hydroxyeicosanoic acid Oxidised fatty acids 0.32 
329.1605 496 Positive Prostaglandin M Oxidised fatty acids 0.36 
159.1029 283 Negative Hydroxyoctanoic acid Oxidised fatty acids 0.48 
361.2354 603 Positive 10,11-dihydro-12-epi-leukotriene 
B4;11,12-DHET;11-deoxy-PGE1;11-
deoxy-PGF2a;11-deoxy-PGF2beta;12-
keto-tetrahydro-Leukotriene B4;14,15-
DHET;15-hydroperoxyeicosa-
8Z,11Z,13E-trienoate;5,6-DHET;5,6-
dihydroxy-8,11,14-eicosatrienoic acid;6,7-
dihydro-12-epi-leukotriene B4;8,9-
DHET;8,9-dihydroxy-5,11,14-
eicosatrienoic acid 
Oxidised fatty acids 0.57 
259.0926 38 Negative L-alpha-glutamyl-L-hydroxyproline Peptides 0.51 
696.9590 60 Positive UDP-D-galacturonate;UDP-D-glucuronate Sugar nucleotide metabolism -0.65 
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602.0526 50 Negative Thymidine-5'-Diphospho-Beta-D-Xylose Sugar nucleotide metabolism 0.36 
267.1191 394 Positive S-Acetyldihydrolipoamide Oxidative phosphorylation 0.32 
651.7983 483 Positive Triiodothyronine Thyroid and steroid 
metabolism 
-0.37 
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10.7 Metabolites correlated with LV MPI pre-FLA 
All metabolites listed demonstrated a Spearman Rank correlation between -1.0 to -0.3 or +0.3 to +1.0 and are grouped into 
classes of chemical structure or metabolic pathway. 
Mass/ 
charge 
ratio 
Retention 
time 
Ion 
mode 
Metabolite Metabolite Class Correlation 
Coefficient 
203.1502 67 Positive N,N-dimethylarginine Acyl amino acids 0.34 
287.2442 57 Positive N,N-Diacetylspermine Acyl amino acids 0.39 
270.1092 72 Positive Butanoylcarnitine Acyl carnitine -0.46 
444.3049 636 Positive Palmitoylcarnitine Acyl carnitine -0.42 
406.2173 447 Positive Decanoylcarnitine Acyl carnitine -0.34 
202.1093 252 Negative Acetylcarnitine Acyl carnitine -0.31 
548.2890 606 Positive Docosapentaenoyl carnitine Acyl carnitine 0.41 
781.6437 650 Positive DG(43:0) Acyl glycerides -0.52 
855.7422 797 Positive TG(52:4) and/or TG(50:1) Acyl glycerides -0.47 
634.5399 612 Positive DG(36:4) Acyl glycerides -0.41 
535.4343 693 Positive DG(28:0) Acyl glycerides -0.40 
707.5434 697 Positive TG(36:0) Acyl glycerides -0.39 
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547.4343 635 Positive DG(29:1) Acyl glycerides -0.38 
759.4971 687 Positive DG(44:11) Acyl glycerides -0.34 
698.6628 650 Positive DG(40:0) Acyl glycerides -0.32 
961.6651 384 Positive TG(58:12) Acyl glycerides -0.31 
843.6096 437 Positive DG(46:6) Acyl glycerides -0.31 
647.4595 763 Positive DG(35:4) Acyl glycerides 0.40 
909.7193 435 Positive TG(51:4) Acyl glycerides 0.54 
281.1008 231 Negative S-aminomethyldihydrolipoamide Amino acid metabolism -0.48 
154.0836 68 Positive Isoleucine and/or Leucine Amino acid metabolism -0.47 
172.0397 60 Positive Methionine Amino acid metabolism -0.41 
314.0174 349 Positive Indoleacrylic acid Aromatic metabolites -0.37 
228.0636 365 Positive Methoxyindoleacetate and/or 
Indolelactate 
Aromatic metabolites -0.31 
495.2383 512 Positive Chenodeoxycholic acid sulfate and/or 
Ursodeoxycholic acid 3-sulfate 
Bile acid metabolism -0.38 
532.2874 484 Negative Glycocholic acid Bile acid metabolism 0.32 
478.2889 549 Positive Glycolithocholic acid Bile acid metabolism 0.44 
259.0137 230 Negative Galactose 6-sulfate and/or Glucose 6-
sulfate 
Carbohydrates -0.57 
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692.1633 37 Negative 3'-Sialyllactose and/or 6'-Sialyllactose Carbohydrates 0.33 
732.1963 40 Negative 3-Sialyl-N-acetyllactosamine and/or 6-
Sialyl-N-acetyllactosamine 
Carbohydrates 0.65 
792.5794 736 Positive Cer(d18:1/26:1) Ceramides and sphingolipids -0.43 
873.6764 438 Positive SM(d18:1/25:0) Ceramides and sphingolipids -0.41 
854.6703 745 Positive GlcCer(d18:0/22:0) Ceramides and sphingolipids -0.34 
729.5918 715 Positive SM(d18:1/18:1) Ceramides and sphingolipids -0.34 
814.6887 800 Positive SM(d18:1/24:1) Ceramides and sphingolipids -0.33 
608.4995 640 Positive Cer(d18:1/18:1) Ceramides and sphingolipids -0.32 
675.5445 688 Positive SM(d18:1/14:0) Ceramides and sphingolipids -0.31 
759.6381 703 Positive SM(d18:1/20:0) Ceramides and sphingolipids -0.30 
952.1884 414 Positive Octanoyl-CoA CoA metabolism -0.34 
242.0998 82 Positive Pantothenic acid CoA metabolism 0.36 
285.1799 77 Positive Pentadecenoic acid Fatty acid metabolism -0.67 
194.1525 526 Positive Decanamide Fatty acid metabolism -0.46 
399.2425 678 Positive Heneicosenoic acid Fatty acid metabolism -0.43 
369.2408 529 Positive Octadecanoic acid Fatty acid metabolism -0.39 
413.1948 585 Positive Nonadecenoic acid Fatty acid metabolism -0.37 
374.3033 592 Positive Anandamide (20:2, n-6) Fatty acid metabolism -0.37 
 450 
 
272.2586 575 Positive Amino-hexadecanoic acid and/or 
hexadecenoic acid 
Fatty acid metabolism -0.34 
241.1418 399 Positive Decanoic acid Fatty acid metabolism -0.34 
224.1623 499 Positive Amino-undecanoic acid Fatty acid metabolism 0.31 
551.4441 709 Positive Hentriacontanoic acid Fatty acid metabolism 0.54 
720.4816 464 Negative PC(28:1) Glycerophospholipids -0.53 
786.6395 389 Positive PE(22:0/dm18:1) and/or 
PE(22:1/dm18:0) and/or 
PE(24:1/dm16:0) 
Glycerophospholipids -0.49 
580.2962 572 Positive PC(18:1) Glycerophospholipids -0.48 
946.5888 423 Positive PC(42:6) Glycerophospholipids -0.46 
636.3620 636 Positive PC(22:1) Glycerophospholipids -0.45 
802.5731 746 Positive PE(22:4/dm18:0) and/or 
PE(20:0/dm18:1) and/or 
PE(20:1/dm18:0) and/or 
PE(22:1/dm16:0) 
Glycerophospholipids -0.44 
608.2570 618 Positive LysoPS(18:1) Glycerophospholipids -0.43 
615.1862 515 Positive PG(16:0) Glycerophospholipids -0.43 
923.5036 716 Positive PI(38:5) Glycerophospholipids -0.43 
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778.6338 646 Positive PA(40:0) Glycerophospholipids -0.42 
496.3403 596 Positive LysoPC(16:0) Glycerophospholipids -0.41 
890.5874 399 Positive PE(42:5) and/or PE(40:2) Glycerophospholipids -0.40 
626.3007 466 Positive LysoPC(22:6) Glycerophospholipids -0.40 
692.5241 684 Positive PE(32:0) Glycerophospholipids -0.40 
896.6722 437 Positive PC(22:0/dm18:1) and/or 
PC(22:1/dm18:0) and/or 
PC(24:1/dm16:0) 
Glycerophospholipids -0.40 
760.5012 643 Positive PE(16:0/dm18:1) and/or 
PE(16:1/dm18:0) and/or 
PE(18:1/dm16:0) 
Glycerophospholipids -0.39 
932.6470 405 Positive PC(44:4) Glycerophospholipids -0.39 
912.5263 735 Positive PC(42:10) Glycerophospholipids -0.38 
623.3181 598 Positive LysoPI(18:0) Glycerophospholipids -0.38 
700.4900 694 Positive PC(28:0) Glycerophospholipids -0.37 
759.5735 717 Positive PC(34:2) Glycerophospholipids -0.37 
836.5374 721 Positive PC(34:0) and/or PE(38:4) and/or 
PE(36:1) 
Glycerophospholipids -0.36 
910.5107 704 Positive PC(42:11) Glycerophospholipids -0.36 
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522.3579 598 Positive LysoPC(18:1) Glycerophospholipids -0.35 
918.5439 735 Positive PC(44:11) Glycerophospholipids -0.35 
837.5403 726 Positive PG(36:0) Glycerophospholipids -0.34 
546.3537 614 Positive LysoPC(20:3) Glycerophospholipids -0.34 
923.5885 528 Negative PC(38:4) Glycerophospholipids -0.34 
524.3708 617 Positive LysoPC(18:0) Glycerophospholipids -0.34 
768.5534 726 Positive PE(38:4) and/or PE(36:1) Glycerophospholipids -0.31 
720.5549 726 Positive PE(34:0) Glycerophospholipids -0.31 
544.3379 585 Positive LysoPC(20:4) Glycerophospholipids -0.31 
791.5685 731 Positive PE(22:6/dm18:1) Glycerophospholipids -0.31 
916.5281 717 Positive PC(44:12) Glycerophospholipids -0.30 
740.5576 748 Positive PC(18:3/dm16:0) and/or PC(O-14:0/20:4) 
and/or PC(16:0/dm16:0) and/or PC(O-
14:0/18:1) 
Glycerophospholipids 0.34 
922.5065 443 Positive PS(37:0) Glycerophospholipids 0.35 
554.2765 469 Positive LysoPC(dm16:0) Glycerophospholipids 0.41 
642.2114 605 Positive LysoPE(22:4) Glycerophospholipids 0.44 
619.3017 280 Negative PC(20:2) Glycerophospholipids 0.46 
922.7293 446 Positive PC(42:4) Glycerophospholipids 0.48 
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830.6646 444 Positive PE(42:1) Glycerophospholipids 0.50 
629.2355 592 Positive Phytochromobilin and/or Dihydrobiliverdin 
and/or Bilirubin 
Heme metabolism -0.61 
605.2399 643 Positive Biliverdin Heme metabolism -0.41 
595.3468 441 Positive Urobilin Heme metabolism 0.38 
729.2107 517 Positive Coproporphyrin and/or Uroporphyrin Heme metabolism 0.42 
331.0182 57 Positive 2-deoxyglucose-6-phosphate and/or 
Glycerophosphoglycerol 
Mixed class 0.44 
310.0095 96 Positive N-Acetylgalactosaminate and/or Choline 
sulfate 
Mixed class 0.61 
168.0631 64 Positive Isobutyrylglycine and/or Aminoadipate 6-
semialdehyde and/or Methyl-
pyrrolidinone 
Mixed class 0.66 
320.0972 58 Positive Methylguanosine and/or Deoxyadenosine Nucleoside -0.48 
338.0624 38 Negative Methyladenosine and/or deoxyguanosine Nucleoside -0.43 
306.0926 64 Positive Orotidine Nucleoside 0.34 
210.1101 382 Positive 8-Amino-7-oxononanoate Other class -0.39 
743.5405 695 Positive Cholesteryl 11-hydroperoxy-
eicosatetraenoate 
Other class -0.32 
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511.0943 506 Positive CDP-choline Other class 0.31 
933.6153 378 Positive all trans Decaprenyl diphosphate Oxidative phosphorylation -0.56 
833.5874 732 Positive Ubiquinone-9 Oxidative phosphorylation -0.39 
459.1296 383 Positive Oxidised flavin mononucleotide Oxidative phosphorylation 0.42 
744.5905 482 Positive Coenzyme Q8 and/or ubiquinone-8 Oxidative phosphorylation 0.42 
209.1154 444 Positive Oxo-decanoic acid and/or hydroxy-
decenoic acid 
Oxidised fatty acids -0.31 
325.1607 490 Positive Oxo-hydroxy-tetradecenoate Oxidised fatty acids -0.31 
442.2607 665 Positive Leukotriene E3 Oxidised fatty acids -0.30 
435.3804 646 Positive Hydroxyhexacosanoic acid Oxidised fatty acids -0.30 
259.0926 38 Negative L-alpha-glutamyl-L-hydroxyproline Peptides 0.32 
463.0587 374 Positive 5'-Butyrylphosphoinosine Purine metabolism -0.36 
255.9818 81 Positive Se-Methylselenomethionine Selenocompound metabolism -0.48 
448.9128 53 Positive Selenohomocystine Selenocompound metabolism -0.30 
651.7983 483 Positive Triiodothyronine Thyroid and steroid 
metabolism 
-0.45 
369.1749 324 Negative Dihydrotestosterone sulfate and/or 
Androsterone sulfate 
Thyroid and steroid 
metabolism 
-0.41 
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10.8 All miRNAs tested by Exiqon profiling array 
hsa-miR-107 
hsa-let-7b-5p 
hsa-miR-30b-5p 
hsa-miR-26b-5p 
hsa-let-7c-5p 
hsa-miR-582-3p 
hsa-miR-9-5p 
hsa-miR-135a-5p 
hsa-miR-519d-3p 
hsa-miR-556-3p 
hsa-miR-517c-3p 
hsa-miR-197-3p 
hsa-miR-33a-3p 
hsa-miR-361-5p 
hsa-miR-517a-3p 
hsa-miR-17-5p 
hsa-miR-223-3p 
hsa-miR-144-3p 
hsa-let-7d-3p 
hsa-miR-519a-3p 
hsa-miR-140-5p 
hsa-miR-140-3p 
hsa-miR-518c-3p 
hsa-miR-501-3p 
hsa-miR-519b-3p 
hsa-miR-629-5p 
hsa-miR-20b-5p 
hsa-miR-28-3p 
hsa-miR-543 
hsa-miR-625-3p 
hsa-miR-335-3p 
hsa-miR-194-5p 
hsa-miR-432-5p 
hsa-miR-525-5p 
hsa-miR-193a-5p 
hsa-miR-146a-5p 
hsa-miR-26b-3p 
hsa-miR-340-5p 
hsa-miR-130a-3p 
hsa-miR-15a-3p 
hsa-miR-1296-5p 
hsa-miR-502-3p 
hsa-miR-491-5p 
hsa-miR-345-5p 
hsa-miR-501-5p 
hsa-miR-1249 
hsa-miR-339-5p 
hsa-let-7i-5p 
hsa-miR-191-5p 
hsa-miR-769-5p 
hsa-miR-484 
hsa-miR-1271-5p 
hsa-miR-21-5p 
hsa-miR-582-5p 
hsa-miR-493-3p 
hsa-miR-431-5p 
hsa-miR-30e-3p 
hsa-miR-99a-5p 
hsa-miR-181a-5p 
hsa-miR-146b-5p 
hsa-miR-362-3p 
hsa-miR-941 
hsa-miR-126-5p 
hsa-miR-93-3p 
hsa-miR-101-3p 
hsa-miR-378a-5p 
hsa-miR-101-5p 
hsa-miR-532-3p 
hsa-miR-139-3p 
hsa-miR-628-3p 
hsa-miR-15b-5p 
hsa-miR-376a-3p 
hsa-miR-519c-3p 
hsa-miR-505-5p 
hsa-miR-126-3p 
hsa-miR-15b-3p 
hsa-let-7f-2-3p 
hsa-miR-33a-5p 
hsa-miR-342-3p 
hsa-miR-337-5p 
hsa-miR-518f-3p 
hsa-miR-223-5p 
hsa-miR-339-3p 
hsa-miR-152-3p 
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hsa-miR-940 
hsa-miR-148b-5p 
hsa-miR-660-5p 
hsa-miR-424-5p 
hsa-miR-186-5p 
hsa-miR-103a-3p 
hsa-miR-125a-5p 
hsa-miR-155-5p 
hsa-miR-218-5p 
hsa-miR-331-3p 
hsa-miR-329-3p 
hsa-let-7b-3p 
hsa-miR-1 
hsa-miR-335-5p 
hsa-miR-127-3p 
hsa-let-7g-3p 
hsa-miR-509-3p 
hsa-miR-518b 
hsa-miR-551a 
hsa-miR-515-3p 
hsa-miR-598-3p 
hsa-miR-196b-5p 
hsa-miR-1537-3p 
hsa-miR-24-3p 
hsa-miR-214-3p 
hsa-miR-454-3p 
hsa-miR-525-3p 
hsa-miR-365a-3p 
hsa-miR-148a-3p 
hsa-miR-324-3p 
hsa-miR-320b 
hsa-miR-520h 
hsa-miR-2110 
hsa-miR-320d 
hsa-miR-142-3p 
hsa-miR-377-3p 
hsa-miR-515-5p 
hsa-miR-379-5p 
hsa-miR-96-5p 
hsa-miR-32-5p 
hsa-miR-627-5p 
hsa-miR-27b-3p 
hsa-miR-153-3p 
hsa-miR-145-3p 
hsa-miR-16-2-3p 
hsa-miR-664a-3p 
hsa-miR-542-5p 
hsa-miR-618 
hsa-miR-26a-5p 
hsa-miR-550a-3p 
hsa-miR-16-5p 
hsa-miR-99b-5p 
hsa-miR-520a-5p 
hsa-miR-450b-5p 
hsa-miR-520g-3p 
hsa-miR-122-3p 
hsa-miR-143-3p 
hsa-miR-425-3p 
hsa-miR-25-3p 
hsa-let-7f-5p 
hsa-miR-376a-5p 
hsa-miR-30e-5p 
hsa-miR-326 
hsa-miR-376b-3p 
hsa-miR-328-3p 
hsa-miR-106b-5p 
hsa-miR-744-5p 
hsa-miR-624-5p 
hsa-miR-518c-5p 
hsa-miR-370-3p 
hsa-miR-524-5p 
hsa-miR-106b-3p 
hsa-let-7g-5p 
hsa-miR-10a-5p 
hsa-miR-19b-1-5p 
hsa-miR-106a-5p 
hsa-miR-574-3p 
hsa-miR-144-5p 
hsa-miR-889-3p 
hsa-miR-203a 
hsa-miR-1260a 
hsa-miR-320a 
hsa-miR-7-1-3p 
hsa-miR-136-3p 
hsa-miR-519e-3p 
hsa-miR-30a-3p 
hsa-miR-128-3p 
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hsa-miR-425-5p 
hsa-miR-19b-3p 
hsa-miR-337-3p 
hsa-miR-125b-5p 
hsa-miR-221-5p 
hsa-miR-132-3p 
hsa-miR-502-5p 
hsa-miR-654-5p 
hsa-miR-188-3p 
hsa-miR-30a-5p 
hsa-miR-141-3p 
hsa-miR-496 
hsa-miR-20a-5p 
hsa-miR-1972 
hsa-miR-423-3p 
hsa-miR-526b-5p 
hsa-let-7d-5p 
hsa-miR-584-5p 
hsa-miR-579-3p 
hsa-miR-518e-5p 
hsa-miR-301a-3p 
hsa-miR-182-5p 
hsa-miR-151a-5p 
hsa-miR-29a-5p 
hsa-miR-224-5p 
hsa-miR-143-5p 
hsa-miR-23b-3p 
hsa-miR-185-5p 
hsa-miR-548j-5p 
hsa-miR-215-5p 
hsa-miR-450a-5p 
hsa-miR-22-3p 
hsa-miR-100-5p 
hsa-miR-29b-3p 
hsa-miR-512-3p 
hsa-miR-874-3p 
hsa-miR-518f-5p 
hsa-miR-942-5p 
hsa-miR-409-3p 
hsa-let-7a-5p 
hsa-let-7f-1-3p 
hsa-miR-324-5p 
hsa-miR-548k 
hsa-miR-487b-3p 
hsa-miR-16-1-3p 
hsa-miR-154-5p 
hsa-miR-524-3p 
hsa-miR-195-5p 
hsa-miR-654-3p 
hsa-miR-205-5p 
hsa-miR-24-2-5p 
hsa-miR-199a-3p 
hsa-miR-423-5p 
hsa-miR-342-5p 
hsa-miR-374b-5p 
hsa-miR-675-3p 
hsa-miR-18b-5p 
hsa-miR-21-3p 
hsa-miR-505-3p 
hsa-miR-30d-5p 
hsa-miR-486-3p 
hsa-miR-539-5p 
hsa-miR-532-5p 
hsa-miR-22-5p 
hsa-miR-145-5p 
hsa-miR-296-5p 
hsa-miR-483-3p 
hsa-miR-130b-5p 
hsa-miR-142-5p 
hsa-miR-139-5p 
hsa-miR-330-3p 
hsa-miR-495-3p 
hsa-miR-10b-5p 
hsa-miR-518e-3p 
hsa-miR-192-5p 
hsa-miR-148b-3p 
hsa-miR-320c 
hsa-miR-369-3p 
hsa-miR-181b-5p 
hsa-miR-545-3p 
hsa-miR-34a-3p 
hsa-miR-628-5p 
hsa-miR-27a-5p 
hsa-miR-133b 
hsa-miR-181c-3p 
hsa-miR-375 
hsa-miR-522-3p 
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hsa-miR-188-5p 
hsa-miR-93-5p 
hsa-miR-18a-3p 
hsa-miR-766-3p 
hsa-miR-210-3p 
hsa-miR-376c-3p 
hsa-let-7i-3p 
hsa-miR-19a-3p 
hsa-miR-122-5p 
hsa-miR-29c-3p 
hsa-miR-652-3p 
hsa-miR-382-5p 
hsa-miR-33b-5p 
hsa-miR-548c-5p 
hsa-miR-338-3p 
hsa-miR-885-5p 
hsa-miR-493-5p 
hsa-miR-136-5p 
hsa-miR-222-3p 
hsa-miR-200b-3p 
hsa-miR-193a-3p 
hsa-miR-133a-3p 
hsa-miR-301b 
hsa-miR-451a 
hsa-miR-18a-5p 
hsa-miR-95-3p 
hsa-miR-424-3p 
hsa-miR-23a-3p 
hsa-miR-15a-5p 
hsa-miR-150-5p 
hsa-miR-34a-5p 
hsa-miR-27a-3p 
hsa-miR-323a-3p 
hsa-miR-219a-5p 
hsa-miR-193b-3p 
hsa-miR-151a-3p 
hsa-miR-29c-5p 
hsa-miR-181c-5p 
hsa-miR-421 
hsa-miR-29a-3p 
hsa-miR-483-5p 
hsa-miR-363-3p 
mmu-miR-378a-3p 
hsa-miR-134-5p 
hsa-miR-409-5p 
hsa-miR-17-3p 
hsa-miR-98-5p 
hsa-miR-518a-3p 
hsa-miR-190a-5p 
hsa-miR-589-3p 
hsa-miR-576-5p 
hsa-miR-486-5p 
hsa-miR-7-5p 
hsa-miR-199b-5p 
hsa-miR-518d-5p 
hsa-miR-183-5p 
hsa-miR-551b-3p 
hsa-miR-452-5p 
hsa-miR-200c-3p 
hsa-miR-130b-3p 
hsa-miR-877-5p 
hsa-miR-485-3p 
hsa-miR-30d-3p 
hsa-miR-20a-3p 
hsa-miR-199a-5p 
hsa-miR-548a-3p 
hsa-miR-340-3p 
hsa-miR-651-5p 
hsa-miR-92a-3p 
hsa-miR-519e-5p 
hsa-miR-374a-5p 
hsa-miR-28-5p 
hsa-miR-590-5p 
hsa-miR-29b-2-5p 
hsa-miR-497-5p 
hsa-miR-221-3p 
hsa-miR-30c-5p 
hsa-miR-410-3p 
hsa-let-7e-5p 
hsa-miR-516b-5p 
hsa-miR-744-3p 
hsa-miR-590-3p 
hsa-miR-361-3p 
hsa-let-7a-3p 
hsa-let-7e-3p 
hsa-miR-106a-3p 
hsa-miR-10a-3p 
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hsa-miR-10b-3p 
hsa-miR-1178-3p 
hsa-miR-1181 
hsa-miR-1183 
hsa-miR-1185-5p 
hsa-miR-1205 
hsa-miR-1207-5p 
hsa-miR-1224-3p 
hsa-miR-1227-3p 
hsa-miR-1237-3p 
hsa-miR-1243 
hsa-miR-124-3p 
hsa-miR-1244 
hsa-miR-1247-5p 
hsa-miR-1253 
hsa-miR-1254 
hsa-miR-1255b-5p 
hsa-miR-1256 
hsa-miR-1258 
hsa-miR-125a-3p 
hsa-miR-125b-2-3p 
hsa-miR-1269a 
hsa-miR-1270 
hsa-miR-127-5p 
hsa-miR-135a-3p 
hsa-miR-135b-5p 
hsa-miR-137 
hsa-miR-138-5p 
hsa-miR-1468-5p 
hsa-miR-146a-3p 
hsa-miR-146b-3p 
hsa-miR-1471 
hsa-miR-149-5p 
hsa-miR-1538 
hsa-miR-154-3p 
hsa-miR-181a-2-3p 
hsa-miR-181a-3p 
hsa-miR-181d-5p 
hsa-miR-182-3p 
hsa-miR-184 
hsa-miR-185-3p 
hsa-miR-187-3p 
hsa-miR-18b-3p 
hsa-miR-1908-5p 
hsa-miR-190b 
hsa-miR-1911-5p 
hsa-miR-1912 
hsa-miR-1913 
hsa-miR-191-3p 
hsa-miR-192-3p 
hsa-miR-193b-5p 
hsa-miR-194-3p 
hsa-miR-195-3p 
hsa-miR-196a-5p 
hsa-miR-196b-3p 
hsa-miR-198 
hsa-miR-19a-5p 
hsa-miR-200a-3p 
hsa-miR-200b-5p 
hsa-miR-204-5p 
hsa-miR-206 
hsa-miR-208b-3p 
hsa-miR-20b-3p 
hsa-miR-2113 
hsa-miR-211-5p 
hsa-miR-212-3p 
hsa-miR-214-5p 
hsa-miR-216a-5p 
hsa-miR-219a-2-3p 
hsa-miR-224-3p 
hsa-miR-23a-5p 
hsa-miR-23b-5p 
hsa-miR-24-1-5p 
hsa-miR-25-5p 
hsa-miR-26a-1-3p 
hsa-miR-26a-2-3p 
hsa-miR-27b-5p 
hsa-miR-296-3p 
hsa-miR-299-3p 
hsa-miR-299-5p 
hsa-miR-300 
hsa-miR-302d-5p 
hsa-miR-31-3p 
hsa-miR-31-5p 
hsa-miR-32-3p 
hsa-miR-330-5p 
hsa-miR-331-5p 
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hsa-miR-338-5p 
hsa-miR-33b-3p 
hsa-miR-346 
hsa-miR-34b-5p 
hsa-miR-34c-5p 
hsa-miR-362-5p 
hsa-miR-365b-5p 
hsa-miR-369-5p 
hsa-miR-371a-3p 
hsa-miR-373-3p 
hsa-miR-373-5p 
hsa-miR-374b-3p 
hsa-miR-379-3p 
hsa-miR-380-3p 
hsa-miR-380-5p 
hsa-miR-381-3p 
hsa-miR-382-3p 
hsa-miR-411-3p 
hsa-miR-411-5p 
hsa-miR-429 
hsa-miR-431-3p 
hsa-miR-433-3p 
hsa-miR-449a 
hsa-miR-449b-3p 
hsa-miR-450b-3p 
hsa-miR-454-5p 
hsa-miR-455-3p 
hsa-miR-487a-3p 
hsa-miR-491-3p 
hsa-miR-494-3p 
hsa-miR-498 
hsa-miR-499a-5p 
hsa-miR-500a-5p 
hsa-miR-503-5p 
hsa-miR-504-5p 
hsa-miR-511-5p 
hsa-miR-512-5p 
hsa-miR-514a-3p 
hsa-miR-516a-3p 
hsa-miR-516a-5p 
hsa-miR-517-5p 
hsa-miR-518d-3p 
hsa-miR-520a-3p 
hsa-miR-520c-3p 
hsa-miR-520d-3p 
hsa-miR-520d-5p 
hsa-miR-520e 
hsa-miR-521 
hsa-miR-523-3p 
hsa-miR-544a 
hsa-miR-548a-5p 
hsa-miR-548b-3p 
hsa-miR-548d-5p 
hsa-miR-548e-3p 
hsa-miR-548i 
hsa-miR-548l 
hsa-miR-548n 
hsa-miR-550a-5p 
hsa-miR-552-3p 
hsa-miR-566 
hsa-miR-567 
hsa-miR-570-3p 
hsa-miR-571 
hsa-miR-576-3p 
hsa-miR-577 
hsa-miR-589-5p 
hsa-miR-592 
hsa-miR-593-3p 
hsa-miR-595 
hsa-miR-596 
hsa-miR-601 
hsa-miR-604 
hsa-miR-605-5p 
hsa-miR-609 
hsa-miR-610 
hsa-miR-615-3p 
hsa-miR-616-3p 
hsa-miR-616-5p 
hsa-miR-619-3p 
hsa-miR-623 
hsa-miR-629-3p 
hsa-miR-631 
hsa-miR-635 
hsa-miR-640 
hsa-miR-642a-5p 
hsa-miR-643 
hsa-miR-645 
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hsa-miR-646 
hsa-miR-649 
hsa-miR-650 
hsa-miR-655-3p 
hsa-miR-661 
hsa-miR-662 
hsa-miR-663a 
hsa-miR-663b 
hsa-miR-668-3p 
hsa-miR-671-3p 
hsa-miR-671-5p 
hsa-miR-708-3p 
hsa-miR-708-5p 
hsa-miR-758-3p 
hsa-miR-760 
hsa-miR-761 
hsa-miR-765 
hsa-miR-769-3p 
hsa-miR-770-5p 
hsa-miR-873-5p 
hsa-miR-875-5p 
hsa-miR-876-5p 
hsa-miR-877-3p 
hsa-miR-885-3p 
hsa-miR-887-3p 
hsa-miR-922 
hsa-miR-92a-1-5p 
hsa-miR-92b-3p 
hsa-miR-92b-5p 
hsa-miR-933 
hsa-miR-934 
hsa-miR-936 
hsa-miR-937-3p 
hsa-miR-9-3p 
hsa-miR-99a-3p 
hsa-miR-99b-3p 
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10.9 Additional validation of candidate miRNAs methods 
 
The validation of the candidate miRNAs was performed by Dr Andrew Beggs and 
Miss Agata Stodolna at the University of Birmingham. miRNA was extracted from 
serum with miRNeasy Serum/Plasma Kit (Qiagen, Manchester, UK) according to 
manufacturer’s instructions. The quality and the concentration of the samples was 
investigated with High Sensitivity RNA TapeStation (Agilent, Stockport, UK). Two 
endogenous controls were used: miR-361-5p and miR-451a. Samples were 
converted to cDNA and miRNA was amplified using TaqMan Advanced miRNA cDNA 
Synthesis Kit (Applied Biosystems, Thermo Fisher Scientific, Warrington UK). To 
create the cDNA templates, samples, and reagents were thawed on ice and vortexed 
to ensure adequate mixing. The samples were then centrifuged to remove air 
bubbles. 3 μL of Poly(A) Reaction Mix was added to each well of the reaction plate 
with 2 μL of serum sample. The reaction plates were sealed, vortexed and 
centrifuged. The plate was placed in the thermal cycles at 37°C for 45 minutes, 65°C 
for 10 minutes, and then held at 4°C before performing the adaptor ligation reaction. 
10 μL of Ligation Reaction Mix was added to each well and the reaction plate was 
sealed, vortexed and centrifuged. The plate was placed in the thermal cycler and 
incubated at 16°C for 60 minutes, and then held at 4°C. 
 
RT-PCR was performed with TaqMan Advanced miRNA Assays (Applied 
Biosystems). The RT Reaction Mix was prepared and 15 μL were added to each well 
of the reaction plate, the plate was sealed, vortexed and centrifuged. The plate was 
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placed in the thermal cycler and incubated at 42°C for 15 minutes, 85°C for 5 
minutes, and then held at 4°C. 
miR-Amp Reaction Mix was prepared and 45 μL was added to a new reaction plate. 
5 μL of the RT reaction product was added to each reaction well, the plate was 
sealed, vortexed and centrifuged. The plate was placed in the thermal cycler and 
incubated at 95°C for 5 minutes for 1 cycle, 95°C for 3 seconds then 60°C for 30 
seconds for 14 cycles, 99°C for 60 minutes and then held at 4°C. 
5µl of 1:10 dilution of cDNA template was used for the RT-PCR reaction with 10µl of 
2X TaqMan Fast Advanced Master Mix (Applied Biosystems), 1µl of 20X TaqMan 
Advanced miRNA Assay and 4µl of RNase-free water. The reaction was run on the 
QuantStudio 5 instrument (Applied Biosystems) under conditions: 1 cycle for 20 
seconds at 95ºC, then 40 cycles of 1 second at 95ºC and 20 seconds at 60ºC.  
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10.10 Significantly different miRNAs in investigation cohort 
Significantly different miRNAs, prior to Benjamini-Hochberg correction, in pregnancies complicated by twin-twin transfusion 
syndrome, compared to uncomplicated MCDA pregnancies 
Assay Average dcq  
TTTS (SD) 
Average dcq  
Control (SD) 
ddcq TTTS –  
Control 
Fold change  
TTTS / Control 
t-test  
p-value 
Benjamini- 
Hochberg FDR 
hsa-miR-107 2.581 (-0.305) 1.765 (0.209) 0.816 1.761 0.002 0.486 
hsa-miR-519c-3p -3.212 (0.551) -4.600 (0.373) 1.388 2.618 0.003 0.486 
hsa-miR-551a -2.259 (0.560) -1.098 (0.219) -1.160 -2.235 0.007 0.494 
hsa-let-7b-5p 3.219 (0.366) 2.299 (0.409) 0.919 1.891 0.012 0.494 
hsa-miR-361-5p 1.196 (0.175) 1.611 (0.191) -0.416 -1.334 0.014 0.494 
hsa-miR-140-5p 0.493 (0.145) 1.303 (0.359) -0.810 -1.753 0.015 0.494 
hsa-miR-9-5p -6.594 (0.567) -4.768 (0.529) -1.826 -3.545 0.015 0.494 
hsa-miR-135a-5p -6.030 (0.900) -4.501 (0.331) -1.529 -2.886 0.016 0.494 
hsa-miR-517a-3p 0.695 (0.522) -0.228 (0.404) 0.923 1.896 0.020 0.494 
hsa-miR-33a-3p -4.193 (0.483) -5.326 (0.608) 1.133 2.193 0.024 0.494 
hsa-let-7c-5p -0.032 (0.516) -0.856 (0.361) 0.823 1.769 0.026 0.494 
hsa-miR-519d-3p -0.868 (0.635) -2.246 (0.770) 1.377 2.598 0.029 0.494 
hsa-miR-128-3p -1.117 (0.250) -0.460 (0.376) -0.656 -1.576 0.030 0.494 
hsa-miR-519a-3p -2.319 (0.743) -3.632 (0.697) 1.313 2.484 0.031 0.494 
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hsa-miR-30b-5p 2.585 (0.147) 1.908 (0.383) 0.677 1.599 0.032 0.494 
hsa-miR-518c-3p -2.275 (1.176) -3.958 (0.499) 1.683 3.211 0.033 0.494 
hsa-miR-26b-5p 0.995 (0.578) -0.262 (0.736) 1.257 2.390 0.033 0.494 
hsa-miR-517c-3p -0.793 (0.602) -1.828 (0.562) 1.035 2.048 0.034 0.494 
hsa-miR-450a-5p -1.175 (0.684) -0.224 (0.160) -0.950 -1.932 0.034 0.494 
hsa-miR-582-3p -3.722 (0.977) -2.096 (0.877) -1.627 -3.088 0.035 0.494 
hsa-miR-99a-5p -0.643 (0.421) -1.375 (0.411) 0.732 1.661 0.036 0.494 
hsa-miR-26b-3p -4.091 (0.689) -2.986 (0.609) -1.105 -2.151 0.039 0.494 
hsa-miR-151a-5p 1.935 (0.193) 2.300 (0.219) -0.365 -1.288 0.039 0.494 
hsa-let-7d-3p 2.093 (0.480) 2.724 (0.169) -0.630 -1.548 0.040 0.494 
hsa-miR-20b-5p -4.324 (0.561) -6.309 (1.228) 1.985 3.958 0.040 0.494 
hsa-miR-519b-3p -4.841 (0.552) -6.357 (0.707) 1.516 2.859 0.041 0.494 
hsa-miR-556-3p -5.746 (0.547) -4.483 (0.489) -1.262 -2.399 0.041 0.494 
hsa-miR-144-3p 6.066 (0.566) 5.028 (0.637) 1.039 2.054 0.042 0.494 
hsa-miR-223-3p 9.903 (0.437) 10.570 (0.373) -0.667 -1.588 0.043 0.494 
hsa-miR-17-5p -1.374 (0.353) -1.832 (0.196) 0.457 1.373 0.047 0.515 
hsa-miR-543 -2.876 (0.797) -1.899 (0.293) -0.976 -1.967 0.050 0.526 
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10.11 Biological plausibility of candidate miRNAs for 
validation identified in the investigation cohort 
The miRNAs in which a difference was revealed in TTTS pregnancies in the 
investigation cohort may reflect overlapping clinical features often seen in the disease 
process. Up to 70% of recipient twins have associated cardiac right ventricular 
dysfunction (Van Mieghem 2013); interestingly, in adults with congestive heart failure, 
circulating hsa-miR-140-5p is reported as being downregulated, and hsa-miR-107 
and hsa-let-7b-5p appears upregulated (Marques 2016), which is what was found in 
TTTS patients in the investigation cohort. TTTS is also associated with significant 
changes in renal physiology in both the donor and recipient (Kilby 2001, Mahieu-
Caputo 2001, Verbeek 2017). Circulating hsa-miR-223-3p has been found to be 
downregulated in adults with chronic kidney disease (stages 4–5) (Ulbing 2017), 
again echoing the findings in the TTTS investigation cohort.  
 
Approximately 60% of TTTS pregnancies are also affected by fetal growth restriction 
(FGR) (Lewi 2014) and changes have been demonstrated in miRNA in placental 
tissue from FGR singleton pregnancies, although there was no overlap with the 
miRNA changes demonstrated in the maternal serum samples from the investigation 
cohort (Maccani 2011). However, another study compared placental tissue and 
maternal plasma from FGR pregnancies and demonstrated changes in placental 
tissue, but not maternal plasma, despite miRNAs being able to cross into the 
maternal circulation (Higashijima 2013). A recent study compared miRNA expression 
in placental samples taken from each twin’s umbilical cord root insertion, within 
monochorionic twinsets in which one twin had FGR and the other twin was normally 
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grown (Wen 2017). This was performed as although monochorionic placentation 
involves a single placenta, there is differing ‘vascular territories’ between the two 
fetuses and this may vary considerably depending upon the severity of the FGR 
(Chang 2009). Wen et al. identified 14 differentially expressed miRNAs (7 
upregulated, 7 downregulated) in the placental samples of the larger twin compared 
with smaller twin. These 14 miRNAs were not significantly different between the two 
normally grown twins in the one monochorionic twin pregnancy which acted as their 
control for the miRNA profiling. All 14 miRNAs were successfully validated in a 
separate unmatched cohort (15 monochorionic twin pregnancies with FGR, 15 
monochorionic twin pregnancies with appropriately grown fetuses). Unfortunately 
Wen et al. did not collect the respective maternal blood samples to compare with the 
miRNA expression in the placental samples, although there was an overlap with four 
miRNAs that were significantly different in TTTS pregnancies in the investigation 
cohort: hsa-let-7c, hsa-miR-518c-3p, hsa-miR-144-3p, and hsa-miR-543. hsa-let-7c, 
was upregulated in TTTS pregnancies in the investigation cohort and upregulated in 
the larger twin in Wen’s study, however the changes in the other three miRNAs were 
in line with the smaller twin, not the larger twin: hsa-miR-518c-3p and hsa-miR-144-
3p were upregulated in TTTS and upregulated in the smaller twin, and hsa-miR-543 
was downregulated in TTTS, and downregulated in the smaller twin, indicating that 
an association may exist between miRNA expression in placental samples and 
maternal serum, and TTTS and FGR.  
Changes were also demonstrated in the investigation cohort in hsa-miR-517a-3p, 
hsa-miR-519a-3p and hsa-miR-519c-3p which are members of the C19MC group of 
placenta-specific miRNAs (Morales-Prieto 2012, Zhang 2016), and are detectable 
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from the first trimester in chorionic villi stromal cells (Flor 2012). hsa-miR-17-5p is 
known to be associated with angiogenesis (Hromadnikova 2015), and increased hsa-
miR-17 and hsa-miR-20b expression with reduced spiral artery remodelling (Chen 
2013a) and pre-eclampsia (Wang 2012b). A recent study has found that 
downregulation of hsa-miR-17-5p improves cardiac function after myocardial 
infarction, thought to be due to aiding repair of vascular injury, and decreasing the 
rate of apoptosis (Yang 2018). Other miRNAs that were significant prior to correction 
for multiple testing have also been demonstrated to be significantly different in 
maternal serum from singleton pregnancies complicated by pre-eclampsia: hsa-miR-
107, hsa-miR-223, hsa-miR-26b, hsa-miR-30b, hsa-miR-517c, hsa-miR518c, hsa-
miR-519d, hsa-miR-99a (Li 2013, Ura 2014). This again fits with issues of 
placentation and abnormal placental vasculogenesis seen in TTTS, although the 
majority of this work has been performed in singleton pregnancies.  
With regards to potential gene targets of the differentially expressed miRNA in the 
investigation cohort identified from miRTarBase, although there is a paucity of gene 
target validation studies in pregnancy, the potential gene targets do have biological 
plausibility. One example is miR-107 whose targets include NOTCH2 and DICER1 
which have been shown to be involved in pre-eclampsia and spiral artery remodelling 
(Hunkapiller 2011, Doridot 2013). This supports further investigation of these miRNAs 
in pregnancy to both to improve knowledge of the pathophysiology of TTTS, and also 
to enable further study of miRNAs as potential biomarkers of TTTS. 
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10.12 OMMIT 2 Patient information sheet 
  
Monochorionic Twins Screening Study - Patient Information Sheet 
 
What is the purpose of the study? 
Approximately 15% of monochorionic (identical) twins develop a complication, such 
as twin-twin transfusion syndrome (TTTS) or selective in-uterine growth restriction 
(sIUGR) where there is unbalanced blood flow between the twins because they share 
the placenta. However, we don’t know which twins will develop these complications.  
The aim of this study is to develop a formula which we can use to predict which twins 
will develop complications, from measurements we do in the first trimester (up to 14 
weeks). We will do this using results from your routine ultrasound scan and a blood 
test. If you are unfortunate enough to develop a complication such as TTTS or sIUGR 
and require fetoscopic laser ablation (FLA) we will ask to perform blood tests and 
take extra amniotic fluid during FLA which is part of normal clinical care to try to help 
us discover more about why women develop these complications. 
 
Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information to keep and asked to sign a consent form. If you decide 
to take part you are free to withdraw at any time without giving a reason. If you do not 
feel able to take part it will not in any way affect the care you or your family receives. 
 
What will happen to me if I take part? 
If you agree to take part we will ask your permission to access your hospital records 
to obtain the results of your ultrasound scan, basic information about you such as 
your age, and the outcome of your pregnancy. We will also ask you to give us a 
maximum of 2 extra blood samples during your pregnancy. In addition (with your 
permission) we will store your blood sample for use in future, ethically approved 
research. You would not get results from this.  
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If there are complications at this time we may ask you to consent to further tests: an 
extra 4 small blood tests after FLA. We will also take an extra small bottle of blood as 
part of the routine blood tests we perform prior to FLA. During FLA it is routine to take 
a small sample of amniotic fluid, we would also take a small sample before we start 
the FLA, and another sample after we have finished the FLA. If you deliver at 
Birmingham Women’s Hospital, we will ask your permission to collect your placenta 
after delivery. In addition (with your permission) we will store your blood samples and 
amniotic fluid samples for use in future, ethically approved research. With your 
permission, we may contact you in the future regarding further research on your 
stored samples. You would not get results from this as it will not change your medical 
care.  
 
We are also interested to see how having FLA can affect how you feel about your 
babies, and your emotions, so we will ask you and your partner to complete a 
questionnaire before FLA, after FLA, and after you have the babies. 
 
Will my taking part in this study be kept confidential? 
Yes. We will follow ethical and legal practice and all information will be handled in 
confidence. Any information you give us will only be used in the course of the 
research to develop these new tests. Any samples and data stored will be stored 
securely in a swipecard access area. They will be coded, and no personal data 
(name and address) will be available to the researchers. We need to keep this 
information to match up your test results with the outcome of your pregnancy. We will 
inform your GP that you are participating in the study, unless you would prefer your 
GP not to know. If your answers to the questionnaire reveal that you are at high-risk 
of postnatal depression then we will tell you and advise you to see your GP for further 
assessment so that they are able to provide additional support if necessary.  
 
What are the possible benefits of taking part? 
There are no direct benefits to you and your twins, but you will be helping future 
women with monochorionic (identical) twin pregnancies. 
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What are the possible disadvantages and risks of taking part? 
The main disadvantage will be collecting extra blood samples, but this will not require 
any extra appointments to what you have as part of your routine care. This will be 
carried out by someone who is skilled in venepuncture (taking blood). Some people 
may experience bruising at the site which will resolve over a few days. Taking the 
amniotic fluid samples will not put you or your babies at any higher risk, as it is all 
performed as part of the FLA, and doesn’t require any extra needles into your womb.  
 
What will happen if I don’t want to continue in the study? 
You are free to withdraw at anytime. If you withdraw from the study we will not 
access any further samples and will destroy any of your samples that were collected 
for the study.  We will also remove any data held on our own computers. 
 
What will happen to any samples I give? 
Blood samples, amniotic fluid samples and placental samples will be collected for this 
study. The samples will be stored and analysed in Birmingham Women’s Hospital, 
the University of Birmingham and collaborative Universities both in the UK and 
overseas.  
 
What will happen to the results of the research study? 
The results from our project will be published as research papers in medical journals. 
No data will be published that will allow individuals to be identified.  
 
Where can I get further information or discuss any problems? 
Please contact a member of the research team on 0121-623-6652/627-2778 to 
discuss any questions or worries about the study, or if you have any complaints. If 
the problems are not resolved, or if you wish to speak to someone independent of the 
study please contact the Patient Advisory Liaison Services (PALS) if you have any 
concerns regarding the care you have received, or as an initial point of contact if you 
have a complaint. Please phone contact PALS on 0121 627 2747 or email 
pals@bwnft.nhs.uk , you can also visit PALS by asking at any hospital reception. 
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Who is organising and funding the research?  
This research is organised by Birmingham Women’s Hospital, and funded by the 
Wiseman Trust (a medical research charity into twin pregnancy). 
 
Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and given favourable opinion by the East Midlands Committee.  
 
**Thank you for taking the time to read this information leaflet.** 
 
Detail of researchers 
 
1. Dr Fiona Mackie, 
Clinical Research Fellow, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-623-6652 
 
2. Professor M.D. Kilby, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-627-2778 
 
Patient Advice Liaison Service  
Tel: 0121 627 2747  
Email: pals@bwnft.nhs.uk  
 
 
 
Fetal Medicine Centre, Birmingham Women’s Foundation Trust, 
Metchley Park Road, Edgbaston, Birmingham. B15 2TG 
Tel.No:  0121 627 2683 
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10.13 OMMIT 2 consent forms 
 
 
 
Centre Number:   Study Number:  
Patient Identification Number for this trial:  
 
CONSENT FORM  
Monochorionic Twin Pregnancy Outcomes – a prospective screening study 
Name of Researcher: Professor Mark Kilby, Miss Katie Morris, Dr Fiona Mackie 
 
SECTION A – AT BOOKING APPOINTMENT 
 
Please initial box  
 
1. I confirm that I have read and understand the information sheet version 3.0 dated 
04/11/15 for the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being affected.                        
 
3. I understand that relevant sections of my medical notes and data collected during the 
study, may be looked at by individuals from regulatory authorities, the University of 
Birmingham or from the NHS Trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records.        
4. (a) I agree to allow medical information about my pregnancy to be entered on a 
confidential computer database. 
     (b) If further medical information is requested by members of the project team, I 
agree to be contacted again for this purpose and agree to be contacted for any future 
ethically agreed studies. 
 
  (c) I agree to extra blood samples being taken, by a trained professional. 
 
5. I agree to take part in the above Monochorionic Twin Screening and Pregnancy 
Outcomes study.              
 
6. I agree that some of my blood (the plasma) can be stored by the laboratory for use in 
future ethically approved research. (OPTIONAL) 
 
7. I understand that I will not be told the results of the extra blood samples as it will not 
change the medical care that I receive. 
 
8. I agree to my GP being informed of my participation in the study.   
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_______________________  ________________________ _________________  
Name of Patient   Signature    Date 
 
_______________________     _______________________  _________________  
Name of Person (taking consent)  Signature   Date 
 
 
 
 
 
 
Centre Number:   Study Number:  
 
CONSENT FORM  
 
SECTION B – When a complication of monochorionic twin pregnancy is 
diagnosed or if an intervention in pregnancy is being considered  
 
Please initial box  
 
1. I confirm that I have read and understand the information sheet version 3.0 dated 
04/11/15 for the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without my medical care or legal rights being affected.                        
 
3. I understand that relevant sections of my medical notes and data collected during the 
study, may be looked at by individuals from regulatory authorities, the University of 
Birmingham or from the NHS Trust, where it is relevant to my taking part in this 
research. I give permission for these individuals to have access to my records.   
 
4. (a) I agree to allow medical information about my pregnancy to be entered on a 
confidential computer database. 
 
(b) If further medical information is requested by members of the project team, I agree 
to be contacted again for this purpose and agree to be contacted for any future 
ethically agreed studies. (OPTIONAL) 
 
5. I agree to have an extra blood test (maximum 10mls) taken at the time of ultrasound 
diagnosis of a complication and prior to any intervention and then at time points after 
any intervention (6 hours, 24 hours and at 1 week).     
          
6. If undergoing a fetoscopic laser ablation procedure I agree to have a small sample 
(5mls) of my amniotic fluid being taken just before and after fetoscopic laser ablation 
procedure. 
 
7. If undergoing amniocentesis for another indication as part of the standard 
investigation, I agree to a small extra sample (5mls) being collected. 
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8. I agree that some of my blood sample (the plasma) and/or amniotic fluid sample can 
be stored by the laboratory for future research which gains ethical approval. 
(OPTIONAL)  
 
9. I agree that my placenta can be collected after delivery for testing, and stored 
(OPTIONAL) 
 
10. I agree that researchers may use stored blood samples from my first trimester 
screening, if these samples were analysed and stored at Birmingham Women’s 
Hospital. 
 
11. I agree to complete the questionnaires before laser, after laser, and after delivery. I 
understand that if my answers to these questions show that I am at high risk of 
depression that the researcher will contact me and advise me to see my GP.   
 
12. I agree to being contacted again in the future by the researchers for any follow up 
information. 
 
13. I understand that I will not be told the results of the extra blood or amniotic fluid 
samples or placental analysis as they will not change the medical care that I receive. 
 
14. I agree to my GP being informed of my participation in the study.   
           
      
_______________________  ________________________ _________________  
Name of Patient   Signature    Date 
 
_______________________     _______________________  _________________  
Name of Person (taking consent)  Signature   Date 
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10.14 Prognosis of the co-twin following spontaneous single 
intrauterine fetal death systematic review search strategy 
 
1. exp Fetal Death/  
2. exp Diseases in Twins/  
3. exp pregnancy, multiple/ or exp pregnancy outcome/  
4. single twin death.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, 
ui, sy, tc, id, tm]  
5. co-twin demise.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui, 
sy, tc, id, tm]  
6. single twin demise.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, 
ui, sy, tc, id, tm]  
7. co-twin death.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui, 
sy, tc, id, tm]  
8. surviving twin.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, ui, 
sy, tc, id, tm]  
9. intrauterine death.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, 
ui, sy, tc, id, tm]  
10. intrauterine demise.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, 
an, eu, pm, ui, sy, tc, id, tm]  
11. perinatal death.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, 
eu, pm, ui, sy, tc, id, tm]  
12. single fetal death.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, 
an, eu, pm, ui, sy, tc, id, tm]  
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13. single fetal demise.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, 
an, eu, pm, ui, sy, tc, id, tm]  
14. fetal loss . [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fs, nm, kf, px, rx, an, eu, pm, 
ui, sy, tc, id, tm]  
15. 1 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 
16. 2 or 3  
17. 15 and 16  
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10.15 Prognosis of the co-twin following spontaneous single 
intrauterine fetal death systematic review data collection form 
 
Reviewer ID:………………  paper:…………………………………………………………. 
 
Selection or rejection (must have all 5 as yes) 
a) Population- pregnant with twins with ≥1 twin which died >14 weeks   Y / N 
b) Outcome- co-twin IUFD/NND, AN/PN brain imaging, neurodevelopment, gestation at delivery                               
           Y / N 
c) Population ≥ 5 sIUFDs                                                   Y / N 
d) Chorionicity defined         Y / N 
e) Excluded twins affected by structural/chromosomal anomalies   Y / N/ not stated 
 
Data Collection 
 
Population   
Total number of patients recruited (n) ………. 
Country of study:   ………………………………………………….. 
Data collection:    retrospective / prospective / unreported / other   
Patient enrolment:    consecutive / arbitrary / unreported / other 
Method of confirming chorionicity:  Scan / placental pathology / not stated………… 
Gestational age at single twin demise (i) average  (……..) 
                         (ii) range  (     ) to (      )wks 
Inclusion criteria: 
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………….... 
………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………… 
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Exclusion criteria: 
………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………… 
………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………… 
 
Interventions 
Description of management following sIUFD e.g. frequency of monitoring, delivery, not stated etc.  
………………………………………………………………………………………………………………………
………………………………………………………………………………………………………….... 
………………………………………………………………………………………………………………………
…………………………………………………………………………………………………………… 
Outcomes 
Percentage of follow up:  (…………..….)% 
Number of patients with data available……………… 
 
Study design 
Well defined sample at uniform early stage  
antenatal care protocolised  yes/ no/ can’t tell 
 
Length of antenatal follow up  ……………………………………………… 
Length of neonatal follow up ……………………………………………… 
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“Surviving” co-twin intrauterine demise (IUFD) 
1st Twin demise ≥14 weeks; 2nd (co-twin) intrauterine death any GA 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise 14-27+6 weeks; 2nd (co-twin) intrauterine death any GA 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise ≥28 weeks; 2nd (co-twin) intrauterine death any GA 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
Any further sub-group analysis: 
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“Surviving” co-twin early neonatal death (<7 days) 
1st Twin demise ≥14 weeks; 2nd (co-twin) early NND 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise 14-27+6 weeks; 2nd (co-twin) early NND  
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise ≥28 weeks; 2nd (co-twin) early NND  
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
Any further sub-group analysis: 
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“Surviving” co-twin late neonatal death (7-28 days) 
1st Twin demise ≥14 weeks; 2nd (co-twin) late NND 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise 14-27+6 weeks; 2nd (co-twin) late NND  
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise ≥28 weeks; 2nd (co-twin) late NND  
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
Any further sub-group analysis: 
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Surviving co-twin preterm delivery (24-34 weeks) 
What was the definition of preterm delivery? 
 
 
Did the paper divide preterm delivery into spontaneous and iatrogenic? Yes / No 
(If yes, further sub-group analysis) 
 
 
 
 
1st Twin demise ≥14 weeks; 2nd (co-twin) preterm delivery (spont. and iatrogenic) 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise 14-27+6 weeks; 2nd (co-twin) preterm delivery (spont. and iatrogenic) 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
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1st Twin demise ≥28 weeks; 2nd (co-twin) preterm delivery (spont. and iatrogenic) 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
Any further sub-group analysis: 
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Abnormal antenatal brain imaging in surviving co-twin 
Mode of scanning: ultrasound / fetal MRI / other 
Timing of scan (e.g. 4 weeks post-sIUFD): 
………………………………………………… 
Definition of abnormal head scan: 
…………………………………………………………………………………………………
…………………………………………………………………………………………… 
……………………………………………………………………………………………… 
1st Twin demise ≥14 weeks; 2nd (co-twin) abnormal antenatal brain imaging  
(state mode) ……………………………. 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise 14-27+6 weeks; 2nd (co-twin) abnormal antenatal brain imaging (state 
mode) ……………………………. 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
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1st Twin demise ≥28 weeks; 2nd (co-twin) abnormal antenatal brain imaging 
(state mode) ……………………………. 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
Any further sub-group analysis (e.g. TTTS vs no TTTS, antenatal USS vs antenatal 
MRI): 
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Abnormal postnatal brain imaging in surviving co-twin 
Mode of scanning: ultrasound / fetal MRI / other 
Timing of scan (e.g. 4 weeks of age): ………………………………………………… 
Definition of abnormal head scan: 
…………………………………………………………………………………………………
…………………………………………………………………………………………… 
……………………………………………………………………………………………… 
1st Twin demise ≥14 weeks; 2nd (co-twin) abnormal postnatal brain imaging  
(state mode) …………………………. 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise 14-27+6 weeks; 2nd (co-twin) abnormal postnatal brain imaging (state 
mode) ……………………………. 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
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1st Twin demise ≥28 weeks; 2nd (co-twin) abnormal postnatal brain imaging 
(state mode) ……………………………. 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
Any further sub-group analysis (e.g. TTTS vs no TTTS, postnatal USS vs postnatal 
MRI): 
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Abnormal postnatal neurological signs in surviving co-twin 
Mode of assessment: …………………………………………………………………. 
Age of assessment: ………………………………………………… 
Definition of abnormal neurological signs: 
…………………………………………………………………………………………………
…………………………………………………………………………………………… 
……………………………………………………………………………………………… 
Length of follow-up: …………………………………. 
1st Twin demise ≥14 weeks; 2nd (co-twin) abnormal neurological signs  
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise 14-27+6 weeks; 2nd (co-twin) abnormal neurological signs 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
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1st Twin demise ≥28 weeks; 2nd (co-twin) abnormal neurological signs 
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
Any further sub-group analysis (e.g. TTTS vs no TTTS, postnatal USS vs postnatal 
MRI): 
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TTTS 
Definition of TTTS: 
…………………………………………………………………………………………………
…………………………………………………………………………………………… 
1st Twin demise ≥14 weeks; 2nd (co-twin) intrauterine death any GA 
 TTTS  No TTTS Total 
Present    
Absent    
Total    
 
1st Twin demise 14-27+6 weeks; 2nd (co-twin) intrauterine death any GA 
 TTTS  No TTTS Total 
Present    
Absent    
Total    
 
1st Twin demise ≥28 weeks; 2nd (co-twin) intrauterine death any GA 
 TTTS  No TTTS Total 
Present    
Absent    
Total    
 
Any further sub-group analysis (e.g. intervention vs. no intervention, stage of TTTS): 
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selective IUGR (or other fetal complication) 
Definition of sIUGR: 
…………………………………………………………………………………………………
…………………………………………………………………………………………… 
1st Twin demise ≥14 weeks; 2nd (co-twin) intrauterine death any GA 
 TTTS  No TTTS Total 
Present    
Absent    
Total    
 
1st Twin demise 14-27+6 weeks; 2nd (co-twin) intrauterine death any GA 
 TTTS  No TTTS Total 
Present    
Absent    
Total    
 
1st Twin demise ≥28 weeks; 2nd (co-twin) intrauterine death any GA 
 TTTS  No TTTS Total 
Present    
Absent    
Total    
 
Any further sub-group analysis (e.g. intervention vs. no intervention, stage of TTTS): 
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Coagulopathy and pre-eclampsia 
1st Twin demise ≥14 weeks; maternal coagulopathy  
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise ≥14 weeks; pre-eclampsia  
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
 
1st Twin demise ≥14 weeks; other maternal complication …………………………….  
 Monochorionic  Dichorionic  Total 
Present    
Absent    
Total    
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10.16 Additional forest plots and extracted 2x2 data for 
prognosis of surviving co-twin systematic review 
 
MC vs DC twins risk of co-twin intrauterine fetal death 
Barigye, Dias, Farah, Fichera, Gratacós 2004 and 2008, Griffiths, Hoffmann, Jou, 
Lewi, Robinson, Rustico and van Klink did not include DC twin pregnancies in their 
studies (Jou 1996, Gratacós 2004, Barigye 2005, Gratacós 2008, Lewi 2008, Fichera 
2009, Dias 2011, Farah 2012, Hoffmann 2013, Griffiths 2015, van Klink 2015, 
Robinson 2017, Rustico 2017), Hagay (Hagay 1986) did not include MC twins, 
therefore these studies were only included in the summary event rate calculation for 
MC and DC twins respectively.  
 
Studies and extracted data used to calculate the summary event rate and 
perform sub-group analysis of co-twin intrauterine fetal death (IUFD) following 
single intrauterine fetal death in monochorionic (MC) and dichorionic (DC) twin 
pregnancies 
GA: gestational age at sIUFD, IUGR: intrauterine growth restriction, TTTS: twin-twin transfusion 
syndrome 
 
Study Year MC co-
twin 
IUFD 
MC twins 
total 
DC co-
twin IUFD 
DC twins 
total 
Sub-group 
Hagay 1986 0 0 0 11 GA 
Cherouny 1989 0 8 0 4 - 
Fusi 1990 0 7 1 8 IUGR 
Gaucherand 1994 0 6 0 2 GA, IUGR 
Ishimatsu 1994 0 12 0 3 GA 
Kilby 1994 0 2 0 13 - 
Santema 1995 2 13 0 16 - 
Jou 1996 1 12 0 0 GA, TTTS 
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Study Year MC co-
twin 
IUFD 
MC twins 
total 
DC co-
twin IUFD 
DC twins 
total 
Sub-group 
Tordjeman 1996 0 2 0 8 GA, IUGR 
Sebire 1997 12 15 4 12 GA, TTTS 
Krayenbuhl 1998 0 12 0 7 TTTS 
Axt 1999 0 4 0 2 GA, TTTS, IUGR 
Bajoria 1999b 13 50 1 42 GA, TTTS, IUGR 
(concurrent) 
Petersen 1999 0 4 0 6 TTTS, IUGR, only GA for 
MC twins 
Malinowski 2000 0 1 0 5 GA 
Baghdadi 2003 1 1 2 12 - 
Malinowski 2003 0 3 0 9 GA, TTTS 
Gratacós 2004 3 6 0 0 IUGR cohort only 
Barigye 2005 3 7 0 0 GA 
Gratacós 2008 3 9 0 0 IUGR cohort only 
Lewi 2008 11 13 0 0 GA, TTTS, IUGR 
Chelli 2009 0 9 1 19 - 
Fichera 2009 1 12 0 0 TTTS, IUGR (MC only) 
Dias 2011 9 16 0 0 GA, IUGR, TTTS 
Mahony 2011 5 11 2 11 GA, TTTS, IUGR 
Farah 2012 6 9 0 0 GA, TTTS (acute only thus 
not in sub-group) 
McPherson 2012 11 28 19 49 - 
Deveer 2013 0 9 0 16 - 
Hoffmann 2013 0 4 0 0 - 
Griffiths 2015 1 28 0 0 GA 
van Klink 2015 0 40 0 0 - 
Robinson 2017 0 8 0 0 GA, IUGR 
Rustico 2017 10 18 0 0 IUGR cohort only 
 
MC vs DC twins risk of preterm birth  
Bajoria, Barigye, Dias, Fichera, Griffiths, Hoffmann, Jou, Robinson, Szymonowicz 
and van Heteren (Szymonowicz 1986, Jou 1996, van Heteren 1998, Bajoria 1999b, 
Barigye 2005, Fichera 2009, Dias 2011, Hoffmann 2013, Griffiths 2015, Robinson 
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2017) did not include DC twins in their studies, Baghdadi and Hagay (Hagay 1986, 
Baghdadi 2003) did not include MC twins, therefore these studies were only included 
in the summary event rate calculations for MC and DC twins respectively.  
 
Studies and extracted data used to calculate the summary event rate and 
perform sub-group analysis of preterm birth (PTB) following single intrauterine 
fetal death in monochorionic (MC) and dichorionic (DC) twin pregnancies 
GA: gestational age at sIUFD, IUGR: intrauterine growth restriction, spont: spontaneous delivery PTB, 
TTTS: twin-twin transfusion syndrome 
 
Study Year MC 
PTB 
MC 
twins 
total 
DC 
PTB 
DC 
twins 
total 
Sub-group 
Hagay 1986 0 0 2 11 GA 
Szymonowicz 1986 5 6 0 0 GA 
Fusi 1990 4 7 3 7 iatrogenic/spont, IUGR 
Gaucherand 1994 2 6 0 2 GA, IUGR 
Ishimatsu 1994 6 12 1 3 GA 
Jou 1996 2 11 0 0 GA, TTTS 
Tordjeman 1996 1 2 5 8 GA, IUGR 
Sebire 1997 0 3 4 8 GA, TTTS 
van Heteren 1998 9 11 0 0 GA, TTTS 
Axt 1999 2 4 1 2 GA, iatrogenic/spont, TTTS, IUGR 
Bajoria 1999b 29 37 0 0 GA, TTTS, IUGR (MC only) 
Petersen 1999 4 4 2 6 GA, TTTS, iatrogenic/spont, IUGR 
Saito 1999 11 17 1 8 GA, TTTS 
Malinowski 2000 0 1 0 5 GA 
Baghdadi 2003 0 0 3 6 GA 
Barigye 2005 0 4 0 0 GA 
Fichera 2009 4 11 0 0 GA 
Dias 2011 3 7 0 0 GA, TTTS, IUGR 
Hoffmann 2013 1 4 0 0 - 
Griffiths 2015 5 27 0 0 GA 
D'Antonio 2017b 13 21 28 41 - 
Robinson 2017 1 7 0 0 GA, IUGR 
 
 497 
 
Forest plot comparing the risk of preterm birth (PTB) following single 
intrauterine fetal death in monochorionic (MC) and dichorionic (DC) twin 
pregnancies 
 
 
MC vs DC risk of abnormal antenatal brain imaging 
 
 
 
 
 
 .05 .1         .5   1   2     5  10   25     100 
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MC twins risk of abnormal antenatal brain imaging  
None of the six studies in the antenatal brain imaging analysis included DC twin 
pregnancies therefore a forest plot could not be drawn (Jelin 2008, Fichera 2009, 
Hoffmann 2013, Griffiths 2015, van Klink 2015, Robinson 2017). Each study 
performed USS and MRI in the same pregnancies. 
 
Studies and extracted data used to calculate the summary event rate and 
perform sub-group analysis of abnormal antenatal brain imaging following 
single intrauterine fetal death in monochorionic (MC) twin pregnancies 
fMRI: fetal magnetic resonance imaging, fUSS: fetal ultrasound scan, GA: gestational age at sIUFD, 
IUGR: intrauterine growth restriction, TTTS: twin-twin transfusion syndrome 
 
Study Year Abnormal 
antenatal 
brain fUSS 
MC 
twins 
total 
Abnormal 
antenatal 
brain fMRI 
MC 
twins 
total 
Sub-group 
Jelin 2008 3 18 3 18 GA, TTTS, imaging modality 
Fichera 2009 0 11 0 11 Imaging modality 
Hoffmann 2013 0 6 0 6 Imaging modality 
Griffiths 2015 5 39 5 39 GA, imaging modality 
van Klink 2015 3 35 3 35 GA, TTTS, IUGR (abnormal 
scan group only), imaging 
modality 
Robinson 2017 2 10 2 10 GA, IUGR, imaging modality 
 
MC vs DC risk of abnormal postnatal brain imaging 
Fichera, Gratacós, Lewi, van Heteren and van Klink did not include DC twins in their 
studies therefore these studies were only included in the summary event rate 
calculation for MC twins (van Heteren 1998, Gratacós 2004, Lewi 2008, Fichera 
2009, van Klink 2015). 
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Studies and extracted data used to calculate the summary event rate and 
perform sub-group analysis of abnormal postnatal brain imaging following 
single intrauterine fetal death in monochorionic (MC) and dichorionic (DC) twin 
pregnancies 
GA: gestational age at sIUFD, IUGR: intrauterine growth restriction, TTTS: twin-twin transfusion 
syndrome 
 
Study Year MC 
abnormal 
postnatal 
brain 
MC 
twins 
total 
DC 
abnormal 
postnatal 
brain 
DC 
twins 
total 
Sub-group 
Gaucherand 1994 1 5 0 2 GA, IUGR 
Ishimatsu 1994 6 11 0 3 GA 
Tordjeman 1996 1 2 0 8 GA, IUGR 
van Heteren 1998 7 11 0 0 GA, TTTS 
Axt 1999 2 4 0 2 GA, TTTS, IUGR 
Bajoria 1999b 17 30 0 41 GA, TTTS, IUGR (MC only) 
Lin  1999 5 8 0 4 - 
Gratacós 2004 1 3 0 0 IUGR only in cohort 
Lewi 2008 0 2 0 0 GA 
Chelli 2009 1 7 5 15 - 
Fichera 2009 2 11 0 0 GA 
van Klink 2015 10 28 0 0 GA, TTTS, IUGR (abnormal scan 
group only) 
 
Forest plot comparing the risk of abnormal postnatal brain imaging (abnorm 
brain PN) following single intrauterine fetal death in monochorionic (MC) and 
dichorionic (DC) twin pregnancies 
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MC vs DC risk of neurodevelopmental comorbidity 
Fichera, Jou, Rustico, Szymonowicz and van Heteren did not include DC twins in 
their studies therefore these studies were only included in the summary event rate 
calculation for MC twins (Szymonowicz 1986, Jou 1996, van Heteren 1998, Fichera 
2009, Rustico 2017).  
 
Studies and extracted data used to calculate the summary event rate and 
perform sub-group analysis of neurodevelopmental comorbidity (neuro signs) 
following single intrauterine fetal death in monochorionic (MC) and dichorionic 
(DC) twin pregnancies 
GA: gestational age at sIUFD, IUGR: intrauterine growth restriction, TTTS: twin-twin transfusion 
syndrome 
 
Study Year MC neuro 
signs 
MC twins 
total 
DC neuro 
signs 
DC twins 
total 
Sub-group 
Szymonowicz 1986 2 2 0 0 GA 
Fusi 1990 3 6 0 6 IUGR 
Gaucherand 1994 1 5 0 2 GA, IUGR 
Ishimatsu 1994 4 9 0 3 GA 
Jou 1996 1 8 0 0 GA, TTTS 
van Heteren 1998 3 9 0 0 GA, TTTS 
Axt 1999 1 4 0 2 GA, IUGR, TTTS 
Lin 1999 2 7 0 3 - 
Petersen 1999 0 3 0 5 GA, TTTS 
Saito 1999 1 12 0 8 GA, TTTS, IUGR 
Bajoria 1999b 2 21 0 33 GA, IUGR, TTTS (MC only) 
Fichera 2009 2 11 0 0 GA 
Rustico 2017 1 6 0 0 GA, IUGR in cohort only 
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Forest plot comparing the risk of neurodevelopmental comorbidity (neuro 
signs) following single intrauterine fetal death in monochorionic (MC) and 
dichorionic (DC) twin pregnancies 
 
 
 
 
 
 
 
 
 
MC vs DC risk of neonatal death 
Fichera, Jou, Lewi, Rustico, van Heteren and van Klink did not include DC twins in 
their studies (Jou 1996, van Heteren 1998, Lewi 2008, Fichera 2009, van Klink 2015, 
Rustico 2017), Baghdadi did not include MC twins (Baghdadi 2003), therefore these 
studies were only included in the summary event rate calculation for MC, and DC 
twins respectively. 
 
Studies and extracted data used to calculate the summary event rate and 
perform sub-group analysis of neonatal death (NND) following single 
intrauterine fetal death in monochorionic (MC) and dichorionic (DC) twin 
pregnancies 
GA: gestational age at sIUFD, IUGR: intrauterine growth restriction, TTTS: twin-twin transfusion 
syndrome 
 
Study Year MC 
NND 
MC twins 
total 
DC 
NND 
DC twins 
total 
Sub-group 
Szymonowicz 1986 4 6 0 0 GA 
Fusi 1990 1 7 1 7 IUGR 
Gaucherand 1994 1 6 0 2 GA, IUGR 
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Study Year MC 
NND 
MC twins 
total 
DC 
NND 
DC twins 
total 
Sub-group 
Ishimatsu 1994 3 12 0 3 GA 
Santema 1995 2 11 3 16 - 
Jou 1996 3 11 0 0 GA, TTTS 
Tordjeman 1996 0 2 1 8   
van Heteren 1998 2 11 0 0 GA, IUGR 
Axt 1999 0 4 0 2 GA, IUGR, TTTS 
Petersen 1999 1 4 1 6 GA, TTTS, IUGR 
Saito 1999 5 17 0 8 GA, TTTS 
Bajoria 1999b 16 37 8 41 GA, IUGR, TTTS 
Malinowski 2003 1 3 2 9 - 
Baghdadi 2003 0 0 4 10 GA 
Lewi 2008 0 2 0 0 GA 
Fichera 2009 1 11 0 0 GA 
Chelli 2009 2 9 4 18 TTTS, IUGR 
van Klink 2015 5 46 0 0 - 
Rustico 2017 1 7 0 0 GA, IUGR in cohort only 
 
Forest plot comparing the risk of neonatal death (NND) following single 
intrauterine fetal death in monochorionic (MC) and dichorionic (DC) twin 
pregnancies 
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10.17 Funnel plots for prognosis of surviving co-
twin systematic review 
 
Studies included in outcome: summary event rate of co-twin IUFD in MC twin 
pregnancies. Egger’s test p=0.00. 
 
 
 
 
 
 
 
 
 
 
Studies included in outcome: summary event rate of co-twin IUFD in DC twin 
pregnancies. Egger’s test p=0.00. 
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Studies included in outcome: summary event rate of PTB in MC twin pregnancies. 
Egger’s test p=0.005. 
 
 
 
 
 
 
 
 
 
 
Studies included in outcome: summary event rate of PTB in DC twin pregnancies. 
Egger’s test p=0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
.5
1
1.5
St
an
da
rd
 er
ro
r o
f lo
g 
ra
tio
.025 .05 .1 .25 .5 1 2 4 8
Log ratio
Funnel plot with pseudo 95% confidence limits
0
.5
1
1.5
St
an
da
rd
 er
ro
r o
f lo
g 
ra
tio
.025 .05 .1 .25 .5 1 2 4 8
Log ratio
Funnel plot with pseudo 95% confidence limits
 505 
 
Studies included in outcome: summary event rate of abnormal postnatal brain imaging in 
MC twin pregnancies. Egger’s test p=0.40. 
 
 
 
 
 
 
 
 
 
 
Studies included in outcome: summary event rate of neurodevelopmental comorbidity in 
MC twin pregnancies. Egger’s test p=0.058. 
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Studies included in outcome: summary event rate of NND in MC twin pregnancies. 
Egger’s test p=0.04. 
 
 
 
Studies included in outcome: summary event rate of NND in DC twin pregnancies. 
Egger’s test p=0.225 
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10.18 Paternal consent form for parental attachment 
and depressive symptoms work 
 
 
Centre Number:   Study Number:  
 
Patient Identification Number for this trial:  
CONSENT FORM - PATERNAL 
 
SECTION B – When a complication of monochorionic twin pregnancy is diagnosed 
or if an intervention in pregnancy is being considered  
 
 
Please initial box  
 
1. I confirm that I have read and understand the information sheet version 3.0 dated 
4.11.15 for the above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time without giving any reason, without the medical care or my legal rights being 
affected.                        
 
3. I agree to complete the questionnaires before laser, after laser, and after delivery. I 
understand that if my answers to these questions show that I am at high risk of 
depression then the researcher will contact me and advise me to see my GP.   
 
4. I agree to being contacted again in the future by the researchers for any follow up 
information 
           
  
 
_________________________     __________________  _____________  
Name of Patient       Signature      Date 
 
________________________       __________________   _____________  
Name of Person (taking consent)  Signature     Date 
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10.19 Questionnaires for parental attachment and 
depressive symptoms 
 
OMMIT (Optimal Management of Monochorionic Twins) Patient 
Questionnaire  
Pre laser Maternal 
 
Twin to twin transfusion syndrome is a very nasty complication of pregnancy that if 
untreated carries a very high risk of mortality for babies. The treatment of fetoscopic laser 
ablation significantly improves fetal outcomes in many pregnancies, but outcomes may be 
unpredictable. We realise that having laser surgery is a difficult time for most parents, so 
we would be very grateful if you could answer the following questions so that we can help 
other people in the same position as you in the future. 
We will ask you to complete the questionnaire at different time points (before laser, 1 
month after laser, and 6 weeks after you deliver). The aim of our questionnaire is to: 
1) investigate if undergoing laser surgery affects parental bonding/attachment during 
pregnancy and after delivery 
2) learn more about how parents feel who are having laser surgery, so that we are able 
to provide better support to parents in the future. 
These questionnaires will be slightly different, but some of the questions are the same so 
that we can look at how your feelings change during pregnancy, and after you’ve 
delivered. Please read each question carefully. There are no right or wrong answers. If 
you would like to discuss any issues raised by this questionnaire with a member of the 
research team, the contact information is at the bottom.  
 
Background Information 
 
OMMIT study number __________ 
 
1. Do you currently have a mental health illness? Yes / No 
a. If yes, please specify which condition(s) 
_____________________________________________________________
_____________________________________________________________
______________________ 
2. Do you currently take any medication for a mental health illness? Yes / No 
a. If yes, please list any medication 
_____________________________________________________________
___________ 
3. Do you currently attend any counselling for a mental health illness? Yes / No 
a. If yes, please list any counselling / types of therapy 
_____________________________________________________________
___________ 
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4. Have you ever had a mental health illness in the past? Yes / No 
a. If yes, please specify which condition(s) 
_____________________________________________________________
_____________________________________________________________
______________________ 
5. Did you take any medication for a previous mental health illness? Yes / No 
a. If yes, please list any medication 
_____________________________________________________________
___________ 
6. Did you attend any counselling for a previous mental health illness? Yes / No 
a. If yes, please list any counselling / types of therapy 
_____________________________________________________________
___________ 
 
Condon Fetal Attachment Questions  
These questions are about your thoughts and feelings about the developing babies. 
Please tick one box only in answer to each question. 
 
 
MA1: Since the diagnosis of TTTS I have thought 
about, or been preoccupied with the babies inside me: 
Please 
tick 
Almost all the time  
Very frequently  
Frequently  
Occasionally  
Not at all  
 
 
MA2: Since the diagnosis of TTTS when I have spoken 
about, or thought about the babies inside me I got 
emotional feelings which were: 
Please 
tick 
Very weak or non-existent  
Fairly weak  
In between strong and weak  
Fairly strong  
Very strong  
 
 
MA3: Since the diagnosis of TTTS my feelings about 
the babies inside me have been: 
Please 
tick 
Very positive  
Mainly positive  
Mixed positive and negative  
Mainly negative  
Very negative  
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MA4: Since the diagnosis of TTTS I have the desire to 
read about or get information about the developing 
babies. This desire is: 
Please 
tick 
Very weak or non-existent  
Fairly weak  
Neither strong nor weak  
Moderately strong  
Very strong  
 
 
MA5: Since the diagnosis of TTTS I have been trying to 
picture in my mind what the developing babies actually 
look like in my womb: 
Please 
tick 
Almost all the time  
Very frequently  
Frequently  
Occasionally  
Not at all  
 
 
MA6: Since the diagnosis of TTTS I think of the 
developing babies mostly as: 
Please 
tick 
Real little people with special characteristics  
Babies like any other babies  
Human beings  
Living things  
Things not really yet alive  
 
 
MA7: Since the diagnosis of TTTS I have felt that the 
babies inside me is dependent on me for its well-being: 
Please 
tick 
Totally  
A great deal  
Moderately  
Slightly  
Not at all  
 
 
MA8: Since the diagnosis of TTTS I have found myself 
talking to my babies when I am alone: 
Please 
tick 
Not at all  
Occasionally  
Frequently  
Very frequently  
Almost all the time I am alone  
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MA9: Since the diagnosis of TTTS when I think about 
(or talk to) my babies inside me, my thoughts: 
Please 
tick 
Are always tender and loving  
Are mostly tender and loving  
Are a mixture of both tenderness and irritation  
Contain a fair bit of irritation  
Contain a lot of irritation  
 
 
MA10: The picture in my mind of what the babies at 
this stage actually looks like inside the womb is:  
Please 
tick 
Very clear  
Fairly clear  
Fairly vague  
Very vague  
I have no idea at all  
 
 
MA11: Since the diagnosis of TTTS when I think about 
the babies inside me I get feelings which are: 
Please 
tick 
Very sad  
Moderately sad  
A mixture of happiness and sadness  
Moderately happy  
Very happy  
 
 
MA12: Some pregnant women sometimes get so 
irritated by the babies inside them that they feel like 
they want to hurt them or punish them: 
Please 
tick 
I couldn’t imagine I would ever feel like this  
I could imagine I might sometimes feel like this, but I never 
actually have 
 
I have felt like this once or twice myself  
I have occasionally felt like this myself  
I have often felt like this myself  
 
 
MA13: Since the diagnosis of TTTS I have felt: Please 
tick 
Very emotionally distant from my babies  
Moderately emotionally distant from my babies  
Not particularly emotionally close to my babies  
Moderately close emotionally to my babies  
Very close emotionally to my babies  
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MA14: Since the diagnosis of TTTS I have taken care 
with what I eat to make sure the babies get a good diet: 
Please 
tick 
Not at all  
Once or twice when I ate  
Occasionally when I ate  
Quite often when I ate  
Every time I ate  
 
 
MA15: When I first see my babies after the birth I 
expect I will feel: 
Please 
tick 
Intense affection  
Mostly affection  
Dislike about one or 2 aspects of the babies  
Dislike about quite a few aspects of the baby  
Mostly dislike  
 
 
MA16: When my babies are born I would like to hold 
the babies: 
Please 
tick 
Immediately  
After they have been wrapped in a blanket  
After they have been washed  
After a few hours for things to settle down  
The next day  
 
 
MA17: Since the diagnosis of TTTS I have had dreams 
about the pregnancy or babies: 
Please 
tick 
Not at all  
Occasionally  
Frequently  
Very frequently  
Almost every night  
 
 
MA18: Since the diagnosis of TTTS I have found myself 
feeling, or rubbing with my hand, the outside of my 
stomach where the babies are: 
Please 
tick 
A lot of times each day  
At least once per day  
Occasionally  
Once only  
Not at all  
 
 
 
 513 
 
MA19: If the pregnancy was lost at this time (due to 
miscarriage or other accidental event) without any pain 
or injury to myself, I expect I would feel: 
Please 
tick 
Very pleased  
Moderately pleased  
Neutral (i.e. neither sad nor pleased; or mixed feelings)  
Moderately sad  
Very sad  
 
Edinburgh Postnatal Depression Scale 
These questions assess your risk for depression. Although it is called the Postnatal 
Depression Scale, it is also used antenatally before you have your babies. If you score 
highly, we will inform you and advise you to see your GP for further assessment and 
support if required.  
Please tick one box only in answer to each question which comes closest to how you 
have felt since the diagnosis of TTTS. 
 
EPDSM1: I have been able to laugh and see the 
funny side of things: 
Please 
tick 
As much as I always could  
Not quite so much now  
Definitely not so much now  
Not at all  
 
 
EPDSM2: I have looked forward with enjoyment to 
things: 
Please 
tick 
As much as I ever did  
Rather less than I used to  
Definitely less than I used to  
Hardly at all  
 
 
 
 
 
 
 
 
 
EPDSM4: I have been anxious or worried for no 
good reason: 
Please 
tick 
No not at all  
Hardly ever  
Yes, sometimes  
Yes, very often  
EPDSM3: I have blamed myself unnecessarily 
when things went wrong: 
Please 
tick 
Yes, most of the time  
Yes, some of the time  
Not very often  
No, never  
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EPDSM5: I have felt scared or panicky for no very 
good reason: 
Please 
tick 
Yes, quite a lot  
Not quite so much now  
Definitely not so much now  
Not at all  
 
 
EPDSM6: Things have been getting on top of me: Please 
tick 
Yes, most of the time I haven’t been able to cope at all  
Yes, sometimes I haven’t been coping as well as usual  
No, most of the time I have coped quite well  
No, I have been coping as well as ever  
 
 
EPDSM7: I have been so unhappy that I have had 
difficulty sleeping: 
Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
 
 
EPDSM8: I have felt sad or miserable: Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
 
 
EPDSM9: I have been so unhappy that I have been 
crying: 
Please 
tick 
Yes, most of the time  
Yes, quite often  
Only occasionally  
No, never  
 
 
EPDSM10: The thought of harming myself has 
occurred to me: 
Please 
tick 
Yes, quite often  
Sometimes  
Hardly ever  
Never  
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Thank-you very much for taking the time to complete this 
questionnaire 
 
Detail of researchers 
1. Dr Fiona Mackie, 
Clinical Research Fellow, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-626-4535 
 
2. Professor M.D. Kilby, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-627-2778 
 
Patient Advice Liaison Service  
Tel: 0121 627 2747  
Email: pals@bwnft.nhs.uk  
 
Fetal Medicine Centre, Birmingham Women’s Foundation Trust, 
Metchley Park Road, Edgbaston, Birmingham. B15 2TG,  
Tel.No: 0121 627 2683 
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OMMIT (Optimal Management of Monochorionic Twins) Patient 
Questionnaire  
Pre laser Paternal 
Twin to twin transfusion syndrome is a very nasty complication of pregnancy that if 
untreated carries a very high risk of mortality for babies. The treatment of fetoscopic laser 
ablation significantly improves fetal outcomes in many pregnancies, but outcomes may be 
unpredictable. We realise that having laser surgery is a difficult time for most parents, so 
we would be very grateful if you could answer the following questions so that we can help 
other people in the same position as you in the future. 
We will ask you to complete the questionnaire at different time points (before laser, 1 
month after laser, and 6 weeks after your partner delivers). The aim of our questionnaire 
is to: 
1) investigate if undergoing laser surgery affects parental bonding/attachment during 
pregnancy and after delivery 
2) learn more about how parents feel who are having laser surgery, so that we are able 
to provide better support to parents in the future. 
These questionnaires will be slightly different, but some of the questions are the same so 
that we can look at how your feelings change during pregnancy, and after your partner 
has delivered. Please read each question carefully. There are no right or wrong answers. 
If you would like to discuss any issues raised by this questionnaire with a member of the 
research team, the contact information is at the bottom.  
 
Background Information 
OMMIT study number __________P 
 
1. Do you currently have a mental health illness? Yes / No 
a. If yes, please specify which condition(s) 
_____________________________________________________________
_____________________________________________________________
______________________ 
2. Do you currently take any medication for a mental health illness? Yes / No 
a. If yes, please list any medication 
_____________________________________________________________
___________ 
 
3. Do you currently attend any counselling for a mental health illness? Yes / No 
a. If yes, please list any counselling / types of therapy 
_____________________________________________________________
___________ 
4. Have you ever had a mental health illness in the past? Yes / No 
a. If yes, please specify which condition(s) 
_____________________________________________________________
_____________________________________________________________
______________________ 
5. Did you take any medication for a previous mental health illness? Yes / No 
a. If yes, please list any medication 
_____________________________________________________________
___________ 
6. Did you attend any counselling for a previous mental health illness? Yes / No 
a. If yes, please list any counselling / types of therapy 
_____________________________________________________________
___________ 
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Condon Fetal Attachment Questions  
These questions are about your thoughts and feelings about the developing babies. 
Please tick one box only in answer to each question. 
 
PA1: Since the diagnosis of TTTS I have thought about, 
or been preoccupied with the babies: 
Please 
tick 
Almost all the time  
Very frequently  
Frequently  
Occasionally  
Not at all  
 
 
PA2: Since the diagnosis of TTTS when I have spoken 
about, or thought about the developing babies I got 
emotional feelings which were: 
Please 
tick 
Very weak or non-existent  
Fairly weak  
In between strong and weak  
Fairly strong  
Very strong  
 
 
PA3: Since the diagnosis of TTTS my feelings about 
the developing babies have been: 
Please 
tick 
Very positive  
Mainly positive  
Mixed positive and negative  
Mainly negative  
Very negative  
 
 
PA4: Since the diagnosis of TTTS I have the desire to 
read about or get information about the developing 
babies. This desire is: 
Please 
tick 
Very weak or non-existent  
Fairly weak  
Neither strong nor weak  
Moderately strong  
Very strong  
 
 
PA5: Since the diagnosis of TTTS I have been trying to 
picture in my mind what the developing babies actually 
look like in my partner’s womb: 
Please 
tick 
Almost all the time  
Very frequently  
Frequently  
Occasionally  
Not at all  
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PA6: Since the diagnosis of TTTS I think of the 
developing babies mostly as: 
Please 
tick 
Real little people with special characteristics  
Babies like any other babies  
Human beings  
Living things  
Things not really yet alive  
 
 
PA7: Since the diagnosis of TTTS when I think about 
the developing babies my thoughts: 
Please 
tick 
Are always tender and loving  
Are mostly tender and loving  
Are a mixture of both tenderness and irritation  
Contain a fair bit of irritation  
Contain a lot of irritation  
 
 
PA8: Since the diagnosis of TTTS my ideas and 
possible names for the babies have been: 
Please 
tick 
Very clear  
Fairly clear  
Fairly vague  
Very vague  
I have no idea at all  
  
 
PA9: Since the diagnosis of TTTS when I think about 
the developing babies I get feelings which are: 
Please 
tick 
Very sad  
Moderately sad  
A mixture of happiness and sadness  
Moderately happy  
Very happy  
 
 
PA10: Since the diagnosis of TTTS I have been thinking 
about what kind of child the baby will grow into: 
Please 
tick 
Not at all  
Occasionally  
Frequently  
Very frequently  
Almost all the time  
 
 
PA11: Since the diagnosis of TTTS I have felt: Please 
tick 
Very emotionally distant from the babies  
Moderately emotionally distant from the babies  
Not particularly emotionally close to the babies  
Moderately close emotionally to the babies  
Very close emotionally to the babies  
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PA12: When I first see my babies after the birth I 
expect I will feel: 
Please 
tick 
Intense affection  
Mostly affection  
Affection, but I expect there may be a few aspects of the 
babies I will dislike 
 
I expect there may be quite a few aspects of the babies I 
will dislike 
 
I expect I might feel mostly dislike  
 
 
PA13: When the babies are born I would like to hold the 
babies: 
Please 
tick 
Immediately  
After they have been wrapped in a blanket  
After they have been washed  
After a few hours for things to settle down  
The next day  
 
 
PA14: Since the diagnosis of TTTS I have had dreams 
about the pregnancy or babies: 
Please 
tick 
Not at all  
Occasionally  
Frequently  
Very frequently  
Almost every night  
 
 
PA15: Since the diagnosis of TTTS I have found myself 
feeling, or rubbing with my hand, the outside of my 
partner’s stomach where the babies are: 
Please 
tick 
A lot of times each day  
At least once per day  
Occasionally  
Once only  
Not at all  
 
 
PA16: If the pregnancy was lost at this time (due to 
miscarriage or other accidental event) without any pain 
or injury to my partner, I expect I would feel: 
Please 
tick 
Very pleased  
Moderately pleased  
Neutral (i.e. neither sad nor pleased; or mixed feelings)  
Moderately sad  
Very sad  
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Edinburgh Postnatal Depression Scale 
These questions assess your risk for depression. Although it is called the Postnatal 
Depression Scale, it is also used antenatally before you have your babies. If you score 
highly, we will inform you and advise you to see your GP for further assessment and 
support if required.  
Please tick one box only in answer to each question which comes closest to how you 
have felt since the diagnosis of TTTS. 
 
EPDSP1: I have been able to laugh and see the 
funny side of things: 
Please 
tick 
As much as I always could  
Not quite so much now  
Definitely not so much now  
Not at all  
 
 
EPDSP2: I have looked forward with enjoyment to 
things: 
Please 
tick 
As much as I ever did  
Rather less than I used to  
Definitely less than I used to  
Hardly at all  
 
 
 
 
 
 
 
 
 
EPDSP4: I have been anxious or worried for no 
good reason: 
Please 
tick 
No not at all  
Hardly ever  
Yes, sometimes  
Yes, very often  
 
 
EPDSP5: I have felt scared or panicky for no very 
good reason: 
Please 
tick 
Yes, quite a lot  
Not quite so much now  
Definitely not so much now  
Not at all  
 
 
 
 
 
EPDSP3: I have blamed myself unnecessarily 
when things went wrong: 
Please 
tick 
Yes, most of the time  
Yes, some of the time  
Not very often  
No, never  
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EPDSP6: Things have been getting on top of me: Please 
tick 
Yes, most of the time I haven’t been able to cope at all  
Yes, sometimes I haven’t been coping as well as usual  
No, most of the time I have coped quite well  
No, I have been coping as well as ever  
 
 
EPDSP7: I have been so unhappy that I have had 
difficulty sleeping: 
Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
 
 
EPDSP8: I have felt sad or miserable: Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
 
 
EPDSP9: I have been so unhappy that I have been 
crying: 
Please 
tick 
Yes, most of the time  
Yes, quite often  
Only occasionally  
No, never  
 
 
EPDSP10: The thought of harming myself has 
occurred to me: 
Please 
tick 
Yes, quite often  
Sometimes  
Hardly ever  
Never  
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Thank-you very much for taking the time to complete this 
questionnaire 
 
Detail of researchers 
1. Dr Fiona Mackie, 
Clinical Research Fellow, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-626-4535 
 
2. Professor M.D. Kilby, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-627-2778 
 
Patient Advice Liaison Service  
Tel: 0121 627 2747  
Email: pals@bwnft.nhs.uk  
 
Fetal Medicine Centre, Birmingham Women’s Foundation Trust, 
Metchley Park Road, Edgbaston, Birmingham. B15 2TG, Tel.No: 0121 627 2683 
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OMMIT (Optimal Management of Monochorionic Twins) Patient 
Questionnaire  
Post laser Maternal 
We would be grateful if you could complete this questionnaire so that we can help people 
who need laser surgery in the future. As you know twin pregnancies are high-risk and 
people that have twins can have a wide variety of outcomes. Whilst we have tried our 
best to send you the correct questionnaire depending on your outcome, we may 
sometimes get this wrong for which we apologise.  
There are no right or wrong answers. If you would like to discuss any issues raised by this 
questionnaire with a member of the research team, the contact information is at the 
bottom.  
 
Condon Fetal Attachment Questions  
These questions are about your thoughts and feelings about the developing baby/babies. 
Please tick one box only in answer to each question. 
 
MA1: Since the diagnosis of TTTS I have thought 
about, or been preoccupied with the baby/babies inside 
me: 
Please 
tick 
Almost all the time  
Very frequently  
Frequently  
Occasionally  
Not at all  
 
 
MA2: Since the diagnosis of TTTS when I have spoken 
about, or thought about the baby/babies inside me I got 
emotional feelings which were: 
Please 
tick 
Very weak or non-existent  
Fairly weak  
In between strong and weak  
Fairly strong  
Very strong  
 
 
MA3: Since the diagnosis of TTTS my feelings about 
the baby/babies inside me have been: 
Please 
tick 
Very positive  
Mainly positive  
Mixed positive and negative  
Mainly negative  
Very negative  
 
 
MA4: Since the diagnosis of TTTS I have the desire to 
read about or get information about the developing 
baby/babies. This desire is: 
Please 
tick 
Very weak or non-existent  
Fairly weak  
Neither strong nor weak  
Moderately strong  
Very strong  
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MA5: Since the diagnosis of TTTS I have been trying to 
picture in my mind what the developing baby/babies 
actually look like in my womb: 
Please 
tick 
Almost all the time  
Very frequently  
Frequently  
Occasionally  
Not at all  
 
 
MA6: Since the diagnosis of TTTS I think of the 
developing baby/babies mostly as: 
Please 
tick 
Real little people with special characteristics  
Baby/babies like any other baby/babies  
Human beings  
Living things  
Things not really yet alive  
 
 
MA7: Since the diagnosis of TTTS I have felt that the 
baby/babies inside me is dependent on me for its well-
being: 
Please 
tick 
Totally  
A great deal  
Moderately  
Slightly  
Not at all  
 
 
MA8: Since the diagnosis of TTTS I have found myself 
talking to my baby/babies when I am alone: 
Please 
tick 
Not at all  
Occasionally  
Frequently  
Very frequently  
Almost all the time I am alone  
 
 
MA9: Since the diagnosis of TTTS when I think about 
(or talk to) my baby/babies inside me, my thoughts: 
Please 
tick 
Are always tender and loving  
Are mostly tender and loving  
Are a mixture of both tenderness and irritation  
Contain a fair bit of irritation  
Contain a lot of irritation  
 
 
MA10: The picture in my mind of what the baby/babies 
at this stage actually looks like inside the womb is:  
Please 
tick 
Very clear  
Fairly clear  
Fairly vague  
Very vague  
I have no idea at all  
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MA11: Since the diagnosis of TTTS when I think about 
the baby/babies inside me I get feelings which are: 
Please 
tick 
Very sad  
Moderately sad  
A mixture of happiness and sadness  
Moderately happy  
Very happy  
 
 
MA12: Some pregnant women sometimes get so 
irritated by the baby/babies inside them that they feel 
like they want to hurt them or punish them: 
Please 
tick 
I couldn’t imagine I would ever feel like this  
I could imagine I might sometimes feel like this, but I never 
actually have 
 
I have felt like this once or twice myself  
I have occasionally felt like this myself  
I have often felt like this myself  
 
 
MA13: Since the diagnosis of TTTS I have felt: Please 
tick 
Very emotionally distant from my baby/babies  
Moderately emotionally distant from my baby/babies  
Not particularly emotionally close to my baby/babies  
Moderately close emotionally to my baby/babies  
Very close emotionally to my baby/babies  
 
 
MA14: Since the diagnosis of TTTS I have taken care 
with what I eat to make sure the baby/babies get a 
good diet: 
Please 
tick 
Not at all  
Once or twice when I ate  
Occasionally when I ate  
Quite often when I ate  
Every time I ate  
 
 
MA15: When I first see my baby/babies after the birth I 
expect I will feel: 
Please 
tick 
Intense affection  
Mostly affection  
Dislike about one or 2 aspects of the baby/babies  
Dislike about quite a few aspects of the baby  
Mostly dislike  
 
 
MA16: When my baby/babies are born I would like to 
hold the baby/babies: 
Please 
tick 
Immediately  
After they have been wrapped in a blanket  
After they have been washed  
After a few hours for things to settle down  
The next day  
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MA17: Since the diagnosis of TTTS I have had dreams 
about the pregnancy or baby/babies: 
Please 
tick 
Not at all  
Occasionally  
Frequently  
Very frequently  
Almost every night  
 
 
MA18: Since the diagnosis of TTTS I have found myself 
feeling, or rubbing with my hand, the outside of my 
stomach where the baby/babies are: 
Please 
tick 
A lot of times each day  
At least once per day  
Occasionally  
Once only  
Not at all  
 
 
MA19: If the pregnancy was lost at this time (due to 
miscarriage or other accidental event) without any pain 
or injury to myself, I expect I would feel: 
Please 
tick 
Very pleased  
Moderately pleased  
Neutral (i.e. neither sad nor pleased; or mixed feelings)  
Moderately sad  
Very sad  
 
 
 
Edinburgh Postnatal Depression Scale 
These questions assess your risk for depression. Although it is called the Postnatal 
Depression Scale, it is also used antenatally before you have your baby/babies. If you 
score highly, we will inform you and advise you to see your GP for further assessment 
and support if required.  
Please tick one box only in answer to each question which comes closest to how you 
have felt since the diagnosis of TTTS. 
 
 
EPDSM1: I have been able to laugh and see the 
funny side of things: 
Please 
tick 
As much as I always could  
Not quite so much now  
Definitely not so much now  
Not at all  
 
 
EPDSM2: I have looked forward with enjoyment to 
things: 
Please 
tick 
As much as I ever did  
Rather less than I used to  
Definitely less than I used to  
Hardly at all  
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EPDSM4: I have been anxious or worried for no 
good reason: 
Please 
tick 
No not at all  
Hardly ever  
Yes, sometimes  
Yes, very often  
 
 
EPDSM5: I have felt scared or panicky for no very 
good reason: 
Please 
tick 
Yes, quite a lot  
Not quite so much now  
Definitely not so much now  
Not at all  
 
 
EPDSM6: Things have been getting on top of me: Please 
tick 
Yes, most of the time I haven’t been able to cope at all  
Yes, sometimes I haven’t been coping as well as usual  
No, most of the time I have coped quite well  
No, I have been coping as well as ever  
 
 
EPDSM7: I have been so unhappy that I have had 
difficulty sleeping: 
Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
 
 
EPDSM8: I have felt sad or miserable: Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
 
 
 
 
 
 
EPDSM3: I have blamed myself unnecessarily 
when things went wrong: 
Please 
tick 
Yes, most of the time  
Yes, some of the time  
Not very often  
No, never  
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EPDSM9: I have been so unhappy that I have been 
crying: 
Please 
tick 
Yes, most of the time  
Yes, quite often  
Only occasionally  
No, never  
 
 
EPDSM10: The thought of harming myself has 
occurred to me: 
Please 
tick 
Yes, quite often  
Sometimes  
Hardly ever  
Never  
 
 
 
 
 
Thank-you very much for taking the time to complete this 
questionnaire 
 
Detail of researchers 
1. Dr Fiona Mackie, 
Clinical Research Fellow, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-626-4535 
 
2. Professor M.D. Kilby, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-627-2778 
 
Patient Advice Liaison Service  
Tel: 0121 627 2747  
Email: pals@bwnft.nhs.uk  
 
Fetal Medicine Centre, Birmingham Women’s Foundation Trust, 
Metchley Park Road, Edgbaston, Birmingham. B15 2TG, Tel.No: 0121 627 2683 
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OMMIT (Optimal Management of Monochorionic Twins) Patient 
Questionnaire  
Post laser Paternal 
We would be grateful if you could complete this questionnaire so that we can help 
people who need laser surgery in the future. As you know twin pregnancies are high-
risk and people that have twins can have a wide variety of outcomes. Whilst we have 
tried our best to send you the correct questionnaire depending on your outcome, we 
may sometimes get this wrong for which we apologise.  
There are no right or wrong answers. If you would like to discuss any issues raised by 
this questionnaire with a member of the research team, the contact information is at 
the bottom.  
 
Condon Fetal Attachment Questions  
These questions are about your thoughts and feelings about the developing baby/babies. 
Please tick one box only in answer to each question. 
 
 
PA1: Since the diagnosis of TTTS I have thought about, 
or been preoccupied with the baby/babies: 
Please 
tick 
Almost all the time  
Very frequently  
Frequently  
Occasionally  
Not at all  
 
 
PA2: Since the diagnosis of TTTS when I have spoken 
about, or thought about the developing baby/babies I 
got emotional feelings which were: 
Please 
tick 
Very weak or non-existent  
Fairly weak  
In between strong and weak  
Fairly strong  
Very strong  
 
 
 
PA3: Since the diagnosis of TTTS my feelings about 
the developing baby/babies have been: 
Please 
tick 
Very positive  
Mainly positive  
Mixed positive and negative  
Mainly negative  
Very negative  
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PA4: Since the diagnosis of TTTS I have the desire to 
read about or get information about the developing 
baby/babies. This desire is: 
Please 
tick 
Very weak or non-existent  
Fairly weak  
Neither strong nor weak  
Moderately strong  
Very strong  
 
 
PA5: Since the diagnosis of TTTS I have been trying to 
picture in my mind what the developing baby/babies 
actually look like in my partner’s womb: 
Please 
tick 
Almost all the time  
Very frequently  
Frequently  
Occasionally  
Not at all  
 
 
PA6: Since the diagnosis of TTTS I think of the 
developing baby/babies mostly as: 
Please 
tick 
Real little people with special characteristics  
Baby/babies like any other baby/babies  
Human beings  
Living things  
Things not really yet alive  
 
 
PA7: Since the diagnosis of TTTS when I think about 
the developing baby/babies my thoughts: 
Please 
tick 
Are always tender and loving  
Are mostly tender and loving  
Are a mixture of both tenderness and irritation  
Contain a fair bit of irritation  
Contain a lot of irritation  
 
 
PA8: Since the diagnosis of TTTS my ideas and 
possible names for the baby/babies have been: 
Please 
tick 
Very clear  
Fairly clear  
Fairly vague  
Very vague  
I have no idea at all  
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PA9: Since the diagnosis of TTTS when I think about 
the developing baby/babies I get feelings which are: 
Please 
tick 
Very sad  
Moderately sad  
A mixture of happiness and sadness  
Moderately happy  
Very happy  
 
 
PA10: Since the diagnosis of TTTS I have been thinking 
about what kind of child the baby will grow into: 
Please 
tick 
Not at all  
Occasionally  
Frequently  
Very frequently  
Almost all the time  
 
 
PA11: Since the diagnosis of TTTS I have felt: Please 
tick 
Very emotionally distant from the baby/babies  
Moderately emotionally distant from the baby/babies  
Not particularly emotionally close to the baby/babies  
Moderately close emotionally to the baby/babies  
Very close emotionally to the baby/babies  
 
 
PA12: When I first see my baby/babies after the birth I 
expect I will feel: 
Please 
tick 
Intense affection  
Mostly affection  
Affection, but I expect there may be a few aspects of the 
baby/babies I will dislike 
 
I expect there may be quite a few aspects of the 
baby/babies I will dislike 
 
I expect I might feel mostly dislike  
 
 
PA13: When the baby/babies are born I would like to 
hold the baby/babies: 
Please 
tick 
Immediately  
After they have been wrapped in a blanket  
After they have been washed  
After a few hours for things to settle down  
The next day  
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PA14: Since the diagnosis of TTTS I have had dreams 
about the pregnancy or baby/babies: 
Please 
tick 
Not at all  
Occasionally  
Frequently  
Very frequently  
Almost every night  
 
 
PA15: Since the diagnosis of TTTS I have found myself 
feeling, or rubbing with my hand, the outside of my 
partner’s stomach where the baby/babies are: 
Please 
tick 
A lot of times each day  
At least once per day  
Occasionally  
Once only  
Not at all  
 
 
PA16: If the pregnancy was lost at this time (due to 
miscarriage or other accidental event) without any pain 
or injury to my partner, I expect I would feel: 
Please 
tick 
Very pleased  
Moderately pleased  
Neutral (i.e. neither sad nor pleased; or mixed feelings)  
Moderately sad  
Very sad  
 
 
Edinburgh Postnatal Depression Scale 
These questions assess your risk for depression. Although it is called the Postnatal 
Depression Scale, it is also used antenatally before you have your baby/babies. If you 
score highly, we will inform you and advise you to see your GP for further assessment 
and support if required.  
Please tick one box only in answer to each question which comes closest to how you 
have felt since the diagnosis of TTTS. 
 
 
EPDSP1: I have been able to laugh and see the 
funny side of things: 
Please 
tick 
As much as I always could  
Not quite so much now  
Definitely not so much now  
Not at all  
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EPDSP2: I have looked forward with enjoyment to 
things: 
Please 
tick 
As much as I ever did  
Rather less than I used to  
Definitely less than I used to  
Hardly at all  
 
 
 
 
 
 
 
 
 
 
EPDSP4: I have been anxious or worried for no 
good reason: 
Please 
tick 
No not at all  
Hardly ever  
Yes, sometimes  
Yes, very often  
 
 
EPDSP5: I have felt scared or panicky for no very 
good reason: 
Please 
tick 
Yes, quite a lot  
Not quite so much now  
Definitely not so much now  
Not at all  
 
 
EPDSP6: Things have been getting on top of me: Please 
tick 
Yes, most of the time I haven’t been able to cope at all  
Yes, sometimes I haven’t been coping as well as usual  
No, most of the time I have coped quite well  
No, I have been coping as well as ever  
 
 
EPDSP7: I have been so unhappy that I have had 
difficulty sleeping: 
Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
 
EPDSP3: I have blamed myself unnecessarily 
when things went wrong: 
Please 
tick 
Yes, most of the time  
Yes, some of the time  
Not very often  
No, never  
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EPDSP8: I have felt sad or miserable: Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
 
 
EPDSP9: I have been so unhappy that I have 
been crying: 
Please 
tick 
Yes, most of the time  
Yes, quite often  
Only occasionally  
No, never  
 
 
EPDSP10: The thought of harming myself has 
occurred to me: 
Please 
tick 
Yes, quite often  
Sometimes  
Hardly ever  
Never  
 
 
 
Thank-you very much for taking the time to complete this 
questionnaire 
 
Detail of researchers 
1. Dr Fiona Mackie, 
Clinical Research Fellow, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-626-4535 
 
2. Professor M.D. Kilby, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-627-2778 
 
Patient Advice Liaison Service  
Tel: 0121 627 2747  
Email: pals@bwnft.nhs.uk  
 
Fetal Medicine Centre, Birmingham Women’s Foundation Trust, 
Metchley Park Road, Edgbaston, Birmingham. B15 2TG, Tel.No: 0121 627 2683 
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OMMIT (Optimal Management of Monochorionic Twins) Patient 
Questionnaire  
Postnatal Maternal 
As you know twin pregnancies are high-risk and people that have twins can have a wide 
variety of outcomes. Whilst we have tried our best to send you the correct questionnaire 
depending on your outcome, we may sometimes get this wrong for which we apologise. 
Thank-you very much for being part of our study, which we hope will improve care for 
people in your position in the future. 
Please read each question carefully. There are no right or wrong answers. If you would 
like to discuss any issues raised by this questionnaire with a member of the research 
team, the contact information is at the bottom.  
 
Background Information 
OMMIT study number __________P 
 
7. Since the first time we asked you this question before your laser surgery, have 
you been diagnosed with a mental health illness? Yes / No 
a. If yes, please specify which condition(s) 
_____________________________________________________________
_____________________________________________________________
______________________ 
8. Do you currently take any medication for a mental health illness? Yes / No 
a. If yes, please list any medication 
_____________________________________________________________
___________ 
9. Do you currently attend any counselling for a mental health illness? Yes / No 
a. If yes, please list any counselling / types of therapy 
_____________________________________________________________
___________ 
 
 
Condon Fetal Attachment Questions  
These questions are about your thoughts and feelings about your baby/babies. Please 
tick one box only in answer to each question. 
 
MP1: When I am caring for the baby/babies, I get 
feelings of annoyance or irritation: 
Please 
tick 
Very frequently  
Frequently  
Occasionally  
Very rarely  
Never  
 
 
MP2: When I am caring for the baby/babies I get 
feelings that they are deliberately being difficult or 
trying to upset me: 
Please 
tick 
Very frequently  
Frequently  
Occasionally  
Very rarely  
Never  
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MP3: Over the last 2 weeks I would describe my 
feelings for the baby/babies as: 
Please 
tick 
Dislike  
No strong feelings towards the baby/babies  
Slight affection  
Moderate affection  
Intense affection  
 
 
MP4: Regarding my overall level of interaction with the 
baby/babies I: 
Please 
tick 
Feel very guilty that I am not more involved  
Feel moderately guilty that I am not more involved  
Feel slightly guilty that I am not more involved  
I don’t have any guilty feelings regarding this  
 
 
MP5: When I interact with the baby/babies I feel: Please 
tick 
Very incompetent and lacking in confidence  
Moderately incompetent and lacking in confidence  
Moderately competent and confident  
Very competent and confident  
 
 
MP6: When I am with the baby/babies I feel tense and 
anxious: 
Please 
tick 
Very frequently  
Frequently  
Occasionally  
Almost never  
 
 
MP7: When I am with the baby/babies and other people 
are present, I feel proud of the baby/babies: 
Please 
tick 
Very frequently  
Frequently  
Occasionally  
Almost never  
 
 
MP8: I try to involve myself as much as I possibly can 
PLAYING with the baby/babies: 
Please 
tick 
This is true  
This is untrue  
 
 
MP9: When I have to leave the baby/babies: Please 
tick 
I usually feel rather sad (or it’s difficult to leave)  
I often feel rather sad (or it’s difficult to leave)  
I have mixed feelings of both sadness and relief  
I often feel rather relieved (and it’s easy to leave)  
I usually feel rather relieved (and it’s easy to leave)  
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MP10: When I am with the baby/babies:  Please 
tick 
I always get a lot of enjoyment/satisfaction  
I frequently get a lot of enjoyment/satisfaction  
I occasionally get a lot of enjoyment/satisfaction  
I very rarely get a lot of enjoyment/satisfaction  
 
 
MP11: When I am not with the baby/babies, I find 
myself thinking about the baby/babies: 
Please 
tick 
Almost all the time  
Very frequently  
Frequently  
Occasionally  
Not at all  
 
 
MP12: When I am with the baby/babies: Please 
tick 
I usually try to prolong the time I spend with him/her/them  
I usually try to shorten the time I spend with him/her/them  
 
 
MP13: When I have been away from the baby/babies for 
a while and I am about to be with him/her/them again, I 
usually feel: 
Please 
tick 
Intense pleasure at the idea  
Moderate pleasure at the idea  
Mild pleasure at the idea  
No feelings at all about the idea  
Negative feelings about the idea  
 
 
MP14: I now think of the baby/babies as: Please 
tick 
Very much as my own baby/babies  
A bit like my own baby/babies  
Not yet really my own baby/babies  
 
 
MP15: Regarding the things that we have had to give 
up because of the baby/babies: 
Please 
tick 
I find that I resent it quite a lot  
I find that I resent it a moderate amount  
I find that I resent it a bit  
I don’t resent it at all  
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MP16: Over the past three months, I have felt that I do 
not have enough time for myself or to pursue my own 
interests: 
Please 
tick 
Almost all the time  
Very frequently  
Occasionally  
Not at all  
 
 
MP17: Taking care of these baby/babies is a heavy 
burden of responsibility. I believe this is:  
Please 
tick 
Very much so  
Somewhat so  
Slightly so  
Not at all  
 
 
MP18: I trust my own judgement in deciding what the 
baby/babies needs: 
Please 
tick 
Almost never  
Occasionally  
Most of the time  
Almost all the time  
 
 
MP19: Usually when I am with the baby/babies:  Please 
tick 
I am very impatient  
I am a bit impatient  
I am moderately patient  
I am extremely patient  
 
 
Edinburgh Postnatal Depression Scale 
These questions assess your risk for depression. If you score highly, we will inform you 
and advise you to see your GP for further assessment and support if required.  
Please tick one box only in answer to each question which comes closest to how you 
have felt in the last 7 days. 
 
 
EPDSM1: I have been able to laugh and see the 
funny side of things: 
Please 
tick 
As much as I always could  
Not quite so much now  
Definitely not so much now  
Not at all  
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EPDSM2: I have looked forward with enjoyment to 
things: 
Please 
tick 
As much as I ever did  
Rather less than I used to  
Definitely less than I used to  
Hardly at all  
 
 
 
 
 
 
 
 
 
EPDSM4: I have been anxious or worried for no 
good reason: 
Please 
tick 
No not at all  
Hardly ever  
Yes, sometimes  
Yes, very often  
 
 
EPDSM5: I have felt scared or panicky for no very 
good reason: 
Please 
tick 
Yes, quite a lot  
Not quite so much now  
Definitely not so much now  
Not at all  
 
 
EPDSM6: Things have been getting on top of me: Please 
tick 
Yes, most of the time I haven’t been able to cope at all  
Yes, sometimes I haven’t been coping as well as usual  
No, most of the time I have coped quite well  
No, I have been coping as well as ever  
 
 
EPDSM7: I have been so unhappy that I have had 
difficulty sleeping: 
Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
EPDSM3: I have blamed myself unnecessarily 
when things went wrong: 
Please 
tick 
Yes, most of the time  
Yes, some of the time  
Not very often  
No, never  
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EPDSM8: I have felt sad or miserable: Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
 
 
EPDSM9: I have been so unhappy that I have been 
crying: 
Please 
tick 
Yes, most of the time  
Yes, quite often  
Only occasionally  
No, never  
 
 
EPDSM10: The thought of harming myself has 
occurred to me: 
Please 
tick 
Yes, quite often  
Sometimes  
Hardly ever  
Never  
 
 
 
Thank-you very much for taking the time to complete this 
questionnaire and being part of this study 
 
Detail of researchers 
1. Dr Fiona Mackie, 
Clinical Research Fellow, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-626-4535 
 
2. Professor M.D. Kilby, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-627-2778 
 
Patient Advice Liaison Service  
Tel: 0121 627 2747  
Email: pals@bwnft.nhs.uk  
 
Fetal Medicine Centre, Birmingham Women’s Foundation Trust, 
Metchley Park Road, Edgbaston, Birmingham. B15 2TG, Tel.No: 0121 627 2683 
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OMMIT (Optimal Management of Monochorionic Twins) Patient 
Questionnaire  
Postnatal Paternal 
As you know twin pregnancies are high-risk and people that have twins can have a wide 
variety of outcomes. Whilst we have tried our best to send you the correct questionnaire 
depending on your outcome, we may sometimes get this wrong for which we apologise. 
Thank-you very much for being part of our study, which we hope will improve care for 
people in your position in the future. 
Please read each question carefully. There are no right or wrong answers. If you would 
like to discuss any issues raised by this questionnaire with a member of the research 
team, the contact information is at the bottom.  
 
Background Information 
OMMIT study number __________P 
 
10. Since the first time we asked you this question before laser surgery, have you 
been diagnosed with a mental health illness? Yes / No 
a. If yes, please specify which condition(s) 
_____________________________________________________________
_____________________________________________________________
______________________ 
11. Do you currently take any medication for a mental health illness? Yes / No 
a. If yes, please list any medication 
_____________________________________________________________
___________ 
12. Do you currently attend any counselling for a mental health illness? Yes / No 
a. If yes, please list any counselling / types of therapy 
_____________________________________________________________
___________ 
 
 
Condon Fetal Attachment Questions  
These questions are about your thoughts and feelings about your baby/babies. Please 
tick one box only in answer to each question. 
 
PP1: When I am caring for the baby/babies, I get 
feelings of annoyance or irritation: 
Please 
tick 
Very frequently  
Frequently  
Occasionally  
Very rarely  
Never  
 
 
PP2: When I am caring for the baby/babies I get 
feelings that they are deliberately being difficult or 
trying to upset me: 
Please 
tick 
Very frequently  
Frequently  
Occasionally  
Very rarely  
Never  
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PP3: Over the last 2 weeks I would describe my 
feelings for the baby/babies as: 
Please 
tick 
Dislike  
No strong feelings towards the baby/babies  
Slight affection  
Moderate affection  
Intense affection  
 
 
PP4: I can understand what my baby/babies needs or 
wants: 
Please 
tick 
Almost always  
Usually  
Sometimes  
Rarely  
Almost never  
 
 
PP5: Regarding my overall level of interaction with the 
baby/babies I believe I am: 
Please 
tick 
Much more involved than most fathers in my position  
Somewhat more involved than most fathers in my position  
Involved to the same extent as most fathers in my position  
Somewhat less involved than most fathers in my position  
Much less involved than most fathers in my position  
 
 
PP6: When I am with the baby/babies I feel bored: Please 
tick 
Very frequently  
Frequently  
Occasionally  
Almost never  
 
 
PP7: When I am with the baby/babies and other people 
are present, I feel proud of the baby/babies: 
Please 
tick 
Very frequently  
Frequently  
Occasionally  
Almost never  
 
 
PP8: I try to involve myself as much as possible in 
child care and looking after the baby/babies: 
Please 
tick 
This is true  
This is untrue  
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PP9: I find myself talking to people (other than my 
partner) about the baby/babies: 
Please 
tick 
Many times each day  
A few times each day  
Once or twice a day  
Rarely on any one day  
 
 
PP10: When I have to leave the baby/babies:  Please 
tick 
I usually feel rather sad (or it’s difficult to leave)  
I often feel rather sad (or it’s difficult to leave)  
I have mixed feelings of both sadness and relief  
I often feel rather relieved (and it’s easy to leave)  
I usually feel rather relieved (and it’s easy to leave)  
 
 
PP11: When I am with the baby/babies:  Please 
tick 
I always get a lot of enjoyment/satisfaction  
I frequently get a lot of enjoyment/satisfaction  
I occasionally get a lot of enjoyment/satisfaction  
I very rarely get a lot of enjoyment/satisfaction  
 
 
PP12: When I am not with the baby/babies, I find myself 
thinking about the baby/babies: 
Please 
tick 
Almost all the time  
Very frequently  
Frequently  
Occasionally  
Not at all  
 
 
MP13: When I am with the baby/babies: Please 
tick 
I usually try to prolong the time I spend with him/her/them  
Neither  
I usually try to shorten the time I spend with him/her/them  
 
 
PP14: When I have been away from the baby/babies for 
a while and I am about to be with him/her/them again, I 
usually feel: 
Please 
tick 
Intense pleasure at the idea  
Moderate pleasure at the idea  
Mild pleasure at the idea  
No feelings at all about the idea  
Negative feelings about the idea  
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PP15: Over the past 3 months I have found myself just 
sitting looking at the sleeping baby/babies for periods 
of five minutes or more: 
Please 
tick 
Very frequently  
Frequently  
A few times  
Not at all  
 
 
PP16: I now think of the baby/babies as: Please 
tick 
Very much my own baby/babies  
A bit like my own baby/babies  
Not really my own baby/babies  
 
 
PP17: Regarding the things that we have had to give up 
because of the baby/babies: 
Please 
tick 
I find that I resent it quite a lot  
I find that I resent it a moderate amount  
I find that I resent it a bit  
I don’t resent it at all  
 
 
PP18: Over the past 3 months, I have felt that I do not 
have enough time for myself or to pursue my own 
interests: 
Please 
tick 
Almost all the time  
Very frequently  
Occasionally  
Not at all  
 
 
PP19: Usually when I am with the baby/babies:  Please 
tick 
I am very impatient  
I am a bit impatient  
I am moderately patient  
I am extremely patient  
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Edinburgh Postnatal Depression Scale 
These questions assess your risk for depression. If you score highly, we will inform you 
and advise you to see your GP for further assessment and support if required.  
Please tick one box only in answer to each question which comes closest to how you 
have felt over the last 7 days. 
 
 
EPDSP1: I have been able to laugh and see the 
funny side of things: 
Please 
tick 
As much as I always could  
Not quite so much now  
Definitely not so much now  
Not at all  
 
 
EPDSP2: I have looked forward with enjoyment to 
things: 
Please 
tick 
As much as I ever did  
Rather less than I used to  
Definitely less than I used to  
Hardly at all  
 
 
 
 
 
 
 
 
 
EPDSP4: I have been anxious or worried for no 
good reason: 
Please 
tick 
No not at all  
Hardly ever  
Yes, sometimes  
Yes, very often  
 
 
EPDSP5: I have felt scared or panicky for no very 
good reason: 
Please 
tick 
Yes, quite a lot  
Not quite so much now  
Definitely not so much now  
Not at all  
 
EPDSP3: I have blamed myself unnecessarily 
when things went wrong: 
Please 
tick 
Yes, most of the time  
Yes, some of the time  
Not very often  
No, never  
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EPDSP6: Things have been getting on top of me: Please 
tick 
Yes, most of the time I haven’t been able to cope at all  
Yes, sometimes I haven’t been coping as well as usual  
No, most of the time I have coped quite well  
No, I have been coping as well as ever  
 
 
EPDSP7: I have been so unhappy that I have had 
difficulty sleeping: 
Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
 
 
EPDSP8: I have felt sad or miserable: Please 
tick 
Yes, most of the time  
Yes, sometimes  
Not very often  
No, not at all  
 
 
EPDSP9: I have been so unhappy that I have been 
crying: 
Please 
tick 
Yes, most of the time  
Yes, quite often  
Only occasionally  
No, never  
 
 
EPDSP10: The thought of harming myself has 
occurred to me: 
Please 
tick 
Yes, quite often  
Sometimes  
Hardly ever  
Never  
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Thank-you very much for taking the time to complete this 
questionnaire and being part of this study 
 
Detail of researchers 
1. Dr Fiona Mackie, 
Clinical Research Fellow, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-626-4535 
 
2. Professor M.D. Kilby, 
Department of Maternal & Fetal Medicine, Floor 3, 
Birmingham Women’s Hospital, 
Edgbaston, Birmingham, B15 2TG. 
Telephone No: 0121-627-2778 
 
Patient Advice Liaison Service  
Tel: 0121 627 2747  
Email: pals@bwnft.nhs.uk  
 
Fetal Medicine Centre, Birmingham Women’s Foundation Trust, 
Metchley Park Road, Edgbaston, Birmingham. B15 2TG, Tel.No: 0121 627 
2683 
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